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iABSTRACT
The Life Marker Chip instrument, which has been selected to fly as part of the 2018
ExoMars rover mission payload, aims to detect up to 25 organic molecules in martian
rocks and regolith, as markers of extant life, extinct life, meteoritic in-fall and spacecraft
contamination. Martian samples will be extracted with a solvent and the resulting liquid
extracts will be analysed using multiplexed microarray-format immunoassays. The LMC
is under development by an international consortium led by the University of Leicester
and the work described within this thesis was carried out at Cranfield University as part
of the consortium’s broader program of work preparing the LMC instrument for flight in
2018. Within this thesis four specific areas of LMC instrument development are
addressed: the investigation of immunoassay compatible liquid extraction solvents, the
study of likely interactions of martian sample matrix with immunoassays, the
development of antibodies for the detection of markers of extinct life and demonstration
of solvent extraction and immunoassay detection in a flight representative format.
The purpose of the first area of work was to confirm whether the proposed extraction
solvent for the LMC, a water/water miscible organic solvent/surfactant capable of
extracting polar and apolar target molecules, is compatible with LMC format
immunoassays. In order to achieve this, and given the context that the final suite of
assays that will fly on the LMC instrument have not yet been developed, a set of model
immunoassays were tested for compatibility with the proposed extraction solvent, and
also for compatibility with several alternative extraction solvents, in LMC relevant
ELISA and microarray formats. The results indicate that LMC format immunoassays
are compatible with the proposed extraction solvent, allowing instrument development
to progress with this solvent, whilst also indentifying a number of potential alternatives.
In the second area of work the likely impact of the martian sample matrix on LMC
format immunoassays was investigated. This was achieved by testing performance of a
set of model assays, in LMC relevant ELISA and microarray formats, with both
individual Mars relevant sample matrix components that have been reported on Mars
and with liquid extracts from Mars analogue samples collected on Earth. The results of
these experiments indicate that LMC format immunoassays are expected to function
effectively with samples similar to those analysed by the NASA Phoenix lander,
however a number of sample matrix components/sample matrix types were identified
ii
that may have a detrimental impact on the ability of LMC immunoassays to detect
target molecules on Mars. These results enabled recommendations to be made for
future work both to improve assay performance and also to better understand how data
from other ExoMars rover instruments can be used to identify samples that are not
suitable for analysis by the LMC.
The third area of work investigates the use of phage display immunised recombinant
antibody libraries for the rapid production of antibodies against small, apolar and
chemically inert extinct life target molecules. Two strategies, optimised for the selection
of antibodies which bind to small apolar molecules were used to screen an immunised
library, and the selected populations were analysed but no appropriate clones were
isolated. The implication is that this type of library is unlikely to be suitable for the
generation of antibodies against markers of extinct life, within the timescales of the
LMC instrument development. As a result of this study an ongoing program of work has
been implemented within the LMC project to investigate alternative strategies for the
production of suitable antibodies, whose success is more likely as a result of the work
within this section.
The final area of work within this thesis brings together elements of the other three
areas in order to perform an end to end demonstration of extraction and detection by
the LMC instrument. This was achieved by spiking a Mars analogue sample with a
representative target molecule, extracting the spiked sample with the proposed
extraction solvent and analysing the liquid extract with a flight representative
breadboard. This work confirmed the compatibility of a flight representative assay with
a liquid extract from a Mars analogue sample. In addition completion of this end to end
demonstration contributed to attainment of an appropriate technology readiness level
for the LMC instrument, allowing progression to the next stage of instrument
development.
In summary significant progress has been made and improved understanding gained in
four interrelated areas of LMC instrument development, and this has contributed
towards the ongoing preparation of the LMC instrument for flight in 2018, as well as
advancing scientific knowledge in these areas.
Keywords: Astrobiology, ExoMars, extraction solvents, sample matrix effects,
recombinant antibodies, phage display, microfluidics.
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11 Introduction and Context, Thesis Objectives and
Structure
1.1 Introduction
The work described within this thesis is related to the development of the Life Marker
Chip (LMC) instrument for the detection of evidence of past and/or present life on Mars.
This introduction gives background information relating to the LMC instrument,
including an overview of the principles of operation of the LMC, and also explains how
the work within this thesis relates to the broader program of work developing the LMC
instrument for flight.
1.1.1 Mars, the ExoMars mission and the LMC instrument
Although the current environment and climate of Mars are likely to be inhospitable to
Earth-like life, due to factors such as the extreme cold, lack of liquid water and high
levels of surface radiation (Dartnell et al, 2007), there is evidence that Mars may once
have been habitable (Schwartz and Mancinelli 1989; McKay and Davis 1991; Paige
2005; Bibring et al, 2006). From a practical point of view Mars is close to Earth, which
has allowed its exploration in more detail than any other planet (Jakosky et al, 2007).
Therefore Mars is considered to be an appropriate initial target for extraterrestrial life
detection. If life did originate on Mars during early warmer and wetter periods, but has
since died out, preserved evidence of extinct life may persist. In addition the recent
discovery of methane in the martian atmosphere (Formisano et al, 2004) has promoted
speculation that there could be methane producing microbes surviving in protected
environments beneath the martian surface today.
The proposed 2018 joint European Space Agency (ESA) – National Aeronautics and
Space Administration (NASA) ExoMars rover mission (ESA 2011b) will carry a payload
of instruments dedicated to characterising the martian environment and detecting
evidence of past or present life. In contrast to all previous explorations of Mars, which
have examined samples collected from the martian surface or near sub-surface, the
ExoMars rover will be equipped with a drill capable of collecting samples from a
maximum depth of two meters below the martian surface. At these depths the
preservation of evidence of extinct life and the presence of extant life is considered
more likely (Pavlov et al, 2002; Stalport et al, 2008). Included in the ExoMars rover
2payload is the LMC instrument, the first immunoassay based instrument selected to fly
on a planetary exploration mission. The LMC, which is under development by an
international consortium led by the University of Leicester, will analyse samples of
martian rock and regolith for sub-parts per million concentrations of a pre-defined set of
up to 25 organic molecules using multiplexed microarray immunoassays.
Target molecular species for the LMC are drawn from five categories: markers of
extant life, markers of extinct life, abiotically produced organic molecules as markers of
meteoritic in-fall, as well as markers of ground based contamination and a number of
controls (Table 1-1). In-spite of the highly diverse nature of life on Earth, there are
particular biomolecules, membrane components and energy production and storage
mechanisms that are ubiquitous (Parnell et al, 2007). Therefore the detection of these
families of molecules on Mars, or the detection of the stable breakdown products of
these types of molecules would provide good evidence for the presence of extant or
extinct Earth-like life on Mars. In order to be able to detect molecular species, rather
than specific molecules, which would restrict the effectiveness of the LMC since there
are many variations possible in these types of molecules, it is important that the
antibodies selected for the LMC have broad specificity. For example an anti-hopane
antibody should be selected that is cross reactive with hopanes, rather than an
antibody that is specific for a single hopane.
3Table 1-1: LMC target molecule categories (for a full discussion of target molecule
types for the LMC please see Parnell et al (2007))
Category Description Examples
Extant life Biologically produced organic molecules
which are rapidly broken down outside of
the cell.
Informational macromolecules –
e.g. DNA/RNA
Energy storage/transfer – e.g.
adenosine tri-phosphate
Cell membrane components – e.g.
lipoteichoic acid
Extinct life Biologically produced organic molecules
that are stable over geological
timescales and diagenesis (alteration
products) of biologically produced
molecules over geological timescales.
Hopanes (derived from cell
membranes of prokayrotes)
Steranes ( derived from cell
membranes of eukaryotes)
Isoprenoids (from chlorophyll and
archeal membranes)
Meteoritic
in-fall
Abiotically produced organic molecules
known to be contained within meteorites
which are expected to be present on
Mars due to evidence of meteorite
bombardment.
Amino acids - glycine, amino
isobutyric acid, alanine
Polyaromatic hydrocarbons (PAHs)
– e.g. pyrene, phenanthrene
Contamination Organisms commonly found to inhabit
space craft assembly cleanroom
facilities
Staphylococcus
Micrococcus
Bacillus
Controls Synthetically produced organic
molecules, not expected to be present
on Mars
Atrazine
Fluorescein
1.1.2 Immunoassays for life detection in planetary exploration
The exploitation of immunoassays for in-situ planetary exploration applications is a
relatively recent development but immunoassay based detection of organic molecules,
such as pesticides, in environmental samples on Earth is well established (Krotzky and
Zeeh 1995; Mouvet et al, 1997; Knopp et al, 2000; Gauger et al, 2001; Mallet et al,
2001; Rigou et al, 2004). Antibody based technologies can be packaged into small,
lightweight devices for in-situ use, for example in lateral flow tests, and offer the
potential for high sensitivity detection of specific organic molecules in a low volume and
light weight format with low power requirements; all desirable attributes for a space
mission. In addition to the LMC there are a small number of other planetary exploration
immunoassay based instruments under development including the Signs of Life
Detector (SOLID) (Parro et al, 2011), the Biochip for Organic Matter Analysis in Space
(BiOMAS) (Baqué et al, 2011) and the Mars Immunoassay Life Detection Instrument
(MILDI) (McKay et al, 2000).
4Previous attempts to detect complex organic molecules on Mars, have focused on the
use of gas chromatography-mass spectrometry (GC-MS) based instruments (Anderson
et al, 1972; Hoffman et al, 2008) such as those carried by NASAs 1976 Viking landers
and the more recent NASA Phoenix lander. To date no complex organics have been
detected by GC-MS and the recent discovery of perchlorate salts on Mars has led to
the conclusion that this failure may be due to perchlorate mediated degradation of
organics at the high temperatures required for sample volatisation prior to injection onto
a GC column (Hecht et al, 2009; Navarro-González et al, 2010a). Therefore an
additional advantage of an immunoassay based life detection approach, compared to
better established (in terms of space flights) GC-MS type instruments, is that sample
volatisation is unnecessary. This aspect is discussed in more detail in Chapter 4 of this
thesis.
Since proposal of the LMC instrument concept in 2003 immediate concerns regarding
the stability of antibodies and other immunoassay reagents to the operational
conditions of a Mars mission, including the radiation environment and fluctuating
temperature over mission durations, have been addressed in work carried out both
within the LMC consortium, and by other groups developing immunoassay based
instruments for planetary exploration (Thompson et al, 2006; Wilson 2007; Postollec et
al, 2009; Derveni 2010; de-Diego-Castilla et al, 2011). However there are still
challenges/issues to be overcome, a number of which are addressed in this thesis and
are listed in Section 1.2.
1.1.3 LMC instrument design and principles of operation
The current (correct as of November 2011) design of the LMC flight instrument consists
of four “single use” modules that can each extract and analyse a single, approximately
one gram, sample of martian regolith or crushed rock (Figure 1-1). On Mars, the drill
and associated sample processing and distribution system (SPDS) on the ExoMars
rover will deliver a one gram sample of regolith or crushed rock to one sample
processing module of the LMC. The sample will be subject to liquid extraction together
with the application of ultrasonic energy to extract and solubilise target molecules.
5Figure 1-1: Current (2011) design of the LMC flight instrument
The liquid extract will be pumped into a single analysis module of the LMC, which
consists of microfluidic channels that allow the implementation of a multiplexed
inhibition immunoassay (up to 25 assays in a single multiplex) in a format similar to a
lateral flow immunoassay (Posthuma-Trumpie et al, 2009). Note that the LMC
instrument utilises an inhibition format assay because many of target molecules for the
LMC (see Table 1-1 for examples) are small molecules. The key aspects of the
immunoassay within the microfluidic channel are two chambers: chamber one, referred
to as the pad chamber, contains a “freeze-dried cocktail” of immunoassay reagents
including fluorescently labelled antibodies and chamber two, referred to as the array
chamber, contains a microarray of immobilised versions of the target molecules on an
optical waveguide chip. Evanescent field excitation of fluorophores on antibodies
bound to the microarray is achieved by coupling laser light (635 nm) into the optical
waveguides and final readout of the immunoassay signal is achieved via imaging of the
presence of the fluorescent labels on the microarray with a CCD based light detection
system.
On Mars, following extraction of the martian sample, the liquid extract will be pumped
through the microfluidic channel into the first chamber and incubated for approximately
1 hour. During this hour the freeze dried fluorescently labelled antibodies and other
components of the “freeze dried cocktail” dissolve into the liquid extract. If there are
target molecules present in the liquid extract their corresponding antibodies will bind to
them (Figure 1-2).
6Figure 1-2: Schematic of LMC inhibition assay showing effect of extracted target
molecule concentration on signal.
An inhibition assay format was selected for the LMC because many of the LMC targets
are small molecules and are therefore unsuitable for sandwich assay formats and it is
desirable for all assays in the multiplex to be performed using the same format. In
addition inhibition assays require only one antibody per target, rather than a pair of
antibodies as required for a sandwich assay reducing the number of antibodies that
must be sourced/raised for the instrument.
Following this period of incubation in the pad chamber the liquid extract and dissolved
antibodies are pumped into the array chamber where they come into contact with a
microarray consisting of immobilised versions of the target molecules. Antibodies
whose binding sites are not occupied by extracted target molecules will bind to their
corresponding immobilised target molecule on the microarray (Figure 1-2), whereas
those antibodies with occupied binding sites will be unable to bind to the microarray.
Following a period of incubation unbound antibody will be washed away by pumping
more liquid extract through the microfluidic channel and fluorophores on bound
antibodies will be evanescently excited and imaged. The end result is a fluorescent
signal that decreases with increasing target molecule concentration.
71.2 Thesis aim and objectives
The aim of the work reported within this thesis was to advance the understanding of the
use of immunoassays for life detection experiments on Mars, specifically within the
context of development of the LMC instrument for ExoMars. The objectives of this
thesis were focused on four interrelated areas of LMC development relevant to
immunoassays and which are stated in the following sections.
1.2.1 Objective 1: To determine compatibility of the proposed
extraction solvent with LMC format immunoassays
One of the key early challenges for the LMC was the development of an extraction
methodology that efficiently extracts a diverse range of target molecules, from polar
extant life markers to apolar extinct life markers, and critically is also compatible with
immunoassays. Work within the LMC consortium led to the proposal of a water
miscible organic solvent/water/surfactant based extraction solvent. The first aim of this
thesis was therefore to confirm whether the proposed extraction solvent for the LMC, is
compatible with immunoassays performed in LMC relevant formats.
1.2.2 Objective 2: To investigate the impact of liquid extracts from
martian samples on LMC format immunoassays
Sample matrix can have a significant effect on immunoassay performance and
immunoassays have not previously been performed with martian samples. The second
aim of this thesis was to investigate the likely impact of the Mars sample matrix on
immunoassays, in order to determine whether LMC format immunoassays are likely to
function with martian samples and to identify any risks relating to specific sample types
or components.
1.2.3 Objective 3: Generation of antibodies for the detection of
extinct life biomarker targets
There are few antibodies available either commercially, or from other research groups
that can detect markers of extinct life. Therefore in order for the LMC to detect this
scientifically important category of target molecules it is necessary to produce
antibodies within relatively short timescales and within limited resources. Previous work
8carried out within the LMC consortium (Derveni 2010) has identified that immunised
recombinant antibody libraries are a potential route to the rapid production of such
antibodies. This aim was therefore to establish whether an existing immunised
recombinant antibody library could be used, within the context of short timescales and
limited resources, to produce antibodies for detection of extinct life target molecules for
the LMC.
1.2.4 Objective 4: Demonstration of LMC format extraction and
detection in flight representative hardware
This objective was to bring together elements of the other objectives of the work within
this thesis by performing an end to end demonstration of extraction of a representative
target molecule from a spiked sample followed by immunoassay detection using flight
representative hardware and thereby to confirm that the overall LMC concept is valid.
1.3 Thesis structure
Each results chapter within this thesis (Chapters 3 to 6 inclusive) corresponds to
addressing a single thesis objective as described in Section 1.2, and contains an
introduction, detailed aims and objectives and, where relevant, a literature review in
addition to presenting and discussing results. These areas of work, although reported
as distinct chapters, were carried out in overlapping timescales.
Much of the work contained within this thesis adopted a common approach to
experimental design; therefore to avoid unnecessary repetition of information Chapter 2
describes this common experimental design and the corresponding materials and
methods which were used in several of the four areas of work. Experimental design
and materials and methods specific to single areas of work are included within the
appropriate chapter.
The final chapter of this thesis comprises a brief summary of findings for each section
of work together with a discussion/overview of implications for the ongoing
development of the LMC and any broader implications for the planetary exploration and
immunoassay communities and details of planned future work.
92 Common Experimental Design and Materials and
Methods
2.1 Common experimental design
The flight format LMC will include a maximum of 25 antibodies to detect up to 25
molecular species as markers of extant life, extinct life, meteoritic in-fall, contamination
and controls. At the current time antibodies for many of the high priority science targets
for the LMC have not yet been sourced/produced and therefore are not available for
use. However it is desirable to be able to characterise immunoassay performance
under various LMC relevant conditions, e.g. in the proposed extraction solvent, in liquid
extracts from Mars analogue samples and in flight representative hardware, at an early
stage in instrument development in order to mitigate risks and justify continuing funding
of development activities.
The methodology adopted within this thesis, and elsewhere within LMC development
work, was to use a set of antibodies available from commercial and academic sources
to model the likely performance of the 25 flight immunoassays under a variety of
conditions. The suite of antibodies that will fly on the LMC are likely to be derived from
a number of sources which are likely to include polyclonal, monoclonal and
recombinant antibody production techniques. Thus the set of model antibodies used in
this work were selected to include these antibody types in addition to including
antibodies that recognise target molecules drawn from each of the five categories of
target molecule for the LMC, with the exception of the extinct life category1. The model
antibodies used within this thesis are listed in Table 2-1.
1 At the time of this work there were no antibodies available, either commercially or from other
academic groups, that recognised any extinct life target molecules. The extinct marker class of
targets are viewed as the most challenging to raise antibodies against because they are small,
hydrophobic and chemically inert. Chapter 5 of this thesis reports work carried out using a
recombinant antibody library to select antibodies that bind to extinct life target molecules, but for
the purposes of the work reported within chapters 3,4 and 6 of this thesis no immunoassays
from the extinct life marker category were tested.
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Table 2-1: LMC model antibodies used in this study
Target molecule Target category Target function Target molecule
characteristics
Molecular
weight
Antibody type Source
Atrazine Control Synthetically produced
organic molecule
Small, limited water
solubility
215.7 Da Humanised
scAb
Immunised sheep
recombinant antibody
library
Benzo[a]pyrene
/pyrene2
Meteoritic in-fall Abiotically produced
molecule(s) found in
meteorites
Small, apolar, poor
water solubility
252.3 Da
/ 202.3 Da
Monoclonal Mouse
cAMP Extant Intra cellular signalling
molecule
Small polar 329.2 Da Monoclonal Mouse
Fluorescein Control Synthetically produced
organic molecule
Small polar 332.3 Da Polyclonal Rabbit
GroEL Extant Heat shock protein Protein, polar ~ 800 KDa Polyclonal Rabbit
LPS Extant
/contamination
Outer cell membrane of
gram negative bacteria
Glycolipid > 1000 kDa Monoclonal Mouse
LTA Extant
/contamination
Outer cell membrane of
gram positive bacteria
Glycolipid Not
determined
Monoclonal Mouse
cAMP = cyclic adenosine monophosphate, LPS = lipopolysaccharide, LTA = lipoteichoic acid, scAb = single chain antibody fragment
2 This antibody was raised against benzo[a]pyrene but also cross reacts with a number of polyaromatic hydrocarbons more commonly detected in
meteorites including pyrene (Matschulat, 2005).
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Many of these model antibodies are unlikely to fly on the LMC instrument since either
they are not raised against high priority science targets, or are not sensitive enough to
achieve the desired sub-parts per million detection levels for the LMC instrument. For
example GroEL, a molecular chaperone found in a large number of bacteria (Zeilstra-
Ryalls et al, 1991), is a high level biomarker of terrestrial life and therefore unlikely to a
good marker for martian life. Structures of the target molecules for six of the seven
antibodies are shown in Figure 2-1. GroEL, which is a 60kDa molecular chaperone is
not shown.
Figure 2-1: Structures of target molecules for model LMC antibodies
(a) Atrazine, (b) benzo[a]pyrene, (c) pyrene, (d), cyclic adeonosine monophosphate
(cAMP), (e) fluorescein, (f) Lipopolysaccharide (g) Lipoteichoic acid.
Note that as described in Section 1.1 in the flight instrument antibodies are
fluorescently labelled in order to generate a signal. Rather than individually
fluorescently labelling 25 antibodies the LMC utilises indirect labelling via biotinylated
anti-species secondary antibodies and fluorescently labelled streptavidin. Therefore
appropriate biotinylated secondary antibodies were also sourced and used together
with the set of model primary antibodies and labelled streptavidin to perform LMC
format immunoassays.
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2.1.1 LMC relevant immunoassay formats used to model LMC
performance
The flight format LMC immunoassay (multiplexed microarray inhibition immunoassays
implemented within a microfluidic channel with signal generation by evanescent
excitation of fluorophores on antibodies bound to the microarray) is not compatible with
the testing necessary to characterise antibody performance under multiple conditions
due to low throughput and the limited availability of custom made components e.g. the
optical waveguide chips for microarray printing and evanescent excitation. In order to
overcome this, two LMC representative immunoassay formats, with higher throughput
compared to the flight format assay, were developed using the model antibodies listed
in Table 2-1. These two formats were:
(i) an ELISA, which allows high throughput testing of antibody function
(ii) a pooled microarray format assay which has lower throughput compared to
the ELISA but more closely resembles the flight format assay
As explained in Section 1.1, many target molecules for the LMC instrument are small
molecules and therefore assays are performed using an inhibition format. This assay
format requires that versions of each target molecule be immobilised onto a surface.
For small molecule targets such as cAMP and benzo[a]pyrene direct physical
adsorption to hydrophobic3 optical waveguide chips and other hydrophobic surfaces is
not appropriate, therefore carrier protein-target molecule conjugates were prepared or
sourced for use in these assays.
The key differences between the ELISA, the pooled microarray format assay and the
flight format assay are listed in Table 2-2
3 Physical adsorption to hydrophobic surfaces was used throughout this thesis because this was
the implemented immobilisation method for the LMC at the time that this work was commenced.
However covalent immobilisation is likely to offer benefits in terms of assay performance and
current work has moved to the use of covalent immobilisation.
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Table 2-2: Key differences between ELISA, pooled microarray and flight format assays
Flight format ELISA format Pooled microarray format
Immobilisation
surface and
method
Microarray of target molecules (or target
molecule-protein conjugates) immobilised on
hydrophobic slide/chip via physical absorption
Bulk immobilisation of target molecules on
polystyrene 96-well plate via physical
absorption
Microarray of target molecules
immobilised on hydrophobic
slide/chip via physical absorption
Volume of
antibody/liquid
extract
6µl (volume of array chamber in microfluidic
channel)
100 µl/well of 96-well plate 6 µl pooled over microarray on
slide/chip
No. of assays Multiplexed assays – up to 25 assays on a
single microarray
Single assay performed in single well of
96-well plate
Multiplexed assays possible
Liquid handling Antibodies diluted in freeze drying cocktail and
freeze dried into glass fibre pads. Liquid extract
pumped through microfluidic channel into pad
chamber, incubated for one hour, antibodies
etc. dissolve in liquid extract. Following
incubation liquid extract and dissolved
antibodies pumped into array chamber
containing microarray.
Antibodies and freeze drying cocktail
components diluted in liquid extract and
pre-incubated for an hour prior to transfer
into 96-well plate using a pipettor
Antibodies and freeze drying
cocktail components diluted in
liquid extract and pre-incubated for
an hour prior to pooling over
microarray area on slide/chip using
a pipettor
Removal of
unbound
antibody
Additional volume of liquid extract pumped
through microfluidic channel
96-well plate washed with buffer using
commercial plate washer
Slides/chips rinsed either with flow
of buffer using wash bottle or by
immersion in buffer
Assay readout Evanescent excitation of AF633 fluorophore
labels by coupling laser light into optical
waveguides and imaging with CCD based
system
Reaction of substrate with HRP enzyme
label to produce a coloured product
whose absorbance is measured using a
commercial plate reader
Direct excitation of AF633
fluorophore labels and imaging
using commercial microarray
scanner/ breadboard system
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2.1.1.1 LMC format ELISA
ELISAs are a rapid and well characterised laboratory technique, which allow multiple
conditions to be tested with relatively low resource requirements (i.e. personnel and
cost of reagents). The LMC format ELISA enables characterisation of the function of
LMC relevant antibodies under a wide variety of conditions and is designed to mimic,
as far as possible, the flight format assay (Section 1.1). The ELISA uses the same
primary antibodies, and secondary biotinylated antibodies as the microarray format
assay but the fluorescent label on the streptavidin is replaced with a HRP enzyme label
for the purposes of the ELISA. The antibodies and streptavidin-HRP are diluted in
“freeze drying cocktail” and pre-incubated with the sample or standard under test,
mimicking incubation in the pad chamber of the LMC. Following this incubation period
the solution is transferred to the wells of a 96-well plate with immobilised target
molecules mimicking incubation in the array chamber of the LMC. After a period of
incubation, unbound antibody is washed away and the amount of antibody bound to the
immobilised target molecule is measured by means of an enzyme substrate reaction,
which produces a coloured product. Materials and methods for the LMC format ELISA
are given in Section 2.2.2. The general approach adopted throughout this thesis, when
testing the performance of model immunoassays in ELISA format was first to test
binding signal (signal generated in the presence of no inhibiting antigen) as an initial
screen for performance under a wide range of conditions and then to select appropriate
conditions for further study in more involved inhibition ELISAs where immunoassay
sensitivity under various conditions could be assessed.
2.1.1.2 LMC format pooled microarray format
The pooled microarray format assay more closely resembles the LMC flight format
assay, but without any of the microfluidic aspects or evanescent excitation. Microarrays
of immobilised target molecules are printed on hydrophobic surfaces (both
commercially available hydrophobic slides and in-house treated silicon nitride chips
were used in this work). The antibodies and fluorescently labelled streptavidin are
diluted in “freeze drying cocktail” and pre-incubated with the sample or standard under
test, mimicking incubation in the pad chamber of the LMC. This pre-incubated solution
is then “pooled” directly over the microarray area on the hydrophobic surface,
incubated for a period and unbound antibody is then washed away. Fluorophores on
antibodies bound to the array are non-evanescently excited and imaged using either a
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CCD based breadboard system built specifically for the LMC, or a commercial
microarray scanner.
The materials and methods for running immunoassays in pooled microarray format are
given in Section 2.2.3.
2.2 Common materials and methods
The following sections contain protocols for the LMC format ELISA and LMC format
pooled microarray immunoassays. The materials used in each immunoassay and each
assay format are defined and details of materials suppliers and product codes are
given in parenthesis.
2.2.1 General chemicals/biochemicals
All solvents were purchased from Fisher Scientific (Loughborough, UK) and were
HPLC grade unless otherwise stated.
All water used was 18 MΩ.cm grade and was produced with a Direct Q UV-3 water 
purification system (Millipore, Massachusetts, USA).
2.2.2 LMC Format ELISAs in 96-Well Plates
Target molecules/target molecule-protein conjugates were immobilised to the wells of
Nunc MaxiSorb™ F96 MicroWell™ plates (Thermo Scientific, Roskilde, Denmark, cat.
no. 442404) by incubation of 100 µl/well target molecule in 0.05 M carbonate-
bicarbonate buffer pH 9.6 (Sigma Aldrich, Poole, UK, cat. no. C3041) at a temperature
of 37°C for one hour, or at a temperature of 2 – 8°C overnight. The target molecules
immobilised for each immunoassay are described and the concentration at which they
were used are given in Table 2-4. A set of control wells were also prepared by
incubation with carbonate buffer only.
After the immobilisation step excess target molecule or target molecule-protein
conjugate was removed by washing wells with 3 x 300 µl/well 0.05 M phosphate
buffered saline (Sigma Aldrich, Poole, UK, cat. no. P4417) containing 0.05 % (w/v)
Polysorbate 20 (BDH/VWR, Lutterworth, UK, cat. no. 663684B) (PBST buffer) using a
BW50 plate washer (Biohit, Helsinki, Finland). Residual liquid from the washing
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procedure was removed from the wells by inverting the 96-well plate and tapping out
on absorbent paper.
Wells were blocked to reduce non-specific interactions of antibodies with any uncoated
areas of the hydrophobic plastic surfaces by incubation with 200 µl/well BSA blocking
solution (0.5 % (w/v) Cohn fraction V BSA (Sigma Aldrich, Poole, UK, cat. no. A4503)
in 100 mM N[2-hydroxyethyl]piperazine-N[2-ethanesulfonic acid] (HEPES buffer) pH
7.4 (Sigma Aldrich, Poole, UK, cat. no. H-7523) at a temperature of 37°C for one hour
and the wells were then washed as described previously to remove excess BSA.
In the flight format LMC instrument reagents, including fluorescently labelled antibodies
will be dissolved directly in the liquid extract (Table 2-3). For the purposes of LMC
format ELISAs, reagents are not freeze dried. Therefore in order to approximate the
expected concentrations of all components in the flight format assay, antibodies were
prepared in a concentrated solution of the freeze drying cocktail and then diluted with
the sample or standard under test. In addition the fluorescent label was replaced with
an enzyme label for the purposes of the ELISA.
Whilst the 96-well plate was being blocked, primary antibody, biotinylated secondary
antibody and streptavidin-HRP (Zymed, San Francisco, USA, used at 0.1 µg/ml, cat.
no. 43-4323) were diluted in 2 x strength freeze drying cocktail, at 2 x the desired final
concentration. The details and concentrations of primary and biotinylated secondary
antibodies used for each of the seven model immunoassays are given in Table 2-4
(page 19). This solution was then diluted 1:1 with the standard under test, also
prepared at 2 x the desired concentration in 2 x concentrated extraction solvent.
In cases where the extraction solvent was not at 2 x concentration (e.g. where liquid
extracts from analogue samples were used) antibodies were prepared at 2 x
concentration in a solution composed of 2 x concentration freeze drying cocktail with 1
x concentration extraction solvent. This solution was then diluted 1:1 with the liquid
extract under test to maintain the final extraction solvent concentration, although still
resulting in 50 % dilution of the liquid extract.
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Table 2-3: Formulation of Freeze Drying Cocktail (1 x concentration)
Component Concentration Function Supplier Cat. No.
Sucrose 100 mg/ml Protect antibodies duringfreeze drying
Sigma
Aldrich,
Poole, UK
S7903
Cohn fraction V
BSA 0.5 mg/ml
Protect antibodies during
freeze drying A4503
Thimerosal 0.1 mg/ml To prevent microbial growth 71230
Allura red AC 0.05 mg/ml
Dye to aid visualisation of
reagent wash out from glass
fibre pads in fluidic assays
458847
HEPES 100 mM To control pH H-7523
The resulting mixtures, which contained 1 x concentration antibodies and 1 x
concentration freeze drying cocktail components in 1 x concentration extraction
solvent, were incubated for one hour at room temperature in 1.5 ml plastic tubes. Prior
to use 1.5 ml tubes were blocked with BSA blocking solution for a minimum of one hour
at a temperature of 37°C to minimise non-specific binding of antibodies or free target
molecule to hydrophobic plastic surfaces. This incubation mimics the incubation in the
pad chamber for the flight format immunoassay.
After 1 hour incubation in BSA blocked 1.5 ml plastic tubes, antibody/sample/standard
mixtures were transferred to the target molecule coated and BSA blocked wells (as well
as into the blocked but uncoated control wells), 100 µl/well, and incubated for a further
hour at room temperature. This step mimics the incubation step in the array chamber of
the flight format assay. After one hour the 96-well plate was washed as described
previously.
Tetramethylbenzidine.dihydrochloride (TMB) substrate (Sigma Aldrich, Poole, UK, cat.
no. T3405) in 0.05 M phosphate citrate buffer containing 0.03 % sodium perborate pH
5.0 (Sigma Aldrich, Poole, UK, cat. no. P4992) was added to the 96-well plate 100
µl/well; reaction with HRP labelled antibodies, bound to target molecule immobilised on
the surface of the wells, produces a coloured product in quantities proportional to the
amount of immobilised antibody.
After approximately 10 minutes the enzyme-substrate reaction was stopped by the
addition of 50 µl/well of 1 M sulphuric acid. The optical density (OD) of each well was
read at a wavelength of 450 nm using a Varioskan Flash plate reader (Thermo
Scientific, Leicestershire, UK). Signals were background corrected by subtraction of
signal produced in control wells.
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For inhibition assays, where appropriate, IC50 (the concentration of inhibiting antigen
that produces a 50 % drop in assay signal intensity) was calculated by fitting mean
signal to a four parameter binding equation (Equation 1) (Findlay and Dillard 2007).
A1 - A2
y =
1 + (x / x0)p
+ A2
A1 = maximum absorbance at zero inhibi tor concentration
A2 = res idual abs orbance at infini te inhibi tor concentration
p = s lope of curve at midpoint
x0 = inhibi tor concentration at midpoint (IC50)
x = inhibi tor concentration
Equation 1: Four parameter binding equation
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Table 2-4: Model Immunoassay components and concentrations
Immunoassay Component Supplier Cat. No.
Concentration µg/ml
ELISA Microarray
Atrazine
Immobilised
target Atrazine-BSA conjugate
Dr. M. Sathe,
Cranfield University, UK N/A 1 N/A
Primary
Antibody
Anti atrazine humanised single chain
antibody fragments clone 4D8
Dr. K. Charlton,
ImmunoSolv, Aberdeen,
UK
N/A
1/10000
diln of
stock4
N/A
Secondary
Antibody
Goat anti human kappa light chain biotin
(bound and free) AbCam, Cambridge, UK Ab46807 0.5 N/A
Free target Atrazine Sigma Aldrich, Poole, UK 45330
Benzo[a]
pyrene
Immobilised
target Benzo[a]pyren-6-yl)butanoic acid -BSA
Dr. M. Sathe,
Cranfield University, UK N/A 1 N/A
Primary
Antibody mouse anti benzo[a]pyrene clone 22F12
Prof. Dr. D Knopp,
Technical University of
Munich, Germany
N/A 0.25 N/A
Secondary
Antibody Goat anti mouse IgG Fc biotin
QED Biosciences,
San Diego, USA 83400 0.09 N/A
Free target Benzo[a]pyrene Sigma Aldrich, Poole, UK 4-0071
Pyrene Sigma Aldrich, Poole, UK 18551-5
c-AMP
Immobilised
target
2'-O-monosuccinyl adenosine 3', 5' - cyclic
monophosphate - BSA
Dr. M. Sathe, Cranfield
University, UK N/A 1 100
Primary
Antibody
Mouse anti Adenosine 3′,5′-cyclic 
monophosphate clone 250532
R&D Systems,
Minneapolis, USA
MAB214
6 0.02 0.3
Secondary
Antibody Goat anti mouse IgG Fc biotin
QED Biosciences,
San Diego, USA 83400 0.09 20
Free target Adenosine 3′,5′-cyclic monophosphate Sigma Aldrich, Poole, UK A9501 
Immunoassay Component Supplier Cat. No.
Concentration µg/ml
ELISA Microarray
4 Stock concentration of anti atrazine scAb 4D8 as supplied by ImmunoSolv is unknown
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Fluorescein
Immobilised
target BSA-Fluorescein Isothiocyanate Sigma Aldrich, Poole, UK A9771 0.5 100
Primary
Antibody Rabbit anti fluorescein AbCam, Cambridge, UK ab19491 0.1 1
Secondary
Antibody Goat anti rabbit IgG Fc biotin
QED Biosciences,
San Diego, USA 84400 0.09 24
Free target Fluorescein sodium salt Sigma Aldrich, Poole, UK 46969
GroEL
Immobilised
target GroEL Sigma Aldrich, Poole, UK C7688 10 100
Primary
Antibody Rabbit anti GroEL Sigma Aldrich, Poole, UK G6532 10 20
Secondary
Antibody Goat anti rabbit IgG Fc biotin
QED Biosciences,
San Diego, USA 84400 0.09 24
Free target GroEL Sigma Aldrich, Poole, UK C7688
LTA
Immobilised
target Lipoteichoic Acid Sigma Aldrich, Poole, UK L2515 2 N/A
Primary
Antibody Mouse anti Lipoteichoic acid
Hycult Biotechnology,
Uden, Netherlands HM2048 10 N/A
Secondary
Antibody Goat anti mouse IgG Fc biotin
QED Biosciences,
San Diego, USA 83400 0.09 N/A
Free target Lipoteichoic Acid Sigma Aldrich, Poole, UK L2515
LPS
Immobilised
target
lipopolysaccharide from salmonella
enterica serotype enteritidas Sigma Aldrich, Poole, UK L6011 5 N/A
Primary
Antibody Mouse anti Lipopolysaccharide core
Hycult Biotechnology,
Uden, Netherlands HM6001 0.01 N/A
Secondary
Antibody Goat anti mouse IgG Fc biotin
QED Biosciences,
San Diego, USA 83400 0.09 N/A
Free target lipopolysaccharide from salmonellaenterica serotype enteritidas Sigma Aldrich, Poole, UK L6011
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2.2.2.1 Procedure for determining impact of assay conditions on HRP enzyme
The LMC format ELISA uses an enzyme label, whereas the flight format immunoassay
uses a fluorescent label. Therefore it is desirable, for tests carried out in ELISA format,
to be able to discriminate between changes in immunoassay performance caused by
the enzyme label (which are not relevant to the flight format) and changes resulting
from altered antibody performance. In order to achieve this, the response of HRP
enzyme label was tested independently of the immunoassay.
Streptavidin-HRP was immobilised to the wells of Nunc MaxiSorb™ F96 MicroWell™
plates by incubation of 100 µl/well 12 ng/ml streptavidin-HRP in 0.05 M carbonate-
bicarbonate buffer pH 9.6 at a temperature of 37°C for one hour. Excess streptavidin-
HRP was removed by washing using a plate washer as described in Section 2.2.2. The
component/solvent under test was dissolved in 2 x concentration extraction solvent and
diluted 1:1 with 2 x concentration freeze drying cocktail (Table 2-3) and incubated with
the immobilised streptavidin-HRP 100 µl/well, for one hour at room temperature.
Following incubation the plate was washed as described previously and TMB substrate
in 0.05 M phosphate citrate buffer containing 0.03 % sodium perborate pH 5.0 was
added to the 96-well plate, 100 µl/well. After approximately 10 minutes the enzyme-
substrate reaction was stopped by the addition of 50 µl/well of 1 M sulphuric acid. The
optical density of each well was read at a wavelength of 450 nm using a Varioskan
Flash plate reader (Thermo Scientific, Leicestershire, UK).
2.2.3 LMC format pooled microarray assays
This section describes the procedure for performing pooled format microarray assays.
Initial work was carried out with microarrays printed using an adapted XYZ deposition
robot and imaged with a breadboard built for the LMC project (Wilson 2007). Part-way
through the period of time in which the work in this thesis was performed, funding was
released for the purchase of a dedicated spotting robot and commercial imaging
system which allowed for higher sample throughput. Both methods of microarray
printing and microarray imaging are described in the following sections along with
details of reagent preparation and the protocol for performing pooled microarray format
assays.
22
2.2.3.1 Functionalisation of silicon nitride surfaces in preparation for physical
adsorption of target molecule-protein conjugates
The optical waveguide chips that will be used for the flight format LMC are fabricated
from silicon nitride and in order to immobilise target molecules via physical adsorption
silicon nitride surfaces must first be treated with a hydrophobic silane reagent. Pooled
microarray assays were carried out using silane functionalised chips fabricated from
the same materials as the optical waveguide chips, but without the optical waveguides.
Physical adsorption was used as this was the established protocol for LMC format
immunoassays when this thesis was commenced.
Silicon nitride chips (32 mm x 4 mm) Lionix b.v. (Twente, Netherlands) were placed in a
polytetrafluoroethylene (PTFE) chip holder inside a beaker. Chips were immersed in a
0.1 % solution of Dri-Decon® (Decon Laboratories Ltd., Sussex, UK) in 18 MΩ.cm 
water for ten minutes to remove residual organics. After ten minutes the Dri-Decon®
solution was discarded and the chips were rinsed three times with 18 MΩ.cm water to 
remove residual detergent then dried with a flow of filtered air.
The chips were removed from the PTFE holder, placed flat in the bottom of a glass
beaker and immersed in a 1M solution of sodium hydroxide (BDH/VWR, Leicestershire,
UK, cat. no. 28244.262) for 30 minutes to activate the hydroxide groups on the chip
surface. After 30 minutes the sodium hydroxide solution was discarded and the chips
were returned to the PTFE chip holder, rinsed three times with 18 MΩ.cm water to 
remove residual sodium hydroxide and dried with a flow of filtered air.
The chips, still held in the PTFE holder were then immersed in HPLC grade methanol
(Fisher Scientific, Loughborough, UK, cat. no. T/2306/15) for ten minutes, rinsed three
times with methanol and dried with a flow of filtered air.
The PTFE chip holder, containing clean, dry chips was placed inside a glass container
with a lid fitted with two threaded screw caps. In order to minimise hydrolysis of
silanisation reagents this container was dried for a minimum of four hours in an oven
set at a temperature of 200°C, to ensure no water was present prior to use. The
container was purged with argon gas to exclude water. 60 ml of anhydrous toluene
(Sigma Aldrich, Poole, UK, cat. no. 24 451-1) was injected in to the vessel through the
screw cap port, via a glass syringe that had been dried at 200°C and been purged with
argon gas. A volume of 1.2 ml of dichlorodimethylsilane (Fluka, part of Thermo Fisher
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Scientific, Loughborough, UK, cat. no. 40150) was then injected into the vessel in the
same way, to give a 0.4 M solution of dichlorodimethylsilane in toluene. The vessel was
sealed and left to stand at room temperature overnight.
After approximately 16 hours the vessel was opened and the silane coating solution
discarded. The chip holder containing the silane functionalised chips was placed inside
a clean, dry glass beaker and the chips were immersed in HPLC grade toluene (Fisher
Scientific, Loughborough, UK, cat. no. T/2306/15) for ten minutes, rinsed three times
with toluene to remove any remaining dichlorodimethylsilane and dried with a flow of
filtered air. The chips were then immersed in HPLC grade methanol for ten minutes,
rinsed three times with methanol to remove residual toluene, and dried with a flow of
filtered air. The dry silane functionalised chips were stored in a clean polystyrene Petri-
dish until use.
Successful silane functionalisation was confirmed by measuring the contact angle of
the silane functionalised chip surfaces with water. Silane functionalised surfaces are
more hydrophobic than bare silicon nitride and consequently have a higher contact
angle with water (90 – 100° compared to 45° for a bare silicon nitride chip surface). For
each batch of silane functionalised chips three contact angle measurements were
made using three different areas on the surface of a single chip using a KVS CAM 100
contact angle system (KSV Instruments, Helsinki, Finland).
2.2.3.2 Labelling BSA with Alexa Fluor® 633 for control spots on microarrays
Microarrays in the flight format assay will include immobilised spots of target
molecules/target molecule-protein conjugates and also immobilised spots of
fluorescently labelled BSA as calibration controls to confirm appropriate functioning of
the on-board laser excitation system. Therefore spots of fluorescently labelled BSA
were also included in all microarrays printed for pooled microarray assays within this
work. BSA was labelled with Alexa Fluor® 633 fluorescent dye (AF633) at two molar
ratios of dye to protein, 5:1 (high ratio) and 1:1 (low ratio), via reaction of amine groups
on BSA protein with an amine reactive Alexa Fluor® 633 succimidyl ester.
Cohn Fraction V BSA (Sigma Aldrich, Poole, UK, cat. no. A4503) was dissolved in 0.05
M carbonate-bicarbonate buffer pH 9.6 (Sigma Aldrich, Poole, UK, cat. no. C3041) at a
concentration of 5 mg/ml. A stock solution of Alexa Fluor® 633 succimidyl ester
(Invitrogen, Paisley, UK, cat. no. A20005) was prepared by dissolving 1 mg in DMSO
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and was used immediately following dilution, unused stock solution was discarded. For
5:1 ratio labelling 25 µl of the stock solution of Alexa Fluor® 633 succimidyl ester was
added drop wise to 500 µl of 5 mg/ml BSA with stirring. For 1:1 ratio labelling 5 µl of the
stock solution of Alexa Fluor® 633 succimidyl ester was added drop wise to 500 µl of 5
mg/ml BSA with stirring. Reaction mixtures were protected from light and stirred at
room temperature for 1 hour. Unreacted AF633 ester was removed by desalting using
a PD10 column (GE Healthcare, Buckinghamshire, UK, cat. no. 17-0851-01). Protein
concentration of the purified conjugate was determined by Micro BCA™ Protein Assay
Kit (Pierce, part of Thermo Fisher Scientific, Loughborough, UK, cat. no. 23225) and
the conjugates were diluted to a concentration of 500 µg/ml in PBS containing 0.01 %
(w/v) thimerosal (Sigma Aldrich, Poole, UK, cat no, 71230) and stored at 2 – 8 °C until
use.
2.2.3.3 Preparation of printing solutions for deposition of target molecule/target
molecule protein-conjugates onto hydrophobic surfaces by contact
printing
Printing solutions were prepared for each target molecule/target molecule-protein
conjugate to be printed in the microarray (see Table 2-4 for details), and also for high
and low ratio AF633 labelled BSA. Target molecules/target molecule-protein
conjugates/AF633 labelled BSA were diluted in PBS with 2 % glycerol (Sigma Aldrich,
Poole, UK, cat. no. G7757) and were stored at 2-8 °C, for a maximum of one week,
until use.
2.2.3.4 Microarray printing with SPI spotting robot for hydrophobic
immobilisation of target molecules/target molecule-protein conjugates
When the work reported in this thesis commenced the microarraying equipment
available within the laboratories at Cranfield Health and in routine use for LMC related
work, was an SPI GmbH XYZ robot (SPI GmbH, Oppenheim, Germany) fitted with an
ArrayIT™ Stealth™ 32 pin print head and Stealth™ SMP3 Micro-spotting Pin
(Telechem International, Sunnyvale, USA) (Figure 2-2) and two camera microscopes.
The SMP3 spotting pin contains a capillary which draws liquid up inside it. Bringing the
pin into contact with a suitable surface produces a spot with a diameter of 110 µm. The
camera microscopes allow the printing procedure to be observed in detail.
25
Prior to printing, silane functionalised silicon nitride chips were loaded into in a custom
manufactured aluminium holder that is mounted onto the robot base plate and
connected to a Laboport diaphragm vacuum pump (knf Lab, Trenton, USA) to hold the
chip in place. One hundred microlitres of each printing solution was pipetted into the
wells of an F8 strip well (Fisher Scientific, Loughborough, UK, cat. no. 95029350) and
the F8 strip well was loaded into the 96-well plate holder mounted on the base plate of
the spotting robot (Figure 2-2). The ultrasonic bath, also fitted onto the base plate, was
filled with 18 MΩ.cm water.
Figure 2-2: SPI GmbH XYZ robot for microarray printing
Movement of the robot was controlled by Advanced Robotic Control software (version
3.2), which was developed by SPI GmbH and supplied with the robot, using a printing
program written by Dr P.K. Wilson as part of early LMC development work (Wilson
2007).
Running the printing programme resulted in the following actions
1) Pin lowered into the ultrasonic bath for two minutes for cleaning
2) Pin lifted out of the ultrasonic bath and moved over the first well of the F8 strip
contained in the 96-well plate holder
3) Pin primed with printing solution by dipping the pin tip into the first well of the F8
strip containing the target molecule/target molecule protein conjugate
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4) Pin moved over the array area on the chip
5) A column of ten spots printed, 200 µm apart by bringing the tip of the pin in
contact with the chip surface to print one spot, moving the pin away from the
surface by a small distance, adjusting its position in the x axis by 200 µm and
repeating
6) Pin returned to a position over the ultrasonic bath
The cycle was then repeated, loading the pin from the second well of the F8 strip and
printing a second column of spots 200 µm to the right of the first column. The maximum
size of a single array was 10 x 10 spots and up to three arrays, spaced 6 mm apart,
were printed onto a single chip in a period of approximately 1 hour. After printing, the
edges of each microarray were marked with a diamond scribe (to facilitate location of
the microarrays for pooling of reagents and imaging) and chips were incubated for one
hour in a humidity chamber. After incubation chips were blocked, to minimise non-
specific binding, by immersion in a solution of 1 % (w/v) Cohn fraction V BSA (Sigma
Aldrich, Poole, UK, cat. no. A4503) in 100 mM HEPES pH 7.4. After two hours of
immersion the chips were rinsed with water and dried with a flow of filtered air. Chips
were stored at room temperature in the dark until use to avoid photobleaching of the
AF633 spots.
2.2.3.5 Microarray printing with SpotBot® 3 Microarrayer for physical
adsorption of target molecules/target molecule-protein conjugates
Part way through the period over which the work reported in this thesis was carried out
a purpose built commercial microarraying system, the SpotBot® 3 Microarrayer (Array
it Corporation, Sunnyvale, USA) (Figure 2-3), was purchased. The SpotBot® has a
significantly smaller footprint than the SPI XYZ robot, thus is more compatible with
operation inside a glove box within a cleanroom, which will be required for production
of the flight model LMC instrument to minimise potential for contamination by microbes
and organic molecules. The SpotBot® is designed to print microarrays onto
commercially available microarraying slides, but the hardware and software can be
modified in order to print microarrays onto custom produced surfaces such as the LMC
optical waveguide chips. For the purposes of the work reported in this thesis the
SpotBot® was used to print microarrays onto commercially available Superprotein
substrate slides (Arrayit Corporation, Sunnyvale, USA, cat no. SUP) to maximise
experimental throughput.
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The Spotbot® (Figure 2-3) consists of a print head whose position can be altered in the
x, y and z axes, a washing and drying station where the printing pin is washed by
ultrasonication in a flow of PBST buffer and then dried by a flow of filtered air, a holder
for a 384 well plate to contain printing solutions and a base-plate for the positioning of
surfaces for printing.
Figure 2-3: Photograph of Arrayit Spotbot ® 3 Microarrayer
Prior to printing the Spotbot® print head was loaded with a single SMP3 spotting pin,
printing solutions were loaded (20 µl/well) into a 384 well plate, the washing station
buffer reservoir was filled with PBST buffer and commercial microarray slides were
positioned on the base-plate ready for printing.
Movement of the print head was controlled by Spotbot® Spotsuite software (version
3.6.0) which allows control of limited parameters such as the number of spots per row
to be printed, the number of microarrays per slide to be printed and the timings of wash
cycles. The Spotbot® was used to print up to 12 microarrays on a single slide with
microarrays spaced approximately 6 mm apart. Each array consisted of rows of five
replicate spots for each printing solution with a spacing of 400 µm between each spot.
Up to six slides of 12 arrays could be printed in a single print run in a period of 1hr 30
minutes, significantly increasing throughput compared to the SPI spotting robot.
After the printing program had been completed, the corners of each microarray were
marked using a pencil, to enable pooling of reagents over the correct area of the slide
for pooled assays, and the slides were then incubated in a humidity chamber for one
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hour. After one hour, slides were blocked by immersion in a solution of 1% BSA in PBS
for 2 hours in order to reduce non-specific binding to the slide surface. Slides were then
washed by 5 minutes immersion in PBST followed by 5 minutes immersion in water.
Finally slides were rinsed with water and dried with a flow of filtered air. Dried slides
were stored at room temperature, in the dark, until use.
2.2.3.6 Pooled microarray format assays
Primary antibodies for each of the assays to be performed in the multiplex and their
corresponding secondary antibodies (Concentrations are given in Table 2-4 – note that
the concentrations differ from those used in ELISA format) and streptavidin AF633
(Invitrogen, Paisley, UK, used at a concentration of 10 µg/ml, cat. no. S21375)) were
diluted at 2 x the desired final concentration in 2 x concentrated freeze drying cocktail
(Table 2-3) and then added 1:1 to the standard under test in 2 x concentrated
extraction solvent.
In cases where the extraction solvent was not at 2 x concentration (e.g. where liquid
extracts from analogue samples were used) antibodies were prepared at 2 x
concentration in a solution composed of 2 x concentration freeze drying cocktail with 1
x concentration extraction solvent. This solution was then diluted 1:1 with the liquid
extract under test to maintain the final extraction solvent concentration, although still
resulting in 50 % dilution of the liquid extract. Antibody mixtures were then incubated
for 1 hour in BSA blocked 1.5 ml plastic tubes to mimic incubation in the pad chamber
of the flight format LMC.
Following incubation, a volume of 6 µl of antibody/liquid extract/standard solution was
pooled directly over a microarray on a chip or a commercial microarraying slide using a
pipette (Figure 2-4) to mimic incubation in the 6 µl volume array chamber of the LMC.
Microarrays were located using either the diamond scribe marks on silicon nitride
chips, or the pencil marks on commercial hydrophobic slides (Please refer to Sections
2.2.3.4 and 2.2.3.5). The slide/chip, with pooled antibody/liquid extract/standard, was
incubated for one hour in a humidity chamber to minimise loss of liquid by evaporation.
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Figure 2-4: Photograph of pooled microarray immunoassay showing deposition (by
pipette) of antibody/extraction solvent/liquid extract mixtures over microarrays printed
onto an in-house hydrophobic silane functionalised silicon nitride chip which has been
secured onto a microscope slide in this image for ease of handling
After one hour unbound antibodies were removed by washing using one of two
methods
(i) For silicon nitride chips, unbound antibodies were removed by rinsing the
surface of chips with PBST using a wash bottle. The chip was then rinsed
with water and dried with a flow of filtered air
(ii) For commercial slides, which required a more rigorous wash procedure due
to higher levels of background signal, unbound antibodies were removed by
immersion in PBST for 5 minutes with gentle agitation, followed by
immersion in water for 5 minutes with gentle agitation. Finally the slides
were rinsed with a flow of water and dried with a flow of filtered air
2.2.3.7 Excitation and imaging of microarrays on in-house functionalised silicon
nitride chips using in-house developed imaging system
At the beginning of the period over which the work reported in this thesis was carried
out the established method for imaging microarrays within the laboratories at Cranfield
Health was to use an imaging breadboard developed for the LMC project (Wilson
2007). Microarrays were imaged both before and after immunoassays had been
performed to allow comparison of background signal intensity and intensity of high and
low ratio AF633 labelled BSA control spots.
The Cranfield Imaging System is an optical breadboard developed and assembled for
optical imaging of microarrays at a wavelength of 633 nm (Wilson 2007). The layout of
the imaging breadboard is shown in Figure 2-5.
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Figure 2-5: Schematic layout of the imaging breadboard for non-evanescent excitation
and imaging of microarrays (Wilson 2007)
The chip being imaged was attached to a microscope slide and mounted on a
positioning system (OptoSigma, Santa Ana, California, USA) consisting of X-Y-Z linear
translation stages and a rotation stage. Fluorophores were excited by a 10 mW Helium-
Neon 633 nm laser (Polytec, Waldbrom, Germany). The laser beam was passed
through a 10 x beam expander (Intelite Inc., Genoa, USA) which spread the point
source of the laser over the area of a 1 cm diameter circle, in an attempt to provide
uniform illumination of the array area. Each microarray had to be aligned with the
illumination area and imaged individually.
Images were captured by a Peltier-cooled SXV-H9 CCD camera (Starlight Express,
Holyport, UK) mounted on an X-Y linear translation stage (Optosigma, Santa Ana,
USA) with a 4 x microscope objective. A Stopline™ 633 notch filter with an optical
density of 6 at a wavelength of 633nm (Semrock, Rochester, USA) was mounted within
an optical spacer in front of the CCD camera. This filter was designed to block out
reflected and scattered 633nm light. Images were captured using exposure times
varying from 1 to 5 minutes depending on the intensity of the signal generated by the
spots.
2.2.3.8 Excitation and imaging of slides using microarray scanner
Commercial hydrophobic slides were imaged using an InnoScan 700 microarray
scanner (Innopsys, Carbonne, France). The InnoScan is a two colour fluorescence
scanner and uses a stabilised diode laser to excite microarrays at 635 and 532 nm and
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a photomultiplier tube (PMT) to amplify the fluorescent signal. Slides were imaged,
before and after running pooled format microarray assays, using a laser power of 5.0
mW at a single wavelength (635 nm) with a PMT gain of 1%.
2.2.3.9 Analysis of microarray images using ImageJ software
Images of microarrays taken before and after running pooled microarray assays were
analysed using ImageJ software, a public domain Java image processing program
(Rasband 2010).
The ImageJ software was used to measure the mean pixel intensity of each microarray
spot (by positioning a box over each spot and then using the software to calculate the
total pixel intensity within the box divided by the number of pixels within the box). Mean
pixel intensities for each given immunoassay/AF633 labelled BSA spot type were then
averaged. Background signal was estimated by performing the same procedure on
areas of the microarray where no spots had been printed. A background correction was
applied by subtracting mean background signal from mean signal for each
immunoassay spot type.
2.2.3.10 Procedure for determining impact of components on AF633 fluorophore
Like antibodies, fluorescent dyes can also be affected by the conditions under which
they are used. For this reason it was desirable to be able to test the performance of
AF633 fluorophore under a range of conditions, independently of the immunoassay.
This was achieved by incubating the component under test with 10 µg/ml of
streptavidin-AF633 and freeze drying cocktail components (Table 2-3) diluted in
extraction solvent for 1 hour at room temperature in a total volume of 100 µl in the wells
of a black micro titre plate (Fisher scientific, Loughborough, UK, cat no. DIS-210-
190W). After one hour the fluorescence of the AF633 fluorophore was measured using
a Varioskan Flash plate reader (Thermo Scientific, Leicestershire, UK). Excitation
wavelength = 633 nm, emission wavelength = 660 nm).
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3 Compatibility of the Proposed Extraction Solvent for
the LMC with LMC Format Immunoassays
3.1 Introduction and context
The LMC will receive up to four one-gram samples of crushed martian rock or regolith
from the drill on the ExoMars rover and the crushed sample will be extracted by liquid
extraction with the application of ultrasonic energy. The liquid extract from the martian
rock or regolith sample will then be analysed for the presence of up to 25 pre-selected
molecular species using a multiplexed microarray-based immunoassay in a lateral flow
type format.
Target molecules for the LMC fall into 5 categories, with varying physiochemical
properties, comprising polar water soluble markers of extant life (e.g. informational
macromolecules like DNA, energy transport/storage molecules such as cAMP/ATP
and apolar and chemically inert markers of extinct life with limited/no solubility in
aqueous solvents including hopanes and straight chain alkanes. Therefore the LMC
extraction solvent must efficiently extract molecules with varying physiochemical
properties and must also be compatible with antibodies and other immunoassay
reagents. Given the intended multiplexed format for the LMC, where up to 25 assays
may be run in a single microarray, it is essential that the LMC extraction solvent is
compatible with a wide range of immunoassays, in order to have a realistic expectation
of successful operation.
LMC consortium members based at Imperial College have proposed the use of 20/80
% (v/v) methanol/water with 1.5 g/L polysorbate 80 (MeOH P80), together with the
application of ultrasonic energy, as a suitable extraction solvent for the LMC and have
demonstrated extraction of polar and apolar LMC target molecules from spiked
samples, with reasonable efficiency using this solvent (Court et al, 2010). In aqueous
solution, at concentrations of surfactant greater than the critical micelle concentration
(CMC), surfactant molecules form micelles which provide an apolar environment for
hydrophobic organic molecules with poor water solubility to be extracted into, whilst
more polar hydrophillic molecules are extracted directly into the bulk organic solvent
water solution.
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The fundamental goal of this work was therefore to confirm that immunoassays
function in the proposed extraction solvent for the LMC. The LMC flight instrument
design (circa 2009) incorporated an evaporation chamber to facilitate up to 30 fold
concentration of liquid extracts by evaporation under reduced pressure. This feature
was included to maximise the probability of detecting low concentrations of extracted
target molecules. Therefore there was also a need to establish whether immunoassays
are capable of functioning in the proposed LMC extraction solvent when concentrated
30 fold by evaporation.
A secondary goal of this work was to identify alternative extraction solvents, compatible
with LMC format immunoassays, in-case unforeseen circumstances should arise
during instrument development, resulting in a need to change the composition of the
extraction solvent.
3.2 Chapter objectives
The goal of the work reported in this chapter was to confirm the compatibility of the
proposed LMC extraction solvent with LMC format immunoassays. This was addressed
by setting the following specific objectives:
1) To test functionality of LMC format immunoassays in the proposed extraction
solvent, MeOH P80
2) To establish functionality of LMC format immunoassays in the proposed
extraction solvent concentrated 30 fold by evaporation
3) To explore alternative extraction solvents for compatibility with LMC format
immunoassays, should some aspect of the LMC instrument prove to be
incompatible with the proposed extraction solvent in the future
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3.3 Literature review
This literature review is divided into three sections. The first section describes methods
for organic molecule extraction used previously in planetary exploration experiments
and planned for future missions, including the aqueous based low temperature
extraction technique planned for the LMC on ExoMars. The subsequent two sections
go on to review the use of organic solvents and surfactants in immunoassays.
3.3.1 Extraction of organic molecules in the context of planetary
exploration
Simple organic molecules, like methane, have been detected in the atmosphere of
several other planetary bodies, including on Mars, by remote sensing using ground
based infrared spectroscopy and by other instruments onboard orbiting and fly-past
spacecraft (Encrenaz 1990; Formisano et al, 2004; Schaller and Brown 2007). There
have only been two previous attempts to perform in-situ extraction and detection of
organic molecules on other planetary bodies, both attempts were on Mars and both
involved pyrolysis based extraction techniques. The GC-MS on the 1970s NASA Viking
Landers (Anderson et al, 1972) and NASA Phoenix’s GC-MS based Thermal and Gas
Analyser (TEGA) (Boynton et al, 2001; Sutter et al, 2009) both failed to detect any
evidence of complex organics in samples collected from the martian surface and near-
subsurface. This is despite the known delivery of significant quantities of organic
molecules, such as polyaromatic hydrocarbons (PAH), to the martian surface by
meteorites, irrespective of any biological source of organics on Mars (Biemann et al,
1976).
Many theories were proposed to account for the failure to detect complex organics
including inadequate sensitivity of the Viking GC-MS instrument (Levin and Straat
1977) and the degradation of organics by an oxidising agent (Levin and Straat 1981;
Zent and McKay 1994; Quinn and Zent 1996; Tsapin et al, 2000). In 2008, oxidising
perchlorate salts were detected in martian regolith by the Wet Chemistry Laboratory on
Phoenix5 at a concentration of 0.4-0.6 weight percent (Hecht et al, 2009; Kounaves et
al, 2010) and Navarro-González et al (2010) demonstrated that when organic carbon
containing Mars like soils from the Atacama desert are mixed with one weight percent
5 The implications of the presence of perchlorate salts for the LMC immunoassays are
addressed in more detail in Chapter 4 of this thesis
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magnesium perchlorate and heated, the organics present are decomposed. Therefore
the failure to detect complex organics by both the Viking GC-MS and Phoenix’s TEGA
may have been due to perchlorate mediated degradation of organic molecules
promoted by the high temperatures experienced during pyrolysis.
The future NASA Mars Science Laboratory mission will carry a pyrolysis GC-MS
instrument, Sample Analysis at Mars (SAM), for analysis of the martian atmosphere
and volatised organics from martian regolith samples (NASA 2010) and the ExoMars
rover payload includes the Mars Organics Molecule Analyser (MOMA) a compact, low
power ion trap mass spectrometer with the capability to extract organics from martian
rock and regolith samples using two different methods: pyrolysis, and laser desorption
(Evans-Nguyen et al, 2008). There is therefore a risk therefore that if perchlorates are
widespread over the martian surface SAM and MOMA may also fail to detect organics,
although the impact of perchlorate salts on organic compounds extracted by laser
desorption is unknown.
There are numerous examples of non-pyrolysis based extraction methodologies for
trace analysis of organic molecules e.g. environmental pollutants (Lopez-Avila 1999),
but the majority are not compatible with the stringent mass, power and volume
requirements of an instrument designed for a space mission and are therefore not
considered here. Other non-pyrolysis based extraction techniques that have been
proposed for use in instruments for Mars exploration missions include high temperature
and pressure sub-critical water extraction, proposed for use in the Urey instrument for
the detection of amino acids (Aubrey et al, 2008) and recently it has been
demonstrated that solid phase microextraction can be used to extract the organic
content of martian analogues for analysis by GC-MS (Orzechowskaa et al, 2011).
Selection of the LMC extraction methodology was driven by three requirements, (i)
efficient extraction of a range of polar and apolar target molecules, (ii) compatibility with
immunoassays and (iii) the need to comply with mass, power and volume constraints.
In order to meet these requirements an aqueous based solvent, with a low percentage
of an organic solvent and a surfactant was developed for use in a liquid extraction with
the application of ultrasonic energy to break up the sample matrix and increase
extraction efficiency (Court et al, 2010). This proposed extraction technique has the
additional benefit that it is unlikely to promote perchlorate mediated degradation of
organic molecules, although this had not been determined experimentally when this
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thesis was commenced. The LMC therefore potentially offers a complementary
extraction strategy to previous and planned future instrumentation for the detection of
organic molecules in martian samples. In addition to the LMC there are also a number
of other immunoassay based sensors under development such as the Signs of Life
Detector (SOLID) (Parro et al, 2011) and the Mars Immunoassay Life Detection
Instrument (MILDI) (McKay et al, 2000) which also propose to use organic
solvent/aqueous solution based extractions.
3.3.2 Use of organic solvents in immunoassays
Immunoassays are traditionally performed in aqueous solutions, buffered to
physiological pH, thus restricting immunoassay detection to target molecules with
appropriate water-solubility. However interest in rapid in-situ immunoassay detection of
poorly water soluble compounds such as pesticides, and other environmental
contaminants such as polyaromatic hydrocarbons, has led to study of the performance
of immunoassays in the presence of a range of organic solvents. There are numerous
examples in the literature of detection of apolar target molecules, including
agrochemicals and other environmental pollutants, by inhibition or competition format
immunoassays in low concentrations (10-20 % (v/v)) of water miscible organic
solvents. These solvents include methanol, dimethyl sulphoxide (DMSO), acetonitrile
and ethanol, (Goh et al, 1990; Matsuura et al, 1993; Stöcklein et al, 1995; Kim et al,
2004; Sun et al, 2009).
Antibodies interact with target molecules through relatively weak non-covalent
hydrogen bonding, electrostatic, Van Der Waals, and hydrophobic forces, which are
dependent on the three dimensional structure and charge distribution of the antibody
and the target molecule. Antibody binding sites are formed by three dimensional folding
of the protein chain to create binding pockets and the way that the protein chain folds in
aqueous solution is determined by the interaction of amino acids in the protein chain
with water i.e. proteins fold in order to minimise interactions between hydrophobic
amino acid side chains and polar water molecules (Petsko and Ringe 2004).
Addition of low concentrations of organic solvents can affect protein folding and
therefore change the characteristics of the antibody binding site and impact on the
antibody-antigen binding interaction. The physio-chemical environment in which the
antibody-target molecule binding interaction takes place can also have an effect on the
antibody-antigen interaction irrespective of any changes in the antibody binding site.
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For example, interactions between hydrophobic target molecules and antibodies are
driven by hydrophobic binding and reducing the polarity of the solution, for example by
adding an organic solvent, can reduce the magnitude of hydrophobic binding forces
(Setford 2000).
Antibodies have been shown to exhibit increased affinity, decreased affinity and altered
specificity in low percentages of organic solvent compared to in buffer (Stöcklein et al,
1990; Kröger et al, 1998; Horácek and Skládal 2000) and it is not possible to predict
how a particular antibody will behave. A study which compared the performance of 20
monoclonal antibodies, raised against the same target molecule, showed that the
tolerance of clones to low concentrations of water miscible organic solvent varied
widely (Matsuura et al, 1993).
As solvent concentration is increased above 10 – 20 % (v/v), antibody activity and
sensitivity is generally reduced, and at high solvent concentrations antibodies are no
longer soluble and may precipitate out of solution. However some immobilised
antibodies have shown activity, all be it much reduced, in up to 100 % water miscible
organic solvent including methanol and acetonitrile (Matsuura et al, 1993; Lu et al,
1997). Activity has also been demonstrated in 100% water immiscible solvents such as
hexane and toluene, where a layer of residual water molecules is thought to be
responsible for maintained activity; however under these conditions reaction kinetics
are limited by the rate of target molecule phase transfer between the organic and
aqueous phases and are generally very slow (Stöcklein et al, 1990; Weetall 1991).
In addition to considering the result of adding organic solvents to antibodies and target
molecules it is also important to take into account the effect on other components of the
immunoassay such as enzyme labels which can demonstrate altered activity in organic
solvents (Lu et al, 1997), fluorescent labels which can show reduced fluorescent signal,
immobilised antibodies and immobilised target molecules which may be desorbed from
solid substrates (Stöcklein et al, 1995; Stöcklein and Scheller 1997), and solid
substrates themselves which may be damaged by the solvents.
In summary the proposed extraction solvent for the LMC contains 20 % methanol and a
survey of the literature reveals that 20 % methanol is widely used in immunoassays for
the detection of targets with limited water solubility and is therefore broadly expected to
be compatible with LMC format immunoassays. There are also a number of other
organic solvents that are commonly used at 10 – 20 % (v/v) in immunoassays which
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could be considered for ‘back-up’ extraction solvents. The flight format LMC will utilise
a multiplexed format where up to 25 immunoassays will be performed using a single
microarray. Given the large number of antibodies that may be included in the flight
format LMC, and the potential for variation of performance between different antibodies
in organic solvents, it is unlikely that any organic solvent containing extraction solvent
will be optimum for all assays included on the LMC flight instrument and inevitably
some level of compromise in performance is likely to be necessary.
3.3.3 Use of surfactants in immunoassays
The proposed extraction solvent for the LMC contains 1.5 g/L polysorbate 80 (P80).
This review, to assess the prior use of surfactants in immunoassays will therefore focus
mainly on the literature concerning the use of polysorbate in immunoassays, although
other surfactants will also be considered. Polysorbates (Figure 3-1), known
commercially as Tweens®, are amphipathic, non-ionic surfactants composed of fatty
acid esters of polyoxyethylene sorbitan (Kerwin 2008).
Figure 3-1: Structure of polysorbate 20 (top) and polysorbate 80 (bottom)
(image taken from www.chemblink.com)
Although there is little published data regarding the influence of P80 on immunoassays,
polysorbate 20 (P20) is routinely added to ELISA washing and diluting buffers to
reduce background signal (Kim et al, 2004; Traunmuller et al, 2005), by removing non-
specifically adsorbed biomolecules from solid substrates, and by blocking hydrophobic
patches created by protein removal during wash steps (Matson 2000). Non-ionic
surfactants, like P20, are also commonly added to antibody and other protein solutions
to prevent physical damage during freeze drying and spray drying, for example in
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commercial lateral flow tests (Kerwin 2008). P20 has been shown to increase the
stability of some antibodies to organic solvents (Stöcklein et al, 2000) and in some
cases to increase antibody binding affinity (Stöcklein and Scheller 1997). However
excessive concentrations of surfactants can denature proteins, desorb proteins from
substrates (Selby 1999), and inhibit enzyme-substrate reactions (Matson 2000), so
their use is generally restricted to low concentrations (0.01 - 0.1 % (w/v) or 0.1 – 1 g/L)
and some immunoassays have shown improved performance in the complete absence
of P20 (Abuknesha and Griffith 2004) which may have resulted from interference with
the hydrophobic binding interaction between the antibody and the apolar target
molecule.
P20 is routinely used in immunoassays at a concentration similar to that proposed for
the LMC extraction solvent, and is therefore likely to be compatible with LMC format
immunoassays, although there may be an impact on hydrophobic binding interactions,
which is especially relevant for LMC targets of extinct life. The surfactant selected for
the proposed LMC extraction solvent is P80, which is not commonly used in
immunoassays. P20 and P80 were both considered by the team at Imperial College
responsible for development of the LMC extraction solvent, but P80 containing
extraction solvents were found to be better at extracting a wide range of target
molecules (Baki and Sephton 2007). P80 differs from P20 in that it has a lower CMC
(0.012 mM compared to 0.06mM for P20) and a higher molecular weight (1310 g/L
compared to 1228 g/L for P20) due to its extended hydrophobic chain (Figure 3-1). It is
not anticipated that these differences will have a significant impact on immunoassay
function, but there is a need to determine this experimentally.
If the LMC solvent is concentrated by up to 30 fold following extraction, the proportion
of P80 in the immunoassay will be increased to a maximum of 45 g/L which is
significantly higher than the concentration of P20 that is typically used in
immunoassays. Higher concentrations of P20 have been shown to result in desorption
of immobilised antigens and a reduction in antibody activity, which may prove to be
problematic for LMC format immunoassays.
In summary due to the routine use of P20 in immunoassays it is assumed likely that
similar concentrations of P80 will also be compatible with immunoassays, although it
may also have an impact on hydrophobic binding interactions, but there is a need to
confirm this experimentally. However 30 x concentration of the proposed extraction
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solvent will result in a considerably higher concentration of polysorbate, which is
expected to be problematic for the LMC.
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3.4 Results and discussion
3.4.1 Overview and structure of work
The work within this chapter had three specific objectives:
1) To test functionality of LMC format immunoassays in the proposed extraction
solvent, MeOH P80
2) To establish functionality of LMC format immunoassays in the proposed
extraction solvent concentrated 30 fold by evaporation
3) To explore alternative extraction solvents for compatibility with LMC format
immunoassays should some aspect of the LMC instrument prove to be
incompatible with the proposed extraction solvent in the future
In order to achieve these three objectives, the functionality of seven model
immunoassays in LMC representative formats (please refer to Chapter 2 for details of
model immunoassays) were tested in the proposed LMC extraction solvent (MeOH
P80); in 30 fold concentrated extraction solvent, which was modelled as 45 g/L P80,
making the assumption that all of the methanol in the extraction solvent would be
evaporated; and in a range of alternatives to the proposed extraction solvent.
The results and discussion are presented in two sections; the first section describes
and discusses immunoassay performance in MeOH P80 and in 45 g/L P80. Although
these results cover two of the objectives of this thesis they are grouped together to
prevent unnecessary duplication of information, since the same controls were used for
both sets of data. The second section describes and discusses immunoassay
performance in a selection of potential alternative extraction solvents for the LMC.
Immunoassay performance was initially assessed in binding ELISA to rapidly screen
assays for functionality in the tested extraction solvents. Where possible further studies
were then carried out in pooled microarray binding assays to confirm performance in a
more flight representative format. Finally extended studies were carried out, with a sub-
set of conditions, to test the sensitivity of the immunoassays in the extraction solvents.
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3.4.2 Immunoassay performance in the proposed LMC extraction
solvent and 30 x concentrated extraction solvent
3.4.2.1 Initial assessment of immunoassay performance in MeOH P80 and 45
g/L P80 using ELISA binding signal as a performance indicator
Mean ELISA binding signals and non-specific background signal for each
immunoassay, and for HRP enzyme label independently of the immunoassays (please
see Section 2.2.2.1 for methodology), in MeOH P80 and in 45 g/L P80, are
summarised in Table 3-1.
Mean background corrected binding signals, in MeOH P80 and 45 g/L P80, were
normalised against mean background corrected binding signal in water (for ease of
comparison across all immunoassays) and plotted in Figure 3-2 (all immunoassays
except benzo[a]pyrene) and Figure 3-3 (benzo[a]pyrene). Data for the benzo[a]pyrene
immunoassay was plotted separately because it performed significantly differently from
the other immunoassays.
Table 3-1: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC
relevant ELISAs in MeOH P80 and 45g/L P80 and water as a control.
Also showing binding signal generated by HRP enzyme independently of the
immunoassays as a control. All binding signals are given in units of optical density
measured at an absorption wavelength of 450 nm, n = 2 or 3
Water MeOH P80 45 g/L P80
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP Enzyme 0.78 0.05 0.72 0.04 0.78 0.05
Atrazine 0.59 0.12 0.62 0.07 0.29 0.07
Benzo[a]pyrene 0.18 0.11 0.82 0.07 0.48 0.07
cAMP 1.31 0.13 1.14 0.07 1.19 0.06
Fluorescein 0.69 0.21 0.60 0.08 0.53 0.20
GroEL 0.66 0.10 0.60 0.05 0.67 0.06
LPS 0.64 0.17 0.09 0.05 0.13 0.05
LTA 0.60 0.12 0.39 0.05 0.40 0.05
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Figure 3-2: Normalised background corrected ELISA binding signal for atrazine, cAMP,
fluorescein, GroEL, LPS and LTA immunoassays in MeOH P80 and 45 g/L P80
Binding signals normalised against binding signal in water. Also showing normalised
binding signal produced by HRP enzyme label independently of immunoassays as a
control. Error bars = +/- standard error, n=2 or 3
Figure 3-3: Normalised background corrected ELISA binding signal for benzo[a]pyrene
immunoassay in MeOH P80 and 45 g/L P80
Binding signals normalised against binding signal in water. Also showing normalised
binding signal produced by HRP enzyme label independently of immunoassays as a
control. Error bars = +/- standard error, n=2 or 3
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Effect of MeOH P80 on immunoassay binding signal
The data in Table 3-1, Figure 3-2 and Figure 3-3 show that binding signal was affected
by MeOH P80; however the majority of the seven model immunoassays tested
exhibited only small changes in binding signal (subjectively assigned as ± 20 %), which
are unlikely to have a significant impact on performance of the LMC flight instrument. In
addition non-specific binding (signal generated by incubation of antibodies in wells that
were not coated with target molecule) was reduced in MeOH P80, compared to in
water (Table 3-1) for the all of the immunoassays tested. This is not unexpected given
that P20 is routinely added to ELISA washing and dilution buffers to reduce
background signal (Kim et al, 2004; Traunmuller et al, 2005) and indicates that the use
of MeOH P80 as the LMC extraction solvent may be beneficial in terms of minimising
non-specific binding.
Background corrected binding signal in the cAMP, GroEL and LTA immunoassays fell
in MeOH P80 compared to water (Figure 3-2), but the level of signal reduction was
similar to, or less than, the signal reduction of 10 % observed when HRP enzyme label
was tested independently of the immunoassays. Therefore it is not possible to
determine whether these small changes in immunoassay binding signal were
attributable to changes in immunoassay performance (i.e. a reduction in the quantity of
labelled antibody that bound to the immobilised antigen), or due to altered activity of
the enzyme label after exposure to MeOH P80 which is not relevant for the flight format
LMC which uses fluorescent labels. Binding signal in the fluorescein assay was
unaffected. Overall this indicates that there are no fundamental issues with the use of
MeOH P80 as extraction solvent for immunoassays that use polyclonal and monoclonal
antibodies, raised against small polar targets, protein targets and glycolipid target
molecules in terms of binding to directly immobilised proteins, small molecule protein
conjugates and directly immobilised glycolipid immobilised target molecules.
Binding signal in the LPS immunoassay in MeOH P80 (Figure 3-2) fell to a level that
was not distinguishable above background signal, therefore the LPS immunoassay, in
its current format, could not be used with MeOH P80 as the extraction solvent. Since
the anti-mouse secondary antibody used in the LPS assay (Table 2-4) is also used in
the benzo[a]pyrene, LTA and cAMP immunoassays which did not exhibit large signal
losses in MeOH P80, signal loss in the LPS assay is most likely due to altered
interaction between the anti-LPS antibody and the immobilised LPS molecule, or due to
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loss of immobilised LPS from the plate surface. Published data indicates that
immobilised mycobacterial glycolipids can be stripped from 96-well plates by
polysorbate 20 (Traunmuller et al, 2005) therefore it seems reasonable to speculate
that polysorbate 80 could have a similar effect, displacing physically adsorbed LPS
from the 96-well plate surface. If signal loss is due to instable immobilisation of the LPS
target molecule, stability might be improved by covalent immobilisation of LPS or by
conjugation of LPS to a carrier protein; there are several examples in the literature of
methods developed for the conjugation of carbohydrate type molecules to proteins
(Boratyn and Roy 1998; Zhang et al, 1998; Saksena et al, 2003; Gildersleeve et al,
2008). If signal loss is due to altered interactions between immobilised LPS and the
anti-LPS antibody, it may be possible to source an anti-LPS antibody which is less
sentitive to the solvent, but if binding forces are largely hydrophobic this may offer little
improvement. This result is not of great concern for the LMC since there are unlikely to
be a large number of glycolipid target molecules in the final set of 25 targets for flight.
Binding signal for the atrazine immunoassay, was increased by approximately 15 % in
MeOH P80 compared to water (Table 3-1and Figure 3-2). The atrazine immunoassay
uses a single chain antibody fragments (scAb) primary antibody and scAbs have been
shown to be less stable than complete IgGs (Fodey et al, 2011) having a tendency to
aggregate. However in this study performance of the tested scAb (in terms of binding to
immobilised conjugate) was not detrimentally changed by MeOH P80 suggesting that
there are no fundamental issues with the stability of scAbs in the proposed LMC
extraction solvent.
The benzo[a]pyrene ELISA (Figure 3-3) performed significantly differently from the
other immunoassays tested in this study in that binding signal was ten times higher in
MeOH P80 compared to water. However it should be noted that benzo[a]pyrene
absolute immunoassay binding signal in water was low compared to the other
immunoassays tested and absolute binding signal in MeOH P80 was comparable to
the other immunoassays (Table 3-1). The observed increase in signal intensity in
MeOH P80 compared to water indicates that MeOH P80 results in increased antibody
affinity for the immobilised benzo[a]pyrene – BSA conjugate. A possible explanation for
this could be that MeOH P80 affects how the benzo[a]pyrene-BSA protein conjugate
folds, resulting in better accessibility by the antibody to the conjugated benzo[a]pyrene
molecules. Benzo[a]pyrene is a small hydrophobic molecule, with low water solubility
(0.0038 mg/L (Lu et al, 2007)) and benzo[a]pyrene and other PAH immunoassays
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reported in the literature generally contain 5- 10 % methanol to solubilise standards
and to extract the target molecules from environmental samples (Knopp et al, 2000;
Matschulat et al, 2005). This data suggests that the use of MeOH P80 does have a
significant affect on immunoassays for the detection of hydrophobic molecules, but
would not prevent these types of assays from functioning in an LMC context.
Effect of 30 x concentrated proposed extraction solvent on immunoassay binding signal
Signal generated by HRP enzyme label after exposure to 45 g/L P80 was unchanged
compared to the signal generated after exposure to water (Figure 3-2), therefore
changes in immunoassay binding signal in 45 g/L P80 are likely to reflect real changes
in antibody performance, rather than changes in the activity of the HRP enzyme label.
The fact that HRP enzyme label is unaffected by 45 g/L P80 is perhaps surprising as a
concentration of 45g/L P80 is considerably higher than surfactant concentrations
typically included in immunoassays and surfactants have been shown to inhibit enzyme
substrate reactions (Matson 2000). However in the LMC format ELISA the extraction
solvent, including the P80 surfactant, is removed prior to addition of the substrate (for
full details of method please see Chapter 2), therefore it is possible that addition of
45g/L P80 does affect the enzyme label on the immobilised protein, but that the
changes are reversed when the surfactant containing extraction solvent is washed
away, resulting in no observed change in signal generated by the enzyme.
Immunoassay binding signal was affected by 45 g/L P80 (Table 3-1, Figure 3-2, Figure
3-3); however the majority of the seven model immunoassays tested exhibited only
small changes in binding signal (subjectively assigned as ± 20 %) which are unlikely to
have a significant impact on performance of the LMC flight instrument. Non specific
binding (signal generated by incubation of antibodies in wells that were not coated with
target molecule) was reduced in 45 g/L P80, compared to in water (Table 3-1) for all of
the immunoassays tested. As discussed for MeOH P80, P80 is routinely added to
ELISA buffers to reduce non-specific binding so this result is not unexpected.
Binding signal was unaffected by 45 g/L P80 in the cAMP and LTA immunoassays,
binding signal fell by ~ 20 % in the fluorescein immunoassay, and binding signal was
enhanced by approximately 10 % for the GroEL immunoassay. The observed changes
in binding signal could be related to changes in one/many of the interactions required
to generate signal in the LMC format immunoassay including the immobilisation of the
target molecules to the 96-well plate and the binding interactions of the primary
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antibodies, secondary antibodies and the streptavidin-biotin. This suggests that there
are no fundamental problems with concentrating the LMC extraction solvent, in terms
of binding signal for immunoassays using monoclonal and polyclonal antibodies, small
molecule-protein conjugates and directly immobilised glycolipids.
Binding signal in the atrazine immunoassay (Figure 3-2), fell by approximately 50 % in
45 g/L P80 compared to water, indicating that the amount of labelled antibody bound to
the 96-well plate was decreased. A reduction in signal of this magnitude is not ideal but
binding signal is still easily distinguishable from non-specific background signal
therefore the assay is still expected to be functional. The drop in binding signal in 45
g/L P80 could indicate that scAbs format antibodies, of which the anti-atrazine antibody
is an example, are generally less stable in high concentrations of P80 than whole IgG
format antibodies, or the signal loss could be specific to this individual clone, or related
to the anti-human kappa light chain biotin secondary antibody used in the atrazine
assay (Table 2-4), or due to altered interactions between the immobilised target and
the anti-atrazine antibody binding site. Testing further scAb format antibodies in 45 g/L
P80 and also a range of different secondary antibodies is required to clarify this. If scAb
format assays are not stable in 45 g/L P80 this may prevent their use in the LMC flight
instrument, assuming that the liquid extract from the martian sample is subject to a
concentration step.
The greatest reduction in binding signal in 45 g/L P80 was observed for the LPS
immunoassay which was rendered non-functional. The drop in signal for the LPS
immunoassay in 45 g/L P80 may be related to instability of immobilisation of the
glycolipid antigen in the presence of P80, as discussed previously for MeOH P80, or
may be related to changes in the interaction between immobilised LPS and the anti-
LPS antibody binding site.
The benzo[a]pyrene immunoassay (Figure 3-3) again performed differently to the other
immunoassays in that binding signal was enhanced in 45 g/L P80 compared to binding
signal in water (approximately x 6). However it should once again be noted that binding
signal in water for this immunoassay was low and that binding signal in 45 g/L P80 was
not significantly higher than for the other immunoassays (Table 3-1). Increased signal
may be a result of the mechanisms described previously for the benzo[a]pyrene assay
in MeOH P80.
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3.4.2.2 Further assessment of immunoassay performance in MeOH P80 and 45
g/L P80 using microarray assay binding signal as an indicator of
performance
In addition to the testing carried out in ELISA format, two immunoassays, GroEL and
fluorescein, were tested for binding signal in MeOH P80 and 45 g/L P80 in multiplexed
pooled microarray format. Note that at the time of this work GroEL and fluorescein
were the only two immunoassays that had been transferred successfully into
microarray format, therefore they were the only assays available for use in this work.
Images of microarrays taken before and after running pooled microarray
immunoassays are presented in Figure 3-4.
Figure 3-4: Images of microarrays of physically adsorbed proteins/protein-small
molecule conjugates before and after running pooled format immunoassays in water,
MeOH P80 and in 45 g/L P80
Microarrays with 4 columns of 10 replicate spots (from left to right on each array,
position indicated by red arrows) high ratio AF633-labelled BSA, GroEL (not visible on
pre-immunoassay images), BSA-FITC (not visible on pre-immunoassay images) and
low ratio AF633- labelled BSA, printed on hydrophobic silane functionalised silicon
nitride chips using SPI spotting robot. Images recorded using imaging breadboard.
Image brightness and contrast has been adjusted to aid visualisation of spots.
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In the images taken before running immunoassays (top of Figure 3-4) only the AF633
labelled BSA spots are visible, whereas in images taken after multiplexed pooled
microarray format immunoassays (bottom of Figure 3-4) the GroEL and BSA-
fluorescein spots become visible. Closer examination of the images shows that the
brightness of microarray spots appears more variable on microarray assays run with
MeOH P80 and with 45 g/L P80 compared to assays run in water. This is particularly
obvious in the images of microarrays run in 45 g/L P80. One interpretation is that
immobilised target molecule has been stripped from the chip surface, resulting in the
highly variable spot structures.
The mean pixel intensity of individual spots on the microarray images shown in Figure
3-4 were measured using ImageJ software (please see Section 2.2.3.9) and the mean
signal intensity calculated for each assay (typically ten replicates) to give the binding
signal for each immunoassay and the mean signal intensity for the AF633 labelled BSA
spots (Figure 3-5).
Figure 3-5: Binding signal for pooled format microarray immunoassays run in water,
MeOH P80 and 45 g/L P80.
Binding signal reported as mean pixel intensity of microarray spots. Microarrays printed
using SPI spotting robot and imaged using imaging breadboard. Error bars = ± 1
standard deviation of the mean, n = 10
The use of MeOH P80 and 45 g/L P80 in pooled microarray immunoassays produced
reductions in immunoassay binding signal compared to binding signal in water. Signal
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reduction was greater in 45 g/L P80 than in MeOH P80 and variability in the signal
intensity was increased (as assessed by comparison of standard deviation from the
mean) with 45 g/L P80 compared to water and MeOH P80.
Comparison of the mean pixel intensity of the AF633 labelled BSA spots in images
taken of the same array before and after running pooled format assays, reveals that
signal was reduced after running pooled assays with water, MeOH P80 and 45 g/L P80
(Table 3-2). The highest loss of signal was observed after pooled format
immunoassays in MeOH P80 (50 % reduction in signal) but signal was reduced by 40
% after running assays with water. This indicates that the immobilisation of the AF633-
BSA conjugates, by physical adsorption, is not stable to the incubation and washing
procedures used to run a pooled assay, even when water is used as the solvent. From
this it can be inferred that immobilisation of all proteins/protein conjugates onto LMC
chips by physical adsorption is also likely to be unstable. It is possible that
immobilisation stability and consequently microarray assay performance in any
extraction solvent could be significantly improved by the use of covalent immobilisation.
Covalent immobilisation would also enable the regeneration of chip surfaces, allowing
more development work to be carried out with a limited number of optical waveguide
chips.
Table 3-2: Mean pixel intensity (x¯ ) of high ratio AF633-BSA spots measured on
images taken before and after pooled microarray immunoassays in MeOH P80 and 45
g/L P80 and water as a control. n=10
Before
Immunoassay
After
Immunoassay
Change in signal
x¯ % CV x¯ % CV
Water 663 10.7 408 22.8 - 39 %
MeOH P80 974 21.7 476 24.4 - 51 %
45 g/L P80 1006 32.5 691 61.5 - 31 %
The result reported in this section demonstrate that binding signal in microarray format
can be generated in MeOH P80 and 45 g/L P80 for the limited set of immunoassays
that were tested, although signals were affected. The data has also highlighted that
there is scope to further optimise the microarray format in order to improve
immunoassay performance.
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3.4.2.3 Extended assessment of immunoassay performance in MeOH P80 and
45 g/L P80 using ELISA sensitivity (IC50) as an indicator of performance
The effect of MeOH P80 and 45 g/L P80 on immunoassay sensitivity was assessed by
running inhibition ELISAs in MeOH P80, 45 g/L P80, and with water as a control
solvent. Since benzo[a]pyrene and atrazine antigens have poor water solubility 10/90
% (v/v) MeOH water was used as a control solvent in place of water for these assays.
Two examples of inhibition immunoassay curves for ELISAs run in MeOH P80 and 45
g/L P80 are plotted in Figure 3-6 (the other graphs are available in Appendix A.1), and
the IC50 values for all immunoassays, calculated by fitting data to a four parameter
binding equation (Findlay and Dillard 2007), are presented in Table 3-3.
Figure 3-6: (a) B[a]P and (b) cAMP inhibition ELISAs in (●) control solvent, (X) MeOH 
P80, (▲) 4.5 g/L P80.  
Each data point represents a single replicate. Immunoassay curves were plotted by
fitting mean signal to a four parameter binding equation for assays run with (solid line)
control solvent (dotted line) MeOH P80, (dashed line) 45g/L P80. The control solvent
was 10 % methanol for the B[a]P assay and water for the cAMP assay
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Table 3-3: IC50 values for inhibition ELISAs run in MeOH P80 and 45 g/L P80
IC50 values were calculated by fitting the data for each immunoassay to a four
parameter binding equation. Sum of squares due to regression was less than 0.02 for
all data fitting
IC50 (ng/ml)
water (*10 % MeOH) MeOH P80 45 g/L P80
Atrazine *1.4 24.2 24.2
B[a]P *6.2 53.8 13.4
cAMP 274.8 717.0 717.0
Fluorescein 300.0 375.0 219.2
GroEL 2447.0 2096.5 1500.1
LPS 190.5 Not calculated6 Not calculated5
LTA 2.0 1.0 2.1
Immunoassay sensitivity in MeOH P80
Target molecules for six of the seven model immunoassays were successfully detected
in MeOH P80, detection was not achieved for the LPS immunoassay because binding
signal was too low. This reveals that immunoassays encompassing a broad range of
antibody types can be used for the detection of a variety of target molecule types in
MeOH P80, validating its selection as extraction solvent for the LMC. Immunoassay
sensitivity (estimated as IC50) in MeOH P80 (Table 3-3) was poorer (i.e. IC50 was
increased) for 4 out of the 7 immunoassays tested (atrazine, benzo[a]pyrene, cAMP
and fluorescein) and sensitivity was improved (i.e. IC50 was reduced) in two
immunoassays (GroEL and LTA) in MeOH P80 compared to in a control solvent. These
findings broadly agree with the findings of published studies which have determined
that IC50 is generally increased in methanol and other organic solvent containing
solutions compared to aqueous buffers (Penalva et al, 2000; González-Martínez et al,
2003; Sun et al, 2009). Changes in immunoassay sensitivity are a result of altered
affinity of the antibody for the free target molecule in MeOH P80 compared to the
control solvent.
In the case of more traditional immunoassays, e.g. for environmental monitoring, or
medical diagnostics, variations in sensitivity (and binding signal) of the magnitude
6 IC50 was not calculated because the data did not fit a four parameter binding equation. In most
cases this was because binding signal was not distinguishable from background signal in the
solvent under test
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observed in this study would be problematic due to the level of precision required
(Krotzky and Zeeh 1995) and would need to be well characterised and controlled. The
LMC instrument is intended to be qualitative rather than quantitative – i.e. to indicate
whether or not a particular molecule is present above a given detection threshold, not
to measure precisely how much of that molecule is there. Therefore these types of
changes in immunoassay sensitivity and binding signal observed in this study are
unlikely to be highly significant, particularly if the antibodies used in the flight model
have high affinity and sensitivity.
The assays which demonstrated the greatest reduction in sensitivity were
benzo[a]pyrene and atrazine, both molecules with limited water solubility. Stocklein et
al (2000) proposed that binding of antigens to antibodies is more favourable in solvents
in which the antigen is poorly soluble and data generated by LMC consortium members
at Imperial College has shown that the solubility of pyrene, a PAH with a structure
related to benzo[a]pyrene, is increased by more than tenfold in MeOH P80 compared
to 20/80 % (v/v) methanol water (Court 2011). The implication is that addition of P80 to
the extraction solvent increases the solubility of benzo[a]pyrene but also reduces the
favourability of the antibody – benzo[a]pyrene binding interaction. This view is
supported by data from a previous study in which Matschulat et al (2005) found that
sensitivity of an immunoassay using the same anti-benzo[a]pyrene clone was
unaffected by methanol at concentrations of up to 40 % (v/v). Therefore the reduction
in sensitivity observed in this study is likely to be related to the presence of P80. This
has implications for other immunoassays for target molecules with poor water solubility,
particularly extinct life marker target molecules, where immunoassay sensitivity is likely
to be poorer in P80 containing solutions. However it is also important that the extraction
solvent is able to extract apolar molecules. Stocklein et al (2000) sought to determine
the optimum solvent for both the extraction of pesticide molecules from soil samples
and for the detection of extracted pesticide molecules in immunoassays and concluded
that both conditions cannot be met optimally by the same solvent. For the LMC where
up to 25 immunoassays will be multiplexed, the selection of an appropriate solvent
becomes even more challenging and some level of compromise, in terms of
immunoassay performance and target extraction efficiency, is inevitable.
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Immunoassay sensitivity in 45 g/L P80
Six of the seven model immunoassays successfully detected target molecule in 45 g/L
P80, detection was not achieved for the LPS immunoassay because binding signal was
too low. This reveals that immunoassays encompassing a broad range of antibody
types can be used for the detection of a variety of target molecule types in 45 g/L P80,
therefore concentration of the proposed extraction solvent by evaporation is likely to be
compatible with immunoassays. The functionality of a high number of the tested
immunoassays in 45g/L P80 is perhaps surprising given that the use of P20 in
immunoassay buffers in generally restricted to much lower concentrations (0.1-1 g/L)
and higher concentrations of surfactants have been shown to denature proteins and to
desorb proteins from substrates (Selby 1999).
IC50 varied in 45 g/L P80 compared to the control solvent for the seven immunoassays
tested with some immunoassays showing improved sensitivity (GroEL and fluorescein),
others worsened sensitivity (atrazine, benzo[a]pyrene and cAMP) and some
immunoassays being unaffected (LTA) (Table 3-3). IC50 was not calculated for the LPS
immunoassay because the binding signal in 45 g/L P80 was too low to fit the data to a
four parameter binding equation. Once again many of the observed changes in IC50
were of a magnitude unlikely to significantly impact on instrument performance.
In summary immunoassay performance, in terms of sensitivity was, for the majority of
immunoassays tested, similar or better than in MeOH P80. This is surprising given that
45 g/L P80 is more different to typical immunoassay buffers than the proposed LMC
extraction solvent. The maximum increase in IC50 in 45 g/L P80 compared to water/10
% methanol was 20 fold, indicating that a 30 fold concentration of the liquid extract is
unlikely to be detrimental to instrument detection limits.
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3.4.2.4 Summary and future Work
This section of work had two specific objectives:
Objective 1
The first objective of this study was to confirm functionality of LMC format
immunoassays in the proposed LMC extraction solvent, by extending the range of
relevant immunoassays tested under these conditions. This objective was addressed
by testing the performance of seven LMC relevant immunoassays in the proposed LMC
extraction solvent, compared to water. As anticipated from information published in the
literature (reviewed in section 3.3), the majority of the assays tested in this study
functioned effectively in MeOH P80. These assays encompassed a broad range of
antibody types, target molecule types and immobilised target types. The results of the
study indicate that MeOH P80 should be broadly compatible with LMC format
immunoassays.
Some changes in immunoassay binding signal and immunoassay IC50 were observed
with MeOH P80 compared to in water, but the vast majority of these changes were not
of significant concern for the LMC due to the analytical requirements of the instrument
and the acceptance that some level of compromise in terms of immunoassay
performance is inevitable given the requirement for the solvent to both extract target
molecules efficiently and be compatible with the multiplexed immunoassays.
In conclusion this data confirms that the selected baseline LMC extraction solvent is
likely to be compatible with the multiplexed LMC format immunoassay. Future
immunoassays should be developed and optimised directly in the proposed LMC
extraction solvent and further work should be carried out to extend the number of
immunoassays tested in microarray format.
Objective 2
The second objective of this work was to establish whether 30 x concentration of the
proposed LMC extraction solvent is compatible with immunoassays. This objective was
achieved by modelling 30x concentrated LMC extraction solvent as 45 g/L P80 and
testing seven LMC format immunoassays for functionality in 45 g/L P80. Some
changes in immunoassay binding signal and immunoassay IC50 were observed with 45
g/L P80 compared to water, but the vast majority of these changes were not of
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significant concern for the LMC due to the analytical requirements of the instrument
and the acceptance that some level of compromise in terms of immunoassay
performance is inevitable in order to meet the dual requirements of efficient extraction
and immunoassay compatibility.
In conclusion, the data established the functionality of a small number of LMC format
assays in the 30 x concentrated extraction solvent, demonstrating that 30-fold
concentration of the liquid extract from the Martian sample is likely to be compatible
with the LMC format multiplexed immunoassay. Since the completion of this work LMC
flight instrument design has evolved and the facility to concentrate the LMC solvent has
been removed in order to reduce mass and power consumption requirements. If a
concentration step was still being considered for the LMC further work would be
required to assess the performance of more immunoassays in 45 g/L P80 and also to
expand the range of immunoassays tested in microarray format.
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3.4.3 Immunoassay performance in alternative extraction solvents
The work in Section 3.4.2 has shown that the proposed LMC extraction solvent, MeOH
P80, is likely to be compatible with LMC format immunoassays. However there is a risk
that the proposed LMC solvent may prove to be unsuitable for use in the flight
instrument, due to as yet unidentified factors such as incompatibility with space
radiation and/or sterilisation procedures. Therefore it is necessary to identify a number
of potential ‘back-up’ extraction solvents as possible alternatives to MeOH P80.
A range of alternative solvents was selected in collaboration with LMC consortium
members based at Imperial College. Selection was based on anticipated extraction
efficiency for a range of polar and apolar organic molecules and expected compatibility
with immunoassays, based on literature information. The solvents and concentrations
that were tested are shown in Table 3-4. Within this work no investigation of alternative
surfactants was made, but this has been identified as a future piece of work for the
LMC consortium7.
Table 3-4: Formulation of alternative LMC extraction solvents tested for compatibility
with LMC format immunoassays
Extraction Solvent Solvent concentrations tested (v/v)
Dimethylsulfoxide (DMSO) P80 2 % DMSO, 98 % water, 2.5 g/L P80
5 % DMSO, 95 % water, 2.5 g/L P80
DMSO MeOH P80 2 % DMSO, 18 % MeOH, 80 % water, 2.5 g/L P80
5 % DMSO, 15 % MeOH, 80 % water, 2.5 g/L P80
Acetone P80 10 % acetone, 90 % water, 2.5 g/L P80
20 % acetone , 80 % water, 2.5 g/L P80
30 % acetone , 70 % water, 2.5 g/L P80
Acetonitrile (MeCN) P80 10 % MeCN, 70 % water, 2.5 g/L P80
20 % MeCN, 80 % water, 2.5 g/L P80
30 % MeCN, 90 % water, 2.5 g/L P80
Determination of the extraction efficiency of the alternative solvents was carried out
elsewhere within the LMC project team (Gomes 2009) and results are not reported in
this thesis.
7 Note - in studies in late 2011, alternative surfactants of Zonyl FS-300 and
Poly(dimethylsiloxane-co-[3-(2-(2-hydroxyethoxy)ethoxy)propyl]methoxysiloxane have been
shown in LMC studies to be compatible with both target molecule extraction and immunoassay
detection
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Immunoassay performance was initially assessed by testing the impact of the
alternative extraction solvents on immunoassay binding signal in ELISA format. No
further studies with pooled microarray format immunoassays were carried out as part of
this work due to resource limitations. Extended studies with a limited set of alternative
extraction solvents were then performed by assessing immunoassay sensitivity in
ELISA format.
It should be noted than when this piece of work was carried out the concentration of
P80 in the proposed LMC extraction solvent had not been finalised and varied between
1.5 and 2.5 g/L. The impact of increasing the P80 concentration from 1.5 g/L to 2.5 g/L
on ELISA binding signal was minimal (data not shown) therefore for the purposes of
this study P80 was included in the alternative extraction solvents at a concentration of
2.5 g/L.
3.4.3.1 Initial assessment of immunoassay performance in potential alternative
extraction solvents using ELISA binding signal as performance indicator
Mean ELISA binding signal for each immunoassay, and for HRP enzyme label tested
independently of the immunoassays (please see Section 2.2.2.1), in a range of
alternative extraction solvents, are summarised in Table 3-5 along with non-specific
background binding signal for each immunoassay in each solvent. The data reported in
the table is restricted to the highest concentration tested for each alternative extraction
solvent. The complete data set for all tested concentrations is available in Appendix A2
Mean background corrected binding signals were normalised against mean
background corrected binding signal in water (for ease of comparison across all
immunoassays) and plotted in Figure 3-7 (all immunoassays except benzo[a]pyrene)
and Figure 3-8 (benzo[a]pyrene). Data for the benzo[a]pyrene immunoassay was
plotted separately because it performed significantly differently from the other
immunoassays.
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Table 3-5: Mean binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in selected concentrations of
proposed alternative LMC extraction solvents and water as a control.
Also showing binding signal generated by HRP enzyme independently of the immunoassays as a control. All binding signals are given in
units of optical density measured at an absorption wavelength of 450 nm and n = 2 or 3.
Water 5 % DMSO
2.5 g/L P80
5 % DMSO
15 % MeOH
2.5 g/L P80
30 % acetone
2.5 g/L P80
30 % acetonitrile
2.5 g/L P80
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.78 0.05 0.82 0.04 0.82 0.04 0.81 0.04 0.66 0.04
Atrazine 0.57 0.14 0.15 0.05 0.25 0.05 0.06 0.05 0.06 0.05
B[a]P 0.27 0.12 0.66 0.20 1.08 0.04 0.96 0.05 0.45 0.05
cAMP 0.71 0.05 0.65 0.04 0.63 0.04 0.55 0.05 0.05 0.05
Fluorescein 0.86 0.05 0.73 0.04 0.70 0.04 0.58 0.05 0.48 0.05
GroEL 0.68 0.05 0.61 0.04 0.62 0.04 0.59 0.04 0.37 0.04
LPS 0.54 0.13 0.22 0.08 0.15 0.08 0.09 0.05 0.06 0.05
LTA 0.97 0.16 0.13 0.05 0.11 0.05 0.07 0.05 0.06 0.06
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Figure 3-7: Normalised background corrected ELISA binding signal for atrazine, cAMP, fluorescein, GroEL, LPS and LTA in proposed
alternative extraction solvents.
Binding signals normalised against binding signal in water. Also showing normalised binding signal produced by HRP enzyme
label independently of immunoassays as a control. Error bars = +/- standard error, n=2 or 3.
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Figure 3-8: Normalised background corrected ELISA binding signal for benzo[a]pyrene in
proposed alternative extraction solvents.
Binding signals normalised against binding signal in water. Also showing normalised binding
signal produced by HRP enzyme label independently of immunoassays as a control. Error
bars = +/- standard error, n=2 or 3
The data presented in Table 3-5, Figure 3-7 and Figure 3-8 show that background corrected
binding signal for each immunoassay varied across the range of alternative extraction
solvents tested, with the majority of immunoassays showing lower binding signal in the
alternative extraction solvents compared to in water.
Organic solvents and surfactants are known to affect enzyme labels (Lu et al, 1997; Matson
2000) and changes in HRP enzyme label activity were observed across the range of
alternative extraction solvents tested, although generally these changes were small (<10 %).
The greatest reduction in activity of the HRP label was evident in acetonitrile containing
extraction solvents. Acetonitrile has previously been shown to cause irreversible changes in
HRP enzyme (Lu et al, 1997) and hydrophilic solvents, such as acetonitrile, have been
observed to be more detrimental to enzymes than less polar organic solvents like methanol
(Stöcklein and Scheller 1997).
The seven immunoassays tested can be broadly be separated into two sub-groups, those
that were generally robust to the addition of a proposed alternative extraction solvents (i.e.
maintained binding signal, showing either no change, or only small reductions or
enhancements in binding signal), and those that were not robust (i.e. those that showed
large reductions in binding signal).
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Four of the seven immunoassays (cAMP, fluorescein, GroEL and benzo[a]pyrene) had high
tolerance to the range of extraction solvents tested, retaining binding signal that was
significantly above background noise in varying concentrations of DMSO, DMSO/MeOH,
acetone and MeCN with 2.5 g/L P80. Immunoassays have previously been successfully
demonstrated in a range of water miscible organic solvents at low (10 – 20 % (v/v))
concentrations including acetone (Kim et al, 2004), MeCN (González-Martínez et al, 2003),
DMSO (Rehan and Younus 2006) and MeOH (Rigou et al, 2004), therefore the finding that
LMC format immunoassays function in low concentrations of acetone, MeCN, DMSO and
MeOH containing extraction solvents is not surprising. The cAMP, fluorescein, GroEL and
benzo[a]pyrene immunoassays are diverse, encompassing a broad range of immobilised
target molecule types, target molecule types and primary and secondary antibody types.
Therefore, assuming that the performance of these immunoassays is representative, it
should be possible to move to an alternative extraction solvent if the MeOH P80 solvent
proves unsuitable for any reason. Some previous studies have shown that monoclonal
antibodies are more resistant to organic media than polyclonals (Penalva et al, 1999), but in
the case of the immunoassays tested here there are examples of immunoassays with both
monoclonal (cAMP, benzo[a]pyrene) and polyclonal (GroEL, fluorescein) primary antibodies
that show good tolerance for a range of organic solvents.
The LPS, LTA and atrazine immunoassays were functional (i.e. binding signal was high
enough to be readily distinguishable from background noise) in a very limited number of the
alternative extraction solvents tested. For LTA and LPS this suggests that the primary
antibodies, or the direct immobilisation of glycoplipid target molecules is sensitive to the
addition of the proposed alternative extraction solvents (since the anti-mouse secondary
antibody used for these assays is also used for the cAMP assay which showed better
funtionality in the alternative extraction solvents). The poor performance of the atrazine
immunoassay, which in contrast to other tested immunoassays utilises a single chain
antibody fragment primary antibody, in the proposed alternative extraction solvents, is of
potential concern for the LMC because it may indicate that single chain antibody fragments
are less stable to organic solvents and surfactants than IgGs, equally it may indicate that this
particular scAb clone is sensitive to organic solvents, whereas other scAbs may not be. The
reduction in signal intensity could also be related to the anti-human kappa light chain
secondary antibody, which is not used in any of the other immunoassays tested. Further
testing with additional scAbs is required to confirm their performance with the alternative
extraction solvents. The implication of this is that if a need arose to move to an alternative
extraction solvent, it is possible that some immunoassays, which function in MeOH P80,
would not function in an alternative solvent.
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The benzo[a]pyrene immunoassay exhibited enhanced binding signal in the proposed
alternative extraction solvents compared to water but as discussed previously (Section
3.4.2.1) absolute binding signal in water was low compared to the other immunoassays
tested (Table 3-5) and therefore it would appear that the benzo[a]pyrene immunoassay
functions better (in terms of binding to immobilised target molecule) in the presence of P80
and organic solvent than in water. It is possible that the immobilised benzo[a]pyrene target
molecules become more accessible to the primary antibody in the presence of organic
solvents and/or P80 and/or adopt a conformation that is better recognised by the antibody,
resulting in higher binding signal in the alternative extraction solvents compared to water.
For the majority of tested immunoassays increasing the proportion of organic solvent
included in the extraction solvent under test resulted in lower binding signal (or a smaller
enhancement in signal in the case of the benzo[a]pyrene immunoassay), this was
particularly evident in acetonitrile and acetone containing extraction solvents where three
concentrations were tested (10, 20 and 30 % (v/v)). Some additional testing, which is not
reported in this thesis, was carried out with additional alternative extraction solvents which
included ethanol and propan-2-ol at concentrations varying from 10 – 30 % and in general
immunoassays that were robust to the solvents tested here were also robust to ethanol and
propan-2-ol.
Previous studies have shown that polar organic solvents are more detrimental to proteins
than less polar organic solvents because they are more water soluble and therefore displace
more of the structural water molecules from the protein (Horácek and Skládal 2000). In this
study acetonitrile was more disruptive to antibody function, and also to enzyme activity, than
the less polar acetone and methanol (Table 3-6) in agreement with the published data.
Table 3-6: Dielectric constant (as a measure of polarity), boiling point and molecular mass of
organic solvents tested for compatibility with LMC format immunoassays
Solvent DielecticConstant Boiling point (°C)
Molecular mass
(g/mol)
Acetone 20.7 65 58.08
Acetonitrile 36.6 56 41.05
Dimethyl sulphoxide 47.2 82 78.13
Methanol 33.0 189 32.04
Water 80.0 100 18.01
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3.4.3.2 Extended assessment of immunoassay performance in selection of proposed
alternative extraction solvents using ELISA sensitivity as a performance
indicator
Immunoassay sensitivity was assessed by running inhibition ELISAs in the highest
concentration of each proposed alternative extraction solvent and with a control solvent,
water or 10/90 % methanol water for immunoassays where target molecules were not water
soluble. Two examples of typical immunoassay inhibition curves are shown in Figure 3-9, the
remaining inhibition assay plots are contained within Appendix A3. Immunoassay IC50 values
were calculated by fitting data to a four parameter IC50 equation and are reported in Table
3-7.
Figure 3-9: (a) fluorescein and (b) LPS LMC format inhibition ELISAs in water and alternative
LMC extraction solvents
(●) water, (X) 5 % DMSO 2.5 g/L P80, (▲) 30 % acetone 2.5 g/L P80 and (+) 30 % 
acetonitrile 2.5 g/L P80. Each data point represents a single replicate. Immunoassay curves
were plotted by fitting mean signal to a four parameter binding equation, or by linear
interpolation of the mean OD where the data did not fit a four parameter binding equation
(solid line) 10 % methanol, (dotted line) 5 % DMSO 2.5 g/L P80, (short dashed line) 30 %
acetone 2.5g/L P80, (long dashed line) 30 % acetonitrile 2.5 g/L P80.
Immunoassay sensitivity was affected by the alternative extraction solvents in the majority of
cases tested, but for several immunoassays it was not possible to calculate IC50 values
because binding signal was reduced to a level where it was not distinguishable from
background noise in the extraction solvent under test.
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Table 3-7: IC50 values for Inhibition ELISA assays run in alternative LMC extraction solvents.
IC50 values were calculated by fitting data to a four parameter IC50 equation. Sum of squares
due to regression were less than 0.05 for all data fitting
IC50 (ng/ml)
Water (* 10 %
methanol)
5 % DMSO 2.5
g/L P80
30 % acetone 2.5
g/L P80
30 % MeCN 2.5
g/L P80
Atrazine *5.6 1.32 106.8 Not calculated
B[a]P *3.2 1.17 50.8 Not calculated
cAMP 331.4 229.3 2000 Not calculated
Fluorescein 352.5 300.0 300.0 347.9
GroEL 601.9 295.1 178.2 1400.0
LPS 319.7 499.9 Not calculated Not calculated
LTA 2.8 2.5 Not calculated Not calculated
Target molecules for each immunoassay were successfully detected in the proposed
alternative extraction solvents, with the exception of instances where the immunoassays
were rendered non-functional due to large reductions in immunoassay binding signal.
Immunoassay sensitivity varied with the alternative extraction solvent. Since the LMC
instrument aims to determine whether classes of organic molecules are present above a
given detection threshold, rather than to quantify specific molecules small changes in
immunoassay sensitivity are unlikely to have a significant impact on the function of the LMC
instrument. However orders of magnitude changes in sensitivity are likely to be more
significant.
The only orders of magnitude changes in sensitivity induced in the alternative extraction
solvents were observed for the atrazine, benzo[a]pyrene and cAMP immunoassays in 30/70
% (v/v) acetone water with 2.5 g/L P80 where sensitivity was reduced. However it is also
important to consider that instrument detection limit is also dependent on target molecule
extraction efficiency, which has not been tested within this work. The ideal extraction solvent
for the LMC will efficiently extract target molecules and also give high immunoassay
sensitivity, however antibody-target molecule binding affinity is improved in solvents in which
the target molecule is less soluble (Penalva et al, 1999; Horácek and Skládal 2000;
Stöcklein et al, 2000), therefore a highly efficient extraction solvent is unlikely to produce the
optimum immunoassay sensitivity.
3.4.3.3 Summary and future work
The specific objective of this section of work was to explore alternative extraction solvents
for compatibility with LMC format immunoassays, in-case some aspect of the LMC
instrument proves to be incompatible with the baseline LMC extraction solvent in the future.
This objective was addressed by testing four alternative water miscible organic solvent P80
solutions, whose formulations were suggested by the team at Imperial College developing
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the LMC extraction solvent, for compatibility with LMC format immunoassays. Changes in
binding signal and sensitivity were observed across the range of solvents tested, but a
diverse range of immunoassays did function in the alternative extraction solvents. The
suitability of these solvents in terms of extraction efficiency of relevant targets was not
assessed in the work reported here. A number of back-up solvents have therefore been
identified that could be explored further should the need arise. Once again no single solvent
was identified that is optimum for immunoassay function and some degree of compromise of
immunoassay function would be required. Should the baseline LMC extraction solvent prove
unsuitable for use in the flight instrument, a significant amount of work would be required to
characterise the performance of each immunoassay in the LMC extraction solvent and also
to assess extraction efficiency for a range of target molecules.
3.5 Conclusions
The LMC instrument will directly analyse extracts from martian samples for the presence of a
wide range of target molecules including markers of extant and extinct life, meteoritic in-fall
and terrestrial contamination. The need to extract a wide range of organic molecules with
varying polarities and critically the requirement that the solvent used for the extraction be
compatible with multiplexed immunoassays led to the proposal of MeOH P80 as a suitable
extraction solvent for the LMC. Built in to the LMC was the option to concentrate the extract
up to thirty fold by evaporation under reduced pressure. The objective of the work reported
within this chapter was to determine whether immunoassays are compatible with extraction
solvents suitable for use in the LMC instrument.
Given that the LMC immunoassay aims to be capable of extracting and detecting up to 25
target molecules with differing properties, it is highly unlikely that an extraction solvent exists
that would be optimal in terms of extraction and detection of every target molecule. However
this study concludes that the proposed LMC extraction solvent, MeOH P80, is an acceptable
compromise in terms of performance of a wide range of LMC relevant immunoassays and
it’s efficiency as an extraction solvent has been confirmed elsewhere and is beyond the
scope of this thesis. In addition to this, extract that has been concentrated up to 30 fold by
evaporation is also acceptable in terms of immunoassay performance and concentration by
evaporation could be used to increase instrument sensitivity, although this feature has
subsequently been removed from the flight instrument design. Finally there are a number of
other organic solvent/surfactant based extraction solvents that have the potential to be
compatible with LMC format immunoassays should they be required in the future.
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This study therefore supports the use of MeOH P80 as the extraction solvent for the LMC. In
future work new assays should be optimised directly in MeOH P80. This will ensure optimum
assay performance in the extraction solvent and allow early identification of any
antibodies/assays which are unsuitable for inclusion in the flight instrument due to poor
compatibility with the extraction solvent.
Although there are many examples in the literature where small numbers of immunoassays
against one, or several closely related target molecules have been tested for performance in
multiple organic solvents e.g. (Melnikova et al, 2000; Matschulat et al, 2005; Rehan and
Younus 2006; Zeng et al, 2007) as far as the author is aware there are no examples in the
literature of studies where the performance of a diverse range of immunoassays, against
different target molecule types have been examined in this way. This work appears to
represent the best example to date of a systematic study of the effect of solvents on a
diverse range of immunoassays
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4 Influence of Liquid Extracts from Martian Samples on
LMC Format Immunoassays
4.1 Introduction and context
In the LMC instrument samples of martian rock or regolith will be extracted via liquid
extraction with ultrasonication and the resulting liquid extract, after particle filtration, will be
analysed via a multiplexed microarray immunoassay. The consequence of using liquid
extraction is that in addition to target molecules, other soluble components of the sample
matrix may also be extracted and carried through into the LMC immunoassay. Hence there
is a risk that extracted components of the sample matrix may compromise immunoassay
performance. Since the LMC immunoassay is in an inhibition format there is a risk that
soluble components of the sample matrix might produce non-specific inhibition of signal
which could incorrectly be interpreted as positive detection of a target molecule. Therefore
there is a need to investigate the likely interaction of the martian sample matrix with LMC
format immunoassays.
One of the difficulties associated with attempting to investigate the impact of the martian
sample matrix on the LMC immunoassay is that the only martian samples on Earth are
meteorites, which are available in small quantities and are unlikely to well represent the
current martian environment (McSween et al, 2009). However there is a large body of data
regarding the likely composition of the martian surface which can be used to identify the
types of sample matrix likely to be encountered by the LMC. Some preliminary work, carried
out early in the development of the LMC, tested the performance of a single ELISA format
immunoassay in the presence of a limited selection of Mars relevant sample matrix
components (Wilson 2007). In the period since this work was carried out the LMC instrument
design has evolved, more LMC relevant immunoassays have been developed and additional
data has been reported from the 2008 Phoenix Lander mission, including the detection of
perchlorate salts at high latitudes on Mars (Hecht et al, 2009; Kounaves et al, 2010). The
discovery of perchlorate salts on Mars has implications for the detection of organic
molecules on Mars by the LMC as well as by other non-immunoassay based instruments
due to the ability of perchlorates to degrade organic molecules under high temperature
conditions; this is discussed further in the literature review contained within this chapter.
Therefore the objective of the work in this chapter was to investigate the likely impact of the
martian sample matrix on the LMC format immunoassay in the context of currently available
data regarding Mars and current LMC instrument design, hence identifying potential risks for
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the operation of the LMC instrument and facilitating future investigation of mitigating
strategies for any problematic sample matrix components/types. More broadly this chapter
also has relevance to the development of other immunoassay based instruments for Mars
missions and for environmental analysis in extreme ‘Mars-like’ environments on Earth.
4.2 Chapter objectives
The objective of the work reported in this chapter was to investigate the potential interaction
of martian sample matrix with LMC immunoassays, in order to identify risks for operation of
the LMC instrument with martian samples and to enable the development of mitigation
strategies. In order to meet this goal the following specific objectives were set
1) To test performance of a number of LMC relevant immunoassays in the presence of
likely individual Mars sample matrix extractable components identified from known
Mars geology/geochemistry.
2) To test performance of a number of LMC relevant immunoassays with liquid extracts
from Mars analogue samples, in order to mimic the complex ‘real’ samples that may
be encountered on Mars
3) To demonstrate extraction and detection of organic molecules in the presence of
perchlorate salts using an LMC relevant immunoassay to address immediate
concerns raised by recent Mars findings
It is important to note that in addition to influencing the LMC immunoassay the martian
sample matrix may also have an impact on other elements of the LMC, for example the
extraction efficiency of the MeOH P80 extraction solution and the potential for the evolution
of heat during addition of the extraction solvent to the martian sample. These factors are not
considered within the context of the work reported in this chapter but are part of ongoing
work elsewhere within the LMC consortium. Additionally in Chapter 6 of this thesis the
interactions of martian sample matrix components with the optical and microfluidic aspects of
the flight format LMC are considered.
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4.3 Literature review
4.3.1 The effect of sample matrix on immunoassays
Since immunoassays have not previously been performed with martian samples, there is no
information in the literature specifically regarding the impact of martian sample matrix
components on immunoassays, although there are examples of immunoassay analyses of
martian analogue samples such as the iron rich acidic waters of the Rio Tinto in Spain
(Fernandez-Calvo et al, 2006; Rivas et al, 2008). Aside from these limited examples, the
most relevant information contained within the literature concerns the impact of terrestrial
soil matrixes on immunoassays for analysis of environmental contaminants such as
pesticides, and while a martian sample is likely to differ significantly from a terrestrial
sample, this body of data provides a useful basis for identifying sample matrix
components/types that affect immunoassays.
It is common to find that an immunoassay which functions well with analytical standards will
function less well when tested with the more complex matrixes found in real samples, and
this is one factor which has limited the more widespread use of immunoassays for
environmental monitoring applications despite advantages such as low cost and the potential
for rapid in-situ testing of samples (Glass et al, 2004; González-Martínez et al, 2007). Matrix
effects in immunoassays have been shown to result in signal loss (Kröger et al, 1998),
underestimation of target molecule concentrations (Székács and Hammock 1995),
overestimation of target molecule concentration due to cross reactivity with structurally
related molecules (Kröger et al, 1998), reduced sensitivity (Bjarnason et al, 2001;
Fernandez-Calvo et al, 2006), and variation in measured target molecule concentration
compared to other analysis methods such as HPLC (Mouvet et al, 1997; Gauger et al,
2001). These types of effects have been attributed to factors such as pH, ionic strength, the
absorption of antibodies to insoluble material from the sample matrix, the presence of
chemical compounds in the sample matrix which adversely and non-specifically affect the
affinity of an antibody for an antigen (Krotzky and Zeeh 1995), the organic content of the
sample (e.g. interference by humic acids) (Kröger et al, 1998), and sample interference with
immunoassay detection mechanisms (e.g. fluorescent labels, enzyme substrate reaction
etc.) (Bjarnason et al, 2001).
Therefore, considering the known effects of terrestrial soil matrixes on immunoassays, the
properties of a martian sample that are most likely to affect immunoassay performance when
analysing a liquid extract include soluble salts leading to altered ionic strength, the presence
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of insoluble sub-0.45 µm particulates - i.e. those that will not be removed by commonly
available sample extraction filters, the presence of components which form acidic or basic
solutions, and the presence of components that interfere with the assay detection system
e.g. fluorescence quenchers. The organic content of the martian sample is unlikely to be a
significant concern given that the concentration of organics on Mars is anticipated to be low.
Cross reactivity with related molecules is desirable for the LMC since the instrument aims to
detect related classes of molecules, rather than being limited to the detection of specific
molecules in order to account for likely variations between Earth life and any martian life.
However cross reactivity with unrelated molecules, or molecules which are not markers of
past or present biology is undesirable.
A number of strategies have been developed in order to avoid or reduce the difficulties
associated with sample matrix effects in analysis of environmental samples by
immunoassay. These strategies include sample dilution with water or buffer prior to analysis
and solid phase extraction (Mouvet et al, 1997; Hennion and Barcelo 1998; Kröger et al,
1998; Rigou et al, 2004). If target molecules are present on Mars, they may only be present
at very low levels therefore dilution of the sample is undesirable and solid phase extraction is
not suitable because of the diverse range of targets that the LMC aims to detect, i.e. multiple
solid phases would be required for extraction of the range of chemically diverse LMC target
molecules. Due to the mass and size constraints of the LMC and the need for autonomous
operation, sample processing must be kept to a minimum: However limited measures to
control/reduce the impact of sample matrix mediated effects have been incorporated into the
current (2011) design of the LMC e.g. to remove particulates liquid extracts will be filtered
through a 0.45 µm filter prior to analysis and buffer salts are included in the freeze drying
cocktail that is freeze dried with the antibodies (Section 2.2.2), offering some level of control
over pH; but other issues relating to the Mars sample matrix have not yet been considered in
detail. For example the LMC instrument uses a fluorescent readout therefore the presence of
fluorescence quenchers in the martian sample may be detrimental to the immunoassay.
In the field of environmental monitoring, changes in immunoassay performance such as
those described here are considered significant due to the level of precision required in order
to meet with legislative requirements (Krotzky and Zeeh 1995). However the LMC is
intended to give an indication of whether classes of target molecules are present on Mars
above a certain detection threshold and some level of compromise regarding the
performance of the instrument in the martian sample matrix is acceptable and inevitable,
given the constraints on sample processing. It is essential that any ambiguity over
immunoassay results which appear to indicate the presence of a target molecule, but could
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also be due to non-specific interference by components of the sample matrix, is avoided.
Therefore it is important that the potential effects of sample matrix are well characterised.
One of the advantages of the multiplexed microarray format of the LMC immunoassay is that
control assays can be run directly alongside target molecule detection assays in the same
sample matrix (Fernandez-Calvo et al, 2006) hence reducing the risk of “false positive”
results.
4.3.2 Mars sample matrix and likely interactions with the LMC
immunoassay
Within this section of the literature review, general information regarding the likely geology of
martian samples is considered and Mars relevant analogue sites on Earth are identified as
potential sources for analogue samples within this study (Section 4.3.2.1). The review then
goes on to specifically consider individual components/properties of Mars samples that are
likely to interact with immunoassays (Sections 4.3.2.2- 4.3.2.7).
4.3.2.1 Mars geology/geochemistry
Since 1965 more than fifteen spacecraft have operated successfully on or near Mars
(Jakosky et al, 2007) gathering data regarding the geology of Mars via remote sensing and
in-situ measurements made at a number of locations on the martian surface. However it
should be noted that all in-situ analyses of martian rocks and regolith to date have been
restricted to samples collected from the martian surface and immediate subsurface
(maximum depth of a few centimeters), whereas the ExoMars rover will collect samples from
a maximum depth of 2 meters below the martian surface.
Data from instrumentation onboard orbitors, landers and rovers has shown that the martian
crust is dominated by basaltic rock (McSween et al, 2009; Rossi and Gasselt 2010) with
localised concentrations of phyllosilicates, hydrated sulphates (including gypsum, jarosite
and kieserite), carbonates and ferric oxides including haematite (Gendrin et al, 2005;
Langevin et al, 2005; Poulet et al, 2005; Bibring et al, 2006; Boynton et al, 2009; Palomba et
al, 2009). Above the martian crust is a layer of regolith – dust and soils formed by physical
weathering of martian rocks. The composition of martian regolith at several different sites
and has been shown to be chemically similar, indicating that martian regolith is
homogeneous on a global scale and is likely mixed and distributed by impact events and
storms (Rieder et al, 1997; Wanke et al, 2001; Yen et al, 2005).
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Data from the OMEGA imaging spectrometer on Mars Express has suggested that Mars’s
geological and climatic history can be split into three distinct eras: (Bibring et al, 2006).
During Mars’s early ‘phyllocial’ era Mars had an active hydrological system where rocks such
as phylosilicates were formed in water rich alkaline environments (Poulet et al, 2005), this
was followed by the ‘theiikian’ era of extensive volcanism leading to the release of sulphur
dioxide creating an acidic environment in which sulphates such as jarosite and kieserite
were formed and finally the ‘siderikian’ era dominated by the non-aqueous oxidation of iron
bearing rocks and minerals.
The landing site for the 2018 NASA/ESA ExoMars Rover mission has not yet been selected,
but the criteria used for selection will be similar to those for NASA’s 2011 Mars Science
Laboratory Mission which were based on a combination of engineering requirements, e.g.
landing site slope, elevation, roughness etc., and science requirements, e.g. indication of
past/present habitability and potential for preservation of markers of extinct life (Grant et al,
2011). Areas on Mars with phylosilicates are likely to be high priority targets due to the
evidence of long standing bodies of water and the potential preservation properties of clay
minerals (Oroﬁno et al, 2010), although recent analysis has suggested that these clays may
have been formed by hydrothermal ground water circulation and that water was only ever
transient on the martian surface (Ehlmann et al, 2011b). Data from OMEGA has revealed a
large diversity in the composition of the martian surface at small spatial scales (< 1km)
(Bibring et al, 2005) therefore there are likely to be a number of different geologies within
reach of a single rover landing site.
There are a number of sites on Earth with geological or environmental conditions similar to
those on Mars which have been used as Mars analogues for scientific studies and for field
testing of planetary exploration instruments. These environments include (but are not limited
to) Iceland with its active volcanism, poorly formed soils, basaltic bedrock and sparse
surface water, the cold and arid Antarctic dry valleys (Léveillé 2009), the acidic iron and
sulphate rich Rio Tinto basin in Spain (González-Toril et al, 2003), the 24 km Haughton
Impact Crater on Devon Island, Northern Canada, with its impact induced hydrothermal
deposits (Lindgren et al, 2009) and the Atacama desert in Chile with its extreme aridity and
oxidising soils (for a comprehensive review please see Léviellé (2009)). Access to samples
collected from these analogue sites will allow assessment of LMC immunoassay
performance using complex real samples with Mars relevant geologies.
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4.3.2.2 Ionic strength of the martian sample matrix
The salt content of martian samples is relevant for the LMC because immunoassays are
sensitive to ionic strength, although only salts that are soluble in the LMC extraction solvent
will be carried though into the immunoassay. Martian regolith has relatively high salt content
(8-25 wt %) thought to be composed primarily of a mixture of sulphates (magnesium,
calcium and iron), chlorides (magnesium or sodium chlorides) and carbonates (Toulmin et al,
1977; Clark and Hart 1981; Wanke et al, 2001; Wang et al, 2006; Yen et al, 2006) although
the solution chemistry of these salts in martian samples has not been extensively studied.
Experiments carried out at high latitudes by the Wet Chemistry Laboratory (WCL) on the
2008 NASA Phoenix Lander, to investigate the solution chemistry of martian regolith,
showed that 1:25 (v/v) extraction of regolith samples with water produced solutions which
contained approximately 10 mM dissolved salts dominated by Na+, Mg2+ and ClO4-, with
smaller contributions from Ca2+, K+, Cl-, CO3H- and possibly SO42- (Hecht et al, 2009).
4.3.2.3 pH of the martian sample matrix
In addition to measuring the concentration of soluble ions in martian regolith, WCL on
Phoenix also performed measurements of the pH of water soluble components of martian
regolith. The pH of a 1:25 (v/v) mixture of martian regolith and water was 7.7 ± 0.5 (Hecht et
al, 2009) which is within the range at which immunoassays normally function. However some
of the salts that have been observed on Mars, such as iron (III) sulphates, form acidic
solutions and it is likely that the results from the WCL may not be representative of all
locations on the martian surface. The pH of the LMC immunoassay is controlled though the
inclusion of buffer salts in the freeze drying cocktail that is freeze dried into the glass fibre
pads (please see Section 2.2.2), therefore the addition of small quantities of acidic or basic
components will not result in large changes in pH. However highly acidic or basic liquid
extracts are likely to have an impact on immunoassay performance. In addition to this the
emission spectra of fluorophores can be affected by changes in pH, although the Alexa
Fluor® dyes, including the selected dye for the LMC, do show better tolerance to changes in
pH than many other fluorophores (Johnson and Spence 2011).
4.3.2.4 Fluorescence quenchers in the martian sample matrix
Fluorescence quenchers are species that are capable of accepting energy from excited state
fluorophores, reducing the emission of photons from excited state fluorophores hence
reducing fluorescence (Atkins and de-Paula 2002). Quenching of fluorescence can occur via
three main mechanisms, collisional deactivation; energy transfer; and electron transfer. Any
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soluble components of the martian sample capable of accepting energy from excited state
AF633 molecules by any of the three mechanisms described above may reduce the
fluorescent signal produced by the LMC instruments. Obvious candidates for fluorescent
quenching in the martian sample include iron (III) ions, which are known to act as
fluorescence quenchers (Lytton et al, 1992).
4.3.2.5 Oxidising agents in the martian sample matrix
The 1970s Viking Landers carried a set of life detection experiments designed to look for
evidence of metabolism in martian samples but results of the experiments were inconsistent
with a biological basis and instead indicated that the martian regolith was chemically
reactive, containing one or more oxidising agents capable of degrading organic molecules
(Klein 1978; Zent and McKay 1994; Quinn and Zent 1996; Tsapin et al, 2000; Hurowitz et al,
2007; Davila et al, 2008). This conclusion was supported by the failure of the Viking GC-MS,
and the more recent Thermal and Evolved Gas Analyser (TEGA) instrument onboard the
Phoenix Lander, to detect any organic molecules in martian samples, despite their known
continuing delivery to the martian surface by meteorites independently of any past or present
biology on Mars (ten-Kate 2010). Many species were proposed as candidates for the martian
oxidant including hydrogen peroxide (Levin and Straat 1977), hydrogen peroxide complexed
with surface minerals (Quinn and Zent 1996) and iron (VI) (Tsapin et al, 2000). The
presence of oxidising agents on Mars is of significance for the LMC, not only because they
may interact with immunoassay reagents, but also because the presence of oxidising agents
has implications for the survival of organic molecules, both on the martian surface, and
during any attempts to extract target molecules from martian rocks/regolith.
In 2008 The Wet Chemistry Laboratory (WCL) on NASA’s Phoenix Lander detected the
presence of 0.4-0.6 wt % perchlorate in samples of martian regolith (Hecht et al, 2009).
Perchlorate salts are oxidizing, but metastable, unless initiated by mechanical action,
heating, or electric shock (Shriver and Atkins 1999), and therefore they are not expected to
destroy organic molecules under martian conditions. Navarro-González et al (2010),
however, demonstrated that when organic carbon containing Mars like soils from the
Atacama Desert were mixed with one weight percent magnesium perchlorate and heated,
the organics present were decomposed. All previous attempts to detect organic molecules
on Mars, for example by the GC-MS instrument on the Viking Landers and by Phoenix’s
Thermal and Evolved Gas Analyser (TEGA), have relied on pyrolysis to volatize organics
present in collected samples. In the Viking experiments, samples were heated to 200, 350,
and 500°C (Anderson et al, 1972), and TEGA progressively heated samples up to a
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temperature of 1000°C (Hoffman et al, 2008). Heating to these temperatures in the presence
of perchlorates may have destroyed the very molecules that the Viking GC-MS and TEGA
were trying to detect.
The LMC’s use of a low temperature (>0°C, <<+100°C, nominally +20°C) liquid extraction
may offer an advantage over other instruments in the analysis of perchlorate containing
samples because perchlorate salts are not expected to act as oxidants under these
conditions. MOMA, the other instrument on the ExoMars rover payload capable of detection
of trace organics, is a compact, low power ion trap mass spectrometer with the capability to
extract organics from martian rock and regolith samples by two different methods: pyrolysis
and laser desorption (Evans-Nguyen et al, 2008). Extraction by pyrolysis will involve
evaporation of volatile organics in the martian sample by heating to high temperatures
followed by injection into a GC column with an electron ionization source. Exposure of the
martian sample to high temperatures could result in perchlorate mediated degradation,
although recently it has been proposed to integrate the use of derivitisation reagents to
increase the volatility of some organics in order to reduce the required temperature
(Eigenbrode et al, 2011). In extraction by laser desorption, the regolith sample will be pulsed
with a high power UV laser to liberate ions (ESA 2011a); it is unknown whether this
technique will be affected by the presence of perchlorates.
The LMC low temperature extraction method may be beneficial in terms of preventing
perchlorate mediated degradation of organic molecules, however, perchlorates are highly
water soluble and therefore expected to dissolve in the LMC extraction solvent and be
carried through into the LMC analysis system where the perchlorates could interact with
immunoassay reagents via changes in parameters such as pH and ionic strength. Within the
immunoassay literature, there appear to be no examples that demonstrate detection of small
organic molecules by immunoassay in the presence of perchlorate salts, although there is
one recently published study that describes no significant effect of 50 mM perchlorate on the
antibody-antigen reaction by sandwich-type antibody microarray fluorescent immunoassays
(Parro et al, 2011).
4.3.2.6 Particle size of the martian sample matrix
The immunoassay literature has demonstrated that the presence of particulates in sample
matrixes can affect immunoassay performance due to absorption of antibodies. The drill on
the ExoMars rover will collect a core of rock or regolith (approx 1 cm diameter x 3 cm length)
which will then be crushed by a crushing station and distributed to the individual instruments
onboard the rover (ESA 2011c). The size distribution of the crushed sample is likely to
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depend heavily on the sample matrix type. In the LMC instrument the sample will be subject
to liquid extraction and then filtered through a 0.45 µm filter. Therefore sub-0.45 µm
particulates may pass into the microfluidic channel where they could cause blockages or
interfere with the immunoassay. In addition to this there is also a risk that precipitation of
solutes may occur within the microfluidic channel, post filtration. For example work carried
out early in LMC development showed that a red precipitate formed when iron (II) sulphate
was dissolved in HEPES buffer and allowed to incubate for an hour (Wilson 2007).
4.3.2.7 Other components/properties of the martian sample matrix that may interact
with immunoassays
In addition to the components whose presence on Mars can be anticipated due to data from
previous missions, there is an unavoidable risk that martian samples collected by the
ExoMars rover may contain unexpected/unknown components which may interact with
immunoassays, particularly given the lack of analysis performed previously with samples
collected from below the martian surface. However there is little that can be done in advance
of the mission to prepare for this eventuality, apart from the inclusion of positive control
immunoassays to enable discrimination between non-specific matrix mediated signal
reduction and specific inhibition due to the presence of target molecules.
4.3.3 Literature review conclusions
Previous studies have demonstrated that immunoassay performance is affected when
immunoassays are performed with real samples compared to with buffers and that changes
are mediated by factors such as the pH and ionic strength of the sample matrix. Data
regarding the geology and geochemistry of Mars indicates that there are a wide range of
geochemistries/geochemical environments which may be encountered by the LMC,
depending on the selected landing site. Review of the available data regarding Mars and
regarding sample matrix effects in immunoassays used for terrestrial environmental analysis
allows the prediction of Mars sample components that are likely to interact with
immunoassays i.e. soluble salts leading to altered ionic strength, the presence of species
that form acidic or basic solutions, and oxidising agents. Therefore this allows the proposal
of experiments to investigate the influence of the Mars sample matrix on immunoassays in
order to determine which sample types might be problematic for the LMC and is the subject
of the following section.
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4.4 Structure of the work
The work in this chapter has three specific objectives; these three objectives have been
addressed by three discrete pieces of work which are reported as three separate studies
within this chapter (Sections 4.5, 4.6 and 4.7). The first study describes work carried out to
investigate the impact of likely components of the Mars sample matrix on immunoassays. As
a fundamental part of this study the effects of sample matrix components on the HRP
enzyme label used in ELISA format, and the fluorescent AF633 label used in microarray
format are also investigated independently of the immunoassays. The second study
investigates the impact of liquid extracts from Mars analogue samples on immunoassays to
mimic the complex nature of real martian samples. The third study extends work carried out
to investigate the impact of perchlorate salts on immunoassays by addressing the combined
impact of perchlorate salts on LMC relevant extraction and detection. Within the following
three sections (Sections 4.5 – 4.7), the experimental design for each study and materials
and methods supplementary to those in Chapter 2 are described, and results of each study
are reported and discussed. The final section of this chapter (Section 4.8) summarises the
work and makes recommendations based on the findings of the three studies.
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4.5 Study 1: Testing the impact of individual likely Mars sample
matrix components on LMC relevant immunoassays
Sample matrix components present in martian rocks and regolith and that are soluble in the
LMC extraction solvent may interact with immunoassays, influencing instrument
performance. The literature review in Section 4.3 of this thesis, revealed that martian regolith
has relatively high (8-25 %) salt content (Toulmin et al, 1977; Clark and Hart 1981; Wanke et
al, 2001; Wang et al, 2006; Yen et al, 2006) and contains one or more oxidising agents. This
objective of this study is to test the compatibility of likely Mars sample matrix components,
such as salts and oxidising agents, with immunoassays in LMC relevant formats in order to:
(i) Determine whether the LMC is likely to function with martian samples
(ii) Identify Mars relevant sample matrix components that are incompatible with
immunoassays
(iii) Identify development opportunities to improve LMC performance in the
presence of likely Mars sample matrix components
4.5.1 Supplementary experimental design
The design adopted for this study aligns with the common experimental design described in
Chapter 2 of this thesis: The set of model immunoassays described in Chapter 2, were used
to assess the likely performance of LMC immunoassays with Mars relevant sample
components. Note that within this study only four of the seven model immunoassays
described in Chapter 2 were used (atrazine; benzo[a]pyrene, cAMP and fluorescein). The
GroEL, LTA and LPS model immunoassays were excluded from this study, mainly due to
time constraints, but their exclusion was also influenced by performance of the model
immunoassays in the proposed LMC extraction solvent and also due to some of the
antibodies being unavailable from the manufacturer at the time of the work.
Initial assessment of immunoassay performance was carried out using the LMC
representative ELISA format (please see Section 2.2.2) to assess the impact of a diverse
range of Mars relevant sample matrix components on immunoassay binding signal, at a
variety of concentrations. Further studies were then carried out in pooled microarray format
(please see Section 2.2.3) to confirm whether behaviour in the more flight representative
microarray format was similar to that observed in ELISA format. Finally an extended study of
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immunoassay sensitivity was carried out, on a limited set of sample matrix components in
ELISA format.
4.5.1.1 Selection of likely Mars sample matrix components
There are many potential geologies/geochemistries, and hence sample matrix components,
that may be encountered on Mars, depending on the landing site selected for the ExoMars
rover. Within this study a broad range of soluble Mars relevant sample matrix components,
including acidic, basic, neutral and iron (II) and (III) containing Mars relevant salts as well as
perchlorate and hydrogen peroxide oxidising agents (see Table 4-1 for complete list) were
tested. Components such as iron oxides, which have been reported on Mars (Bibring et al,
2006) but are insoluble in aqueous solutions, were not tested as individual sample matrix
components, but were tested indirectly as components of some of the analogue samples
which were extracted to produce liquid extracts for the second study in this chapter of work
(please see Section 4.6).
Table 4-1: Mars relevant sample matrix components tested for impact on LMC relevant
immunoassays
Sample matrix component Molecular weight(g mol-1)
Ionic strength of 100 mM
solution (mol dm-3)
Magnesium sulphate 120.4 0.4
Sodium sulphate 142.0 0.3
Sodium chloride 58.4 0.1
Sodium carbonate 105.9 0.3
Iron (III) chloride 162.2 0.6
Magnesium perchlorate 223.2 0.3
Calcium perchlorate 237.9 0.3
Iron (II) perchlorate 254.8 0.3
Iron (III) perchlorate 354.2 0.6
Potassium chloride 74.5 0.1
Iron (II) sulphate 151.9 0.4
Iron (III) sulphate 399.9 1.5
Hydrogen peroxide 34.0 N/A
4.5.1.2 Concentration of sample matrix components tested
Although there is data concerning the abundances of various components, including salts, in
martian regolith, there is limited information regarding the solution chemistry of the martian
regolith. The approach adopted for this study was to test sample matrix components at a
range of concentrations to an upper limit in excess of the highest reported concentration on
Mars.
Phoenix’s WCL made the first measurements of the solution chemistry of martian regolith
and found that when 1 cm3 of regolith sampled from Phoenix’s landing site was mixed 1:25
with water the resulting solution contained approximately 10mM of dissolved salt, which,
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assuming a regolith density of 1g/cm3 equates to 0.25 mmol of soluble salt in the sample
(Hecht et al, 2009). Taking the same sample and performing an LMC relevant extraction with
3 ml of solvent (assuming a regolith density of 1g/cm3) would produce a solution with a
maximum salt concentration of 83 mM. Mars Exploration Rover (MER) AXPS analyses have
been carried out at a number of sites within the Gusev Crater and the wall of the Burough’s
trench was found to contain approximately 16 weight percent sulphates, which were mainly
magnesium sulphate (Yen et al, 2005) but the solution chemistry of these samples was not
determined.
Within this study the selected sample matrix components were tested at concentrations of 10
mM, 100 mM and 500 mM. The upper limit for this study (500 mM) was selected by
calculation of the maximum salt concentration if 1 g of sample with 25 weight percent
kieserite (in excess of the highest salt concentrations detected by MER) was subject to an
LMC extraction with 3 ml of solvent, and all of the kieserite was soluble.
4.5.2 Supplementary materials and methods
Note that the majority of materials and methods for the work within this study are the same
as those used throughout the other chapters of this thesis and are described within Chapter
2. This section contains supplementary materials and methods specific to the work carried
out in this study and where appropriate, cross references the relevant sections of Chapter 2.
4.5.2.1 Preparation of stock solutions of sample matrix components
A 1M stock solution of each sample matrix component was prepared in MeOH P80. Details
of each of the sample matrix components used are given in Table 4-2. In the case of
components that did not dissolve readily at 1M concentration ultrasonic energy was applied
to aid dissolution. Components that would not dissolve at 1M concentration, post
ultrasonication, were used as a saturated solution and are indicated with “*” in Table 4-2.
Where the hydration state of a sample matrix component was unknown, for example for iron
(III) sulphate, calculations were based on a hexahydrated complex.
4.5.2.2 ELISA and microarray immunoassays
Stock solutions of sample matrix components were added into ELISA and pooled microarray
format assays, maintaining a final concentration of 20/80 % (v/v) methanol water 1.5 g/L P80
following the procedures described in Section 2.2.2 and Section 2.2.3. Iron (II) sulphate
stock solutions were freshly prepared for each immunoassay since oxidation to iron (III)
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sulphate was observed (as evidenced by colour change from green to red) upon prolonged
storage.
Table 4-2: Hydration state, supplier and product codes of sample matrix components used in
ELISA and microarray experiments
Sample matrix
component
Hydration
state Supplier
Product
code
Magnesium sulphate .7H2O VWR, Lutterworth, UK 101514Y
Sodium sulphate* anhydrous Sigma-Aldrich, Poole, UK S67795
Sodium chloride anhydrous Fisher Scientific, Loughborough, UK BP358-1
Sodium carbonate* anhydrous Sigma-Aldrich, Poole, UK S7795
Iron (III) chloride .6H2O Sigma-Aldrich, Poole, UK F-2877
Magnesium perchlorate .6H2O Sigma-Aldrich, Poole, UK 309303
Calcium perchlorate .4H2O Sigma-Aldrich, Poole, UK 401420
Iron (II) perchlorate .xH2O Sigma-Aldrich, Poole, UK 334081
Iron (III) perchlorate .xH2O Sigma-Aldrich, Poole, UK 326348
Potassium chloride anhydrous Sigma-Aldrich, Poole, UK P4504
Iron (II) sulphate .7H2O Sigma-Aldrich, Poole, UK 21, 542-2
Iron (III) sulphate .xH2O Riedel-de-Haën (Sigma-Aldrich), Poole, UK 12357
Hydrogen peroxide N/A Sigma-Aldrich, Poole, UK 216763
4.5.3 Results and discussion
4.5.3.1 Initial studies of immunoassay performance in all sample matrix components
using ELISA binding signal as performance indicator
Confirmation of impact of Mars relevant sample matrix components on enzyme label
The LMC format ELISA uses enzyme labels to measure the quantity of antibody bound to
immobilised target molecule via an enzyme-substrate reaction to generate a coloured
product, whereas the flight format microarray immunoassay uses fluorescent labels.
Therefore changes in ELISA signal due to altered activity of the enzyme label are not directly
relevant to the flight format assay. In order to enable discrimination between changes in
ELISA signal due to the enzyme and changes due to altered antibody performance, the
signal produced by HRP enzyme after exposure to each sample matrix component was
assessed independently of the immunoassays following the method described in Chapter 2
(Section 2.2.2.1). Figure 4-1 shows the normalised background corrected signal generated
by immobilised HRP label, upon addition of TMB substrate, following exposure to the full
range of Mars relevant sample matrix components.
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Figure 4-1: Normalised background corrected ELISA signal for immobilised HRP enzyme
after incubation in MeOH P80 and freeze drying cocktail containing martian relevant salts at
10 mM, 100 mM and 500 mM concentration.
Background corrected signals normalised against background corrected signal after
incubation with MeOH P80 and freeze drying cocktail only. Error bars = ± standard error,
n=2
Although signal produced by immobilised HRP enzyme did vary after exposure to Mars
relevant sample matrix components, for the majority of the components tested the variations
were small (subjectively assumed as < ± 20 %) (Figure 4-1). Changes in enzyme activity of
this magnitude are unlikely to mask any significant changes in the performance of antibodies
after exposure to sample matrix components, thus validating the use of the ELISA format to
investigate the effect of sample matrix components on LMC immunoassays. However iron
ion containing components and hydrogen peroxide, which has previously been shown to
deactivate HRP enzyme at high concentrations (Weinryb 1966), did have a significant impact
on signal generated by the HRP enzyme particularly at concentrations of 100 mM and
above. The consequence of this observation is that in ELISA format changes in binding
signal due to altered antibody performance may be difficult to discern from changes in
binding signal resulting from altered enzyme activity following exposure to hydrogen
peroxide and iron ion containing sample matrix components. Therefore results must be
interpreted with care for these components.
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Impact of Mars relevant sample matrix components on binding signal in LMC relevant ELISA
format
LMC format ELISAs for atrazine, benzo[a]pyrene, cAMP and fluorescein were performed in
the presence of 10 mM, 100 mM and 500 mM of each Mars relevant sample matrix
component. Binding signals were background corrected and normalised against binding
signal with 0 mM sample matrix component to facilitate comparison of the data for multiple
immunoassays and plotted in Figure 4-2, Figure 4-3, Figure 4-4 and Figure 4-7. The
absolute values of binding signal, and non-specific background signal, are contained within
Appendix B1.
Figure 4-2: Normalised background corrected ELISA binding signal for atrazine
immunoassay run in MeOH P80 with martian relevant sample matrix components at
concentrations of 10, 100 and 500 mM.
Binding signals normalised against binding signal with no sample matrix component. Error
bars = ± standard error, n = 2
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Figure 4-3: Normalised background corrected ELISA binding signal for cAMP immunoassay
run in MeOH P80 with martian relevant sample matrix components at concentrations of 10,
100 and 500 mM.
Binding signals normalised against binding signal with no sample matrix component. Error
bars = ± standard error, n = 2
Figure 4-4: Normalised background corrected ELISA binding signal for fluorescein
immunoassay run in MeOH P80 with martian relevant sample matrix components at
concentrations of 10, 100 and 500 mM.
Binding signals normalised against binding signal with no sample matrix component. Error
bars = ± standard error, n = 2
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Figure 4-5: Normalised background corrected ELISA binding signal for benzo[a]pyrene
immunoassay run in MeOH P80 with martian relevant sample matrix components at
concentrations of 10, 100 and 500 mM.
Binding signals normalised against binding signal with no sample matrix component. Error
bars = ± standard error, n = 2
ELISA binding signal for the four tested immunoassays varied across the range of sample
matrix components tested and in general higher concentrations of sample matrix
components had greater impact on ELISA binding signal. The atrazine, cAMP and
fluorescein immunoassays showed similar performance to one another with the range of
tested sample matrix components, although there were some subtle differences – for
example the atrazine immunoassay was less sensitive to the addition of iron (II) sulphate
than the cAMP and fluorescein immunoassays. The benzo[a]pyrene immunoassay
demonstrated greater loss of binding signal upon addition of salts compared to the other
three immunoassays tested, although the general trends observed were the same for all four
immunoassays. The implication is that the 22F12 mouse anti benzo[a]pyrene clone is
particularly sensitive to the addition of salts (note that the benzo[a]pyrene immunoassay
uses the same anti-mouse secondary antibody as the cAMP assay, which was much less
sensitive to the addition of salts and therefore the signal loss in the benzo[a]pyrene assay
can be attributed to the 22F12 primary antibody). Antibodies, like the 22F12 clone, with this
level of sensitivity to the addition of Mars relevant sample matrix components are not
suitable for inclusion in the LMC flight instrument.
The sample matrix components tested can be grouped according to the lowest concentration
at which they had a significant effect on ELISA binding signal (Table 4-3). Note that most
sample matrix components tested had a significant effect on the benzo[a]pyrene assay at
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lower concentrations than those stated in the table, but that this assay was felt to be an
outlier in terms of its performance.
Table 4-3: Table grouping tested sample matrix components according to the lowest
concentration for a given matrix component where significant signal loss (more than 20%)
was observed
Concentration of sample matrix component at which ELISA binding signal was reduced by
> 20 %
10 mM 100 mM 500 mM > 500 mM
Fe(III)Cl3
Fe(II)(ClO4)2
Fe(III)2(ClO4)6
Fe(II)SO4
Fe(III)2(SO4)3
Ca(ClO4)2
Mg(ClO4)2
Na2CO3
MgSO4
Na2SO4
NaCl
H2O2
KCl
The Mars relevant sample matrix components that reduced signal by a significant amount at
10 mM concentration were all iron ion containing salts. Iron ion containing components also
had a significant impact on HRP enzyme activity; therefore care is required in the
interpretation of these results. However when the HRP enzyme label was tested
independently of the immunoassays (Figure 4-1) iron ion containing salts significantly
reduced signal produced by the enzyme at concentrations of 100 mM and above, whereas
concentrations of 10 mM significantly reduced ELISA binding signal. In most cases 10 mM
iron ions reduced ELISA binding signal to a level where it was not distinguishable above
background. This indicates that iron ion containing salts have a significant impact on
antibody function, as well as on the enzyme label in LMC format ELISAs. Therefore martian
samples with low levels of extractable iron salts may be problematic for the antibody based
assays in the LMC.
The mechanism for the loss of binding signal at low concentrations of iron ion containing
solutions cannot be wholly attributed to increased ionic strength, because a 10 mM solution
of iron (II) sulphate, which produces a significant reduction in binding signal, has the same
ionic strength (assuming an ideal solution) as a 10 mM solution of magnesium sulphate
(Table 4-1), which does not produce a significant reduction in binding signal. Therefore it is
likely that some of the signal loss is caused by a specific property of iron ion containing
solutions, one possibility is that the buffering capacity of the LMC freeze drying buffer is
insufficient to control the pH of the solution upon addition of iron ions.
Iron (II) ion containing sample matrix components produced an increase in non-specific
binding (Appendix B Table B4 and Table B11Table ) and the formation of precipitates were
observed in ELISA wells containing iron (II) ions. These precipitates may account for the
observed high background signals, resulting from non-specific adsorption of labelled
antibodies to the particulates, which were then not all removed from the wells by washing.
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Perchlorates and sodium carbonate at concentrations of 100 mM and greater had a
significant impact on ELISA binding signal and at 500 mM the majority of the immunoassays
tested were rendered non-functional. The effect of these components is unlikely to be purely
related to ionic strength, for example solutions of magnesium and calcium perchlorate have
lower ionic strength than equimolar solutions of magnesium sulphate (Table 4-1) (assuming
ideal solutions) but magnesium sulphate did not produce similar reductions in signal.
Perchlorate salts and sodium carbonate had little impact on the enzyme label (Figure 4-1);
therefore it is likely that the observed signal loss is entirely due to changes in the
immunological interactions. If an LMC extraction was performed on samples similar to those
detected by Phoenix, which contained 0.4 – 0.6 wt % perchlorates (Hecht et al, 2009) the
maximum extracted perchlorate concentration fed through into the immunoassay would be
17 mM (assuming extraction of 1 g regolith contsining 1 % wt perchlorate with 3 ml of
extraction solvent) and the data from this experiment indicates that immunoassays do
function in a concentration of up to 100 mM perchlorate salts. It should be noted that calcium
perchlorate increased non-specific background signal (Appendix B Table B2) whereas
magnesium perchlorate did not (Appendix B Table B1), suggesting that these two
compounds, which differ only by cation, are interacting differently with the immunoassays.
The components that had the least effect on the immunoassays were sodium chloride,
sodium sulphate, magnesium sulphate, potassium chloride and hydrogen peroxide. For
hydrogen peroxide, the changes observed in immunoassay signal were similar in magnitude
to the changes observed when the HRP enzyme was tested independently of the
immunoassay, suggesting that the majority of the observed signal losses were attributable to
exposure of the enzyme to hydrogen peroxide.
In summary, immunoassay binding signal can successfully be generated after exposure to
Mars relevant sample matrix components at concentrations of 100 mM, and in some cases
after exposure to concentrations of up to 500 mM. However concentrations of 10 mM and
above iron ion containing sample matrix components have a particularly detrimental impact
on binding signal. Signal loss may be occurring due to changes in antibody performance,
caused by increased ionic strength and altered pH, and also due to loss of immobilised
target molecules from 96-well plate surfaces. Two aspects, control of pH; and stability of
conjugate immobilisation, are further investigated in the following two sections.
89
Further experiment to investigate buffering capacity of freeze drying buffer
In order to determine whether the buffering capacity in the LMC immunoassay, which is
provided by the buffer salts contained within the freeze drying buffer (Section 2.2.2) is
sufficient to control immunoassay pH upon addition of Mars relevant sample matrix
components, the pH of solutions of freeze drying buffer made up in MeOH P80 was
measured after the addition of a range of sample matrix components.
The pH of the solution was unaffected for the majority of sample matrix components tested
(Figure 4-6). However a sub-set of the components, including all of the iron-ion containing
salts, did produce changes in pH. Solutions of sodium carbonate at concentrations above 10
mM in the LMC solvent and freeze drying buffer were basic, with a 500 mM solution giving a
pH of approximately 10, whereas solutions of sample matrix components containing iron
ions were acidic.
Figure 4-6: pH of sample matrix components diluted in LMC extraction solvent and freeze
drying buffer
Iron (III) sulphate produced the largest change in pH with a 10 mM solution giving a pH of
5.0 and a 500 mM solution giving a pH of 1.0. These changes in pH may account for the
changes in both enzyme activity and antibody performance in the presence of these sample
matrix components and it is possible that immunoassay performance could be improved by
increasing the buffering capacity of the freeze drying cocktail.
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Further experiment to determine whether sample matrix components effect immobilisation
stability or antibody function
In an attempt to better understand the interaction of Mars relevant sample matrix
components with immunoassays, specifically to separately test (i) interaction of Mars
relevant sample matrix with immobilised target molecules and (ii) interaction of Mars relevant
sample matrix with antibodies in solution, an experiment was performed where conjugates
and antibodies for two immunoassays (benzo[a]pyrene and cAMP) were separately
incubated with a sub-set of Mars relevant salts (sodium chloride, iron (III) chloride,
magnesium perchlorate and iron (III) perchlorate). For both immunoassays 96-well plates
were coated with target-molecule protein conjugate and then blocked with BSA. Half of the
coated and blocked wells were then incubated with buffer and the other half were incubated
with 100 mM salt in buffer for one hour. Antibodies were diluted in LMC extraction solvent
and freeze drying buffer. Half of the antibody solution was incubated with 100 mM salt, the
other half with 0 mM salt. The pre-incubated antibody solutions were then transferred to the
coated and blocked ELISA plates such that there were four separate sets of conditions as
illustrated in Table 4-4.
Table 4-4: Details of experiment to determine impact of salt on immobilised conjugates and
on antibodies in solution
Condition Conjugate incubation Antibody incubation
1 0 mM salt 0 mM salt
2 100 mM salt 0 mM salt
3 0 mM salt 100 mM salt
4 100 mM salt 100 mM salt
The plotted background corrected binding signals for the cAMP and the benzo[a]pyrene
immunoassays are shown in Figure 4-7. Binding signal in the cAMP immunoassay was
unaffected by incubation of sodium chloride, a salt that produces a pH neutral solution in the
LMC extraction solvent and freeze drying buffer, with the immobilised cAMP-BSA conjugate
or with the cAMP assay antibodies, and with combinations of both (Graph A in Figure 4-7).
This implies that immobilisation of the cAMP-BSA conjugate is stable in the presence of 100
mM NaCl and that the antibodies (and the HRP enzyme label) for the cAMP immunoassay
are also unaffected by incubation in the presence of 100 mM sodium chloride. Binding signal
in the benzo[a]pyrene immunoassay was unaffected by incubation of the immobilised B[a]P-
BSA conjugate, implying that immobilisation of the benzo[a]pyrene conjugate is stable in the
presence of 100 mM sodium chloride (incubation condition 2), but binding signal was
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reduced where 100 mM sodium chloride was incubated with the antibodies (condition 3).
This observation is in agreement with previous results where the 22F12 clone was shown to
be more sensitive to changes in ionic strength than other tested antibodies.
Binding signal in the cAMP and B[a]P immunoassays was also unaffected by the incubation
of 100 mM magnesium perchlorate with immobilised conjugates (condition 2) (Graph C in
Figure 4-7), indicating that immobilised conjugates were stable to the presence of 100 mM
magnesium perchlorate. However addition of 100 mM magnesium perchlorate to the
antibodies (condition 3) and to both the antibodies and the immobilised conjugate (condition
4) did produce a reduction in binding signal, which was greater for the benzo[a]pyrene
immunoassay than for the cAMP immunoassay. This indicates that the loss in binding signal
observed for the cAMP and B[a]P immunoassays in the presence of 100 mM magnesium
perchlorate is due to changes in antibody performance and also supports the previous
observation that the B[a]P immunoassay is more sensitive to the addition of salts, that the
cAMP immunoassay.
For both the cAMP and B[a]P immunoassays incubation of immobilised conjugate with 100
mM iron (III) chloride, a salt which produces acidic solutions in the LMC solvent and freeze
drying buffer, (condition 2) produced a significant reduction in binding signal (Graph B in
Figure 4-7). This indicates that immobilisation of both cAMP-BSA and B[a]P-BSA conjugates
is unstable to 100 mM iron (III) chloride, assuming that the washing procedure was sufficient
to remove all traces of iron (III) chloride prior to addition of the antibodies to the 96-well
plate. Incubation of iron (III) chloride with the antibodies (condition 3) and with both the
antibodies and the conjugate (condition 4) produced a further reduction in binding signal.
Note that as shown by the data in Figure 4-1, 100 mM iron (III) chloride has a significant
impact on the HRP enzyme label independently of the immunoassay therefore it is not
possible to determine whether the enzyme or the antibodies are responsible for the loss of
signal from this experiment, but it seems likely that it is a combination of both since
antibodies are unlikely to perform well at pH 2.0 (Figure 4-6). Incubation with iron (III)
perchlorate, which also forms acidic solutions (Graph D in Figure 4-7) had similar
consequences for immunoassay binding signal.
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Figure 4-7: ELISA binding signal for B[a]P and cAMP immunoassays run in 20/80 % (v/v) methanol/water with 1.5 g/L P80 after incubation with
100 mM Martian relevant sample matrix components
A NaCl, B FeCl3, C Mg(ClO4)2 and D Fe(III)(ClO4)3. Incubation condition 1 no sample matrix component included incubation condition 2
sample matrix component incubated with immobilised conjugate incubation condition 3 sample matrix component added during incubation of
antibodies incubation condition 4 sample matrix component incubated with immobilised conjugate and added during incubation of antibodies.
Binding signals were background corrected by subtracting signal generated in uncoated wells. Error bars are ± standard error, n = 2.
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In summary this data indicates that acidic Mars relevant sample matrix components such as
iron (III) chloride and iron (III) perchlorate reduce binding signal in ELISA format by more
than one mechanism, i.e. by stripping immobilised conjugate from the 96-well plate and by
interaction with the antibodies and/or enzyme label, whereas sample matrix components
which do not produce changes in pH have no impact on the immobilised conjugate therefore
changes in binding signal are caused only by interaction with the antibodies and enzyme
label. It may therefore be possible to reduce the impact of acidic sample matrix components
by covalently linking target molecule-protein conjugates to the plate surface, or to the chip
surface for microarray format assays. This is being implemented in current LMC
development work.
Summary
In summary ELISA binding signal is affected by the addition of sample matrix components
with the greatest changes in signal resulting from the addition of iron ion containing salts.
The buffering capacity in the freeze drying buffer is insufficient to control pH in the presence
of high concentrations of iron ions and these components interfere with the immunoassay by
changing antibody/enzyme performance and stripping immobilised target molecule from the
surface of 96-well plates. Therefore implementation of covalent immobilisation and improved
pH control may be beneficial in reducing some of the sample matrix mediated signal
changes. The implications of these findings are further discussed in Section 4.5.3.4.
4.5.3.2 Further studies to confirm immunoassay performance in pooled microarray
format
Effect of sample matrix component on fluorescent labels
In the flight format LMC microarray immunoassays will be performed directly in a liquid
extract from a martian sample. After incubation within the array chamber, antibodies that
have not bound to the microarray will be washed away using several chamber volumes of
liquid extract. Fluorophores on bound antibodies will then be evanescently excited whilst the
liquid extract is still present in the chamber, therefore sample matrix components that
interfere with the fluorescence of the fluorophores on the bound antibodies may be
detrimental to the function of the flight instrument.
In order to assess the potential impact of sample matrix components on fluorescence of
AF633 fluorescent label, independently of the impact on immunological interactions,
streptavidin-AF633 was incubated with Mars relevant sample matrix components in the LMC
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solvent and freeze drying buffer and the fluorescence of the fluorophore was then measured
(please see Section 2.2.3.10 for detailed methodology).
The data in Figure 4-8 show that the majority of Mars relevant sample matrix components
tested had little impact on the fluorescent signal generated by AF633 label in solution at
concentrations of 10 mM, 100 mM and 500 mM. The only components that produced a
significant reduction (subjectively assigned as > 20 %) in the fluorescent signal generated
were iron ion containing and 500 mM sodium carbonate. At 10 mM concentration of iron (III)
chloride, iron (II) perchlorate, iron (III) perchlorate, iron (II) sulphate and iron (III) sulphate the
fluorescent signal generated by the AF633 label in solution was reduced to a level where is
was not distinguishable above background noise.
Figure 4-8: Impact of sample matrix components on fluorescence of AF633 in solution
Fluorescent signal generated in the presence of each sample matrix component was
normalised by dividing by fluorescent signal produced with no sample matrix component.
Error bars = ± standard error n=2.
Invitrogen/Molecular Probes, the manufacturer of the Alexa Fluor® series of dyes claims that
the dyes are insensitive to pH in the range 4-10 (Panchuk–Voloshina et al, 1999). A 500 mM
solution of sodium carbonate has a pH of 11.0 and therefore would be expected to interfere
with fluorescence of AF633 whereas 10 mM solutions of iron chloride, iron (II) and iron (III)
perchlorate and iron (II) and iron (III) sulphate had a pH of greater than 4.0 and therefore
would not be expected to induce large reductions in fluorescence. This implies that there
may be another quenching mechanism in addition to changes in pH. Experiments performed
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to establish the lowest iron ion containing concentration that produced signal reduction (data
not shown) demonstrated that concentrations of iron ions of as low as 0.1 mM still affect the
fluorescent signal generated by AF633.
This result is potentially of concern for the LMC since Mars samples are likely to contain iron
salts, although the likely solubility of iron in martian rock/regolith samples has not been
determined. Therefore it may be necessary to replace the liquid extract present in the
sample chamber with fresh extraction solvent, prior to optically exciting the fluorophores to
prevent reduced fluorescent signal. Technically this should possible with the current (2011)
design of the flight model; however work would be required with flight representative
hardware to confirm this. In the pooled microarray format sample matrix components are
washed away prior to fluorescent imaging of the microarray, therefore data from experiments
performed in pooled microarray format can be used to confirm if removing the sample matrix
components prior to imaging is effective at minimising loss of fluorescent signal.
Effect of sample matrix components on microarray assay binding signal
Since the microarray format assay is less well established than the ELISA format, and
because this work was carried out at an early stage in the use of the newly purchased
commercial microarraying system (Section 2.2.3.5), the reproducibility of the printing and
assaying process was first assessed by running 12 identical pooled assays on 12
microarrays printed onto a single commercial hydrophobic slide. The mean pixel intensity of
microarray spots, and AF633 labelled BSA spots are plotted in Figure 4-9. Observe that
signals (pixel intensities) for each set of microarray spots vary across the slide by 5000-
10000. The source of these variations in signal intensity is undetermined but could be due to
many factors including, but not limited to, printing reproducibility, humidity and temperature
during printing, reproducibility of pooling reagents over an array area for the microarray
assay and consistency of washing following a microarray assay.
This intrinsic variation within arrays produced by the current printing and assaying protocol
makes interpretation of data within this study more problematic and may mask underlying
effects, since it is not possible to be certain whether changes in immunoassay and labelled
BSA binding signal are due to the sample matrix component under test, or due to the
intrinsic variability across the 12 arrays on each slide. Work is ongoing to optimise
microarray printing for the LMC to reduce variability. However within this study there were
some sample matrix components where microarray binding signal was reduced to an extent
where, despite the variability in the data, it was possible to be confident that changes in
signal were directly attributable to the sample matrix components.
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Figure 4-9: Mean pixel intensity of low ratio (1:1) AF633 labelled BSA, benzo[a]pyrene, high
ratio (1:5) AF633 labelled BSA, fluorescein and cAMP microarray spots after running pooled
multiplexed microarray immunoassays on all 12 arrays printed onto a single commercial
hydrophobic microarraying slide.
Error bars = ± 1 std error, n = 5. Note that cAMP assay spots were missing on array 12 and
low ratio AF633 labelled BSA spots were missing on arrays 9 and 10 (not printed, due to the
microarraying pin sticking in the print head).
Maximum microarray binding signal (binding signal with zero inhibiting target molecule) for
the benzo[a]pyrene, cAMP and fluorescein immunoassays was assessed in the presence of
a selection of Mars relevant sample matrix components, at a range of concentrations, by
running pooled multiplexed microarray format immunoassays using microarrays printed onto
commercially available hydrophobic microarraying slides. Slides were imaged using the
Innopsys microarray scanner (representative fluorescent image shown in Figure 4-10). Mean
pixel intensities were measured from the captured images and are plotted in Figure 4-11,
Figure 4-12 and Figure 4-13.
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Figure 4-10: Representative fluorescent images of 12 microarrays printed and physically
adsorbed onto commercial hydrophobic slide using ArrayIt® SpotBot. Images taken using
Innopsys Microarray scanner before (left) and after (right) running pooled multiplexed
microarray format immunoassays in the presence of Mars relevant sample matrix
components.
In images taken before running the pooled immunoassays two rows of five spots are visible
in each array comprising from top to bottom low ratio labelled AF633 labelled BSA and high
ratio AF633 labelled BSA. In images taken after running pooled microarray assays (right)
five rows of five spots are visible in each array comprising from top to bottom low ratio
AF633 labelled BSA, benzo[a]pyrene immunoassay spots, high ratio AF633 labelled BSA,
fluorescein immunoassay spots and cAMP immunoassay spots. Image brightness and
contrast have been optimised to aid visualisation of spots in both images. Note that for two
of the arrays the low ratio AF633 labelled BSA spots are missing from the image because
they did not print. Microarray spots are 110 µm in diameter and are spaced 400 µm apart
(centre to centre).
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Figure 4-11: Mean pixel intensity of benzo[a]pyrene assay microarray spots after multiplexed
pooled microarray immunoassay with Mars relevant sample matrix components.
Error bars = ± 1 std error, n = 2-5
Figure 4-12: Mean pixel intensity of cAMP assay microarray spots after multiplexed pooled
microarray immunoassay in the presence of Mars relevant sample matrix components.
Error bars = ± 1 std error, n = 2-5
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Figure 4-13: Mean pixel intensity of fluorescein assay microarray spots after multiplexed
pooled microarray immunoassay with Mars relevant sample matrix components.
Error bars = ± 1 std error, n = 2-5
Given the demonstrated variability within the microarray data, using the current printing and
assay protocols, results must be interpreted with care. However the general trends in the
microarray data, are in agreement with those observed for the experiments carried out in
ELISA format i.e. iron ion containing components reduce binding signal to levels which
render the immunoassay non-functional at concentrations of 10 mM and above and
immunoassays function (in terms of generating binding signal) in concentrations of up to 100
mM of the non iron-ion containing sample matrix components.
None of the sample matrix components produced a significant increase in non-specific
background signal in microarray format, compared to a control assay run with no sample
matrix component, indicating that the increases in background signal observed with some
sample matrix components in ELISA format were specifically related to the enzyme-
substrate reaction and are therefore irrelevant to the flight format immunoassay. Note
however that some scatter was observed in microarray images, around the edges of the
arrays. This is thought to be a result of evaporation of pooled solutions, resulting in the
deposition of particles on the slide surfaces (Figure 4-10).
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Further analysis of impact of sample matrix components on fluorescent dyes by analysis of
AF633-BSA spots on microarrays
In addition to the immunoassay spots, each printed microarray included two sets of control
spots consisting of high ratio AF633 labelled BSA (1:5 dye: protein labelling ratio) and low
ratio AF633 labelled BSA (1:1 dye: protein labelling ratio). The signal intensity of these
control spots was measured both before and after running pooled microarray
immunoassays. This was carried out to (i) investigate the impact of sample matrix
components on fluorescence of immobilised AF633 BSA and (ii) to further investigate
whether removal of sample matrix components from the array chamber in the flight
instrument, prior to imaging the microarray, will mitigate the loss of fluorescent signal
observed in the presence of iron ions.
Figure 4-14: Mean pixel intensity of low ratio (1:1 ratio) AF633 labelled BSA and high ratio
(1:5 ratio) AF633 labelled BSA microarray spots after multiplexed pooled microarray assay
with Mars relevant sample matrix components.
Error bars = ± 1 std error, n = 2-5
For the three control arrays (microarrays incubated with no sample matrix component, but
subjected to the same washing conditions) signal intensity of the AF633 labelled BSA spots
was reduced by between 0 and 20 % after running a pooled microarray immunoassay
indicating that a quantity of immobilised AF633 labelled BSA may have been lost from the
chip surface during the incubation and/or washing procedures (Figure 4-14).
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Some sample matrix components produced significantly greater signal loss compared to the
control arrays, even taking into account the variability observed between microarrays. i.e.
100 – 500 mM sodium chloride, 100 – 500 mM calcium and magnesium perchlorate and 10
– 500 mM iron (II) and iron (III) sulphate. Sodium chloride, magnesium perchlorate and
calcium perchlorate at 100 – 500 mM concentration reduced fluorescent signal produced by
the labelled BSA spots but did not reduce the fluorescence of AF633 when tested in solution
(Figure 4-8), therefore AF633 labelled BSA spot signal loss is unlikely to be due to reduced
fluorescence and more likely a result of loss of fluorescently labelled BSA from the slide
surface. Conversely Iron (II) and iron (III) sulphate did reduce fluorescence of AF633 labelled
BSA in solution with 10 mM concentrations reducing signal to a level that was not
distinguishable from background. In the case of immobilised AF633 labelled BSA spots
although incubation with iron sulphate salts did reduce the fluorescent signal, signal was still
discernable above background noise, even at 500 mM concentration. This is significant
because it indicates that removing the iron salts prior to imaging microarrays at least partially
recovers the fluorescent signal. Therefore this may be a viable route to mitigate the impact of
iron ions on fluorescent signal in the flight format instrument. Additionally it may be possible
to improve immobilisation stability to the presence of sample matrix components by
investigating the use of covalent immobilisation of target molecule-protein conjugates to the
microarraying slide and by improving the pH control of the LMC freeze drying cocktail.
In the flight format immunoassay liquid extract will be pumped over the surface of the
microarray, whereas in the pooled microarray immunoassay liquid extract was pooled on-top
of the microarray and rinsed away by immersion in buffer. Therefore future work should also
include assessment of sample matrix components in a microfluidic format microarray assay
to determine whether the physical flow of the liquid extract over the surface has an influence
on the severity of sample matrix mediated effects.
Summary
In summary binding signal in microarray immunoassays is affected by the addition of sample
matrix components with the greatest changes in signal resulting from the addition of non-pH
neutral salts. The mechanism for this signal loss is likely to be a combination of changes in
antibody performance and loss of immobilised target molecule-protein conjugate from the
surface of the microarraying substrate, therefore implementation of covalent immobilisation
and improved pH control may be beneficial in reducing some of the sample matrix mediated
signal changes. In solution iron ions significantly reduce fluorescent signal, probably due to
fluorescence quenching, however when immobilised fluorophores are exposed to iron ions
and the iron ions are then removed, signal loss is reduced, implying that washing away iron
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ions prior to imaging microarrays may minimise the loss of fluorescent signal which results
from the presence of these components. The implications of these findings are further
discussed in Section 4.5.3.4.
4.5.3.3 Extended study with limited range of sample matrix components using ELISA
sensitivity as performance indicator
In order to determine the impact of sample matrix components on the sensitivity of LMC
relevant immunoassays, inhibition ELISAs were performed in the presence of a selection of
martian relevant sample matrix components at concentrations of 10 mM, 100 mM and 500
mM. Studies were performed with a sub-set of sample matrix components excluding any
components which prevented immunoassays from functioning. Representative inhibition
assay data for the cAMP immunoassay are plotted in Figure 4-15 (other inhibition assay data
plots are included in Appendix B Figure B1, Figure B2 and Figure B3). IC50 values (Table 4-
5) for each immunoassay were calculated by fitting data to a four parameter binding
equation (Section 2.1.1.1).
The four target molecules atrazine, pyrene, cAMP and fluorescein were successfully
detected in the tested sample matrix components, except at high concentrations of sample
matrix components where binding signal was reduced to a level where it was not
distinguishable from background signal. Immunoassay IC50 varied in the presence of the
sample matrix components, however for the LMC which aims to perform a threshold
detection, variations in IC50, such as those observed within this study, are unlikely to be
significant.
The literature contains many examples of individual immunoassays tested for performance
at a range of ionic strengths. In some examples ionic strength has strongly influenced
immunoassay performance with high ionic strength producing increased IC50 (Liang et al,
2008; Hao et al, 2009), whereas in other examples ionic strength had had little effect of
immunoassay IC50 (Liu et al, 2009), implying that the effect of increased ionic strength is
highly antibody/target specific. The 22F12 anti-benzo[a]pyrene clone used within this study
has previously been reported to show reduced immunoassay IC50 in higher ionic strength
solutions (Matschulat et al, 2005) in agreement with the observed performance in this study.
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Figure 4-15: cAMP inhibition ELISA in the presence of sample matrix components A sodium chloride, B magnesium sulphate and C
magnesium perchlorate at ■ 0 mM, ♦ 10 mM, ▲100 mM and X 500 mM concentration.  
Each data point represents a single replicate. Immunoassay curves for each concentration of each sample matrix component were plotted by
fitting mean signal to a four parameter binding equation, or by linear regression of the mean signal where the data did not fit a four parameter
binding equation (solid line) 0 mM, (dotted line) 10 mM, (short dashed line) 100 mM and (long dashed line) 500 mM
Table 4-5: IC50 values (ng/ml) for inhibition ELISAs run in the presence of Mars relevant sample matrix components at 10, 100 and 500 mM
concentration.
Control NaCl MgSO4 Mg (ClO4)2
10 mM 100 mM 500 mM 10 mM 100 mM 500 mM 10 mM 100 mM 500 mM
Atrazine 6.9 6.9 5.6 3.3 7.4 5.8 3.1 7.9 406 N/A
B[a]P 118.5 94.5 76.4 N/A 101.3 40.0 N/A 94.0 57.9 N/A
cAMP (µg/ml) 150.30 126.5 71.9 23.3 90.7 50.0 24.0 62.3 29.5 N/A
Fluorescein 444 380 470 250 470 150 100 440 410 N/A
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4.5.3.4 Study 1 General Discussion
The objective of the work reported in this section was to test performance of a number of
LMC relevant immunoassays in the presence of likely individual Mars sample matrix
extractable components identified from known Mars geology/geochemistry. In order to
achieve this immunoassays, in both ELISA and microarray format, were performed in the
presence of a selection of Mars relevant salts and oxidising agents.
LMC relevant Immunoassay performance in the presence of sample matrix components
Data from ELISA and pooled microarray format assays indicate that LMC immunoassays are
likely to function with martian samples with similar levels of extractable salts to those tested
by Phoenix (Hecht et al, 2009). However samples with salt levels similar to some of the
samples analysed by MER (Yen et al, 2005), assuming that all of the salt is soluble, are
likely to compromise immunoassay performance and may even prevent assays from
functioning entirely. Therefore it may be necessary to avoid analysis of samples with high
salt content using the LMC. Early in LMC development work the use of ion exchange resins
to remove ions from liquid extracts was considered (Wilson 2007), however this has since
been rejected as an option due to the high likelihood that hydrophobic target molecules
would be absorbed by the high surface area de-salting resins that were proposed.
One key limitation of this study is that the likely solubility of Mars relevant sample matrix
components, once incorporated into a real matrix, may differ significantly from those tested
here as pure compounds. Future work should therefore be carried out to characterise the
soluble components of the types of rocks that may be encountered on Mars in order to better
understand the likely solution chemistry of martian samples and the resulting implications for
the LMC.
Of the four immunoassays tested the benzo[a]pyrene assay showed lower tolerance to the
addition of sample matrix components and as such the 22F12 antibody would probably be
considered unsuitable for inclusion in the flight suite of immunoassays. This highlights the
need to assess the tolerance of antibodies to sample matrix components at an early stage in
assay development, prior to investing significant effort transferring assays into flight
representative formats. Screening recombinant antibody libraries has been identified as a
potential route to the production of antibodies against LMC relevant target molecules and
recombinant libraries have previously been used to generate receptors that function in high
ionic strength solutions such as sea water (Goldman et al, 2002). Therefore it may be
possible to design the screening procedure to favour the selection of antibodies that tolerate
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high ionic strength and other conditions such as extremes of pH, although this may be
unrealistic within the schedule for development of the LMC instrument.
Data from immunoassays performed in both ELISA and microarray format suggests that the
Mars relevant components that have the most detrimental impact on immunoassays are
those that form acidic/basic solutions in the LMC solvent and freeze drying buffer, and those
that contain iron ions. It may be possible to reduce these effects by altering the formulation
of the LMC freeze drying buffer to increase buffering capacity, however this may have other
implications for the LMC such as changing assay performance, altering solubility of extracted
target molecules and leading to the risk of precipitation of buffer salts in the microfluidic
channels of the flight format immunoassay. For some Mars relevant sample matrix
components it may not be possible to build in sufficient buffering capacity, therefore it may
be necessary for the LMC to reject any samples that are likely to contain iron sulphates and
other similar salts by using data available from the other ExoMars rover contextual
instruments.
One of the major concerns for the LMC is the importance of being able to distinguish
between specific inhibition of signal due to the presence of target molecule, from signal
losses mediated by sample matrix effects. The primary strategy adopted to address this
issue is the inclusion of control immunoassays in the flight instrument, for targets that are not
expected to be present on Mars. Therefore if signal loss is observed in the control
immunoassays, the implication is that the signal loss is sample matrix mediated. The data
generated in this study, which used LMC relevant immunoassays with a number of differing
primary and secondary antibodies, is that there were differences in the degree of signal loss
between the immunoassays tested with the same sample matrix component. This result
highlights the need to include a number of well characterised control assays in the flight
format assay with a range of tolerances to changes in pH and ionic strength.
Impact of sample matrix components on fluorescence of AF633
Since the flight format instrument has a fluorescent readout, the impact of Mars relevant
sample matrix components on fluorescence is of high significance. For the majority of Mars
relevant sample matrix components tested, fluorescent signal was unaffected; however iron
ion containing sample matrix components had a detrimental impact on fluorescence in
solution, even when tested at low concentration. However analysis of immobilised AF633
labelled BSA microarray spots following pooled microarray assays revealed that removal of
the iron ion containing sample matrix components prior to fluorescent imaging, resulted in
visible fluorescent spots, which had similar intensities to control microarrays which had not
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been exposed to iron salts. Therefore removal of sample matrix components prior to imaging
microarrays in the flight instrument should reduce the loss of fluorescent signal resulting
from the presence of iron ions. Therefore in the flight format instrument liquid extract
containing soluble components of the Mars sample matrix should be washed away from the
assay chamber using fresh extraction solvent, prior to imaging the arrays. Given the current
design of the flight instrument this should be possible, but testing needs to be performed to
confirm this.
Comparison to literature data
There are a number of immunoassay based instruments under development for life detection
experiments on Mars, and for planetary exploration more generally, e.g. Steele et al (2001),
Parro et al (2011), however there are no published studies where immunoassay
performance has been systematically tested in a range of Mars relevant sample matrix
components. The group developing the SOLID instrument, based at Centro de
Astrobiologica in Spain, describe an experiment to determine the impact of perchlorate salts,
at up to 50 mM concentration on sandwich type microarray assays and report that no
substantial differences were observed compared to a control (Parro et al, 2011), which is in
agreement with data reported within this study. The group at CAB have also published data
relating to the use of their SOLID instrument prototype instrument with a range of Mars
analogue samples. These results are discussed in the context of results from Study 2
(Section 4.6) where LMC format immunoassays were tested with liquid extracts from Mars
analogue samples.
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4.6 Study 2: Testing the impact of liquid extracts from Mars
analogue samples on LMC relevant immunoassays
The work in Study 1 has shown that Mars relevant sample matrix components have a
significant impact on the function of LMC format immunoassays, particularly at the highest
tested concentration (500 mM). However when incorporated into complex real samples
sample matrix components may behave differently, especially in terms of their solubility, and
there is limited information available regarding the solution chemistry of martian rocks and
regolith. In addition sub 0.45 µm particulates generated from the processing/crushing of real
samples by the Sample Processing and Distribution System (SPDS) on the ExoMars rover
may pass through the filter and into microfluidic channels where they may interact with the
immunoassays. Therefore the objective of the work reported in Study 2 was to investigate
the performance of LMC format immunoassays with liquid extracts from a range of Mars
analogue samples, in an attempt to better understand likely interactions with complex ‘real’
samples.
4.6.1 Supplementary experimental design
The design adopted for this study aligns with the common experimental design described in
Chapter 2 of this thesis: The set of model immunoassays described in Chapter 2, were used
to assess the likely performance of LMC immunoassays with liquid extracts from Mars
analogue samples. Note that within this study a sub-set of the immunoassays (B[a]P, cAMP
and fluorescein) were used due to resource constraints.
Initial assessment of immunoassay performance, was carried out using the LMC
representative binding ELISA format (Section 2.1.1.1). Further studies, with a sub-set of
Mars analogue samples, were then carried out in pooled microarray binding format (Section
2.1.1.2) to confirm whether behaviour in the more flight representative microarray format was
similar to that observed in ELISA format and finally an extended study of immunoassay
sensitivity was carried out, on a selected set of Mars analogues in pooled microarray format.
Pooled microarray format was used here in preference to inhibition ELISA format due to the
lower volumes of liquid extract required for pooled microarray assays.
4.6.1.1 Selection of Mars analogues for use in study
The martian crust is dominated by basaltic rock (McSween et al, 2009; Rossi and Gasselt
2010) with localised concentrations of phyllosilicates (clays), hydrated sulphates (including
gypsum, jarosite and kieserite), carbonates and ferric oxides including haematite. Since the
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landing site for the ExoMars Rover has not yet been selected, and is unlikely to be selected
prior to instrument delivery in early 2015 (correct as of late 2011), it is important to test
analogue samples from as wide a range of Mars relevant geologies as possible, with the
potential for more targeted testing once the landing site has been selected. Analogue
samples used within this study were either selected as examples of specific mineralogies
relevant to Mars e.g. phyllosilicates (clays) and gypsum, or were selected due to their origin
from a relevant Mars analogue site on Earth offering a more diverse / complex sample set
e.g. Iceland, which is predominantly a volcanic island, has poorly formed soils, basaltic
bedrock and sparse surface water and has therefore been considered to be an analogue site
for early volcanic environments on Mars (Cousins et al, 2010; Ehlmann et al, 2011a). In
addition a martian simulant regolith, JSC Mars-1, developed by NASA’s Johnson Space
Centre, and commonly used in studies where a Mars analogue is required, was also tested.
Analogue samples were not specifically collected for this work and their selection was
influenced by their availability within the LMC project team and from other related academic
groups. Details of all of the analogue samples used are given in Table 4-6.
Table 4-6: Analogue samples used to test performance of immunoassays in liquid extracts
Sample Description/relevance to Mars Source
JSC Mars-1 martian regolith simulant palagonitic tephra
(< 1mm size fraction). Contains haematite
Pu’u Nene cinder cone on the
Island of Hawaii
(Allen et al, 1997)
Gypsum hydrated calcium sulphates Haughton impact crater, Northern
Canada
Marl a calcium carbonate rich mud or mudstone,
deposited in marginal marine setting
Vigo Meano, Northern Italy
(Watson et al, 2005)
Kimmeridge Clay sedimentary deposit of fossilferous marine
clay
Kimmeridge Bay, Dorset, UK
(Farrimond et al, 1984)
Rheolite igneous volcanic extrusive rock Iceland
Basalt rock igneous volcanic extrusive rock Iceland
Edfell ash pulverised rocks and glass Iceland
Obsidian glass igneous volcanic extrusive rock Iceland
4.6.2 Supplementary materials and methods
The majority of materials and methods used within this study are the same as those used
throughout the other chapters of this thesis and are described in Chapter 2. This section
contains supplementary materials and methods specific to the work carried out in this study
and where appropriate cross references the relevant sections of Chapter 2.
4.6.2.1 Sourcing and processing of Mars analogue samples
Analogue samples collected from Iceland’s volcanic fields (basalt rock, rheolite, edfell Ash
and obsidian glass) and gypsum from the Haughton Crater in northern Canada were
supplied by Prof. Charles Cockell (Open University, Milton Keynes, UK) as rocks and ash
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composed of particles of varying size (varying from a few mm to tens of cm). These samples
were crushed prior to extraction as described in Section 4.6.2.2.
JSC Mars-1 regolith simulant, the < 1 mm fraction from palagonitic tephra, was developed by
NASA’s Johnson Space Centre (Allen et al, 1997) and was used as supplied.
Kimmeridge Clay and Marl were supplied by Dr Alex Baki, Dr Rachel Gomes and Dr Richard
Court (Imperial College, London, UK) in the form of fine powders prepared by manual
grinding in a pestle and mortar. The powders were used as supplied.
4.6.2.2 Preparation of Mars analogue samples for extraction
In order to mimic the action of the rock crusher in the ExoMars rover SPDS, samples that
were not supplied ready processed were crushed using a Clarke strong arm 10 tonne
hydraulic press. Note that at the time of this work no detailed specifications were available
regarding the size distribution of crushed samples produced by the SPDS and no attempt
was made to characterise the size distribution of samples crushed using the hydraulic press.
Analogue samples consisting of large pieces of rock were first broken into smaller fragments
using the hydraulic press. Approximately 4 g of each analogue sample, broken into small
(approx. 1 cm pieces), was placed between two stainless steel plates (approx 10 cm x 10 cm
x 1 cm) together with two stainless steel spacers (10 cm x 1cm x 1 mm) (shown in bottom
right hand image in Figure 4-16) and the analogue sample was crushed by using the
hydraulic press to bring the two plates together until they met the spacers.
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Figure 4-16: Photographs illustrating processing of analogue samples
(left) unprocessed analogue samples supplied by Prof. Charles Cockell, (top right) 10 tonne
hydraulic press used for crushing samples in preparation for liquid extraction (bottom right)
analogue sample after crushing on stainless steel plate with 1 mm spacers.
4.6.2.3 LMC representative extraction of analogue samples
Note that analogue samples were tested in two separate batches, with approximately 6
months in-between the two sets of testing. During the intervening six months work carried
out at Imperial College identified that extracted target molecules were being retained by the
cellulose acetate filters used to clarify liquid extracts as part of the LMC extraction process
(Court and Sephton 2011). In order to avoid the loss of target molecules, and until
identification of suitable alternative membrane filters was possible, it was decided to replace
the filtration step with a centrifugation step. Therefore the extraction procedure used for the
two batches of testing varied in terms of the method used to remove large particulates from
the extract. Both protocols are described in the following two sections.
Protocol 1 – used for extraction of JSC Mars-1, Marl and Kimmeridge Clay
Three ml of MeOH P80 was added to 1g analogue sample in a glass test tube and sonicated
for 20 minutes with a Sonotrode Ultasonic UP100H probe and UP50H ultrasonic processor
set at 40 % amplitude (Hielscher Ultrasonics, Teltow, Germany). The mixture was allowed to
stand for 10 minutes, and the cloudy supernatant that had formed above the sedimented
111
analogue sample was filtered through a 0.45 µm cellulose acetate filter and stored at 2 – 8°C
in glass vials until tested in the immunoassay.
Protocol 2 – modified extraction protocol used for extraction of gypsum, rheolite, basalt,
edfell ash and obsidian glass
Three ml MeOH P80 was added to 1g analogue sample in a glass test tube and sonicated
for 20 minutes with a Sonotrode Ultasonic UP100H probe and UP50H ultrasonic processor
set at 40 % amplitude (Hielscher Ultrasonics, Teltow, Germany). The mixture was allowed to
stand for 10 minutes, and the cloudy supernatant that had formed above the sedimented
analogue sample was decanted into 1.5 ml centrifuge tubes. To minimize loss of extracted
components by adsorption to surfaces of the hydrophobic polymer centrifuge tubes, the
tubes were first blocked with 0.5 % (w/v) BSA in 100 mM HEPES pH 7.4. The supernatants
were clarified by centrifugation at 17000 G for 10 minutes and stored at 2 – 8°C in glass
vials until tested in the immunoassay.
4.6.2.4 LMC format immunoassays
ELISA and microarray immunoassays were performed following the methods described in
Section 2.2.2 and Section 2.2.3 with liquid extracts from analogue samples.
4.6.3 Results and discussion
4.6.3.1 Initial studies of immunoassay performance in liquid extracts from a range of
analogue samples using ELISA binding signal as a performance indicator
The LMC flight format immunoassay will be performed directly in the liquid extract from a
martian sample with freeze dried antibodies and other immunoassay reagents dissolved
directly into the liquid extract. For ELISA format assays the antibodies and other
immunoassay reagents are not freeze dried and therefore have to be added to the extract in
liquid form, resulting in dilution of the extract. The maximum concentration of liquid extract
that could be tested in ELISA format, whilst maintaining flight representative concentrations
of solvent and buffer salts etc, was 50 % (v/v) liquid extract, diluted with 25 % (v/v) 2 x
concentration MeOH P80 and 25 % (v/v) 4 x concentration antibodies in 4 x concentration
freeze drying buffer.
Since it was not possible to test higher concentrations of liquid extract it was decided to test
a range of liquid extract concentrations from 0 % (v/v) up to 50 % (v/v) in order to allow
extrapolation of the effect of increasing the liquid extract concentration further.
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The graphs in Figure 4-17, Figure 4-18 and Figure 4-19 show how ELISA binding signal and
non-specific background signal was affected by adding increasing concentrations of liquid
extracts from Mars analogue samples into ELISAs (whilst maintaining the same final solvent
concentration), up to a maximum of 50 % (v/v) liquid extract, for the benzo[a]pyrene, cAMP
and fluorescein immunoassays. ELISA binding signal and ELISA background binding signal
were plotted separately for liquid extracts from each analogue sample in order to also
illustrate the impact that each sample matrix type had on non-specific binding signal.
The graphs in Figure 4-17, Figure 4-18 and Figure 4-19 show that ELISA binding signal was
generated for each immunoassay in the presence of up to 50 % (v/v) liquid extracts from a
range of Mars analogue samples including igneous rocks, clays and gypsum. This indicates
that all of the primary and secondary antibodies used in these three immunoassays, and the
streptavidin-HRP label, function in the presence of extractable components from the tested
analogue samples.
For the majority of analogue samples tested, increasing the proportion of liquid extract
included in the ELISA immunoassay had minimal effect on immunoassay binding signal and
on non-specific background signal indicating that the immunoassays were robust to the
extractable components contained within the analogue samples (note that no attempt was
made to characterise the soluble components in the liquid extracts). For a number of the
analogue samples tested there was some evidence of reduction in binding signal at high
extract concentration and it is likely that increasing the concentration of liquid extract to 100
% (v/v), as is the case for the flight format assay, would reduce the signal further. It is
unclear whether signal loss is attributable directly to dissolved components of the analogue
samples, or due to feed through of sub-0.45 µm particulates which may adsorb some of the
antibodies (Krotzky and Zeeh 1995), or a combination of both.
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Figure 4-17: Benzo[a]pyrene binding ELISA performed in the presence of increasing concentration of liquid extract from (A) rheolite, (B) basalt
rock, (C) obsidian glass, (D) Edfell ash, (E) Haughton Crater calcium sulphates, (F) Marl, (G) Kimmeridge clay and (H) JSC Mars-1.
Data points are single replicates for ● binding to immobilised BSA-benzo[a]pyrene conjugate and ♦ non-specific binding to BSA. Lines are the 
linear interpolation of mean OD for (solid line) binding to immobilised BSA-benzo[a]pyrene conjugate and (dotted line) non-specific binding to
BSA
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Figure 4-18: cAMP binding ELISA performed in the presence of increasing concentration of liquid extract from (A) rheolite, (B) basalt rock, (C)
obsidian glass, (D) Edfell ash, (E) Haughton Crater calcium sulphates.
Data points are single replicates for ● binding to immobilised BSA-cAMP conjugate and ♦ non-specific binding to BSA. Lines are the linear 
interpolation of mean OD for (solid line) binding to immobilised BSA-benzo[a]pyrene conjugate and (dotted line) non-specific binding to BSA
Note that cAMP ELISAs were not performed with Marl, Kimmeridge Clay and JSC Mars-1 because this immunoassay had not yet been
developed at the time of testing of these analogue samples.
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Figure 4-19: Fluorescein ELISA performed in the presence of increasing concentration of liquid extract from (A) rheolite, (B) basalt rock, (C)
obsidian glass, (D) Edfell ash, (E) Haughton Crater calcium sulphates, (F) Marl, (G) Kimmeridge clay and (H) JSC Mars-1.
Data points are single replicates for ● binding to immobilised BSA-FITC conjugate and ♦ non-specific binding to BSA. Lines are the linear 
interpolation of mean OD for (solid line) binding to immobilised BSA-benzo[a]pyrene conjugate and (dotted line) non-specific binding to BSA
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For all three immunoassays liquid extract from basalt rock produced an increase in non-
specific background signal at high extract concentrations (Graph B in Figure 4-17, Figure
4-18 and Figure 4-19). However when microarray format immunoassays were tested (see
following section), no increase in non-specific background signal was observed, therefore
increased ELISA background signal was most likely due to an interaction of extracted
components, or sub 0.45 µm particulates, with the HRP enzyme rather than an interaction
with the immunoassay antibodies. Since the HRP enzyme label is not used in the flight
format immunoassay this is unlikely to be problematic for the LMC instrument.
4.6.3.2 Further studies to confirm impact of liquid extracts from a range of analogue
samples on microarray format assays using binding signal as a performance
indicator
In order to confirm whether the observations made in ELISA format were also valid in a
format that more closely resembles the flight format, liquid extracts from selected Mars
analogue samples was assessed in multiplexed pooled microarray format (Figure 4-20).
Tests were performed using a single concentration of liquid extract, 50 % (v/v). This is the
maximum concentration that can be tested using pooled microarray format since, as
described previously for ELISA format assays, the antibodies and other immunoassay
reagents for pooled microarray assays are not freeze dried and are in liquid format therefore
resulting in dilution of the liquid extract.
The pixel intensities of microarray spots after running multiplexed pooled microarray
immunoassays in the presence of 50 % (v/v) liquid extract from each analogue matrix are
given in Figure 4-21, Figure 4-22 and Figure 4-23 for the benzo[a]pyrene, cAMP and
fluorescein immunoassays and a representative fluorescent image is shown in Figure 4-20.
As discussed in Section 4.5.3.2, there is inherent variation in microarray assay data, thought
to be due to inconsistencies introduced by the current printing and pooled microarray assay
protocols. Data from microarray assays must therefore be interpreted in the context of this
variability.
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Figure 4-20: Representative fluorescent images of 12 microarrays after (right) running
pooled multiplexed microarray format immunoassays in the presence of 50 % (v/v) liquid
extracts from Mars analogue sample matrixes.
Microarrays printed onto commercial hydrophobic slide using ArrayIt® SpotBot, images
recorded using Innopsys Microarray scanner. In images taken after running pooled
microarray assays five rows of five spots are visible comprising from top to bottom low ratio
AF633 labelled BSA, benzo[a]pyrene immunoassay spots, high ratio AF633 labelled BSA,
fluorescein immunoassay spots and cAMP immunoassay spots. Image brightness and
contrast have been optimised to aid visualisation of spots. Note that for two of the arrays the
low ratio AF633 labelled BSA spots are missing from the image because they did not print.
Microarray spots are 110 µm in diameter and are spaced 400 µm apart.
Figure 4-21: Mean pixel intensity of microarray spots for multiplexed pooled benzo[a]pyrene
immunoassay run in 50 % (v/v) liquid extract from Mars analogue sample matrixes.
Error bars = ± 1 standard deviation of the mean, n = 5
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Figure 4-22: Mean pixel intensity of microarray spots for multiplexed pooled cAMP
immunoassay run in 50 % (v/v) liquid extract from Mars analogue sample matrixes.
Error bars = ± 1 standard deviation of the mean, n = 5
Figure 4-23: Mean pixel intensity of microarray spots for multiplexed pooled fluorescein
immunoassay run in 50 % (v/v) liquid extract from Mars analogue sample matrixes.
Error bars = ± 1 standard deviation of the mean, n = 5
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Microarray spots for the benzo[a]pyrene, cAMP and fluorescein immunoassays all
fluoresced after running multiplexed pooled microarray immunoassays in 50 % (v/v) liquid
extract, indicating that all of the primary antibodies, secondary antibodies and the
streptavidin-AF633 bound successfully in the presence of 50 % (v/v) liquid extracts. Note
that in the flight format assay imaging is performed in a chamber containing the liquid
extract, whereas in the pooled microarray format fluorescent imaging was performed after
the liquid extract (and any associated particulates/precipitates) had been washed away.
Therefore no comment can be made on the likely effect of the liquid extract components,
including particulates, on fluorescent imaging. This aspect is further investigated in Chapter
6 of this thesis.
Binding signal was generally reduced in all of the liquid extracts tested compared to control
microarrays run with extraction solvent only. Binding signal response varied across the three
immunoassays tested with the cAMP immunoassay appearing to be most robust (i.e.
exhibiting the smallest loss of binding signal) in the liquid extracts. The observed reduction in
signal for all three immunoassays may be due to altered antibody performance as well as
loss of immobilised target molecule-protein conjugate from the chip surface during
incubation and washing procedures and the presence of particulates interfering with the
immunoassay.
In microarray format the signal loss observed was generally greater than signal loss
observed in ELISA format, but no issues with increased background signal were observed.
Therefore for the flight format immunoassay some loss of signal intensity should be
expected with real samples compared to with standards prepared in extraction solvent. The
fact that immunoassays showed differing degrees of signal loss in liquid extracts from the
same sample matrix further highlights the need to include a range of well characterised
control assays in the flight instrument suite of assays.
4.6.3.3 Extended study with liquid extracts from a limited number of analogue
samples using microarray assay sensitivity as a performance indicator
In order to investigate the impact of liquid extracts from analogue samples on immunoassay
sensitivity, liquid extracts were spiked with target molecules and then run in pooled
multiplexed microarray immunoassays. Pooled format microarrays were used in preference
to ELISAs in this case due to the limited liquid extract volumes available. Figure 4-24 shows
the mean pixel intensity for microarray spots when incubated with 50 % (v/v) liquid extracts
from three Mars analogue samples spiked with varying concentrations of cAMP target
molecule.
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Figure 4-24: Mean background corrected pixel intensity for pooled multiplexed format
fluorescein and cAMP microarray assays run with cAMP spiked liquid extracts
from (A) control (extraction solvent only), (B) liquid extract from basalt rock, (C) liquid extract
from gypsum (Haughton Crater), (D) liquid extract from JSC Mars-1. Error bars = ± 1 std
deviation, n = 5
As the concentration of cAMP spiked into liquid extracts from basalt rock, gypsum and JSC
Mars-1 was increased, signal for the cAMP immunoassay was inhibited confirming that the
cAMP inhibition immunoassay functions in liquid extracts from these analogue samples
(Figure 4-24). Signal for the fluorescein immunoassay was unaffected by increasing the
concentration of cAMP spiked into the liquid extract, showing that there was no cross
reactivity of the anti-fluorescein antibodies with the cAMP target molecule in any of the liquid
extracts tested. (Figure 4-24). Note however that independently of the concentration of
spiked cAMP, signal for the fluorescein assay was reduced by approximately 90 % in liquid
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extracts from JSC Mars-1 compared to in extraction solvent and in liquid extracts from basalt
rock and Haughton crater sulphates (Graph D in Figure 4-24).
In the flight format immunoassay if low signal was observed for a target molecule, but also
for a control immunoassay, the likely interpretation would be that the signal loss for both
assays was due to a generic matrix effect. However in the case shown here signal intensity
in the fluorescein ‘control’ immunoassay was reduced by a matrix effect which did not affect
the cAMP immunoassay to the same degree and loss of signal in the cAMP immunoassay
was due to specific inhibition by the presence of cAMP target molecule spiked into the liquid
extract. This result highlights the need to include a number of well characterised control
immunoassays, with differing performance in sample matrixes, within the flight instrument, to
reduce the risk of data misinterpretation.
Figure 4-25 shows the mean pixel intensity for microarray spots when incubated with liquid
extracts from three Mars analogue samples spiked with varying concentrations of fluorescein
target molecule. As the concentration of fluorescein spiked into liquid extracts from basalt
rock, gypsum and JSC Mars-1 was increased, signal for the fluorescein immunoassay was
inhibited demonstrating that the fluorescein inhibition immunoassay functions in liquid
extracts from these analogue samples. Signal for the cAMP immunoassay was unaffected
by increasing the concentration of fluorescein spiked into the liquid extract, showing that
there was no cross reactivity of the anti-cAMP antibodies with the fluorescein target
molecule in any of the liquid extracts tested. (Figure 4-25). Note however that independently
of the concentration of spiked fluorescein, signal for the fluorescein assay was reduced by
approximately 90 % in liquid extracts from JSC Mars-1 compared to in extraction solvent
(Graph D in Figure 4-25).
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Figure 4-25: Mean background corrected pixel intensity for pooled multiplexed format
fluorescein and cAMP microarray assays run with fluorescein spiked liquid extracts
from (A) control (extraction solvent only), (B) liquid extract from basalt rock, (C) liquid extract
from gypsum (Haughton Crater), (D) liquid extract from JSC Mars-1. Error bars = ± 1 std
deviation, n = 5
Note that no attempt was made to calculate the IC50 of the fluorescein or cAMP microarray
immunoassay in the liquid extracts due the limited volume of liquid extracts available for
spiking studies, therefore no specific conclusions can be drawn regarding how liquid extracts
from Mars analogue samples effect immunoassay sensitivity, except to say that inhibition
immunoassays do function in spiked liquid extracts and that no gross changes in sensitivity
were apparent in the tested extracts from the limited concentration range tested.
123
4.6.3.4 Study 2 general discussion
The objective of the work reported in Study 2 was to test performance of a number of LMC
relevant immunoassays with liquid extracts from Mars analogue sample matrixes in order to
mimic the complex ‘real’ samples that may be encountered on Mars.
In order to achieve this, a selection of Mars analogue samples, selected on the basis of their
relevance to Mars as well as by their availability within the time scales of this study, were
extracted using an LMC representative liquid extraction with sonication and the liquid
extracts were then added in to ELISA and microarray format immunoassays. In both ELISA
and microarray format immunoassays some loss of binding signal was observed in all of the
liquid extracts tested. Signal loss may be due to a number of factors including changes in
antibody performance and adsorption of antibodies to particulate material contained within
the liquid extract. Note that for all of the sample matrixes tested, although assay signal was
reduced, it was not reduced to a level where it was no longer distinguishable from
background, indicating that it should be possible to perform immunoassays in liquid extracts
from samples such as those tested here. Different immunoassays showed varying
susceptibility to signal loss in liquid extracts, which highlights the risk of misinterpreting non-
specific matrix mediated signal loss as specific inhibition. The inclusion of a number of well
characterised control assays in the flight instrument, with differing tolerances to sample
matrix types, should help to mitigate this risk. As antibody immunoassays are developed it is
important that their performance in extracts from analogue samples is characterised at an
early stage as it may be necessary to (i) deselect antibodies/assays which show poor
tolerance for sample matrix types likely to be encountered on Mars and (ii) to include
appropriate controls for each assay.
A limitation of this study was that ELISA and pooled microarray format immunoassays were
performed in a maximum concentration of 50 % (v/v) liquid extract, whereas the flight format
assay will be performed in 100 % liquid extract. Additionally in the flight format immunoassay
the extract will be pumped through microfluidic channels and across the surface of the
microarray therefore future studies should be performed in a more flight representative
format to confirm whether the use of 100 % liquid extract and the physical flow of liquid
extract across the microarray surface, will have a significant impact on binding signal. This
aspect is investigated further in Chapter 6 of this thesis.
There are many possible geologies that may be encountered on Mars and this study
considered only a small selection of analogue samples, which by no means encompass all
possible types of sample that may be encountered by the ExoMars rover. Therefore the
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findings of this study are preliminary and extensive future testing must be carried out with a
wider range of analogue samples. Once the landing site for ExoMars is selected, more
information as regards the likely geology of samples to be encountered by the ExoMars
rover will be available, but landing site selection is unlikely to occur until after the LMC
instrument is integrated within the ExoMars rover (current schedule for instrument delivery is
early 2015) therefore as broad a range of samples should be tested in advance of this.
Potential sources of a wide variety of samples with Mars relevant geologies have been
identified and include the European Space Analogue rock collection (ESAR) (Westall et al,
2011). No attempt was made in this study to characterise the soluble components that were
released from the tested sample matrixes. In future studies it would be useful to have this
information in order to be able to correlate performance in liquid extracts from analogue
samples with the extractable components of that analogue sample.
The group developing the SOLID instrument have published a number of studies describing
analysis of Mars analogue samples including ferric iron enriched waters and sediments from
the Rio Tinto, goethite, hematite and jarosite, sands and clays. They found that these
analogue samples had no effect on assay performance, with the exception of clay type
samples which reduced assay signal (Parro et al, 2005). This contrasts with the findings of
the study performed here with LMC relevant immunoassays, where all of the sample matrix
types tested produced a reduction in immunoassay signal intensity. There are a number of
differences between the SOLID immunoassay and the LMC immunoassay. The most
significant of these differences is that SOLID immunoassays are predominantly performed in
sandwich format for the detection of markers of extant life e.g. large biological molecules
such as proteins. In the sandwich format SOLID assay liquid extracts are directly incubated
over a covalently immobilised microarray of antibodies. The sample is then washed away
and a second set of fluorescently labelled antibodies are incubated in buffer with the
microarray. Therefore only one of the immunological interactions required for signal
generation in SOLID occurs in the liquid extract, which may be beneficial in minimising
sample matrix mediated effects compared to the LMC, where the entire assay is conducted
directly in the liquid extract. However a sandwich assay format is unsuitable for the LMC
since many of the target molecules for the LMC, including high science priority markers of
extinct life, are small molecules and therefore cannot be detected using a sandwich assay.
The use of covalent immobilisation, like that used in the SOLID instrument, may be
beneficial for the LMC and this is being investigated as part of the package of work
implemented to improve microarray reproducibility.
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A further difference between SOLID and the LMC is that the extraction buffer used by SOLID
is composed of 0.4 M Tris HCl pH 8 with 0.3 M NaCl and 5 % BSA and the buffering
capacity is therefore likely to be superior to that of the LMC (100 mM HEPES buffer included
in freeze drying cocktail). This may partly explain why SOLID format immunoassays are
more robust when used to analyse real samples than LMC format immunoassays.
Improvement of the buffering capacity of the LMC was identified as a possible route to
improving LMC performance in Study 1 within this chapter, but buffer concentration is likely
to be constrained due to the sparingly soluble nature of markers of extinct life and the risk of
precipitation in solutions with high buffer salt concentrations.
Summary
In summary ELISA and pooled microarray format immunoassays function in liquid extracts
from a range of Mars analogue samples including clays, basalts and gypsum. However
signal intensity was generally lower compared to signal in assays run with extraction solvent
only as a control. Different immunoassays showed differing degrees of signal loss in the
same liquid extract further highlighting the need to include a range of well characterised
control assays with differing performances in different sample matrix types. Opportunities for
improving assay performance were identified, including increasing the buffering capacity in
the LMC freeze drying solvent and investigating covalent immobilisation of target
molecules/target molecule-protein conjugates to chip surfaces.
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4.7 Study 3: the impact of perchlorate salts on LMC extraction and
detection8
The work performed in Study 1 has shown that LMC format immunoassays can in principle
function in the presence of up to 100 mM perchlorate added directly into standards. This
implies that perchlorate containing samples, similar to those encountered by the Phoenix
lander, are unlikely to detrimentally affect LMC format immunoassay detection of target
molecules. However Study 1 made no attempt to address the effect that perchlorates salts
might have on target molecules during the LMC extraction step, and the resulting impact that
this might have on the immunoassay. As discussed in Section 4.3.2.5 perchlorate salts can
act as oxidising agents at high temperatures, and their presence on Mars may account for
the failure of the GC-MS on Viking and TEGA on Phoenix to detect any organic molecules in
martian samples (Navarro-González et al, 2010b). Under the relatively mild conditions of an
LMC liquid extraction, perchlorate is not expected to act as an oxidising agent. This study
was designed to extend the work carried out in Study 1 by investigating the effect of
perchlorate salts on combined LMC liquid extraction and immunoassay detection to
determine whether the LMC is capable of extracting and detecting organic molecules from
perchlorate containing analogue samples.
4.7.1 Supplementary experimental design
In order to confirm that organic molecules can be extracted and detected from spiked
samples in the presence of perchlorate salts a martian simulant regolith, JSC Mars-1, was
spiked with pyrene and perchlorate, extracted with LMC solvent and the extracts were
analysed by immunoassay. Pyrene was selected as an LMC relevant model target for this
study because pyrene is an abiotically produced organic molecule, which has previously
been detected in meteorites (Sephton and Botta 2005) and may have been delivered to the
martian surface by meteoritic in-fall. JSC Mars-1, a martian simulant regolith developed by
the Johnson Space Center (Houston, USA) (Allen et al, 1997), was selected for use in this
study because it is commonly used in studies where a martian analogue is required (Court et
al, 2010; Gough et al, 2010; Kral et al, 2011).
8 Note that the work in this study forms the basis for an article which has been published in
Astrobiology (Rix, 2011)
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4.7.2 Supplementary materials and methods
The following sections describe materials and methods used for the work within this study
supplementary to those described in Chapter 2 and where appropriate cross-references to
the relevant sections in Chapter 2 are provided.
4.7.2.1 Spiking of Mars analogue with target molecule and perchlorate salts
The martian simulant regolith JSC Mars-1 (used as supplied) was spiked with pyrene in
methanol, to a final concentration of 500 µg pyrene/g simulant regolith. This level was
chosen in the combined context of the expected extraction efficiency, the known sensitivity
of the model immunoassay used, and an additional factor to produce extracts that gave
100% immunoassay inhibition in the control samples. It is noted that this results in a higher
level of pyrene than could be expected on Mars. To achieve this, 500 µl of 1 mg/ml pyrene in
methanol was added to 1 g of JSC Mars-1 in a 7 ml glass tube, mixed by vortexing, and
allowed to stand at room temperature for approximately 30 minutes. The JSC Mars-1, which
consisted of a free flowing granular matrix when dry, formed into clumps when wetted with
solvent. After standing, methanol was removed by evaporation; vials were loosely sealed
and placed in an oven set at a temperature of +37°C overnight. After approximately 18
hours, the JSC Mars-1 had reverted to a free flowing granular matrix. Control samples were
spiked with methanol containing no pyrene and mixed and dried in the same way as the
pyrene spiked samples.
After spiking with pyrene, JSC Mars-1 was spiked with 1 weight percent perchlorate anion by
addition of solid calcium perchlorate tetrahydrate (Sigma Aldrich, Poole, UK, cat no. 401420)
or magnesium perchlorate hexahydrate (Sigma Aldrich, Poole, UK, cat no. 309303) to the
dry simulant regolith. This concentration is slightly in excess of that detected by the Phoenix
lander (Hecht et al, 2009). Fifteen and seven-tenths mg of calcium perchlorate or 16.7 mg of
magnesium perchlorate (both fine crystalline powders, used as supplied) were weighed into
7 ml glass vials, and 1 g of dried pyrene-spiked JSC Mars-1 was transferred into each vial
and mixed well by inversion and by vortex mixer.
4.7.2.2 Extraction and immunoassay of spiked samples
Three ml of 20/80 % (v/v) methanol/water with 1.5 g/L polysorbate 80 was added to 1g JSC
Mars-1 in a glass test tube and sonicated for 20 minutes with a Sonotrode Ultasonic
UP100H probe and UP50H ultrasonic processor set at 40 % amplitude (Hielscher
Ultrasonics, Teltow, Germany). Over twenty minutes of sonication the temperature of the
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solution increased to above ambient temperature but less than 50°C. This extraction
protocol simulates the baseline extraction protocol for the LMC. The mixture was allowed to
stand for 10 minutes, and the cloudy supernatant that had formed above the sedimented
analogue sample was decanted into 1.5 ml centrifuge tubes. To minimize loss of extracted
components by adsorption to surfaces of the hydrophobic polymer centrifuge tubes, the
tubes were first blocked with 0.5 % (w/v) BSA in 100 mM HEPES pH 7.4. The supernatants
were clarified by centrifugation at 17000 G for 10 minutes and stored at 2 – 8°C in glass
vials until tested in the immunoassay.
After centrifugation, it was observed that extracts from 500 µg/g and 0 µg/g pyrene spiked
JSC Mars-1 samples with 1 weight percent calcium or magnesium perchlorate were
colourless liquids, whereas extracts from 500 µg/g and 0 µg/g pyrene spiked JSC Mars-1
samples with no added perchlorate were yellow in colour (Figure 4-26).
Figure 4-26: Photograph of extracts from pyrene spiked JSC Mars-1 samples. JSC Mars-1
spiked with 500 µg/g pyrene and (from left to right) spiked with no perchlorate, 1 wt %
calcium perchlorate and 1 wt % magnesium perchlorate prior to extraction.
Note that this yellow coloration had not been observed with the liquid extracts from JSC
Mars-1 prepared in Study 2, but that the extracts from JSC Mars-1 in Study 2 had been
clarified by filtration through a cellulose acetate filter, rather than by centrifugation as was
used in this study.
Liquid extracts were analysed using an LMC format ELISA as described in Chapter 2
(Section 2.1.1.1) maintaining a final concentration of 20/80 % (v/v) methanol water with 1.5
g/L P80.
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4.7.3 Results and discussion
Figure 4-27 shows the immunoassay curves produced by running dilutions of extracts from
spiked samples in an LMC format ELISA: Extracts from six samples comprising
combinations of pyrene spike level (0 or 500 µg/g) and perchlorate spike (no perchlorate or 1
wt % calcium perchlorate or 1 wt % magnesium perchlorate).
Immunoassays with extracts from JSC Mars-1 sample spiked with 500 µg/g pyrene and 1 wt
% perchlorate (Figure 4-27a) all showed decreasing immunoassay signal as extract
concentration was increased, which implies that pyrene was extracted from the spiked JSC
Mars-1 and detected in the immunoassay. This conclusion is further supported by
examination of the immunoassay curves produced with extracts from JSC Mars-1 spiked
with 0 µg/g pyrene and 1 wt % perchlorate (Figure 4-27b), where no reduction in
immunoassay signal was observed with increasing extract concentration. This suggests that
the reduction in immunoassay signal produced with extracts from 500 µg/g pyrene and 1 wt
% perchlorate spiked JSC Mars-1 was not caused by either the perchlorate salts or by an
interfering substance extracted from the JSC Mars-1 simulant regolith. Therefore, these
results indicate that the presence of martian relevant levels of perchlorate salts in a well
studied martian analogue sample matrix had no significant effect on LMC representative
combined sample extraction and inhibition immunoassay detection of a representative small
organic molecule LMC target (pyrene).
At high (> 6%) concentrations of extract from JSC Mars-1 spiked with 500 µg/g pyrene but
no perchlorate however, immunoassay signal began to increase with increasing extract
concentration. In addition to this, the immunoassay curve produced with the extract from the
un-spiked sample (no pyrene and no perchlorate) (Figure 4-27b) showed a gradual reduction
in binding signal at high extract concentrations which was not observed with extracts spiked
with perchlorates (no pyrene). The extract concentration over which this reduction in signal
was observed was the same as the concentration that produced anomalous results for
pyrene spiked samples (no perchlorates) (Figure 4-27). This observation suggests a
common underlying effect.
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Figure 4-27: Pyrene inhibition ELISA run with extracts diluted in 20/80 % (v/v)
methanol/water with 1.5 g/L polysorbate 80. Extractions performed on JSC Mars-1 spiked
with (a) 500 µg/g pyrene (b) 0 µg/g pyrene and in each graph, (●) no perchlorate, (X) 1 wt %
calcium perchlorate and (▲) 1 % wt  magnesium perchlorate.  
Each data point represents a single replicate. OD values (A) were normalised against
maximum binding signal with 0 % extract (A0). Plotted immunoassay curves are the fit to a
four parameter binding equation, or where such a fit was deemed inappropriate; curves to
show trends in the data were drawn by using linear interpolation between the mean
normalised OD values. (solid line) no perchlorate, (dotted line) 1 wt % calcium perchlorate,
and (dashed line) 1 wt % magnesium perchlorate
The immunoassay curve produced with extract from JSC Mars-1 spiked with 500 µg/g
pyrene but no perchlorate (Figure 4-27a) is significantly, and unexpectedly, different from all
the other relevant immunoassay curves. At low extract concentrations, the immunoassay
curve is similar to that for extracts from 500 µg/g pyrene and 1 wt % perchlorate spiked JSC
Mars-1, that is, immunoassay signal decreased as the extract concentration was increased.
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It was noted that the anomalous behaviour correlated with the yellow coloration of the
extracts that only occurred from samples where no perchlorate was added (Figure 4-26). It is
therefore inferred that the substance responsible for the yellow colour of the extract, from
samples that had no perchlorate, caused the anomalous changes in immunoassay signal
intensity. Since the final immunoassay readout of the HRP enzyme label was carried out
after the yellow coloured extract was washed away, any optical absorption due to the yellow
coloration can be discounted. The conclusion is that the species producing the yellow colour
interacted with the immunoassay reagents by an as yet unidentified mechanism. To better
understand the absence of the yellow coloration in extracts from the perchlorate containing
samples, further investigations were carried out. It was observed that when perchlorate or
chloride salts were directly added to a yellow coloured extract, precipitation of a fine yellow
solid occurred. This yellow solid could be removed by centrifugation to give a colourless
extract. Therefore, in extracts from JSC Mars-1 spiked with 1 wt % perchlorate, the inference
is that the species producing the yellow colour was precipitated due to the presence of the
perchlorate salts and removed during clarification of the extracts by centrifugation, which
resulted in colourless extracts.
The mechanism for this observation is unknown, but it is unlikely to be pH related given that
the pH of both the yellow and colourless extracts were similar to one another. Studies have
not been performed to date with other Mars relevant salts to confirm whether this
observation is perchlorate salt specific or a more general effect due to presence of salts. It
should be noted that this anomalous behaviour was not observed in Study 2 when ELISAs,
including the benzo[a]pyrene immunoassay, were tested in liquid extracts from JSC Mars-1.
This discrepancy could be a result of the different methods used to clarify the liquid extracts
in the two studies i.e. in Study 2 liquid extracts from JSC Mars-1 were clarified by 0.45 µm
cellulose acetate membrane filtration whereas in this study liquid extracts from JSC Mars-1
were clarified by centrifugation.
In addition to the anomalous changes in binding signal, the slopes of the curves produced
with the three extracts from pyrene spiked JSC Mars-1 with and without perchlorate salts
(Figure 4-27) also differ in that the IC50 value for the extract from a sample spiked with
pyrene but no perchlorate was 50 % lower than for extracts from samples spiked with pyrene
and calcium perchlorate or magnesium perchlorate. The IC50 values were calculated from
the immunoassay data for extracts from the samples spiked with both perchlorate and
pyrene, as described in Section 2.2.2, which resulted in values of 2.4 % extract
concentration for the calcium perchlorate spiked sample and 2.3 % extract concentration for
the magnesium perchlorate spiked sample. The immunoassay data for extracts from the
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sample spiked with pyrene but with no perchlorate was not appropriate to fit to a four-
parameter binding model. Nevertheless, IC50 was estimated by using only values of extract
concentration below 6%, which resulted in an IC50 value of 1.0 % extract concentration.
This observation could be a result of changes in the immunoassay or changes in the
extraction, or both, and it is not possible to determine which from this study. One possibility
is that some pyrene may have been lost from the extract during the precipitation of the
yellow solid in extracts from perchlorate spiked samples, but retained in the extracts from
samples with no perchlorate, where no precipitation of the yellow solid occurred.
4.7.3.1 Study 3 General discussion
In Section 4.7 a representative immunoassay (benzo[a]pyrene) was used to demonstrate the
extraction and detection of pyrene, an example of a marker of abiotic meteoritic infall, in the
presence of Mars relevant concentrations of calcium and magnesium perchlorate salts.
While the main objective of this study was met, that is, to demonstrate that immunoassays
can be performed in the presence of martian levels of perchlorate, including an LMC
representative extraction step, an unexpected sample matrix effect was observed in the
absence of perchlorate. The results of this study highlight that there is a difference between
performing LMC extractions and immunoassays with JSC Mars-1 spiked with and without
perchlorate; the addition of perchlorate salts prevented a component of the JSC Mars-1 from
interfering with the immunoassay, but also doubled immunoassay IC50. This warrants further
investigation, but JSC Mars-1 is only representative of one class of a diverse range of
possible sample matrixes that may be encountered on Mars. Therefore, it is unlikely that this
sample matrix effect will be present in all cases.
Future work will be carried out in microarray format utilizing fluorescent labels to clarify
whether the observed changes in immunoassay performance are related to the HRP
enzyme label, or are true changes in antibody affinity. This may result in the effects
observed with the yellow coloured extracts becoming negligible. The LMC flight instrument
will not incorporate a centrifugation step; rather the martian extract will be filtered through a
0.45 micrometer pore-size filter prior to introduction into the microfluidic channel. Thus, it is
important to understand the implications of the findings of this study in a more flight
representative format.
Recent work published by Parro et al (2011) describes no significant effect of 50 mM
perchlorate on the liquid extraction and subsequent fluorescent microarray immunoassay
detection of large biological molecules, using sandwich format assays, from spiked samples
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in the presence of up to 50 mM perchlorate. The work within this study, extends the work of
Parro et al by specifically testing the impact of perchlorates on the extraction and detection
of small organic molecules in LMC relevant formats.
The LMC instrument will include up to 25 immunoassays; therefore, further work is required
to determine whether the findings also apply to other LMC relevant immunoassays, and
other Mars relevant sample matrixes. In addition, it should be taken into account that a
spiked sample may not effectively mimic a real sample where organic molecules may be
incorporated differently into the matrix; therefore, testing with natural samples spiked with
martian relevant levels of perchlorate will be carried out. Ideally, trials would be performed
with natural samples with naturally occurring perchlorate salts, but there are no known
terrestrial samples available with martian relevant levels of perchlorates.
4.8 Chapter conclusions and recommendations for future work
The aim of the work reported in this chapter was to investigate the potential interaction of the
Mars sample matrix with the LMC immunoassay in order to identify risks for operation of the
LMC instrument and to enable the development of mitigation strategies. To achieve this, the
impact of individual likely Mars sample matrix components and liquid extracts from a number
of Mars analogue samples on LMC relevant immunoassays was tested. In addition a further
study was carried out to specifically test the impact of perchlorate salts on combined LMC
extraction and detection. From the work carried out in the three studies within this chapter it
is possible to draw a number of conclusions and also to make recommendations relating to
the future program of work for the LMC.
Work carried out in ELISA and microarray formats has demonstrated that the LMC
immunoassays are likely to function with martian samples similar to those encountered by
the Phoenix lander, however some of the samples encountered by MER may be more
challenging for the immunoassays, particularly if all of the salt component of these samples
is extractable. This highlights the need for future work to better understand the likely solution
chemistry of martian samples by characterising the solution chemistry of a range of Mars
analogue samples and correlating the solution chemistry data with immunoassay
performance data.
A further conclusion that can be drawn from work carried out with Mars relevant sample
matrix components is that the buffering capacity in the freeze drying buffer is insufficient to
control pH of the immunoassay when components such as iron ions are dissolved in the
LMC extraction solvent. Therefore a further piece of future work had been identified to
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investigate increasing buffering capacity, however this may be limited by factors such as
solubility of buffer salts and the risk of precipitation within the microfluidic channels of the
LMC. Other opportunities identified to improve assay performance under high/low pH include
the investigation of covalent immobilisation of immobilised target molecules to the
waveguide surfaces as acidic salts were shown to remove immobilised target molecules
from 96-well plates.
Immunoassays run with liquid extracts from martian samples are likely to have reduced
signal intensity compared to immunoassays run with standards prepared directly in
extraction solvent. In addition different immunoassays may show different levels of signal
loss in liquid extracts from martian samples with specific geologies. There is therefore the
need to characterise the performance of antibodies at an early stage in their development for
the LMC, in order to exclude antibodies with particularly poor performance and to allow the
identification of appropriate control assays, to mitigate the risk of data misinterpretation. This
has been incorporated into the standard assay development procedure adopted within the
LMC consortium.
Iron ions, which may be present in liquid extracts from martian samples, reduce fluorescent
signal. However their effect can be reduced by washing away iron ions prior to excitation and
imaging. Therefore in order to mitigate the risk of fluorescent signal loss due to iron ions, or
any other species from the martian sample, the liquid extract within the array chamber of the
flight instrument should be replaced with fresh extraction solvent, prior to excitation and
imaging of the microarray. This is possible with the current flight model design and this
capability should be retained in any future design iterations.
Both LMC immunoassay detection and the LMC low temperature aqueous extraction with
ultra-sonication are not negatively influenced by the presence of perchlorate salts in martian
samples at levels similar to those detected at the NASA Phoenix landing site. These results
increase confidence in the LMC instruments capability to detect small organic molecules on
Mars in perchlorate rich samples. The testing of further combinations of immunoassay and
sample matrices will be performed to validate the assumption that the model target
molecules and analogue sample used in this work are broadly representative and will include
testing within a multiplexed microarray immunoassay format.
It is likely that even with improved buffering capacity and optimised immobilisation stability
some samples will be unsuitable for analysis. The LMC instrument is only capable of
analysing four samples therefore it is of critical importance to understand how data from the
other ExoMars instruments can be used to identify samples that may be unsuitable for
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analysis, due to likely sample matrix effects. Other ExoMars instruments that may provide
useful information on the geological context of samples are PanCam, a multi-spectral
imager, MicroOmega, a microimaging system consisting of a visible light microscope and a
near IR imaging spectrometer, XRD an X-ray diffractometer and fluorescence spectrometer,
and the onboard Ramen spectrometer. It is therefore recommended that prior to flight the
suite of ExoMars instruments should be used to analyse multiple diverse analogue samples
to enable correlation of datasets regarding the geology of the samples with LMC instrument
performance.
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5 Generation of Antibodies for the Detection of Extinct
Life Biomarker Targets: Use of an Immunised
Recombinant Antibody Library
5.1 Introduction and context
Although interest in the use of antibodies for the detection of markers of life in planetary
exploration is growing (McKay et al, 2000; Steele et al, 2001; Vandenabeele-Trambouze et
al, 2002; Parro et al, 2005; Schweitzer et al, 2005), there are few examples of antibodies
developed specifically for planetary exploration applications. However there are antibodies
which have been developed for use in other fields, e.g. in microbiology, and in the detection
of environmental pollutants, that recognise markers of extant life, markers of meteoritic in-fall
and markers of contamination and may therefore be suitable for use in the LMC instrument.
Critically there are very few antibodies which recognise markers of extinct life, which are
high priority science targets for the LMC because if life did exist during warmer and wetter
periods on Mars it is considered unlikely that it could survive under current cold and dry
martian conditions (Knoll et al, 2005; Bibring et al, 2006). Therefore there is a need to
develop antibodies that recognise markers of extinct life for the LMC instrument. Extinct life
markers are generally small, hydrophobic and chemically inert organic molecules therefore
the production of antibodies that recognise these types of molecule is expected to be
challenging.
The LMC aims to detect up to 25 target molecules or molecular species, including a number
of markers of extinct life. Prior to this thesis, the LMC science team identified five extinct life
markers (Figure 5-1) as preliminary targets for the production of antibodies. The selection of
these targets was a pragmatic compromise based on:
 priority for the ExoMars mission as defined at a workshop held in 2006 to identify and
prioritise targets for the ExoMars mission (Parnell et al, 2007)
 the availability of suitable materials for the production of immunogens (since extinct life
markers are too small to illicit an immune response unless conjugated to an
immunogenic carrier protein)
 an attempt to select a range of different types of structure to more broadly represent all
molecular classes encompassed by extinct life biomarker targets for the LMC (acyclic
aliphatic, cyclic aliphatic and cyclic aromatic)
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Figure 5-1: Structure of extinct life markers selected as preliminary targets for the generation
of antibodies for the LMC (a) porphyrin, (b) hopane, (c) phytane, (d) a straight chain alkane
(octadecane) and (e) 5β sterane. Note that the ideal antibodies for the LMC would recognise 
a family of closely related molecules, rather than being highly specific for the one example of
each molecular type shown here.
In 2008/2009 the LMC consortium attempted to generate antibodies to these five preliminary
targets using traditional polyclonal antibody technology via immunisation of rabbits.
However, the polyclonal sera showed no recognition of the relevant free target molecule,
and cross reacted with irrelevant small molecule-carrier protein conjugates (Buckley 2009).
At this stage in the project the production of monoclonal antibodies had already been
discounted due to the long time scales and high costs involved, therefore an alternative
antibody generation strategy was required and the production of recombinant antibodies, by
screening phage display libraries, was identified as a promising option.
Screening recombinant antibody libraries using phage display is a powerful technique that
allows the isolation of a large number of antibody clones in a short space of time.
Traditionally these libraries have been used for the production of therapeutic antibodies
against large target molecules, but phage display libraries are now increasingly being used
for the production of antibodies against small molecule targets, primarily for use in the field
of environmental analysis (Kramer and Hock 2003).
Prior to the work reported in this thesis, a naive recombinant antibody library (please see
Section 5.3.3.1 for description of recombinant antibody library sources including naive
libraries) was screened for antibodies that bound to phytane, hopane, 5β sterane and 
porphyrin (Derveni 2009), but suitable antibodies were not isolated. It was therefore decided
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to construct an immunised library with the five selected target molecules since immunisation
was expected to bias the library repertoire towards clones that recognised the relevant target
molecules, increasing the probability of successfully isolating appropriate antibodies.
Derivatives of the five preliminary target molecules were synthesised and conjugated to
keyhole limpet hemocyanin (KLH) carrier protein to produce immunogens (Figure 5-2)9. The
immunogens were supplied to ImmunoSolv Ltd., (Aberdeen, UK), who organised
immunisation of two sheep and constructed a phage display recombinant antibody library
using standard methods as described in the literature (Charlton et al, 2001). Sheep were
used for the construction of the library because anti-hapten antibodies have previously been
obtained from immunised sheep libraries (Charlton et al, 2001) and because ImmunoSolv
Ltd. has previous experience with the use of sheep for the construction of immunised
libraries.
Figure 5-2: Immunogens used for production of phage display immunised recombinant
antibody library
(a) hopane-KLH conjugate, (b) 5β sterane-KLH conjugate, (c) phytane-KLH conjugate, (d) 
porphyrin-KLH conjugate, (e) octadecane straight chain alkane-KLH conjugate
Therefore the fundamental goal of this work was to determine whether screening the
immunised recombinant antibody library, produced by ImmunoSolv, could generate
antibodies capable of detecting any of the five selected markers of extinct life. Successful
isolation of appropriate antibodies would not only provide antibodies that could be included
on the flight instrument, but would also de-risk the future production of antibodies against a
9 Derivatives and conjugates were synthesised by Dr Manisha Sathe and Mrs Marjorie Allen, Cranfield
University, UK
139
wider range of extinct life marker target molecules using recombinant antibody library
technology.
5.2 Chapter objectives
The objective of the work reported in this chapter was to determine if screening the available
phage display immunised recombinant antibody library could isolate antibodies that
specifically recognise extinct life markers, within the context of the available resources and
timescales for development of the LMC instrument.
In order to meet this goal the following specific objectives were set:
1) To attempt to isolate antibodies that bind to an extinct life marker molecule/molecular
class by screening the immunised recombinant antibody library using a selected
literature procedure for one or more targets.
2) To test the output of the selected literature procedure, i.e. both as antibody fragments
expressed as fusion proteins on phage (scFvs) and, where relevant, as soluble single
chain antibody fragments (scAbs), for appropriate function in an LMC relevant
context.
3) To review the output of the selected literature procedure and if necessary to modify
the protocol in order to favour the selection of clones against extinct life marker
molecules.
As discussed in the introduction to this chapter the immunised library used in this work
was generated using five target molecules: porphyrin, hopane, phytane, a straight chain
alkane (octadecane) and 5β sterane as examples of five molecular classes porphyrins, 
hopanes, isoprenoids, straight chain alkanes and steranes. Within this thesis work was
carried out to isolate antibodies to three of these molecular species; hopane, octadecane
and 5β sterane. Additional screening for the remaining target molecules was carried out 
independently of the work reported in this thesis, but in a similar timeframe, by other
members of the LMC team at Cranfield University and by ImmunoSolv Ltd in Aberdeen.
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5.3 Literature review
5.3.1 Introduction
As described in the introduction to this chapter, extinct life markers are high priority targets
for the LMC, but this class of target molecule is not typically detected using antibody based
techniques and consequently very few antibodies are currently available to this type of
molecule. Traditional antibody generation routes have been ruled out for the generation of
antibodies to markers of extinct life for the LMC, for the reasons discussed in Section 5.1
and the production of recombinant antibodies by screening an immunised phage display
library has been identified as a potential route forward. This review therefore aims to
consider information in the literature relevant to the production of antibodies against these
types of target molecule, with a specific focus on phage display and is divided into two
sections. The first section considers the nature of extinct life markers and the challenges in
producing antibodies to these types of molecule, with particular reference to the five targets
used to construct the immunised recombinant antibody library used in this work. The second
section reviews the use of phage display technology, specifically focusing on the generation
of antibodies that recognise small hydrophobic target molecules.
5.3.2 Extinct life biomarkers as hydrophobic small molecule targets for
the generation of antibodies
Markers of extinct life comprise biologically produced molecules that are stable over
geological timescales and the geologically stable break down products of biologically
produced molecules. Markers of extinct life are therefore mostly derived from lipid
membranes, and from chlorophyll type pigments. Over geological timescales biologically
produced molecules are altered through the reduction of double bonds and the loss of
functional groups (Peters et al, 2005). Therefore extinct biomarkers typically comprise a
saturated carbon skeleton, with few or no functional groups and consequently are
hydrophobic and chemically inert in nature. Markers, such as those shown in Figure 5-1, are
routinely detected in terrestrial samples using laboratory based chromatographic and
spectrometric detection techniques (Fernandez-Calvo et al, 2006). The LMC intends to
detect markers of extinct life in liquid extracts of martian samples using an antibody
microarray immunoassay, therefore it is necessary to raise antibodies against these
molecules.
Antibodies bind to their corresponding target molecules via relatively weak non-covalent
hydrogen bonding, electrostatic, Van Der Waals, and hydrophobic forces, which are
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dependent on the three dimensional structure and charge distribution of the antibody and the
target molecule, however markers of extinct life are small, chemically inert and apolar and
some lack a defined three dimensional structure, reducing the opportunity for binding
interactions with an antibody. For this reason the production of antibodies to extinct life
markers is expected to be challenging. Furthermore in order to have a realistic expectation
of detecting trace levels of target molecules the LMC instrument must have a low detection
limit (e.g. in the order of parts per billion or less) and therefore the antibodies selected for
use in the flight instrument must have high affinities (e.g. nanomolar affinities) for their target
molecules.
For the purposes of antibody generation, markers of extinct life are defined as haptens due
to their low molecular weight (< 1000 Da) and it is more difficult to produce high affinity
antibodies to haptens than to larger protein target molecules (Strachan et al, 2002). Hapten
molecules are too small to illicit an immune response and must therefore be conjugated to a
large immunogenic protein (termed a carrier protein) in-order to activate recognition by the
immune system (Fodey et al, 2011). Since haptens occupy only a small fraction of the
immunogen, most of the animals B cells are triggered by the conjugate and carrier protein
and only a few are triggered by the hapten (Kramer 2002). Some small molecules fail to
invoke an immune response even when conjugated to a carrier protein (Moghaddam et al,
2001). The design of conjugates used for immunisation in the production of anti-small
molecule antibodies is critical to the production of antibodies with appropriate binding
properties. For example the position used for conjugation of the small molecule to the carrier
protein may affect the specificity of the antibodies generated (Gani et al, 1994), and the
length of the linker used to join the small molecule and the carrier protein is also critical; if
the linker is too short the determining groups of the hapten may be masked (Li et al, 2006).
Furthermore hydrophobic molecules are viewed as particularly challenging targets for
antibody generation due to difficulties associated with solubilisation for conjugation to carrier
proteins. Attempts to produce antibodies to hydrophobic small molecule targets frequently
result in the generation of antibodies that recognise the conjugate, or the derivative form of
the small molecule but not the free target molecule (Makvandi-Nejad et al, 2010).
In the following sections the five markers of extinct life, all small hydrophobic molecules,
used in the production of the immunised library that was screened in this work (hopane,
phytane, porphyrin, 5β sterane, and straight chain alkanes) (Figure 5-1), are described in 
more detail, together with examples of antibodies produced against these or related
molecules where they have been documented in the literature.
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5.3.2.1 Hopanes
Hopanes (Figure 5-1) are geologically stable molecules derived from hopanoids which
originate in the cell membrane of prokaryotes, constituting 0.1 –5 mg/g of the dry weight of a
cell (Peters et al, 2005). Hopanes are a high priority potential biomarker of Martian life
because their bio-synthesis does not require molecular oxygen, which appears never to
have been present on Mars in significant quantities (Parnell et al, 2007). Hopanes are
viewed as challenging molecules to produce antibodies to because they consist of aliphatic
carbon rings, with no polar functional groups to facilitate hydrogen bonding with an antibody
binding site and they also have poor water solubility.
A conference paper given at the 2003 Lunar and Planetary Space Science Conference by
the group developing the MILDI instrument briefly reported the production of polyclonal anti-
hopane antibodies (Maule et al, 2003). This would indicate that it is possible to raise
antibodies against this type of target molecule. However attempts by the LMC project team
to produce polyclonal antibodies to hopane were unsuccessful (Buckley 2009).
5.3.2.2 Phytane
Phytane (Figure 5-1) is a highly stable biomarker that originates from the phytol side chain of
chlorophyll and bacteriochlorophyll and also from the cell membranes of archea (Peters et
al, 2005). Phytane was assigned as a high priority target for the ExoMars mission because it
is geologically stable and has a wide variety of biological pre-cursors (Parnell et al, 2007).
Phytane, an acyclic aliphatic molecule, is anticipated to be a particularly challenging target to
produce an antibody to, as in addition to having no functional groups, it has no conserved
three dimensional structure.
There are commercially available antibodies that recognise phytanic acid (phytane with a
terminal carboxylic acid group) including a rabbit polyclonal available from AbCam
(Cambridge, UK, product code ab51309), but when tested by the LMC project team this
antibody showed no recognition of free phytanic acid, no cross reactivity with phytane and
appeared to only recognise the protein-phytanic acid conjugate (Derveni 2008). It is
unknown whether it is possible to produce antibodies to this target.
5.3.2.3 Porphyrins
Porphyrins (Figure 5-1) are highly stable geological derivatives of well characterised
biomolecules such as heme, chlorophyll and bacteriochlorophyll that are widely distributed
among all terrestrial living organisms, from prokaroytes to mammals (Suo et al, 2007). In the
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2006 biomarker workshop, held to define targets of relevance for the ExoMars mission,
porphyrins were assigned a high priority due to their diverse sources and geological stability
(Parnell et al, 2007).
Porphyrins have a well defined three dimensional structure as well as delocalised electron
density around the pyrrole rings and nitrogen atoms which can hydrogen bond when not
chelated to a metal ion. Porphyrins can chelate metal ions, which enhances their stability to
diagenesis (Killops and Killops 2005) and may also influence how well they are recognised
by antibodies (Schwabacher et al, 1989). In terrestrial living organisms porphyrin precursors
contain magnesium, copper or cobalt ions, but in petroleum vanadium and nickel commonly
replace these metals (Peters et al, 2005).
Schwabacher et al report the production of monoclonal antibodies, that bind to a synthetic
metallo-porphyrin (Schwabacher et al, 1989), although the substituent groups on the pyrrole
rings of the synthetic metallo-porphyrin were more polar compared to the expected
hydrophobic side chains for extinct life marker porphyrin molecules. There are also
commercially available antibodies to structures related to porphyrins such as haemoglobin
e.g. an anti-haemoglobin antibody is available from Sigma (product code H4890) (Sigma-
Aldrich).
5.3.2.4 Sterane
Steranes (Figure 5-1) are a geologically stable class of tetracyclic saturated biomarkers
constructed from six isoprene sub-units and are derived from sterols which originate in the
cell membranes of eukaroytes (Peters et al, 2005; Parnell et al, 2007). Unlike the structurally
similar hopanoids, molecular oxygen is required for the bio-synthesis of sterols, reducing the
priority of steranes as biomarker targets of ancient martian life compared to hopanes
(Parnell et al, 2007).
There are no examples in the literature of attempts, successful or not, to raise antibodies
against steranes. However there are numerous examples of monoclonal and recombinant
antibodies that bind to steroids, which have a similar tetracyclic ring structure but more polar
functional groups than steranes (White. et al, 1985; Kobayashi et al, 2009).
5.3.2.5 Straight chain alkanes
Lipid membranes in eubacteria and eukarya are composed of glycolipids and phospholipids;
fatty acid chains (12 – 24 carbons long) attached to a polar head group (Peters et al, 2005).
Fatty acids can be synthesised abiotically, but the probability of abiotic synthesis of long un-
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branched chains is very small (Parnell et al, 2007). Fatty acids are stable and synthesised by
two out of three of the domains for life and were therefore assigned as high priority
biomarkers for the ExoMars mission (Parnell et al, 2007). Further discussions with various
experts highlighted that on Mars, a decarboxylated straight chain alkane (i.e. non-branched)
would be a more relevant target than a fatty acid and therefore octadecane was selected as
a target for this work.
Fatty acids and straight chain alkanes are considered to be challenging targets to raise
antibodies to due to their low molecular weight and conformational flexibility. There is one
example in the literature of an antibody that recognises methyl palmitate, selected from a
semi-synthetic human antibody library, that bound specifically to a C16 chain with an IC50
value of 0.2 µM (Gargir et al, 2002) suggesting that it is possible to raise antibodies against
this type of molecule, although this sensitivity would be too low for the LMC flight instrument.
5.3.2.6 Summary
In summary markers of extinct life are hydrophobic small molecules. Their small apolar
nature results in limited opportunities for interaction with an antibody binding site, therefore
the production of high affinity antibodies that recognise these types of molecules is likely to
be challenging. There are some examples in the literature of antibodies raised against
related structures using traditional monoclonal, polyclonal and recombinant approaches;
however the majority of these related structures are more polar than the targets for the LMC.
Therefore part of the novelty of the work reported in this chapter is to attempt to produce
antibodies against targets that are significantly more hydrophobic than the vast majority of
targets against which antibodies have successfully been raised against in previous work.
5.3.3 Phage display technology for the production of antibodies that
recognise small, hydrophobic and chemically inert target
molecules
Phage display is the display of foreign peptides, proteins or antibody fragments on the
surface of filamentous phage by fusion of the DNA coding sequence of the protein to be
displayed to the gene encoding one of the phage surface proteins, most commonly the pIII
coat protein (Sidhu 2001). This results in the antibody fragment or protein being displayed as
a fusion protein on the surface of a phage particle which contains the genetic material that
encodes the displayed protein fragment, thus creating a link between genotype and
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phenotype. Phage particles displaying fusion proteins with the desired binding properties can
rapidly be separated using in-vitro affinity selection. Because the phage particles contain the
gene that encodes the displayed protein fragment it is then straightforward to isolate and
clone the gene into an appropriate vector for expression, offering a rapid route to the
production of the desired product.
Antibodies generated by phage display have mostly been used in therapeutic and
biomedical applications, and it is only recently that interest has expanded to the
development of anti-small molecule antibodies using phage display, primarily for the
monitoring of pesticides, antibiotics and drug contamination in water, food and environmental
samples (Brichta et al, 2005). This literature review focuses on applications of phage display
relevant to the production of antibodies that bind to hydrophobic and small molecule targets.
For more detailed information concerning the principles of phage display there are a number
of comprehensive review papers available (Hoogenboom et al, 1998; Azzazy and Highsmith
2002; Brichta et al, 2005; Hoogenboom 2005).
5.3.3.1 Construction of phage display libraries for the production of antibodies that
recognise small and hydrophobic targets
Phage display libraries can be produced from immunised sources (i.e. immunised animals)
like the library used in this work, non-immunised sources (i.e. non-immunised animals), or
can be derived synthetically/semi-synthetically. The following three sections consider each
type of library in turn, discussing advantages and disadvantages and highlighting examples
where specific library types have been used to generate antibodies against hydrophobic and
small molecule targets.
Immunised libraries
Libraries from immunised sources are constructed by cloning genes coding the variable
portions of antibody heavy and light chains directly from the B-lymphocytes of an immunised
host animal. Since the immune system of the animal has been biased towards recognition of
the target molecule by immunisation it is possible to select high affinity clones from a
relatively small library (Brichta et al, 2005). The recombinant antibody library will also contain
clones that are not present in the immune system of the animal due to the recombination of
heavy and light chains during library construction, which increases library diversity.
Immunised libraries are limited by the immune repertoire of the animal host and it can be
difficult to isolate antibodies against self antigens, non immunogenic antigens and toxic
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antigens which cannot be used for immunisation (Hoogenboom 2005). This is of relevance
to the LMC because many of the extinct life targets are likely to be poorly immunogenic due
to their small size and lack of functional groups. For each target, or set of targets against
which antibodies are to be generated, an animal must be immunised and a recombinant
antibody library constructed, which takes several months. This is an important consideration
for the LMC as should the screening of immunised recombinant antibody libraries by phage
display prove effective in isolating antibodies that recognise selected extinct life markers, the
production of further libraries using animals immunised with additional targets would be
required, but this has to be carried out within the context of flight instrument delivery
(currently scheduled for early 2015).
Immunised libraries have been used to successfully select antibodies, including high affinity
antibodies with nanomolar sensitivities against a number of small molecule targets, some
examples of which are listed in Table 5-1. Note that all of these molecules are more polar
than the markers of extinct life selected as target molecules for the LMC.
Table 5-1: Examples of small molecule binding antibodies selected from immunised phage
display recombinant antibody libraries
Target Target MW (Da) Host IC50 Reference
Atrazine 216 Sheep 0.13 nM (Charlton et al, 2001)
Mecoprop
Simazine
215
202
Rabbit
Rabbit
Not given
Not given
(Li et al, 2000)
(Li et al, 2000)
Fluorescein 332 Chicken Not given (Andris-Widhopf et al, 2000)
Monensin 671 Mouse 31 nM (Makvandi-Nejad et al, 2010)
Methamidophos 141 Mouse 142 nM (Li et al, 2006)
Naive/native libraries
Non immunised libraries can be created by cloning antibody diversity from the B-
lymphocytes of non-immune animals. Therefore the source of genes used to construct the
library is not explicitly biased to contain clones that bind to a specific target molecule
(Hoogenboom 2005) and the library is expected to contain greater sequence diversity than
an immunised library (Brichta et al, 2005). Naive libraries can be screened against any target
molecule, without the need for immunisation or construction of a new library (Sheedy et al,
2007). In some instances antibodies against self, non-immunogenic and toxic antigens,
which cannot be used for immunisation, have been isolated from naïve libraries (Brichta et
al, 2005). Antibodies selected from non-immune libraries are often of lower affinity than
those isolated from immunised libraries of a similar size, but this can be overcome by the
construction of larger libraries which offer better opportunities for isolating specific and high
affinity antibodies (Little et al, 1999; Sheedy et al, 2007).
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Anti-small molecule antibodies have previously been isolated from naive libraries and some
examples are listed in Table 5-2. Once again the target molecules against which antibodies
have been selected are generally more polar than LMC biomarker molecules of extinct life.
Table 5-2: Examples of small molecule binding antibodies selected from naive phage display
recombinant antibody libraries
Target MW (Da) Library Source IC50 Reference
FITC
Tri nitrophenol
389
401
Salmon
Salmon
Not given
Not given
(Jørgensen et al, 2002)
(Jørgensen et al, 2002)
Phenyl-ox-azolone 161 Human Not given (de-Haard et al, 1999)
Progesterone
Testosterone
314
413
Human
Human
Not given
Not given
(Little et al, 1999)
(Little et al, 1999)
Synthetic/semi-synthetic libraries
Synthetic/semi-synthetic libraries, can be created in-vitro by introducing diversity into the
CDRs V genes (either synthetic V genes, genes derived from a monoclonal hybridoma line,
or a single phage clone (Hoogenboom 2005)). The use of synthetic/semi-synthetic libraries
removes the need to use animals in the generation of recombinant antibody libraries and a
single synthetic/semi-synthetic library can be screened against multiple targets.
Synthetic/semi-synthetic libraries can also be used to generate antibodies against non-
immunogenic and toxic target molecules. In addition, the contents, local variability and
overall diversity of a synthetic/semi-synthetic library can be controlled and well defined
facilitating library design (Brichta et al, 2005). For example a library specifically designed to
produce high affinity antibodies to small molecule targets, termed a cavity library, was built
using a hapten binding antibody, with a pronounced antigen binding pocket, as a structural
backbone and performing site directed mutagenesis at residues commonly involved in
hapten contacts (Persson et al, 2006).
Anti-small molecule antibodies have been isolated from both synthetic and semi-synthetic
libraries, including the cavity library mentioned above, some examples of which are given in
Table 5-3. Once again the majority of target molecules are more polar than the markers of
extinct life selected as targets for the LMC, although it should be noted that an antibody
against methyl palmitate generated from the semi-synthetic Nissim library, showed cross
reactivity with hexadecane, a straight chain alkane (IC50 = 0.2 µM), and straight chain
alkanes are a marker of extinct life.
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Table 5-3: Examples of small molecule binding antibodies selected from synthetic/semi-
synthetic phage display recombinant antibody libraries
Target MW (Da) Library Source IC50 Ref
Fluorescein
NIP
332
323
Semi-synthetic (chicken)
Semi-synthetic (chicken)
Not given
Not given
(van-Wyngaardt et
al, 2004)
Microcystin
Microcystin
1000
1000
Synthetic (Tomlinson I library)
Semi-synthetic (Griffin library)
4 µM
13 nM
(Strachan et al,
2002)
Methyl
palmitate
270 Semi-synthetic (Nissim library) 0.5 µM (Gargir et al, 2002)
FITC
Testesterone
NIP
389
413
323
Semi synthetic (cavity library)
Semi synthetic (cavity library)
Semi synthetic (cavity library)
0.7 nM
0.2 µM
2.4 µM
(Persson et al, 2006)
4-hydroxy-3-iodo-5-nitrophenylacetic acid = NIP
Summary
Anti-small molecule antibodies have been successfully isolated from immunised, naive and
synthetic/semi-synthetic phage display recombinant antibody libraries. The molecular
weights of the target molecules against which antibodies have been isolated are similar to
those of the five preliminary markers of extinct life identified in Section 6.1, but the target
molecules to which these antibodies bind are more polar than extinct life target molecules for
the LMC. Each of the three library types discussed here has its own advantages and
disadvantages. The library available for screening within the work reported in this chapter
was a phage display recombinant antibody library produced using an immunised sheep.
5.3.3.2 Strategies for screening phage display recombinant antibody libraries for
antibodies that bind hydrophobic and hapten targets
Recombinant antibody libraries are screened for antibodies that bind to the desired target
molecule using a two stage process. The first stage of screening involves the isolation of a
sub-population of the library which is enriched in relevant clones using an affinity selection
process commonly called panning. In the second stage of screening the enriched population
is analysed, including isolation and testing of individual clones.
In a single round of panning a recombinant antibody library, displayed as fusion proteins
expressed on phage particles, is exposed to an immobilised version of the desired target
molecule (Figure 5-3). Phage particles expressing antibody fragments that recognise the
target molecule bind to the immobilised target, whereas unbound phage, which does not
recognise the target, is washed away. Bound phage is then recovered and infected into E.
coli for amplification, to produce a population enriched in relevant binders displayed as
fusion proteins on phage particles. Several rounds of panning are usually required because
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non-specific binding limits the enrichment that can be achieved in a single panning round
(Hoogenboom et al, 1998; Brichta et al, 2005; Hoogenboom 2005).
Figure 5-3: Diagram showing recombinant antibody library screening process for the
isolation of relevant clones from a phage display recombinant antibody library
Panning is a versatile process and the physical parameters imposed during panning can
strongly influence the nature of the antibodies that are enriched and subsequently isolated
(Lou et al, 2001). For example using short incubation times and long wash steps can
preferentially enrich clones with fast on-rates and slow off-rates, and reducing the
concentrations of immobilised target molecule favours the enrichment of clones with high
binding affinities (Hoogenboom 2005; Li et al, 2006). The ability to favour the enrichment of
antibodies with specific properties, by making minor changes in panning conditions may be
useful for the LMC since due to the format of the flight immunoassay it is desirable to have
antibodies which have high affinities and also fast on-rates and slow off-rates. There are also
examples in the literature where panning protocols have been adapted to adjust the
specificity of antibodies (Zhu et al, 2011) which may be relevant for the LMC given the desire
to produce antibodies that recognise classes of related molecules, rather than specific
molecules, due to natural variation in the substituent groups on the molecules, and due to
the likelihood that any life on Mars may not have evolved in an identical fashion to life on
Earth.
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Panning for small molecule binding antibodies
Unlike protein targets, small molecule targets are not usually directly immobilised to a
substrate for panning. Within the literature there are two methods which are commonly
adopted for the immobilisation of small molecule targets when panning for hapten binding
antibodies. Small molecules can be conjugated to a large carrier protein (Andris-Widhopf et
al, 2000; Li et al, 2000; Charlton et al, 2001; Li et al, 2006; McKenzie et al, 2007), often BSA
or KLH, for immobilisation to solid surfaces in the panning process. In order to minimise the
enrichment of carrier protein binding clones, panning is usually carried out in a background
of free carrier protein, and the carrier protein used is often alternated between panning
rounds (Sheedy et al, 2007). The second strategy that is used to immobilise small molecule
target molecules for panning is to biotinylate the target molecule and then to immobilise the
biotinylated target via streptavidin coated surfaces (Korpimäki et al, 2002; Kobayashi et al,
2009). In order to minimise the enrichment of streptavidin binding clones, a subtractive
panning step can be used. In this step streptavidin binding clones are depleted by incubation
over streptavidin coated surfaces, prior to exposure to the immobilised biotinylated target
molecule.
Some previous attempts to screen phage display recombinant antibody libraries for hapten
binding antibodies have resulted in the enrichment of clones that bind to the conjugated
version of the target molecule, but not to the free target molecule (Moghaddam et al, 2001;
Makvandi-Nejad et al, 2010). In order to avoid this, panning strategies have been adapted to
incorporate the use of competitive elution, where bound phage is eluted from the target
molecule-protein conjugate using the free target molecule prior to amplification in E. coli.
This has been demonstrated to favour the enrichment and subsequent isolation of phage
clones that have a higher affinity for the free target molecule, over carrier protein conjugates
(Charlton et al, 2001; Moghaddam et al, 2001).
Panning for antibodies that bind to hydrophobic molecules
There are few examples in the literature of attempts to screen recombinant antibody libraries
for antibodies that bind to hydrophobic targets. Antibodies against selected pesticides and
herbicides with limited water solubility, such as atrazine, have been selected from
recombinant antibody libraries (Li et al, 2000; Charlton et al, 2001), but such molecules are
significantly more polar that LMC biomarkers of extinct life. The main issue of concern with
attempting to screen phage display libraries for antibodies against hydrophobic small
molecules, is that the target molecules will have poor water solubility, making it difficult to
introduce a competitive elution step. However filamentous phage have been demonstrated
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to retain their ability to infect E. coli after exposure to up to 80/20 % (v/v) methanol water, 20
%/80 % (v/v) propan-2-ol water, 99 %/1% (v/v) acetonitrile water and 60 %/40 % (v/v)
dimethylformamide water mixtures (Olofsson et al, 1998). Therefore it is possible to perform
library screening in aqueous buffers with a proportion of water miscible organic solvent to
facilitate solubilisation of hydrophobic markers of extinct life.
Summary
Screening phage display recombinant antibody libraries represents a rapid and flexible
means for the generation of antibodies with desired binding characteristics and also offers
the potential to favour the isolation of antibodies with specific properties by making small
changes in the panning protocol. There are two main panning strategies that have been
used when screening for antibodies that bind small molecule targets; panning with small
molecule-carrier protein conjugates and panning with small molecule-biotin conjugates.
5.3.4 Literature review conclusion
Markers of extinct life are challenging molecules to raise antibodies to due to their small size
and their hydrophobic nature and there are very few examples of antibodies raised
successfully against these types of molecule. Recombinant antibody technology appears to
offer an efficient way to optimise the generation of antibodies against these sorts of targets.
This is ideal for the LMC due to the short timescales required and the ability to optimise the
properties of the antibodies selected during the panning process.
Attempting to screen phage display recombinant antibody libraries for antibodies that
recognise markers of extinct life will represent one of the first attempts to (i) specifically
generate antibodies for use in planetary exploration, (ii) to generate antibodies against
targets that are hydrophobic and chemically inert.
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5.4 Materials and methods
This section describes in detail the protocols used to screen the immunised recombinant
antibody library and unlike the other chapters in this thesis is independent of the common
materials and methods described in Chapter 2.
Materials used during screening are defined and details of suppliers and product codes are
given in parenthesis. All reagents and consumables used were either supplied as sterile, or
were sterilised using a benchtop autoclave (Prestige Medical, Blackburn, UK) and were
subsequently handled aseptically.
5.4.1 Preparation of growth media for bacterial cultures
5.4.1.1 Liquid media
Bacterial cultures were grown in two types of commonly used liquid media, tryptone yeast
extract (2xTY) and Lysogeny Broth (LB), providing the trace elements and vitamins required
for growth of Escherichia coli (E. Coli) (Table 5-4). Tryptone enzymatic digest from casein
(cat no. 95039), yeast extract (cat no. 70161) and sodium chloride (cat no. BP358-1) were
purchased from Fisher Scientific (Loughborough, UK). The appropriate quantities of
tryptone, yeast extract and sodium chloride were dissolved in 500 ml 18 MΩ.cm water in a 
Schott bottle and sterilised by autoclave. Liquid media was stored sealed, at room
temperature, until use.
Table 5-4: Formulation of liquid media used for growth of E. coli cultures
Medium Tryptone (mg/ml) Yeast extract (mg/ml) NaCl (mg/ml)
2xTY 16 10 5
LB 10 5 10
5.4.1.2 Agar plates
Tryptone yeast extract agar plates (TYE) with glucose and antibiotics were used for the
selective growth of bacterial cultures for colony counting and colony picking (Table 5-5).
Glucose, a catabolic repressor of the lac2 promoter which is used to drive expression of the
pIII-antibody fragment fusion protein (Hoogenboom et al, 1998), was purchased from Sigma
Aldrich (Poole, UK, cat. no. G5767) and was sterilised before use by making up a 50 % (w/v)
solution in water and then autoclaving. The antibiotics ampicillin (cat no. A5354) and
kannamycin (cat no. K0245) were purchased from Sigma Aldrich (Poole, UK) and were used
for the selective growth of library phage infected (ampicillin) and helper phage infected
(kannamycin) cells.
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Table 5-5: Formulation of agar plates used for growth of E. coli cultures
Medium Tryptone(mg/ml)
Yeast
extract
(mg/ml)
NaCl
(mg/ml)
Agar
(mg/ml)
Glucose
(w/v %)
Ampicillin
(µg/ml)
Kannamycin
(µg/ml)
TYE 8 5 5 15 1 %
TYEAG 8 5 5 15 1 % 100
TYEKG 8 5 5 15 1 % 50
TYEAKG 8 5 5 15 1 % 100 50
Soft agar 8 5 5 7.5 1 %
Tryptone, yeast extract, sodium chloride and agar were dissolved in water and sterilised by
autoclave, then allowed to cool until comfortable to handle. The appropriate quantities of
sterile 50 % (w/v) glucose solution and antibiotics were then added and the mixture was
poured into Petri dishes. After the agar had solidified the agar plates were stored at 2-8°C
until use. Soft agar was kept in a Schott bottle at room temperature and was warmed in a
45°C waterbath to liquefy before use.
5.4.2 General protocols for amplification and purification of phage
The following sections describe the protocols used for the amplification and purification of
phage used during the screening of the immunised recombinant antibody library.
5.4.2.1 Preparation of E. coli cultures in logarithmic phase of growth
Phage infection of E. Coli is most efficient when E. Coli are in logarithmic phase of growth
(log phase). In order to prepare log phase E. Coli cells for infection an autoclaved glass
baffled flask containing 2xTY with 1 % (w/v) glucose was inoculated with approximately 1 x
108 TG1 E. Coli cells (Stratogene Stockport, UK, cat no. 200123) per ml of culture medium
and the culture was grown in an KS4000i shaking incubator (IKA, Staufen, Germany) set at
a temperature of 37°C and a rotation speed of 180 rpm. The increase in cell density was
monitored periodically by removal of 1 ml of culture and measurement of optical density at a
wavelength of 600 nm (OD600) using a WPA cell density meter (Biochrom, Cambridge, UK).
Once an OD600 of 0.4 – 0.5 had been reached the cells were deemed to be in log phase and
were used immediately.
5.4.2.2 Preparation of a high titre stock of M13K07 helper phage
The immunised recombinant antibody library was constructed using the pHEN2 phagemid
vector. This vector contains the gene that encodes the p3 fusion protein, in addition to an
ampicillin resistance gene, but the vector lacks the genetic material required for the
generation of progeny phage. Amplification of phage is achieved by superinfection with
M13K07 helper phage, which contains the necessary genes to enable assembly of progeny
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phage and a kannamycin resistance gene, but also has a compromised origin of replication,
ensuring that phagemid DNA is preferentially packaged. M13K07 helper phage is used in
large quantities in the panning process and therefore a high titre stock was prepared from a
commercially available product.
Commercial M13KO7 helper phage (New England Biolabs, Hitchen, UK, cat. no. NO315S),
supplied at a concentration of 1011 infective phage/ml, was diluted in 2xTY (10-2 – 10-12
dilution) and 50 µl of each dilution was used to infect 500 µl log phase TG1 E. coli. cells
(Stratagene, Stockport, UK, cat. no. 200123) grown to log phase as described in Section
5.4.2.1. Helper phage infection was carried out by incubation of phage dilutions with log
phase TG1 E. coli in sterile 1.5 ml plastic tubes placed in a Clifton waterbath (Bennett
Scientific, Newton Abbot, UK) set at a temperature of 37°C for 30 minutes. After 30 minutes
the helper phage infected TG1 E. coli were added to 3 ml of pre-warmed soft agar (please
see Section 5.4.1.2 for details of preparation) and poured over TYEKG plates. The plates
were incubated overnight in a Heraeus Kelvitron® 30°C static incubator (Thermo Fisher
Scientific, Loughborough, UK). The following day a single colony was picked from the TYE
plates and inoculated into 10 ml of 2xTY in a sterile 50 ml plastic tube and incubated for 2
hours at 37°C in a shaking incubator set at a rotation speed of 180 rpm. After two hours the
contents of the 50 ml tube were transferred to a 2L baffled flask containing 500 ml of 2xTY
medium and incubated for a further hour. After one hour kannamycin antibiotic was added to
a final concentration of 50 µg/ml and the contents of the flask were returned to the shaking
incubator overnight.
After approximately 18 hours progeny helper phage were concentrated and purified by PEG
precipitation as described in Section 5.4.2.4. The concentration of the purified helper phage
was determined as described in section 5.4.2.4 and was 2.8 x 1013 infective phage/ml.
5.4.2.3 Phage rescue by helper phage infection
A small inoculum of E. coli cells containing the pHEN2 vector (either through transformation
during library build, or through phage infection during library panning) (sufficient to give an
OD600 of approximately 0.1 = 1 x 108 cells/ml) was added to a 250 ml baffled flask containing
100 ml 2xTY with 1% (w/v) glucose and 100 µg/ml ampicillin. The culture was grown in a
shaking incubator set at a temperature of 37°C and a rotation speed of 180 rpm to log
phase. A volume of 50 ml of log phase cells were superinfected with M13KO7 helper phage
at a ratio of 1:20 cells to helper phage. Helper phage was added to the cells followed by 30
minute infection in a waterbath set at 37°C and a further 30 minutes in a 37°C shaking
incubator set at a rotation speed of 180 rpm. Ten microlitres of culture was retained for
155
determining the efficiency of helper phage infection and the remaining volume of culture was
centrifuged at 6000 G for ten minutes. The supernatant was discarded and the resulting
bacterial pellet was re-suspended in 100 ml of 2xTY (no glucose) with 100 µg/ml ampicillin in
a baffled flask. The culture was incubated in a shaking incubator (30°C, 180 rpm) for 30
minutes before addition of 50 µg/ml kannamycin. The baffled flask was then returned to the
shaking incubator overnight.
The efficiency of helper phage infection was determined by titration of serial dilutions (10-2-
10-7 in 2xTY) of helper phage infected culture on TYEAKG plates (50 µl/plate, in duplicate).
Plates were incubated overnight at 30°C and the number of colonies that had grown were
counted allowing calculation of the rate of helper phage infection. Typical infection rates
were 108 superinfected cells/ml. Progeny phage was purified and concentrated by PEG
precipitation.
5.4.2.4 Purification and concentration of rescued phage by PEG precipitation
Phage particles expressed in E. coli were separated from cellular debris and concentrated
by PEG precipitation with polyethylene glycol 6000 (PEG 6000). PEG precipitation is an
established method for the purification and concentration of phage particles expressed in
bacteria (Yamamoto and Alberts 1970). PEG NaCl precipitation solution (20 % (w/v) PEG
6000, 2.5 M NaCl) was prepared by dissolving the appropriate quantities of PEG 6000
(Thermo Fisher Scientific, Loughborough, UK, cat. No. 192280051) and NaCl (Thermo
Fisher Scientific, Loughborough, UK, cat. No. BP358-1) in water and then autoclaving.
Overnight liquid cultures of phage producing bacteria from phage rescue (Section 5.4.2.3) or
from helper phage preparation (Section 5.4.2.2) were split into 30 ml aliquots in 50 ml sterile
plastic tubes and centrifuged at 6000 G for twenty minutes using a Megafuge 11R centrifuge
(Thermo Fisher Scientific, Loughborough, UK). Phage supernatants were retained and
collected in clean 50 ml plastic tubes. To each tube containing 30 ml of phage supernatant
was added 10 ml PEG NaCl solution and the plastic tubes were then chilled on ice for 1
hour. After one hour the tubes were centrifuged at 10700 G for 30 minutes, the supernatants
were discarded and the soft white phage pellets were re-suspended in 10 ml of water and
centrifuged at 6000 G for twenty minutes to remove remaining bacterial debris. Phage
supernatants were retained and pooled into 30 ml lots in 50 ml plastic tubes. 10 ml PEG
NaCl was added to each tube and the tubes were then chilled on ice for 20 minutes. After 20
minutes the tubes were centrifuged at 10700 G for 30 minutes and the supernatant
discarded. The soft white phage pellets were re-suspended in 2 ml of PBS buffer. Finally the
re-suspended phage was split between 1.5 ml plastic tubes (1 ml per tube) and centrifuged
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at 16 G for ten minutes using a benchtop Heraeus Fresco minifuge (Thermo Fisher
Scientific, Loughborough, UK) to remove any last traces of bacterial debris. After
centrifugation the supernatants were transferred to sterile cryovials (Fisher, Loughborough,
UK, cat. no. 10-500-26) and sterile glycerol (Sigma, Poole, UK, cat. no. G7893) was added
to a final concentration of 20 % (v/v). PEG precipitated phage was stored at -80°C until use.
The titre of infective phage was determined by infecting log phase TG1 E. coli with dilutions
of the PEG precipitated phage stock and titrating on TYEAG plates. PEG precipitated phage
was diluted in 2xTY (10-2 – 10-12) and 50 µl of each dilution was used to infect 450 µl log
phase TG1 E. coli cells. Infection was allowed to take place for 30 minutes whilst the
dilutions of phage mixed with log phase cells were incubated in a water bath set at a
temperature of 37°C. After infection, 50 µl of each dilution of phage infected into TG1 E. coli
was spread onto TYEAG plates in duplicate. Plates were incubated in a static incubator set at
a temperature of 30°C overnight. The number of colonies that grew on the titration plates
was counted and the concentration of the phage was calculated. Typical infective phage
concentrations obtained were in the range 1012-1013 infective phage/ml
5.4.3 Protocols for panning
The following protocols describe the general panning protocols used in the screening of the
immunised recombinant antibody library. Each round of panning involves affinity selection,
followed by amplification of the selected pool of phage and subsequent purification. Note
that these protocols describe the general panning procedures. Specific details for individual
rounds of panning are described within the experimental design for each panning strategy
used.
5.4.3.1 Preparation of library phage for panning
An immunised recombinant antibody library was supplied by ImmunoSolv (Aberdeen, UK)
consisting of 8 sub-libraries (different VH-VL pairings), four with lambda light chains and four
with kappa light chains, as glycerol stocks of XL1 Blue E. coli cells containing the gene
encoding the variable antibody binding regions as an scFv cloned into the pHEN2 vector.
Total library size was 108 clones.
In preparation for panning, phage displaying single chain variable antibody fragments
(scFvs) were produced from the supplied bacterial cells by performing phage rescue
(Section 5.4.2.3) followed by PEG precipitation (Section 5.4.2.4) on each sub-library
individually.
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Following phage rescue and PEG precipitation, all PEG precipitated phage from the lambda
sub-libraries were pooled together in equal volumes. This was repeated for all of the kappa
sub-library phage. Lambda and kappa library phage was then pooled together in 9:1 ratio.
Pooled phage was stored at -80 °C as a 20 % (v/v) glycerol stock until use.
5.4.3.2 Target molecule-carrier protein conjugates and target molecule-biotin
conjugates used in panning
All of the target molecule-carrier protein conjugates and target molecule-biotin conjugates
used in library panning and subsequent analysis were synthesised for the LMC project by Dr
Manisha Sathe, Dr Marijan Stefinovic, Mr Luis Miguel Garcia Con and Mrs Marjorie Allen
(Cranfield University, UK). Details of these conjugates are given in Sections 5.6.1 and 5.7.1.
The free target molecules 17β(H),21α(H)-Hopane (cat. no. 07562), octadecane (cat. no. 
74691) and 5β-coprostane (cat. no. C2005) were purchased from Sigma-Aldrich (Poole, 
UK). Hopane was solubilised by dissolving at high concentration in dichloromethane (DCM).
The DCM solution was then diluted into 20 % (v/v) methanol in PBS buffer. Octadecane and
coprostane were solubilised in methanol and then diluted into 20 % (v/v) methanol in PBS
buffer. Biotinylated conjugates were solubilised using DMF, diluted into methanol and then
diluted into 20 % (v/v) methanol 1.5 g/L P80 in PBS buffer.
5.4.3.3 Panning with target molecule-protein conjugates (screening strategy 1)
Nunc MaxiSorpTM ImmunoTMtubes (Thermo Fisher Scientific, Roskild, Denmark, cat. no.
444202) were coated with a target molecule-carrier protein conjugate (for details of
conjugates and concentrations used please see Section 5.6.1 and Section 5.7.1) by
incubation with 4 ml of target molecule-protein conjugate in sterile PBS at a concentration
ranging from 1 – 10µg/ml overnight at 2-8°C, or for 2 hours at 37°C. The coating solution
was poured away and excess unbound conjugate was removed by washing the
ImmunoTMtube 3 times with 4 ml of PBS buffer (Sigma Aldrich, Pool, UK, cat no. P4417).
The ImmunoTMtube was then blocked to prevent non specific interactions of phage clones
with uncoated areas of the hydrophobic plastic surface using 4 ml of a 2 % (w/v) solution of
Marvel skimmed milk powder in PBS buffer (MPBS). Blocking was allowed to occur for two
hours in an incubator set at a temperature of 37°C, or at 2-8°C overnight. Excess blocking
buffer was removed by washing with 3 x 4ml of PBS buffer.
For the first round of panning 1ml of rescued PEG precipitated pooled library phage
(approximately 1012 phage particles) was added to the coated and blocked ImmunoTMtube in
a buffer mix, termed in this work as the “binding buffer” (the binding buffer used was varied
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depending on the panning strategy used, for details please see Section 5.6.1 and Section
5.7.1). For subsequent rounds of panning 1 ml of PEG precipitated phage recovered from
the previous panning round was used (approximately 1012 phage). The ImmunoTMtube was
sealed with Parafilm® (Thermo Fisher Scientific, Loughborough, UK, cat.no. 13-374-10) and
incubated at room temperature for a total of two hours. For the first 30 minutes of the two
hour incubation period the ImmunoTMtube was rotated at 20 rpm using a Stuart SB3 rotator
(Bibby Scientific Ltd, Stone, Staffordshire), followed by 90 minutes static incubation. After
two hours unbound phage was discarded and the ImmunoTMtube was washed with a wash
buffer. The wash buffer and the number of washes used varied depending on the panning
strategy (for details please see Section 5.6.1 and Section 5.7.1).
Subtractive panning
Note that in some panning rounds (please see Section 5.6.1 and Section 5.7.1 for details)
phage was subject to an additional subtractive panning step, prior to application to the
coated and blocked ImmunoTMtube, to deplete carrier protein binding phage. In order to
achieve this 1 ml of phage in binding buffer was incubated for 1 hour at room temperature
(rotating) in an ImmunoTMtube that had been coated with 1 mg/ml carrier protein. Following
this hour long incubation the phage and binding buffer was transferred to the coated and
blocked ImmunoTMtube as described above.
Elution of bound phage
Following incubation and washing away of unbound phage, phage bound to the immobilised
conjugate were eluted either by non-specific elution or by competitive elution. Eluted phage
were infected into log phase TG1 E. coli cells as described below.
Non-specific elution and infection
Phage bound to immobilised conjugate was eluted by the addition of 1 ml of 100mM
triethylamine in water (Sigma Aldrich, Poole, UK, cat. no. T0886) to the ImmunoTMtube
followed by ten minutes of rotation on a Stuart SB3 rotator. After ten minutes the
triethylamine was neutralised (to prevent damage of the phage, which would result in
reduced infectivity) by transferring the contents of the ImmunoTMtube into a 1.5 ml plastic
tube containing 0.5 ml of 1M Tris buffer pH 7.4 (Severn Biotech Ltd., Kidderminster, UK, cat.
No. 207901-10). A further 200 µl of 1M Tris buffer was added directly to the ImmunoTMtube,
so that any phage still contained within the tube could also be infected into E. coli. A volume
of 0.75 ml of eluted phage was used to infect 9.25 ml of log phase TG1 E. coli cells in a 50
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ml plastic tube, by static incubation in a 37°C waterbath for 30 minutes. A further 4 ml of log
phage TG1 E. coli cells were added directly to the ImmunoTMtube. The remaining unused
0.75 ml of eluted phage was stored as a 20 % (v/v) glycerol stock at a temperature of -80°C.
After 30 minutes incubation in the waterbath the TG1 E. coli cells in the ImmunoTMtube were
pooled with those in the 50 ml tube.
Competitive elution and infection
4 ml of a solution of 0.1 – 10 µM of free target molecule (for details of target molecules and
concentrations used please refer to Section 5.6.1 and Section 5.7.1) dissolved in a buffer
termed the “elution buffer” was added to the ImmunoTMtube and incubated at room
temperature, rotating for 30 minutes and static for 30 minutes. A volume of 2 ml
competitively eluted phage was used to infect 10 ml of log phage TG1 E. coli by incubation
in a 50 ml tube in a 37°C waterbath for 30 minutes.
The quantity of both competitively eluted and non-specifically eluted phage was determined
by titration of dilutions of eluted phage infected E. coli (10-2 – 10-7) on TYEAG plates (50
µl/plate in duplicate). The plates were incubated at 30°C overnight and then the
concentration of eluted phage was calculated using the number of colonies that had grown.
The remaining volume of phage infected bacterial culture was pelletted by centrifugation at
6000 G for 10 minutes. The supernatant was discarded and the bacterial pellet was re-
suspended in 0.4 ml of 2xTY. The entire 0.4 ml of re-suspended culture was then spread
onto a large TYEAG plate. Plates were incubated at 30°C overnight. After approximately 18
hours of growth, cells were recovered from the agar plate by addition of 1-3 ml of 2xTY and
loosening with a sterile plastic microbiological spreader (Thermo Fisher Scientific,
Loughborough, UK, cat. No. LPS-141-011R). Recovered bacterial cells were stored as a 20
% (v/v) glycerol, 5 % (w/v) glucose stock at -80°C. Phage was amplified and purified in
preparation for the next round of panning by phage rescue (Section 5.4.2.3) followed by
PEG precipitation (Section 5.4.2.4).
5.4.3.4 Panning with target molecule-biotin conjugates (screening strategy 2)
Preparation of magnetic beads for panning
Streptavidin coated Dynabeads® (Invitrogen, Paisley, UK, cat. no. M280), supplied in PBS
with 0.01 % P20 and 0.02% NaN3, were washed to remove the P20 and azide. Washing was
achieved by adding 1 ml of PBS to 200 µl of Dynabeads® in a 1.5 ml plastic tube and mixing
well, the tube was then placed in a Dynal 1.5 ml tube magnetic separator rack (Invitrogen,
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Paisley, UK) and allowed to stand for 2 minutes during which time the magnetic beads were
drawn to the side of the tube. The rack was briefly inverted to recover any magnetic beads
that had collected in the lid of the plastic tube, then the tube, still contained within the rack
was allowed to stand for a further 1 minute. Supernatant was removed using a pipette,
leaving the magnetic beads on the side of the plastic tube. The beads were resuspended in
1 ml of PBS and the washing procedure was repeated to a total of two washes.
After a total of two washes magnetic beads were re-suspended in 1 ml of 2% MPBS and
rotated for a minimum of one hour at room temperature using a Stuart SB3 tube rotator. Just
prior to use the 1.5 ml tube containing magnetic beads in MPBS was placed into a magnetic
separating rack and left to stand for 2 minutes. The rack was briefly inverted to remove any
magnetic beads that had collected in the lid and then stood for a further 1 minute. Two
percent MPBS was removed using a pipette leaving dry magnetic beads on the side of the
1.5 ml plastic tube.
Preparation of library phage for panning
Five hundred microlitres of rescued and PEG precipitated library phage (from library rescue
for pan 1 and from the previous pan for subsequent panning rounds, approx 1012 phage)
was added to 300 µl of 6.66% MPBS in a 1.5 ml plastic tube and rotated for 1 hour at room
temperature.
Subtractive panning
For some rounds of panning a subtractive panning step was carried out in order to minimise
the enrichment of clones that bound to the streptavidin coated magnetic beads. In panning
rounds where subtractive panning was used 200 µl of washed streptavidin coated magnetic
beads were added to 300 µl of library phage in 6.66% (w/v) MPBS (after an initial 1 hour
incubation as described above). The beads and library phage were incubated with rotation
for 1 hour at room temperature. After one hour the magnetic beads were removed using a
magnetic rack and the phage solution was transferred to a fresh 1.5 ml plastic tube.
Incubation of library phage with biotinylated target molecule
Biotinylated antigen (for details please refer to Section 5.7.1) was dissolved in methanol at a
concentration of 16.5mM. and then further diluted to 2.5 µM in methanol with 7.5g/L P80. A
volume of 200 µl of this solution was added to pre-prepared 300 µl of library phage in 6.66 %
MPBS to give a final formulation of 500nmol biotinylated target molecule, 20 % (v/v)
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methanol 1.5 g/L P80 and 2% (w/v) MPBS. This mixture was incubated at room temperature
rotating for one hour.
After one hour the mixture of library phage and biotinylated antigen was transferred into a
1.5 ml plastic tube containing dry magnetic beads and incubated for 20 minutes rotating to
allow the streptavidin on the magnetic beads to bind to the biotinylated antigen. After 20
minutes the magnetic beads were separated from the solution containing unbound phage
using a magnetic rack. The beads were washed to remove non-specifically bound phage.
Bound phage were either used directly to infect log phase TG1 E. coli whilst still bound to
beads, or were competitively eluted prior to infection using free antigen.
No elution/direct infection
Magnetic beads with associated bioyinylated antigen and bound phage were re-suspended
in 200 µl of PBS and directly used to infect log phase TG1 E. coli. A volume of 200 µl of re-
suspended magnetic beads were added to 9.25 ml of log phase TG1 E. coli in a 50 ml
plastic tube and incubated for 30 minutes in a 37 °C waterbath. The 50 ml plastic tubes were
gently inverted periodically during the 30 minute incubation in the water bath in order to re-
suspend the beads which settled at the bottom of the tube. After infection magnetic beads
were removed from the culture using a Dynal 50 ml tube magnetic separator rack
(Invitrogen, Paisley, UK).
Competitive elution and infection
A volume of 1 ml of 10 – 100 µM free target molecule (please see Section 5.7.1 for details)
dissolved in PBS with 20 % (v/v) methanol 1.5g/L P80 was added to the washed magnetic
beads and the mixture was rotated for one hour at room temperature. After one hour the
magnetic beads were separated from the competitively eluted phage solution using a
magnetic separator rack and the whole 1 ml volume of supernatant was used to infect 9.25
ml of log phase TG1 E. coli in a plastic 50 ml tube for 30 minutes in a 37°C waterbath.
After incubation 10 µl of eluted phage infected E. coli (from both direct infection and infection
with competitively eluted phage) was removed and titrated on TYEAG plates. Dilutions were
prepared in 2xTY (10-2 – 10-7) and 50 µl was spread (in duplicate) onto TYEAG plates. The
plates were incubated at 30°C overnight and then the concentration of eluted phage was
calculated by counting the number of colonies that had grown. After removal of 10 µl for
titration the remaining volume of phage infected bacterial culture was pelletted by
centrifugation at 6000 G for 10 minutes. The supernatant was discarded and the bacterial
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pellet was re-suspended in 0.4 ml of 2xTY. The whole 0.4 ml was then spread onto a large
TYEAG plate. Plates were incubated at 30°C overnight. The colonies that had grown on the
large TYEAG plate were recovered by addition of 1-3 ml of 2xTY and loosening with a sterile
plastic microbiological spreader (Thermo Fisher Scientific, Loughborough, UK, cat no. LPS-
141-011R). Recovered bacterial cells were stored as a 20 % (v/v) glycerol, 5 % (w/v)
glucose stock at -80°C. Phage was amplified and purified in preparation for the next round of
panning by phage rescue (section 5.4.2.3) followed by PEG precipitation (Section 5.4.2.4)
5.4.4 Protocols for analysis of enriched population of clones generated
by panning (including the isolation of individual clones)
5.4.4.1 Polyclonal ELISA
Target molecule-protein conjugates and free carrier proteins were immobilised to the wells of
Nunc MaxiSorbTM F96 MicroWellTM plates (Thermo Fisher Scientific, Roskilde, Denmark, cat.
no. 442404) by incubation of 100 µl/well at a protein concentration of 1µg/ml overnight at 2 –
8°C or for two hours at 37°C. After the immobilisation step, excess target molecule-protein
conjugate and carrier protein was removed from wells by washing with 3 x 300 µl/well
Phosphate buffered saline (Sigma Aldrich, Poole, UK, cat. no. P4417) containing 0.1 % (w/v)
Polysorbate 20 (BDH/VWR, Leicestershire, UK, cat. no. 663684B) (PBST buffer) and then
rinsing with 3 x 300 µl/well PBS. Residual liquid was removed from the wells by inverting the
96-well plate and tapping out on absorbent paper.
Wells were blocked to reduce non-specific interactions of phage with any uncoated areas of
the hydrophobic plastic surfaces by incubation with 200µl/well 2% (w/v) MPBS at a
temperature of 37°C for two hours. After two hours the wells were washed as described
previously. Fifty microlitres of PEG precipitated phage from each round of panning was
added to duplicate wells coated with each target molecule-protein conjugate and each free
carrier protein. For pan 0 material, pooled PEG precipitated phage from the library rescue
(Section 5.4.2.4) was used for the ELISA. Fifty microlitres of 4% (w/v) MPBS was then
added to each phage containing well and the plate was incubated at room temperature for 1
hour then washed as described previously.
After washing, anti-bacteriophage M13 antibody HRP conjugate (GE Healthcare, Chalfont St
Giles, UK, cat. No. 27-9421-01) was added 100 µl/well in 2 % (w/v) MPBS buffer at 1/1000
dilution of stock and incubated for one hour at room temperature. The plate was then
washed as described previously.
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Tetramethylbenzidine.dihydrochloride (TMB) substrate (Sigma Aldrich, Poole, UK, cat. no.
T3405) in 0.05 M phosphate citrate buffer containing 0.03 % (w/v) sodium perborate pH 5.0
(Sigma Aldrich, Poole, UK, cat. no. P4992) was added to the microtitre plate 100 µl/well;
reaction with HRP labelled antibodies bound to phage immobilised on the surface of the
wells produced a coloured product in quantities proportional to the amount of immobilised
antibody.
After approximately 10 minutes the enzyme-substrate reaction was stopped by the addition
of 50 µl/well of 1 M sulphuric acid. The absorbance of each well was read at a wavelength of
450 nm using a Varioskan Flash plate reader (Thermo Scientific, Leicestershire, UK).
5.4.4.2 Monoclonal ELISA
Preparation of phage supernatant for monoclonal ELISA
PEG precipitated phage from panning rounds was diluted 10-2-10-12 in 2xTY. A volume of
100 µl of each dilution was used to infect 900 µl of log phase TG1 E. coli in 1.5 ml plastic
tubes for 30 minutes in a waterbath set at a temperature of 37°C. After 30 minutes 50 µl of
cells infected with each dilution of phage were spread (in duplicate) onto TYEAG plates and
incubated overnight at 30°C.
The following morning individual colonies were picked from the plates using sterile pipette
tips and inoculated directly into 150 µl of 2xTY with 1% (w/v) glucose and 100 µg/ml
ampicillin in the wells of a Nunc 96-well tissue culture plate (Thermo Scientific, Roskilde,
Denmark, cat. no. 167008). Bacterial cultures were grown overnight shaking in a 37°C
incubator. The following morning small inoculums were taken from each well on the 96-well
tissue culture plate using a 96 pin replicator (VWR, Lutterworth, UK, cat. No. 738-0252) and
transferred into a fresh tissue culture plate containing 200 µl/well 2xTY, 1% (w/v) glucose,
100 µ/ml ampicillin . The cultures were grown at 37°C shaking for 4 hours. In order to make
a stock of each clone the tissue culture plates containing overnight cultures were centrifuged
at 1500 G for 10 minutes using a plate spinning rotor head (Thermo Fisher Scientific,
Loughborough, UK, cat. no.11175750). The supernatants were aspirated using a multi-
channel pipetter and the bacterial pellets were re-suspended in 150 µl 2xTY, 5 % (w/v)
glucose, 20 % (v/v) glycerol and stored at -80°C.
After 4 hours the bacterial cultures were removed from the incubator and infected with
M13KO7 helper phage by addition of 25 µl/well 2xTY containing 100 µg/ml ampicillin, 1 %
(w/v) glucose and 4 x 1010/ml M13KO7 helper phage. The tissue culture plate was incubated
static for 30 minutes at 37°C to allow superinfection by helper phage and then incubated for
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a period of 60 minutes shaking at 37°C. Following the 60 minute incubation the plate was
spun at 1500 G for 10 minutes and supernatants were aspirated using a multi channel
pipettor and discarded. Bacterial pellets were re-suspended in 200 µl/well 2xTY with 100
µg/ml ampicillin and 50 µg/ml kannamycin and grown overnight shaking at 30°C.
The following morning tissue culture plates were removed from the incubator and centrifuged
at 3000 rpm for ten minutes. Phage supernatant was aspirated using a multi channel pipettor
and stored in a fresh tissue culture plate at 2-8°C until used in an ELISA.
ELISA protocol
The basic protocol followed in order to run a monoclonal ELISA was the same as the
protocol for running a polyclonal phage ELISA as described in Section 5.4.4.1 with some
modifications which are described below. Clones were first screened for binding to
appropriate conjugates in a binding ELISA. Selected clones were then screened for
recognition of free target in an inhibition ELISA.
Binding ELISA
A single 96-well plate was coated with BSA conjugated to target molecule and a second 96-
well plate was coated with BSA carrier protein following the method described in Section
5.4.4.1. If required, plates were also coated with KLH conjugated to target molecule and free
KLH. The 96-well plates were then blocked as described in Section 5.4.4.1.
To each coated and blocked 96-well plate was added 50 µl/well 4 % (w/v) MPBS and then
50 µl/well of phage supernatant was transferred from the tissue culture plate to both 96-well
plates (therefore each monoclonal phage clone was screened for binding to target molecule-
protein conjugate and for binding to free carrier protein). From this point onwards the ELISA
protocol was identical to that described in Section 5.4.4.1, with incubation of phage for 1
hour, followed by washing, addition of the anti-M13 secondary antibody,a further 1 hour
incubation, washing and then addition of TMB substrate.
Inhibition ELISA
Two 96-well plates were coated with BSA conjugated to target molecule, and then blocked
as described in Section 5.4.4.1. During the blocking step two tissue culture plates were
prepared to facilitate incubation of the monoclonal phage with free target molecule prior to
application to the coated and blocked 96-well plates. One tissue culture plate contained 50
µl/well 40 % (v/v) methanol (Thermo Fisher Scientific, Loughborough, UK, cat. no. M14056)
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with free target molecule at a concentration of 10 µM (for details of free target molecules
used please see Section 5.4.3.2), the other contained 50 µl/well 40 % (v/v) methanol with no
target molecule as a control (to allow direct comparison of binding signal generated with and
without free target molecule in the same solvent). Fifty microlitres per well of phage
supernatant was transferred from the tissue culture plate containing the stock phage
supernatant to each of the tissue culture plates containing methanol/water and free target
molecule. Phage and methanol/water/free target molecule were incubated together for 1
hour before being transferred across to the coated and blocked 96-well plates. From this
point onwards the protocol was identical to that described in Section 5.4.4.1.
5.4.4.3 Sequencing of monoclonal phage
Individual clones were grown up from the glycerol stocks stored in tissue culture plates
prepared during clone picking (Section 5.4.4.2) by inoculation into 5 ml of LB containing 1%
glucose and 100 µg/ml ampicillin. Cultures were grown overnight shaking at 180 rpm in a
37°C incubator. Plasmid DNA was recovered and purified from each individual culture using
a QIA Prep Spin Mini prep kit (Qiagen, Crawley, UK, cat. no.27104). Genes encoding
antibody variable regions were sequenced by Beckman Coulter Genomic (Takeley, UK)
using primers that were custom synthesised by Invitrogen (Paisley, UK).
AH18 Rev 5'-AAA TAC CTA TTG CCT ACG GCA GCC GCT GG-3'
GIII For 5'-GAA TTT TCT GTA TGA GGT TTT GC-3'
Sequences were compared and analysed using Lasergene® 8 software (DNASTAR,
Madison, USA).
5.4.4.4 Expression of soluble scAbs
Antibody fragments were expressed as soluble single chain antibody fragments (scAbs) by
cloning into the expression vector PIMS147 (Hayhurst and Harris 1999) and transforming
into E. coli.
Preparation of PIMS147 expression vector
XL1 Blue E. coli cells containing PIMS147 plasmid (supplied by Ms. B Ravi, ImmunoSolv,
Aberdeen, UK) were grown overnight in 20 ml of LB with 1% (w/v) glucose, 100 µg/ml
ampicillin in a shaking incubator set at 37 °C. Plasmid DNA was recovered and purified
using a QIA Prep Spin Mini prep kit, and quantified using a Picodrop Microliter UV/Vis
Spectrophotometer (Picodrop Ltd, Saffron Walden, UK). Plasmid DNA was then digested
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using the restriction enzymes NcoI and NotI (New England Biolabs, cat. nos. R0193S and
R0189L respectively). A volume of 30 µl of plamid DNA (approx 6 µg) was mixed with 1 µl
(10 units) of each enzyme, 5 µl of NE buffer and 0.5 µl of 100xBSA buffer (buffers supplied
with the enzymes) in a 1.5 ml plastic tube and made up to a total volume of 50 µl with water.
The enzymes and plasmid DNA were incubated together for 1 hour 30 minutes in a
waterbath set at a temperature of 37°C. Digested DNA was run on a Tris-Acetate EDTA
(TAE) 1% (w/v) agarose gel containing 1 µg/ml ethidium bromide using TAE running buffer
(Thermo Fisher Scientific, Loughborough, UK, cat. no. ELR-328-010V), at 125V for
approximately 45 minutes alongside Hyperladder 1 molecular weight marker (Bioline,
London, UK). Bands of DNA on the gel were visualised using a Transluminator and the band
at 6kbp was excised using a clean scalpel. The excised DNA was recovered using a
QIAquick Gel extraction kit (Qiagen, Crawley, UK, cat no. 28706) and purified DNA was
quantified using a Picodrop spectrometer.
To prevent self ligation of the cut vector the 6kbp fragment of PIMS147 was treated with
shrimp alkaline phosphatase (SAP) (Promega, Southampton, UK, cat. no. M8201) to remove
the 5’ terminal phosphate group. Sixty microlitres (approx 2 ug) of purified cut PIMS147
vector was incubated with 1 µl (1 unit) of SAP and 2 µl SAP buffer (supplied with the
enzyme) in a waterbath set at 37°C for 2 hours. SAP was deactivated by heating at 65°C for
30 minutes. SAP treated vector was stored at -20°C until use.
Digestion and purification of library DNA
Plasmid DNA isolated from library cells (prepared as described in Section 5.4.4.3) was
digested using the restriction enzymes NcoI (New England Biolabs, cat. no. R0193S) and
NotI (New England Biolabs, cat. no. R0189L). Thirty microlitres of plamid DNA (approx 6 µg)
was mixed with 1 µl (10 units) of each enzyme, 5 µl of NE buffer and 0.5 µl of 100xBSA
buffer (supplied with enzyme) in a 1.5 ml plastic tube and made up to a total volume of 50 µl
with water. The enzymes and plasmid were incubated for 1 hour 30 minutes in a waterbath
set at 37 °C. Digested DNA was run on a Tris-Acetate EDTA (TAE) 1% (w/v) agarose gel
containing 1 µg/ml ethidium bromide using TAE running buffer (Thermo Fisher Scientific,
Loughborough, UK, cat. no. ELR-328-010V), at 125V for approximately 45 minutes
alongside Hyperladder 1 molecular weight marker (Bioline, London, UK). Bands of DNA on
the gel were visualised using a Transluminator and the band at 800bp was excised using a
clean scalpel. The excised DNA was recovered using a QIAquick Gel extraction kit (Qiagen,
Crawley, UK, cat no. 28706) and purified DNA was quantified using a Picodrop
spectrometer.
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Cloning of library insert DNA into PIMS147
Approximately 100 ng of SAP treated cut PIMS 147 vector was added to approximately 60
ng of library insert DNA (approx 1:6 molar ratio of vector to insert) together with 1 µl of T4
DNA ligase (New England Biolabs, Hitchen, UK, cat no M0202M), 2 µl of 10 x ligase buffer
(supplied with T4 DNA ligase) and made up to a total volume of 20 µl with water in a 1.5 ml
plastic tube. The mixture was incubated overnight at room temperature. The following
morning T4 DNA ligase enzyme was inactivated by heating at 65 °C for 10 minutes. Ligated
DNA was quantified using a Picodrop spectrometer and then stored at -20°C until it was
transformed into E. coli.
Preparation of heat shock competent TG1 cells for expression of sequences containing stop
codons
Several of the sequences isolated from the immunised library contained stop codons and
therefore had to be expressed using an E. coli strain, such as TG1, that is able to read
through these codons. In order to prepare heat shock competent TG1 cells an overnight
culture of TG1 E. coli (Stratogene Stockport, UK, cat no. 200123) was grown in 5 ml of LB
shaking at 37°C. The following morning 250 ml LB broth was inoculated with 5 ml overnight
culture and grown shaking at 37°C to log phase of growth. The culture was then split into 8 x
50 ml sterile plastic tubes and centrifuged at 2680 G for 20 minutes, the supernatant was
discarded and each bacterial pellet was re-suspended in 0.5 ml of ice cold Tris-HCl with 100
mM calcium chloride and incubated on ice for 20 minutes. After 20 minutes the tubes were
centrifuged at 2680 G for 15 minutes, the supernatant was discarded and bacterial pellets
were re-suspended in 3 ml of ice cold 100 mM calcium chloride (Sigma, Poole, UK, cat. no.
C3881) and incubated on ice for 20 minutes. The contents of the 8 tubes were pooled into
two tubes and centrifuged at 2680 G for 15 minutes. The supernatant was discarded and the
bacterial pellets were re-suspended in 12.5 ml 100 mM calcium chloride with 20 % (v/v)
glycerol. The suspension was aliquoted into 1.5 ml plastic tubes and stored at -80°C until
use.
Transformation of PIMS147 vector with cloned library insert into E. coli
Plasmid DNA was transformed into E.coli (TG1 or XL1 Blue) using heat shock. Heat shock
competent XL1 Blue E. coli cells (Stratogene, Stockport, UK, cat. No. 200249), or heat shock
competent TG1 E. coli prepared as described in preceding section, were removed from
storage at -80°C and allowed to thaw on ice. Thawed cells were aliquoted into pre-chilled 1.5
ml plastic tubes (100 µl/tube) and 1.7 µl of mercaptoethanol (supplied with XL1 Blue
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competent cells) was added to each tube. A volume of 3 µl of plasmid DNA was added to
each tube and tubes were then incubated on ice for 30 minutes. Cells were heat shocked at
42°C, by placing into a waterbath for 45 seconds. Tubes were then removed from the
waterbath and returned to the ice for 2 minutes. A volume of 900 µl of pre-warmed (42°C) LB
was added to each transformation mixture and incubated shaking at 37°C for 1 hour. A
volume of 100 µl and 50 µl of each transformation mixture were then spread over TYEAG
plates (in duplicate) and incubated overnight at 37°C (XL1 Blue cells) or at 30°C (TG1 cells).
After overnight growth colonies were picked from the transformant plates and inoculated into
10 ml LB with 1% (w/v) glucose and 100 µg/ml ampicillin and grown overnight at 37°C
shaking at 180 rpm. The following morning 5 ml of overnight culture was removed for
plasmid DNA preparation and sequencing to confirm that the correct sequence had been
cloned across. The remaining culture was centrifuged at 6000 G for 10 minutes. The
supernatant was discarded and the bacterial pellet was resuspended in LB with 5 % (w/v)
glucose and 20 % (v/v) glycerol for long term storage at a temperature of -80°C.
Sequencing of transformed plasmid DNA
Genes encoding the variable regions on the plasmid DNA from transformed clones were
sequenced by Beckman Coulter Genomics (Takeley, UK) using primers that were custom
synthesised by Invitrogen (Paisley, UK) in order to confirm that the correct sequences had
been cloned across.
AH18 Rev 5'-AAA TAC CTA TTG CCT ACG GCA GCC GCT GG-3'
HuCk-FOR 5’-GAA GAT GAA GAC AGA TGG TGC-3’
Sequences were compared and analysed using Lasergene® 8 software (DNASTAR,
Madison, USA).
Expression of scAb in E. coli
5 ml of LB with 100 µg/ml ampicillin and 1 % glucose was inoculated from glycerol stocks of
each transformed clone. Cultures were grown overnight at 37°C shaking. The following
morning overnight cultures were centrifuged at 6000 G for ten minutes. The supernatant was
discarded and the bacterial pellet was re-suspended in 10 ml of LB with 100 µg/ml ampicillin.
The culture was incubated at 25°C shaking for 1 hour and then expression of soluble scAb
was induced by the addition of 50 µl 200mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
169
(Sigma, Poole, UK, cat. no. I1284). Cultures were then returned to the shaking incubator for
a further 4 hours.
After four hours bacterial cultures were centrifuged at 6000 G for ten minutes. Bacterial
pellets were re-suspended in 0.5 ml of ice cold 200 mM Tris pH 7.5 (Severn Biotech Ltd.,
Kidderminster, UK, cat. No. 207901-10) with 20 % (w/v) sucrose (Sigma, Poole, UK, cat. no.
S0389), 10 µl 100 mM EDTA (Thermo Fisher, Loughborough, UK, cat. no. BP120-1) and
0.05 mg lysozyme (Sigma, Poole, UK, cat. no. L6876), then incubated with gentle rotation on
ice for 15 minutes. After 15 minutes, 0.5 ml of ice cold 5 mM magnesium sulphate was
added and the mixtures were incubated on ice, rotating for a further 15 minutes. The
mixtures were then centrifuged at 6000 G for 10 minutes. The supernatants were filtered (0.2
µm) and stored at -20°C until use.
5.4.4.5 Analysis of performance of soluble scAbs by ELISA
Target molecule-protein conjugates and free carrier proteins were immobilised to the wells of
Nunc MaxiSorbTM F96 MicroWellTM plates (Thermo Scientific, Roskilde, Denmark, cat. no.
442404) by incubation of 100 µl/well at a protein concentration of 1µg/ml overnight at 2 –
8°C. After the immobilisation step, excess target molecule-protein conjugate and carrier
protein was removed from wells by washing with 3 x 300 µl/well PBST buffer and then
rinsing with 3 x 300 µl/well PBS using a multichannel pipettor. Residual liquid was removed
from the wells by inverting the 96-well plate and tapping out on absorbent paper.
Wells were blocked to reduce non-specific actions of phage antibodies with any uncoated
areas of the hydrophobic plastic surfaces by incubation with 200 µl/well 2% MPBS at a
temperature of 37°C for two hours. After two hours the wells were washed as described
previously.
In binding ELISAs a ½ dilution series of scAb (50 µl/well) was added to wells coated with
each target molecule-protein conjugate and each free carrier protein. Fifty microlitres of 4%
(w/v) MPBS was then added to each well and the plate was incubated at room temperature
for 1 hour and washed as described previously.
In inhibition ELISAs scAb was incubated with free target molecule dissolved in 20 %
methanol (v/v) 2% (w/v) MPBS for an hour prior to addition to the coated and blocked
microtitre plate, and a second sample of each scAb was incubated with 20 % (v/v) methanol
2% (w/v) MPBS with no free target molecule prior to application to the coated and blocked
ELISA plates.
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Anti human kappa light chain (bound and free) peroxidise conjugate (Sigma, Poole, UK) was
added 100 µl/well in 2 % (w/v) MPBS buffer at a concentration of 1/1000 and incubated for
one hour at room temperature. The plate was then washed as described previously.
Tetramethylbenzidine.dihydrochloride (TMB) substrate (Sigma Aldrich, Poole, UK, cat. no.
T3405) in 0.05 M phosphate citrate buffer containing 0.03 % (w/v) sodium perborate pH 5.0
(Sigma Aldrich, Poole, UK, cat. no. P4992) was added to the microtitre plate 100 µl/well;
reaction with HRP labelled antibodies bound to antigen immobilised on the surface of the
wells produced a coloured product in quantities proportional to the amount of immobilised
antibody.
After approximately 10 minutes the enzyme-substrate reaction was stopped by the addition
of 50 µl/well of 1 M sulphuric acid. The absorbance of each well was read at a wavelength of
450 nm using a Varioskan Flash plate reader (Thermo Scientific, Leicestershire, UK).
5.5 Structure of work
In line with the aims and objectives of this work (Section 5.2) the immunised library was
initially screened by application of a selected literature screening protocol which involved
panning the library and then analysing the resulting enriched population of phage. However,
the clones produced from the application of the selected literature protocol did not give
appropriate performance and therefore it was necessary to modify the screening strategy
used and re-screen the library.
The experimental work and results are therefore presented in two sections. The first section
details the experimental design and describes and discusses the results from the first
attempt to screen the immunised recombinant library using a selected literature screening
protocol. The second section describes the experimental design and reports and discusses
the work from a second attempt to screen the library, modified based on the outcome of the
first screening strategy.
Following these two sections the outcome of both screening strategies are discussed
together and conclusions/recommendations for further work are made.
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5.6 Screening strategy 1: Panning using target molecule-carrier
protein conjugates
5.6.1 Experimental design
The literature protocol selected for initial screening of the immunised library was that of
Charlton et al (2001), who screened a phage display library, constructed from an immunised
sheep, for antibodies that bound to atrazine using atrazine-carrier protein conjugates. The
literature protocol used both non-specific and specific elution of bound phage and the
alternation of carrier proteins between panning rounds. This screening protocol was
selected, on the recommendation of the company who constructed the immunised library,
because it had previously been used for the selection of anti-small molecule antibodies from
similar libraries, including anti-atrazine and anti-homoserine lactone antibodies. The
literature protocol was followed as closely as possible, although some minor modifications
were necessary due to the nature of the selected target molecules.
Two extinct life marker molecules were selected for use in screening strategy 1; hopane as a
representative example of a polycyclic aliphatic target molecule (Section 5.3.2), and
octadecane as an example of a straight chain alkane acyclic aliphatic target molecule
(Figure 5-4). The carrier protein-target molecule conjugates used in the panning of the library
consisted of derivatised versions of the extinct life biomarker target molecules conjugated to
carrier proteins via amide bond linkages (Figure 5-4).
Figure 5-4: Structure of conjugates and free target molecule used in screening strategy 1
(a) hopane conjugate (b) octadecane straight chain alkane conjugate (c) free hopane and (d)
free octadecane
Figure 5-5 illustrates the panning approach adopted for both targets and the details of each
round of panning are summarised in Table 5-6 (hopane) and Table 5-7 (octadecane)
(general procedures for panning are given in Section 5.4.3.3). Each round of panning
involved exposure of phage to immobilised target molecule-protein conjugates, washing to
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remove unbound/weakly bound phage followed by either TEA (non-specific) or competitive
(specific) elution with free target molecule.
Figure 5-5: Block diagram illustrating panning protocol used for screening strategy 1
For each target the first round of panning (pan 1) used non-specific TEA elution. After
amplification the material from pan 1 was split, and half was subject to two further rounds of
panning with TEA elution (pan 2 and 3) whilst the other half was subject to three further
rounds of panning using competitive elution with the free target molecule (pan 2a, 3a and
4a).
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Table 5-6: Summary of panning protocol used in screening strategy 1 for selection of hopane binding clones
Panning
Round
Subtractive
pan Coating antigen
Coating antigen
concentration
(µg/ml)
Binding Buffer No. of washes Elution reagent
1 N/A Hop-BSA 10 2 % MPBS 0.5 mg/ml BSA 10 x PBST, 10 x PBS TEA (100 mM)
2 1 mg/ml BSA Hop-BSA 1 2 % MPBS 0.5 mg/ml BSA 10 x PBST, 10 x PBS TEA (100 mM)
3 N/A Hop-BSA 1 2 % MPBS 0.5 mg/ml BSA 10 x PBST, 10 x PBS TEA (100 mM)
2a 1 mg/ml BSA Hop-BSA 1 2 % MPBS 0.5 mg/ml BSA 10 x PBST, 10 x PBS Hop (10 µM)
3a N/A Hop-BSA 1 2 % MPBS 0.5 mg/ml BSA 10 x PBST, 10 x PBS Hop (1 µM)
4a 1 mg/ml BSA Hop-BSA 1 2 % MPBS 0.5 mg/ml BSA 10 x PBST, 10 x PBS Hop (0.1 µM)
Table 5-7: Summary of panning protocol used for screening strategy 1 for selection of octadecane binding clones
Panning
Round
Subtractive
pan Coating antigen
Coating antigen
concentration
(µg/ml)
Binding Buffer No. of washes Elution reagent
1 N/A Oct-BSA 10 2 % MPBS 0.5 mg/ml BSA 10 x PBST-X, 10 x PBS TEA (100 mM)
2 N/A Oct-KLH 1 2 % MPBS 0.5 mg/ml KLH 10 x PBST-X, 10 x PBS TEA (100 mM)
3 N/A Oct-BSA 1 2 % MPBS 0.5 mg/ml BSA 10 x PBST-X, 10 x PBS TEA (100 mM)
2a N/A Oct-KLH 1 2 % MPBS 0.5 mg/ml KLH 10 x PBST-X, 10 x PBS Oct (10 µM)
3a N/A Oct-BSA 1 2 % MPBS 0.5 mg/ml BSA 10 x PBST-X, 10 x PBS Oct (1 µM)
4a N/A Oct-KLH 1 2 % MPBS 0.5 mg/ml KLH 10 x PBST-X, 10 x PBS Oct (0.1 µM)
PBSTX – 0.05 % (w/v) Triton-X 100 in PBS buffer TEA – triethylamine Oct – octadecane Hop – hopane
Key adaptations vs literature protocol
1) For hopane only one protein conjugate was available, therefore it was not possible to alternate carrier protein between panning rounds.
In order to minimise amplification of BSA binding clones a subtractive panning step was performed in alternate panning rounds. Please
see Section 5.4.3.3 for details
2) The wash buffer used when panning for octadecane binding clones was adapted because P20 in the standard PBST wash buffer has
structural similarities to octadecane. P20 was replaced with Triton-X 100 which has a polyether side chain
3) Free target molecules were solubilised in solutions of 20/80 % (v/v) methanol PBS, due to their poor water solubility. Please see Section
5.4.3.2 for details
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5.6.2 Results and discussion
The selected literature protocol with the adaptations described in Section 5.6.1 was applied
to the immunised library for the isolation of anti-hopane and anti-octadecane antibodies.
Following the completion of all panning rounds the output was initially assessed by
polyclonal ELISA.
5.6.2.1 Assessment of binding to target molecule-carrier protein conjugate by
enriched population of phage via polyclonal ELISA
Polyclonal phage from each round of hopane panning was tested for binding to BSA, BSA-
hopane and KLH (Figure 5-6) and polyclonal phage from each round of octadecane straight
chain alkane panning was tested for binding to BSA, BSA-octadecane, KLH and KLH-
octadecane (Figure 5-7). Pan 0 phage (phage taken from the original library population
before any panning had been carried out) was also tested for binding to BSA-hopane, BSA-
octadecane and KLH- octadecane conjugates, and free BSA and KLH carrier proteins to
determine the inherent binding properties of the starting material.
The ELISA data for polyclonal phage selected by panning for hopane (Figure 5-6) and
octadecane straight chain alkane (Figure 5-7), by both TEA elution and competitive elution
show that binding to target molecule-protein conjugate increased with each panning round,
with no similar increase in binding signal observed for free carrier protein. This indicates that
the panning process was successful in terms of enriching the selected pool with conjugate
binding phage clones.
Maximum binding signal, and therefore enrichment of conjugate binding clones was
achieved by round 2 (TEA elution) and round 2a (competitive elution) for hopane and round
1 (TEA elution) and round 2a (competitive elution) for octadecane. Maximum binding signal
was about 0.4 OD units lower for phage selected by competitive elution than for phage
selected by non-specific elution for both hopane and octadecane, but because the ELISAs
for competitively eluted and non-specifically eluted phage were not run alongside each other,
these variations may be due to subtle differences in the timing of incubation steps during the
ELISA, rather than a true difference in the proportion of phage that bound to the conjugate.
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Figure 5-6: Screening strategy 1 - Hopane polyclonal phage ELISA with phage population
generated by (a) non-specific TEA elution and (b) competitive elution with free hopane.
Data points are individual replicates and lines are the linear interpolation of mean OD values
for polyclonal phage from each panning round.
Figure 5-7: Screening strategy 1 - Octadecane polyclonal phage ELISA with phage
population generated by (a) TEA elution and (b) competitive elution with free octadecane.
Data points are individual replicates and lines are the linear interpolation of mean OD values
for polyclonal phage from each panning round.
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Polyclonal ELISA data is intended to give an indication of the effect of panning on the
population of selected phage, showing trends, rather than allowing comparison of the
absolute binding signal and the concentration of phage used in the ELISA from each
panning round was in the order of 1012 infective phage particles/ml but was not identical
across all pans.
For phage generated by panning for hopane binding clones, a single carrier protein (BSA)
was used during panning, due to limited availability of the required starting materials.
Despite this the polyclonal ELISA data shows no evidence of the presence of BSA binding
clones. This demonstrates that the use of a subtractive panning step against BSA in
alternate panning rounds (Table 5-6) was successful in minimising the enrichment of BSA
binding clones.
The polyclonal ELISA data shows that the panning protocol successfully enriched the
selected population of phage with clones that recognise the relevant carrier protein-target
molecule conjugates. Comparison with previous work, including the selected literature
protocol on which this protocol was based, indicates that with this level of enrichment the
isolation and identification of relevant clones by monoclonal ELISA should be possible.
5.6.2.2 Assessment of binding characteristics of selected phage clones by
monoclonal phage ELISA
Phage from panning rounds which had shown enrichment in binding to conjugate, but no
enrichment in binding to carrier protein (hopane panning rounds 2, 3, 3a and 4a; octadecane
panning rounds 1, 2, 3, 3a and 4a) were taken forward for analysis of individual clones by
monoclonal ELISA. Monoclonal phage was tested for binding to conjugate and to carrier
protein in a monoclonal ELISA (please see section 5.4.4.2 for detailed protocol). Table 5-8
gives an example of some typical monoclonal ELISA data and data from all monoclonal
ELISAs for hopane and octadecane is summarised in Table 5-9 (hopane) and Table 5-10
(octadecane). For the purposes of this assessment clones were defined as conjugate
binding clones if the binding signal produced with conjugate was greater than 5 x the
intensity of the binding signal with free carrier protein. A sub-set of the clones were also
tested in inhibition ELISA format to determine if they recognised the free target molecule.
Clones were defined as recognising the free target if they exhibited 5 % inhibition of signal or
greater with 10µM solutions of free target molecule.
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Table 5-8 :Example of typical monoclonal binding ELISA data for 95 clones from screening strategy 1 pan 3 for hopane.
Data shown as binding signal (OD at 450 nm) laid out in 96-well plate format. Clones that gave a binding signal with hopane-BSA (plate 1) of
greater than 5 x binding signal with BSA (plate 2) were defined as conjugate binding clones and are highlighted in yellow (on plate 1 only).
Plate 1 -Binding of 95 phage clones to hopane-BSA conjugate (well A1 is a negative control)
1 2 3 4 5 6 7 8 9 10 11 12
A 0.05 0.70 0.02 0.03 0.02 0.02 0.02 0.02 0.03 0.02 0.03 0.03
B 0.09 0.03 0.02 0.03 0.02 0.02 0.02 1.15 0.02 0.02 0.08 1.15
C 0.02 0.02 0.02 0.01 0.02 0.02 0.44 0.03 0.29 0.03 1.14 0.07
D 0.03 0.02 0.02 0.02 0.02 0.02 0.01 0.03 0.61 0.89 1.02 0.05
E 0.02 0.91 0.02 0.02 0.02 0.02 1.20 0.45 0.03 1.02 0.60 0.06
F 1.06 0.13 0.02 0.02 0.02 0.02 0.02 0.15 0.82 0.06 1.20 0.06
G 0.02 0.02 0.17 0.02 0.42 1.14 0.03 1.02 0.82 0.05 1.37 1.27
H 0.02 0.01 0.85 0.02 0.02 0.02 0.02 0.03 0.02 0.03 0.03 0.03
Plate 2 Binding of same 95 phage clones to BSA (well A1 is a negative control)
1 2 3 4 5 6 7 8 9 10 11 12
A 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.01 0.02 0.02 0.02 0.02
B 0.02 0.02 0.01 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02
C 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.03
D 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02
E 0.02 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02
F 0.02 0.02 0.03 0.02 0.01 0.02 0.01 0.02 0.02 0.02 0.03 0.02
G 0.02 0.02 0.01 0.01 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.02
H 0.02 0.02 0.01 0.02 0.01 0.02 0.03 0.02 0.02 0.02 0.02 0.02
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Table 5-9: Summary of monoclonal ELISA data for screening strategy 1 for hopane.
Panning Round No of clones (out of 95) showing binding to
Conjugate Free hopane
2 1 Not tested
3 27 Not tested
3a 21 6
4a 5 4
Table 5-10: Summary of monoclonal ELISA data for screening strategy 1 for octadecane.
Panning Round No of clones (out of 95) showing binding to
Conjugate Free octadecane
1 1 Not tested
2 51 Not tested
3 56 Not tested
3a 43 5
4a 18 4
The number of clones from each panning round that showed binding to conjugate varied,
and in general the number initially increased with each panning round and then stabilised or
began to fall. For example, the number of hopane-BSA conjugate binding clones selected
increased from one out of 95 from panning round 2, to 27 out of 95 from panning round 3
(Table 5-9). There was also an increase in the number of selected hopane-BSA binding
clones between panning rounds 1 and round 3a (competitive elution with free hopane) from
1/95 clones to 21/95 clones, but by panning round 4a the number of conjugate binding
clones fell to 5/95.
Increasing the number of panning rounds in a selection generally increases the number of
clones in the selected pool that bind to the conjugate, but also reduces the diversity of the
selected population (Lou et al, 2001) and can result in an increase in the population of non-
specific or non-relevant phage (O’Brien et al, 1999). An enrichment in non-specific phage
may account for the reduction in the proportion of conjugate binding clones observed in later
panning rounds. From the monoclonal ELISA data it is not possible to determine whether the
conjugate binding phage clones selected are all multiple copies of the same clone, or a
number of unique clones.
In order to function in the LMC inhibition immunoassay, antibodies must bind to target
molecule-protein conjugate and must also bind to the free target molecule, ideally with a
higher affinity than binding to conjugate. A small number of clones showed some inhibition of
binding signal in the presence of 10 µM of their respective free antigen for both hopane
(Table 5-9) and octadecane (Table 5-10), but the reduction in signal was low (5 – 20 %
inhibition) compared to that observed by Charlton et al (2001) where a sub-population of
phage clones selected using competitive elution showed 90 – 40 % inhibition of binding
signal in the presence of 1 µM atrazine. This indicates that the affinity of the selected clones
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for their respective free targets is likely to be poor in comparison to the affinity of the anti-
atrazine clones selected by Charlton et al., which had sub nanomolar IC50 values.
5.6.2.3 Assessment of diversity of selected clones via amino acid sequence analysis
of heavy and light chain CDRs
In order to determine the diversity of the pool of phage selected with non-specific and
competitive elution using screening strategy 1, the gene coding for the expressed antibody
fragment was sequenced for a number of hopane conjugate and octadecane conjugate
binding clones.
A total of 20 target molecule-carrier protein conjugate binding clones were sequenced per
target from pans 2 and 3 (hopane) and 1, 2 and 3 (octadecane). In addition all of the clones
from pans 3a and 4a (hopane and octadecane) that had shown binding to conjugate and
inhibition of binding in the presence of free target molecule were also sequenced. The amino
acid sequences of complementarity determining regions (CDRs) on the heavy and light
chains on the scFvs are summarised in Table 5-11 (clones selected by panning for hopane
binders) and Table 5-12 (clones selected by panning for octadecane binders).
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Table 5-11: CDR amino acid sequences of anti-hopane phage clones selected from screening strategy 1 with non-specific elution (TEA) and
competitive elution (C). Variations in the amino acid sequences are highlighted in red. Clones with missing CDRs were truncated
Clone
Identifier
Elution
method
No. of
copies VH1 VH2 VH3 VL1 VL2 VL3
G1 TEA 8 FTSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 2 LTSNAVG DMTSGGRTYYNPALKS GAGAYFVHIDN SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 2 LSSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 2 FTSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGLLGVS ASNRRPS ASADKSANF
TEA 1 LRSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 1 LNSNAVG DMSTGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 1 FTSNAVG DMSTGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 1 LSSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY GSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 1 FTSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNYKRPS ASADKSANF
TEA 1 - - - SGSSSNVGYANYVS DATTRAS ASYDNRDSNI
H1 C 5 LSSVGVG NINSDGVTYYNPALRS GSALGRGFFHGGYPGNIDY TGTSSDIGAYKYVG NVNKRPS GSLKSGGTAL
C 2 - - - SGSSDNVGRFPVG GTNNRPA TSFDSSGSIL
C 1 - - - RTNQNINGFLN HATKLY FQYSTLPLA
C 2 LRSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
Table 5-12: CDR amino acid sequences of anti-octadecane phage clones selected from screening strategy 1 with non-specific elution (TEA)
and competitive elution (C). Variations in the amino acid sequences are highlighted in red. Clones with missing CDRs were truncated
Clone
Identifier
Elution
Method
No. of
copies VH1 VH2 VH3 VL1 VL2 VL3
G1 TEA 9 FTSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 2 FTSNAVG DMSTGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 1 LTSNAVG DMTSGGKTYYNSALKS DSDFGGYFVHITY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 1 LTSNAVG DMTSGGKTYYKSALKS DSGPGGYFVHPTY SGSSSNIGVFGVS RNYKRPS ASADKSANF
TEA 1 LSSNAVG DMTSGGKTYYNSALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 1 LTSNAVG DITSRGNTYFNPALKS GSSTYFIHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
TEA 1 LTSNAVG DMTSGGKTYYKSALKS DSGPGGYFVHPTY SGSSSNIGVFGVS RNYKRPS ASADKSANF
TEA 1 SGSSSNVGTYGVG GTNSRPS AAEDNTIFNGV
TEA 1 SGNIDTWGVG GVGNRPS GTYTEERGNI
G1 C 8 FTSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGVFGVS RNNKRPS ASADNSANF
SA1 C 1 FTSNAVG DMSAGGRTYLNPALKS GTSGYFVHIDY SGSSSNIGLFGVS DTFKRSS ASADRSLSF
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Ten complete unique sequences were identified from the 30 sequenced hopane conjugate
binding clones (Table 5-11), there were also four unique truncated sequences, i.e.
sequences missing the heavy chain region of the antibody binding site. It has been observed
previously that phage with a smaller insert (usually missing the genetic material coding for
the heavy chain (VH), as was observed in this case) can dominate an enriched pool of phage
after only a small number of panning rounds because they may have non selective growth
advantages (Azzazy and Highsmith 2002). The majority of the sequences for hopane
conjugate binding clones were highly conserved with only a few (between 1 and 5) residue
variations, which were mostly located in VH1 and VH2. One of the unique sequences,
identified as H1 and selected by competitive elution, stands out from the others because it
has residue variations in all six hypervariable regions and has 6 additional residues inserted
into VH3.
Eight complete unique sequences were identified from the 18 octadecane conjugate binding
clones (Table 5-12), and a further two truncated sequences were identified. Similarly to the
sequencing data from hopane panning the truncated sequences both lack VH. The
sequences from the octadecane conjugate binding clones showed most variation in the
heavy chain, whereas the light chain was highly conserved and several of the sequences are
identical to, or very closely resemble the sequences from the sequenced hopane conjugate
binding clones. A number of the octadecane clones contained stop codons contained within
the framework regions of the heavy chain. In E. Coli TG1 80 % of CAA and TAG stop
codons are translated as glutamine, whereas the remaining 20 % go to termination reducing
scFv expression. When panning for binders to monensin, an antibiotic, Makvandi-Nejad et al
(2010) observed that by round three of panning 80 % of the selected binders contained a
stop codon and they suggested that this could be a result of the toxic nature of the anti-
monensin scFvs. The presence of stop codons in the selected monoclonal phage for
octadecane binders may indicate that the selected conjugate binding scFvs were toxic in
nature.
One clone, which is identified as clone G1 in Table 5-11 and also in Table 5-12 was present
in multiple copies in the clones sequenced from hopane and octadecane panning. Assuming
that the randomly selected clones that were sequenced are representative of the population
of phage enriched by panning, this clone appears to dominate the enriched pool for both
hopane and octadecane. Critically this clone was also isolated during parallel panning work
that was carried out by ImmunoSolv, using a similar panning strategy for porphyrin and 5β 
sterane binding clones, in a separate facility.
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The implication of the isolation of this clone in panning carried out against four separate
targets (and in two different locations, which negates the possibility that the isolation of this
clone from pans for multiple targets is a result of environmental contamination) is that the
applied panning strategy resulted in the amplification of a non-specific phage clone, which
recognises a generic feature of all of the conjugates used to pan for hopane, octadecane,
porphyrin and 5β sterane. However by monoclonal ELISA a small number of clones were 
identified that showed evidence of inhibition in the presence of free target molecule,
suggesting that some of the selected pool of phage may be specific.
5.6.2.4 Assessment of binding characteristics of clones expressed as soluble scAb
via ELISA
Three unique sequences (G1, H1 and SA1 in Table 5-11 and Table 5-12) were taken
forward for expression as soluble single chain antibody fragments. G1 is the clone that
dominated the output of panning for both octadecane and hopane, and was also observed
by ImmunoSolv when panning for 5β sterane and porphyrin. H1 is a unique clone selected 
from the enriched pool of phage generated by panning for binders to hopane using
competitive elution, containing additional residues in VH3, and SA1 is a unique clone
selected from the enriched pool of phage generated by panning for binders to octadecane.
The binding properties of the scAbs were tested by binding and inhibition ELISA Figure 5-8
(H1), Figure 5-9 (SA1), Figure 5-10 (SA1, H1 and G1).
When expressed as scAbs clone H1 bound to BSA-hopane conjugate but showed no
evidence of inhibition of binding in the presence of free hopane (Figure 5-8). Similarly clone
SA1 bound to octadecane-BSA conjugate, but showed no inhibition of binding in the
presence of free octadecane (Figure 5-9). Both H1 and SA1 had shown a level of inhibition
when expressed as fusion-scFvs displayed on phage particles (18 % and 14 % inhibition of
binding signal respectively). The failure to recognise free target molecules when expressed
as scAbs could be a result of different folding of antigen binding sites on the phage bound
ScFv compared to the soluble scAb, (Makvandi-Nejad et al, 2010), or it may reflect that the
level of inhibition observed in monoclonal phage ELISA was too small to be significant. Note
that the concentration of phage used in inhibition ELISAs was selected using binding ELISA
data to ensure a sub-saturating concentration of phage.
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Figure 5-8: scAb ELISAs with clone H1 showing (a) Binding to hopane-BSA conjugate and
(b) inhibition of binding to hopane-BSA conjugate in the presence of free hopane.
Each data point is a single replicate. Lines are linear interpolation of the mean binding
signal.
Figure 5-9: scAb ELISA with clone SA1 showing (a) binding to octadecane-BSA conjugate
and (b) inhibition of binding to octadecane conjugate in the presence of free octadecane.
Each data point is a single replicate. Lines are linear interpolation of the mean binding
signal.
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Given the results from inhibition assays with the clones SA1 and H1 which both failed to
recognise their respective free target molecules, and in particular due to the recurrence of
clone G1 in panning performed for both hopane and octadecane it was decided to perform
cross reactivity studies with these three clones (Figure 5-10). The three clones were tested
for cross reactivity with protein conjugates of all of the targets used to generate the
immunised library (hopane-BSA, octadecane-BSA, porphyrin-BSA, 5β sterane-BSA and 
phytane-BSA) (Figure 5-2) in addition to testing for cross reactivity with two other
hydrophobic small molecule conjugates produced for other work within the LMC project and
not used for the production of the immunised library (carotane-BSA and benzo[a]pyrene-
BSA).
Figure 5-10: scAb binding ELISA for clones H1, G1 and SA1, with hapten-BSA conjugates.
Plotted values are the mean of two replicates, error bars = +/- standard error.
Assessment of the cross reactivity of H1, SA1 and G1 by binding ELISA (Figure 5-10)
showed that all three clones were cross reactive and bound to a range of hydrophobic small
molecule-BSA conjugates, but not to free BSA. It has been observed previously that panning
for small molecule targets can result in the selection of clones with characteristics such as
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those described here (Charlton et al, 2001). These cross reactive conjugate binding clones
have been described as interface binders, since they appear to recognise the interface
between the small molecule and the carrier protein, but not the free carrier protein or the free
target molecule. The use of competitive elution has previously been shown to reduce the
occurrence of interface binders (Charlton et al, 2001), but all three of these clones were
isolated by competitive elution with free target. Therefore in this case the use of competitive
elution did not have the desired effect.
5.6.3 Summary and review of screening strategy 1
The immunised recombinant antibody library was screened using a literature protocol for
antibodies that bound to hopane and octadecane straight chain alkane. The selected pool of
clones was dominated by interface binders, which recognised the relevant target molecule-
protein conjugate, but did not recognise the free target molecule and also cross reacted with
other small molecule-protein conjugates. Therefore the following section constitutes a review
of the outcome of screening strategy 1, leading to identification of possible adaptations to the
screening protocol for application to a second attempt to screen the library.
There are two top-level scenarios that may have resulted in failure to successfully isolate
appropriate antibodies using screening strategy 1. The first is that the immunised
recombinant antibody does not contain any clones that recognise the free target molecules
(i.e. the immunised sheep from which the library was constructed failed to produce an
appropriate immune response). The second scenario is that target molecule binding clones
were present within the library but screening strategy 1 was inappropriate, with the result
that target molecule binding clones were either not enriched at all, or were enriched but not
enriched sufficiently to allow isolation (given the limited number of individual clones that were
isolated for characterisation). From the work reported here, it is not possible to determine
which of these two scenarios is more likely, but for the purposes of the following discussion
the assumption is made that the second scenario is correct and that the recombinant
antibody library did contain target molecule binding clones but that screening strategy 1 was
non-optimum.
Charlton et al (2001) successfully isolated high affinity clones that recognised atrazine
(Figure 5-11), a small molecule target with limited water solubility, from an immunised
recombinant antibody library using the literature protocol on which screening strategy 1 was
based. However atrazine is significantly more polar than hopane and octadecane having an
electronegative chlorine substituent on an aromatic ring, offering more opportunities for
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binding interactions with an antibody than LMC markers of extinct life such as hopane and
octadecane (Figure 5-11).
Figure 5-11: Structure of atrazine, target molecule for selected literature screening strategy
Markers of extinct life such as hopane and octadecane are expected to be poorly
immunogenic. Therefore it is reasonable to speculate that clones that recognise them may
only be present in the recombinant antibody library in small numbers, since a large
proportion of the immune response is likely to have been generated towards the more
immunogenic carrier protein (Kramer 2002). In addition it has been observed previously,
when panning recombinant antibody libraries for small molecule binding clones, that clones
that recognise the free target molecule with high affinity tend to have lower affinity for the
target molecule-carrier protein conjugate (Charlton 2009). By panning using target molecule-
carrier protein conjugates it is possible that rare target molecule binding clones may be
quickly out competed by more common interface binders which have higher affinity for the
conjugate. An alternative panning strategy that has been used for small molecule targets is
to use biotinylated target molecules in place of protein conjugates (Korpimäki et al, 2002;
Kobayashi et al, 2009). The application of biotinylated targets would remove the need for the
use of a carrier protein and allow the phage antibody – target interaction to be carried out in
solution, rather than with the target immobilised to a surface via a carrier protein. This may
be beneficial in terms of minimising the selection of interface binding clones.
The recurrence of the same clone (G1) in phage enriched by panning with different target
molecule-carrier protein conjugates (hopane, octadecane, 5β sterane and porphyrin), both in 
the work reported here and in parallel work carried out by ImmunoSolv, indicated that the
clones enriched by the selection strategy recognised a common element of the conjugates
used for panning. The conjugates used in panning (Figure 5-2) were all small hydrophobic
molecules conjugated to carrier proteins, with either no linker between the hydrophobic
target molecule and the carrier protein (octadecane and phytane), or were linked to the
carrier protein via a hydrocarbon chain of 3-4 carbon atoms in length. All target molecules,
with or without linker, were linked to their carrier protein via an amide bond. Therefore the
cross reactive clones appear to recognise one or more of these common elements i.e. the
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amide bond linking the target molecule with the carrier protein, the hydrocarbon linker (or the
hydrocarbon chain of the target where there was no linker) and generic small hydrophobic
molecules presented on a protein surface. Investigation of alternative linker chemistry is
impractical within the timescales of this project, but the use of alternating linkers e.g.
hydrophobic and hydrophilic is achievable in terms of the synthetic chemistry required, and
may be beneficial in minimising the selection of interface binders.
An additional concern identified when using competitive elution was that it was difficult to
determine with confidence whether the molecules used for competitive elution had been
successfully solubilised. This is especially relevant given the observation that competitive
elution did not prevent the amplification of interface binders as expected. Extinct life target
molecules such as hopane and octadecane have low solubility in aqueous solutions e.g. the
maximum solubility of octadecane in water is 0.006 mg/L (Singer and Finnerty 1984), and
the maximum solubility of hopane in water has not been determined. The successful
solubilisation of free target molecule in 20/80 % (v/v) methanol PBS for competitive elution
was assessed visually (by inspecting the solution for cloudiness and/or visible particulates)
and it is possible that the target molecules were not well solubilised. If this was the case,
phage that appeared to be competitively eluted may in-fact have been non-specifically
eluted, which may account for the enrichment of interface binders rather than target
molecule binding clones. Work carried out at Imperial College has identified that extinct life
target molecules are significantly more soluble in MeOH P80 than in 20/80 % (v/v) methanol
water, therefore the inclusion of P80 in buffers used during panning may help to solubilise
hydrophobic target molecules, as well as being representative of the conditions under which
the antibody must function in the flight instrument.
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5.7 Screening strategy 2: panning with biotinylated target molecule
with alternating linkers and streptavidin coated magnetic
beads
5.7.1 Experimental design
Screening strategy 2 was designed based on the outcome of screening strategy 1 avoiding
the use of a carrier protein during panning, in order to prevent enrichment of interface
binding clones. To achieve this, a biotinylated target molecule was used in place of a target
molecule-carrier protein conjugate, allowing the interaction between scFvs expressed on
phage and the target molecule to occur in solution without the presence of a carrier protein.
After incubation with phage, the biotinylated target molecule (and associated bound phage)
were separated from unbound phage using streptavidin coated magnetic beads and used to
directly infect E. coli for amplification (Hawkins et al, 1992), or competitively eluted with free
target molecule prior to infection.
The required biotinylated target molecules had to be synthesised specifically for this work,
and within the timescales of this thesis the only available biotinylated target was 5β sterane, 
a cyclic aliphatic molecule, therefore screening strategy 2 used this molecule as the target.
Two different 5β sterane-biotin conjugates were used for panning, one of which had a 
hydrophobic pentylamine group linking the 5β sterane molecule to the biotin and the other 
had a hydrophilic polyethylene glycol group (PEG3) linking the 5β sterane molecule to the 
biotin(Figure 5-12). In order to prevent enrichment of clones that recognised the linker the
hydrophobic and hydrophilic linkers were alternated between panning rounds.
In addition to the use of biotinlyated target molecule, P80 was introduced into the buffers
used during panning in order to improve solubility of hydrophobic target molecules.
Screening strategy 2 was developed based on protocols supplied by Dr. Damjana Kastelic of
the Babraham Institute (Cambridge, UK) and included subtractive panning steps in order to
deplete streptavidin binding clones. The overall panning procedure used is shown in Figure
5-13 and the details of each panning round are given in Table 5-13. Detailed materials and
methods are described in Section 5.4.3.4.
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Figure 5-12: Structure of biotinylated 5β sterane conjugates used for screening strategy 2 (a) 
5β sterane pentyl amine biotin (hydrophobic linker) and (b) 5β sterane PEG 3 biotin 
(hydrophilic linker)
Figure 5-13 Block diagram illustrating panning protocol used for screening strategy 2
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Table 5-13: Summary of panning conditions for screening strategy 2, panning using biotinylated antigen and streptavidin coated magnetic
beads
Panning
Round
Subtractive
pan Biotinylated antigen Binding Buffer No. of washes Elution reagent
1 N/A 5β sterane PEG 3 biotin  2 % MPBS 20 % MeOH P80 3 x PBS 20 % MeOH P80 No elution 
2 Yes 5β sterane pentyl amine biotin 2 % MPBS 20 % MeOH P80 10 x PBS 20 % MeOH P80 10 µM coprostane in PBS 20 % MeOH P80
3 Yes 5β sterane PEG 3 biotin 2 % MPBS 20 % MeOH P80 10 x PBS 20 % MeOH P80 10 µM coprostane in PBS 20 % MeOH P80 
4 Yes 5β sterane pentyl amine biotin 2 % MPBS 20 % MeOH P80 10 x PBS 20 % MeOH P80 1 µM coprostane in PBS 20 % MeOH P80 
2 % MPBS MeOH P80 = 2 % milk powder in PBS buffer with 20 % (v/v) methanol and 1.5 g/L polysorbate 80
Key design features of panning strategy
1) Hydrophobic/hydrophilic linker alternated between panning rounds
2) Binding and washing performed in MeOH P80, to improve solubility of biotinylated and free target molecules
3) Subtractive panning used to deplete streptavidin binding clones
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5.7.2 Results and discussion
Screening strategy 2 was applied to the immunised library for the enrichment of anti-5β 
sterane clones. Following the completion of all four rounds of panning the enriched
population of phage was analysed.
5.7.2.1 Assessment of binding to target molecule-carrier protein conjugate by
enriched population of phage via polyclonal ELISA
After the completion of four rounds of panning, the output of each panning round was
assessed by polyclonal phage ELISA (Figure 5-14). Polyclonal phage from each round of
panning was tested for binding to 5β sterane PEG4 BSA (hydrophillic linker), 5β sterane 
pentylamine KLH (hydrophobic linker), free BSA and free KLH, in addition to BSA-phytane
(no linker) as an additional control for the assessment of cross reactivity with an unrelated
hydrophobic small molecule – protein conjugate. An irrelevant conjugate was introduced at
polyclonal ELISA analysis stage due to the cross reactive nature of the clones that were
isolated by screening strategy 1.
The polyclonal ELISA data (Figure 5-14) show that rounds of panning have enriched the
selected pool with clones that bind to 5β sterane-KLH conjugate, but have also enriched the 
selected pool with clones that bind to free KLH. Binding signal with KLH conjugate and with
KLH is of the same magnitude, which implies that the entire binding signal observed is due
to non-specific binding to KLH carrier protein, rather than recognition of the 5β sterane-KLH 
conjugate. This theory is also supported by the fact that binding signal to 5β sterane-BSA 
and phytane - BSA conjugates does not increase across the four rounds of panning.
Since the immunogens used for construction of the immunised recombinant antibody library
were KLH conjugates (Figure 5-2) it is likely that the recombinant antibody library contains a
proportion of KLH binding clones, however it is unclear how these clones were enriched in a
panning protocol that did not include KLH conjugates. The use of biotinylated target
molecule, with alternating hydrophobic/hydrophilic linkers was intended to minimise the
selection of interface binders (clones that non-specifically recognise small hydrophobic
molecules conjugated to carrier proteins) and in that respect it has been successful, because
the enriched population of clones did not bind to unrelated small molecule-carrier protein
conjugates. However the enriched population did not specifically bind to the relevant target
molecule-carrier protein conjugate.
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Figure 5-14: Screening strategy 2 5β sterane polyclonal phage ELISA with phage population 
generated by panning with biotinylated 5β sterane   and streptavidin coated magnetic beads. 
Data points are individual replicates and lines are the linear interpolation of mean OD values
for each panning round
The polyclonal ELISA data indicated that the probability of isolating target molecule binding
clones from the enriched population of phage was likely to be very small and for this reason
the material was not taken forward for further analysis.
5.7.3 Summary
The use of biotinylated target molecule in screening strategy 2, to replace target molecule-
carrier protein conjugates, resulted in the enrichment of clones that non-specifically bound to
KLH carrier protein. The enriched phage population showed no evidence of recognition of
carrier protein-small hydrophobic molecule conjugates (with the exception of 5β sterane-
KLH). The mechanism for the enrichment of KLH binding clones is unclear. Analysis was
stopped at the polyclonal ELISA stage.
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5.8 General discussion
The objective of the work reported in this chapter was to determine if screening the available
immunised recombinant antibody library, by phage display, could isolate antibodies that
specifically recognise extinct life markers, i.e. small hydrophobic molecules, within the
context of the available resources and timescales for the LMC project.
In order to meet this objective, and given the context that an immunised recombinant
antibody library produced using five pre-selected targets (Figure 5-1) as examples of
markers of extinct life was available for use in this work, the following specific objectives
were set:
1) To attempt to isolate antibodies that bind to extinct life marker molecule by screening
the immunised recombinant antibody library using a selected literature procedure for
one or more targets
2) To test the output of the selected literature procedure, i.e. both as antibody fragments
expressed as fusion proteins on phage (scFvs) and, where relevant, as soluble single
chain antibody fragments (scAbs), for appropriate function in an LMC relevant
context
3) To review the output of the selected literature procedure and if necessary to modify
the protocol in order to favour the selection of clones against extinct life marker
molecules
The immunised recombinant antibody library was screened for antibodies that bound to
hopane and for antibodies that bound to octadecane using a literature procedure that had
previously been used to isolate high affinity small molecule-binding antibodies from an
immunised recombinant antibody library (screening strategy 1). The analysis of the output
showed, that although the polyclonal ELISA and monoclonal ELISA data appeared
promising, the enriched pool of phage was dominated by interface binding clones. In order to
try and address this, modifications were made to the panning strategy introducing the use of
biotinylated target molecules with alternating hydrophobic and hydrophilic linkers, instead of
target molecule-protein conjugates. The adapted protocol did not enrich interface binders,
but instead the selected pool was dominated by non-specific KLH binding clones.
The failure to isolate appropriate clones, using first the literature protocol and second the
adapted protocol may be due to a number of reasons:
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1) There may be no suitable binders present in the library
The immunised recombinant antibody library used in this work may not contain any clones
that bind to the free target molecules either because sheep cannot produce antibodies
against these target molecules (because they are non-immunogenic or because the sheep
has in-built tolerance mechanisms), or because the immunogens used in the generation of
the recombinant antibody library were unsuitable due to ineffective conjugate design.
If sheep are incapable of producing appropriate antibodies against biomarker targets of
extinct life, alternative animals could be used for the generation of an immunised library, or a
library generated from a non-immune source could be used: For example synthetic and
semi-synthetic libraries have previously been used to isolate antibodies that are difficult to
produce from immunised libraries due to in vivo tolerance mechanisms. For example human
anti-self antibodies have been isolated from a naïve library constructed from rearranged VH
and VL genes derived from the peripheral blood lymphocytes of unimmunised health human
volunteers (Griffiths et al, 1993). Antibodies against fatty acids, which are poorly
immunogenic or non-immunogenic (Gargir et al, 2002), and heparan sulphate (Kuppevelt et
al, 1998), a linear polysaccharide that is found in all animal tissues, have been isolated from
semi-synthetic phage display libraries.
Structural studies carried out on hapten binding antibodies have shown that small molecules
are frequently bound in a cavity or pocket formed by the heavy and light chain variable
domains (Kusharyoto et al, 2001), and the linkers used for immunisation for this library may
have been too short (linker lengths varied from 0 – 4 carbons) to allow the target molecules
to access a binding pocket. In the construction of any future immunised libraries it is
important that conjugate design, including the length of the linker used to attach the target
molecule to the carrier protein is carefully considered.
2) Suitable binders were present in the library but were not isolated using either of the
tested screening strategies
It is accepted that no single panning strategy can exploit the full diversity of a recombinant
antibody library (Lou et al, 2001), however it is concerning that the application of two
strategies did not yield any clones that showed recognition of the free target molecule. There
are two principle reasons why the strategies used here may have failed; the first is that the
parameters used in each of the tested panning strategies were non-optimum, in-spite of the
modifications made. Panning is a flexible process and making small adjustments in
conditions such as the washing steps and the binding buffers can have a significant impact
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on the pool of enriched phage (Makvandi-Nejad et al, 2010). It may be possible to further
optimise the panning conditions used in order to favour the selection of appropriate clones. It
is likely that a balance is required between applying enough stringency to minimise
enrichment of non-specific and interface binders, but not so much stringency that target
molecule binding clones, which may well have low affinities and be rare within the library, are
lost. However this is likely to require considerable time to achieve and may be beyond the
resources and timescales available for this project.
The other possibility is that there is a fundamental problem with the panning or analysis
protocol used. Both panning protocols had common factors. One factor that may play a role
in the failure of the protocols attempted was the inclusion of milk powder as a blocking agent
during panning. Milk powder is a poorly defined substance and is likely to contain a range of
small hydrophobic molecules, which may have interfered with the panning process. In future
attempts to screen recombinant antibody libraries consideration should be given to the use
of an alternative blocking protein, or to alternating the blocking protein between panning
rounds. Polysorbate 20 has been demonstrated to prevent non-specific interactions of phage
with plastic (Duan and Siegumfeldt 2010) therefore it may be possible to substitute this for
milk powder in future panning protocols, although this may be problematic when attempting
to isolate clones that bind to straight chain alkanes due to structural similarities with
polysorbate molecules.
Another concern is that LMC target molecules of extinct life may be structurally similar to
those present in E. coli used for amplification during screening. This may have resulted in
the production of phage with occupied binding sites, interfering with successful selection.
Alternative non-cell base selection strategies should also be considered e.g. ribomsome
display to avoid this complication, but one again this has significant resource implications.
The analysis methods used in this thesis were low throughput (approximately 300 individual
clones were analysed for each target in strategy 1). The application of high throughput
selection technologies during the analysis phase of the selection would allow analysis of a
much higher number of clones (in the order of tens of thousands) from the selected pool,
which may facilitate the isolation of rare clones that bind to free target molecules in a pool
dominated by conjugate binding and/or non-specific clones. Once again it is likely that this is
beyond the resources of the project, however it may be possible to use high throughput
screening in collaboration with other organisations.
In summary, although antibodies against extinct life marker targets were not generated in
this work, experience has been gained regarding the challenges in producing antibodies to
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small hydrophobic molecules and routes to future progression have been identified;
specifically the exploitation of different library types, including immunised libraries from other
sources and the use of naive/synthetic libraries in addition to the employment of high
throughput screening techniques to increase the probability of isolating rare clones.
5.9 Conclusions and future work
The LMC aims to use a microarray immunoassay in order to detect the presence of markers
of extant and extinct life in liquid extracts from martian samples. In order to achieve this it is
first necessary to produce antibodies that recognise markers of extinct life. Markers of extinct
life are small hydrophobic molecules, comprised primarily of carbon and hydrogen and are
therefore perceived as challenging to raise antibodies against. The objective of the work
reported in this chapter was to establish if screening an immunised phage display library
would allow the isolation of antibodies that bind to a number of markers of extinct life, within
the context of the limited resources available. Two attempts were made to screen the
immunised recombinant antibody library and analysis of the output of the screenings
determined that no suitable clones had been isolated. Therefore the conclusion is that that
the current immunised recombinant antibody library is unlikely to provide a rapid route to the
selection of appropriate antibodies within the available timescales and resources for the
LMC project.
The work here led to the identification of several potential alternative approaches to the
production of appropriate antibodies, including the use of libraries from alternative sources
and identification of the need for access to high throughput screening facilities. This has
generated useful information that can be fed into future efforts to isolate appropriate
antibodies. The rapid production of antibodies that recognise markers of extinct life is
essential in order for the LMC to be ready to meet its objective of searching for extinct life on
Mars. An ongoing program of work has been implemented, involving the exploitation of a
number of recombinant antibody libraries from a variety of immune and non-immune
sources, including synthetic/semi-synthetic libraries and the use of high throughput
screening (Table 5-14)10 which it is hoped will overcome the limitations of the immunised
library used within this work. Note that in late 2011 the first indications of successful isolation
of clones that recognise free 5β sterane, isolated from the CAT2 semi-synthetic recombinant 
antibody library using biotinylated target molecules and high throughput screening have
been reported by a collaborating partner. .
10 The following description of future work has been designed by the LMC project team and has
included input from the author of this work
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Table 5-14: Future program of work showing recombinant antibody libraries to be screened for the isolation of antibodies against small and
hydrophobic target molecules of extinct life for the LMC
Library
Type
Library
name
Library size Analysis
method
Collaborating organisation Rationale
Immunised
camelid
N/A 1 x 108 Low throughput Vlaams Instituut voor
Biotechnologie (VIB), Gent,
Belgium
Use of different animal for construction of immunised
library with improved conjugate design.
Immunised
sheep
N/A circa 1 x 108 Low throughput ImmunoSolv Ltd, Aberdeen,
UK
Improved conjugate design for immunisation, further
modifications to panning protocols
Semi-
synthetic
human
Nissim > 1x108 Low throughput N/A Non-immune library, may offer benefits in terms of
isolating antibodies against non-immunogenic targets
Semi-
Synthetic
Human
CAT2.0 1.3 x 1011 High throughput Medimmune, Cambridge, UK Large non-immune library, may offer benefits in terms of
isolating antibodies against non-immunogenic targets,
high throughput screening for isolation of rare clones
Semi-
Synthetic
Human
HuCal
PLATINUM®
4.5 x 1010 High throughput AbD Serotech, Munich,
Germany
Large non-immune library, may offer benefits in terms of
isolating antibodies against non-immunogenic targets,
high throughput screening for isolation of rare clones
Semi-
synthetic
Cavity library TBC TBC University of Lund, Sweden Library design to be based around pocket binding
antibodies for hapten binding
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6 Demonstration of LMC Format Extraction and
Detection in Flight Representative Hardware
6.1 Introduction and context
The flight format immunoassay differs from the ELISA and pooled microarray formats
which have been used throughout this thesis. Successful demonstration of
immunoassay function in the proposed LMC extraction solvent (Chapter 3) and with
Mars relevant analogue samples/sample matrix components (Chapter 4) using ELISA
and pooled microarray formats indicates that immunoassays will also function in a
more flight representative format, i.e. in a multiplexed microarray immunoassay
implemented within a microfluidic channel using evanescent excitation of fluorophores,
but this must be confirmed experimentally.
As part of the ESA funded Technology Readiness Level (TRL) Upgrade Study for the
LMC instrument, a flight instrument representative breadboard, which is described in
detail in Section 6.3, was developed to (i) validate the implementation of multiplexed
microarray immunoassays within microfluidic channels, (ii) to demonstrate the optical
waveguide technology proposed for excitation of fluorophores bound to microarrays
and (iii) to demonstrate read out of immunoassay signal for the LMC flight instrument.
Therefore the objective of the work reported in this chapter was to perform an ‘end to
end’ demonstration of the LMC instrument using the flight representative breadboard to
analyse a liquid extract from a Mars analogue sample. The purpose of this work was to
confirm that flight format immunoassays function in the proposed LMC extraction
solvent and with Mars relevant analogues/sample matrix components, and to
investigate the interaction of liquid extracts with the microfluidic and optical aspects of
the flight format immunoassay.
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6.2 Chapter objectives
The objective of the work reported in this chapter was to confirm that LMC
immunoassays function with liquid extracts from Mars analogue samples in a flight
representative format. In order to meet this aim the following specific objectives were
set.
1) To confirm compatibility of liquid extracts from Mars analogue samples with the
optical and microfluidic aspects of the flight format immunoassay i.e. fluid flow
within a microfluidic channel with evanescent excitation of bound fluorophores
by coupling of laser light into optical waveguides
2) To confirm the function of LMC relevant immunoassays in a liquid extract
composed of the proposed LMC extraction solvent and sample matrix
components from a Mars analogue sample in flight representative format i.e.
immunoassays performed within a microfluidic channel with antibodies and
other immunoassay reagents freeze dried in a glass fibre pad
Note that ‘end to end’ demonstration of the LMC instrument, from extraction to
detection, using breadboards in a laboratory environment, was required in-order for the
LMC to meet the required TRL for progression to the next phase of instrument
development.
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6.3 Description of the assay breadboard
The assay breadboard (ABB) is an optical and fluidic demonstrator and was developed
by LMC Consortium members at the University of Leicester, UK; Dutch Space, The
Netherlands; and LioniX b.v., The Netherlands as part of a TRL Upgrade Study funded
by the European Space Agency. The ABB (Figure 6-1) consists of an optical and
imaging system and a fluid control system integrated with a module composed of a
stack of ‘single use’ immunoassay components which form the microfluidic channel
where the LMC immunoassay takes place.
Figure 6-1: Images of the assay breadboard showing from top to bottom outline layout
of the assay breadboard (not to scale), photograph of the assay breadboard top view,
and photograph of assay breadboard side on view
(FAU = fibre alignment unit, used to couple laser light into optical waveguide chip in
immunoassay module).
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In the following sections the key components of the ABB are described in more detail.
6.3.1 Assay breadboard immunoassay module
The ABB immunoassay module, which contains the microfluidic channel where the
multiplexed immunoassays take place, consists of a stack of four components clamped
together in an aluminium holder. The four components are (i) an optical waveguide
chip, (ii) a Viton® gasket, (iii) a glass fibre pad containing freeze dried fluorescently
labelled antibodies and other assay reagents, and (iv) a glass fluidic cover (Figure 6-2).
a b
c
Figure 6-2: Assay breadboard immunoassay module components.
(a) (from left to right within image) glass cover, glass fibre pad, Viton® gasket and
optical waveguide chip. (b) immunoassay module consisting of immunoassay
components assembled into aluminium holder ready for integration onto ABB. (c) Cross
section of assembled immunoassay module showing fluidic flow path through
assembled stack (not to scale), direction of fluid flow is indicated by red arrows.
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6.3.1.1 Optical waveguide chips
LMC optical waveguide chips (Figure 6-3) were custom designed and manufactured by
LioniX b.v. (Twente, The Netherlands). Each chip, with dimensions of 32 x 6 mm, is
fabricated using thin film deposition of silicon oxide and silicon nitride on a silicon
substrate and waveguides are shaped by photolithography and plasma etching. In the
array area of the chip (square area in images in Figure 6-3), the surface of the chip is
etched to expose the optical waveguides to the surface allowing microarray spots to be
printed directly onto the waveguides in this area. Each chip is fabricated so as to have
a single hole at each end to allow fluid to enter the microfluidic channel (Figure 6-3)
and to have alignment crosses at the four corners of the etched array area of the chip
to aid with printing alignment (since printed microarray spots must align precisely with
the waveguides in order to allow evanescent excitation of bound fluorophores). In order
to immobilise target molecules in the form of a microarray the silicon nitride chip must
first to be surface functionalised to create a hydrophobic surface as described in
Section 6.5.2.1. After running an immunoassay laser light is coupled into the
waveguides at a single point and then split into 10 with a multi mode interferometer.
ABB optical waveguide chips are a single use item and can only be used to run a
single multiplexed microarray immunoassay on the ABB.
Figure 6-3: Images of optical waveguide chip
(a) photograph of optical waveguide chip, with dimensions of 32 mm x 6 mm, showing
array area consisting of ten 100 µm optical waveguides spaced 200 µm apart and
fluidic holes at either end of chip (b) Photograph of optical waveguide chip (32 mm x 6
mm) with laser light coupled into incoupling waveguide using FAU. (c) array area of
optical waveguide chip magnified to show ten 100 µm optical waveguides, spaced 200
µm apart, and four alignment crosses, one at each corner of the array area.
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6.3.1.2 Glass fluidic covers
Glass fluidic covers were designed and manufactured by LioniX b.v. The glass covers,
when assembled into the immunoassay module, together with the Viton® gasket and
the optical waveguide chip, form two chambers with connecting channels. The first is a
chamber which holds the glass fibre pad with freeze dried antibodies and the second a
chamber which aligns with the microarray area on the waveguide chip, allowing
incubation of antibodies and liquid extracts over the microarray and allowing
fluorescent and optical imaging of the array area. In the final instrument glass fluidic
covers will be a single use item, but in the work reported here glass covers were
cleaned and re-used for multiple assays due to their limited availability.
6.3.1.3 Viton® gaskets
A Viton® gasket (AAA Acme rubber co. inc. Tempe, Arizona, USA), cut to size using a
Fenix CO2 laser cutting /engraving system (Synrad, Mukilteo, WA, USA), is placed
between the glass cover and the waveguide chip, within the immunoassay module, to
provide a compliant surface against which the microfluidic channel can be sealed and
to form the base of the pad chamber. The Viton® was cut to size so that, when the
gasket was laid over the optical waveguide chip, the array area on the chip was left
uncovered and the in-coupling waveguide on the right hand side of the chip was
unobstructed to allow coupling of laser light into the optical waveguide chip. Two holes
were cut in either end of the gasket to align with the holes in the optical waveguide chip
to complete the fluid flow path (Figure 6-2). In the final instrument Viton® gaskets will be
a single use item, for ABB assays, Viton® gaskets were cleaned and re-used for
multiple assays.
6.3.1.4 Glass fibre pads
Glass fibre pads containing freeze dried fluorescently labelled antibodies are placed
within the pad chamber formed by the glass fluidic cover and the Viton® gasket. The
antibodies are freeze dried with a protective matrix (freeze drying cocktail) and are
stable for long periods of time11. As the liquid extract is pumped through the pad
11 Storage studies carried out by the LMC team at Cranfield have shown no significant change
in assay performance after storage of antibodies freeze dried into pads at room temperature
under an inert gas for up to one year Cullen D, and Allen M (2010). Technical note LMC-CU-
TN-005 One year LMC storage study outcomes. (unpublished report).
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chamber, the freeze dried antibodies are re-dissolved directly into the liquid extract.
Glass fibre pads are single use items. The method for preparation of glass fibre pads,
including freeze drying antibodies, is described in Section 6.5.2.3.
6.3.2 Fluid control system
Fluid flow through the ABB is generated by a vertically mounted NE-501 syringe pump
(Prosense BV, Oosterhout, Netherlands) which is controlled by WinPumpControl
software (version 1.2.1). The syringe pump is connected to the inlet fluid port of the
immunoassay module with capillary tubing, (Figure 6-1). Liquid extract is pumped from
the syringe pump reservoir, through the capillary tubing and into the immunoassay
module. Within the immunoassay module the liquid extract is pumped into the pad
chamber where it dissolves the freeze dried antibodies and associated assay reagents
contained in the glass fibre pad. Fluid from the pad chamber is then pumped into the
array chamber, where it comes into contact with the printed microarray and finally fluid
is pumped out through the outlet fluid port of the immunoassay module to waste, via
another section of capillary tubing. The flow of fluid can be stopped as required in order
to allow appropriate incubation periods in the pad chamber and in the array chamber to
allow immunological reactions to take place.
6.3.3 Optics and imaging
Evanescent excitation of fluorophores on antibodies bound to the microarray is
achieved by coupling laser light into the optical waveguide chips. A Fibre Alignment
Unit (FAU) holds an optical fibre which feeds laser light from a 635 nm LD-635-31A
laser diode (Wavelength Electronics Ltd, Kent, UK) with a power output of 1mW, to the
waveguide in the immunoassay components module. The FAU is mounted on an XYZ
translation table that can be moved using three orthogonally arranged precision linear
translation stages allowing alignment of the optical fibre with the optical waveguide chip
in the immunoassay component module, so that laser light can be coupled into the
waveguides (Figure 6-4).
In order to image the excited fluorophores, an SXV-H9 thermoelectrically cooled CCD
camera with a 4x microscope objective (Starlight Express, Holyport, UK) is mounted
onto a rotation and translation stage above the immunoassay module. A Stopline™
633 notch filter with an optical density of 6 at a wavelength of 633nm (Semrock,
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Rochester, USA) is mounted within an optical spacer in front of the CCD camera, to
block out reflected and scattered 633nm light.
Figure 6-4: Schematic drawing of optical waveguide chip and fibre alignment unit (FAU)
showing coupling of laser light into in-coupling fibre on the waveguide. Top image
shows the optical waveguide chip and the FAU, the black arrows indicate two of the
three axis in which the FAU can be manipulated (the third axis is into the plane of the
page). The bottom image is a magnified view of the array area and the in-coupling area
on the waveguide chip.
In addition to the CCD camera a 50 x magnification microscope and a Philips
SPC900NC webcam are mounted onto the stage to aid with visual conformation of
FAU alignment, for coupling of laser light into the optical waveguide chip, and to allow
inspection of waveguides and visual recording of the fluid flow through the pad and
array chambers.
6.4 Experimental design
In order to confirm functionality of LMC immunoassays in flight representative format
with LMC extraction solvent and Mars relevant sample matrix components, a Mars
analogue sample was spiked with a model target molecule and extracted using an LMC
representative extraction protocol with MeOH P80 extraction solvent. The liquid extract
was then analysed by multiplexed immunoassay using the flight representative assay
breadboard. In order to discriminate between specific inhibition of signal by extracted
target molecules and non-specific inhibition of signal due to sample matrix mediated
effects, an un-spiked sample of a Mars analogue sample matrix was also extracted and
the resulting liquid extract analysed in the same way.
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Due to time constraints and the limited availability of optical waveguide chips, work was
limited to spiking of a single Mars analogue with a single model target molecule and
performing a single multiplexed ABB assay with each liquid extract, with no replicate
runs12.
6.4.1 Selection of immunoassays and model target molecule
Ideally the end to end demonstration would have been performed with a high science
priority target for the LMC, e.g. a marker of extinct life, however as reported in Chapter
5 of this thesis, attempts to produce antibodies that recognise markers of extinct life
have not so far been successful. Immunoassay, and therefore model target molecule
selection was restricted to immunoassays that had been successfully transferred into
microarray format at the time of this piece of work; GroEL and fluorescein13.
The fluorescein assay is intended as a positive control marker for the LMC since
fluorescein, a synthetic organic molecule is not expected to be present on Mars.
However for the purposes of an end to end demonstration fluorescein was considered
to be the most appropriate of the two available targets since it is a small organic
molecule, like many of the intended targets for the LMC. Additionally using fluorescein
as the target molecule for spiking, facilitated easy confirmation of successful extraction
by measuring the fluorescence of the liquid extracts and comparing to a standard
curve.
Fluorescein was therefore used as the model martian target molecule for this study and
the GroEL immunoassay was used as a control assay. In addition to the control assay
spots of high and low AF633 labelled BSA were also printed onto the microarray.
These spots had two functions, the first of which was as a positive control of
fluorescence i.e. to confirm that the excitation and optical aspects of the ABB assay
were functioning independently of the immunoassay and the second was as calibration
12 A problem encountered during the study (described in Section 6.6.1) necessitated one of the
samples to be reanalysed therefore three ABB immunoassays were performed in total for this
study.
13 At the time of completion of this thesis, work was ongoing within the LMC project team to
perform an end-to-end demonstration using the benzo[a]pyrene immunoassay, which was
transferred into microarray format after the work reported in this chapter had been completed.
This second end to end demonstration with involve extraction of Mars analogues spiked with
pyrene (a hydrophobic marker of meteoritic in-fall) using the most recent version of a flight
representative breadboard built for the LMC instrument.
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spots to allow normalisation of signal intensities to correct for differing coupling
efficiencies between optical waveguide chips.
6.4.2 Selection of analogue sample matrix
JSC Mars-1, a martian regolith analogue developed by the Johnson Space Centre
(Houston, USA) (Allen et al, 1997) was selected for use in this study because it is the
standard adopted by the Mars exploration community for studies where a Mars
analogue is required (Court et al, 2010; Gough et al, 2010; Kral et al, 2011).
6.5 Supplementary materials and methods
The following sections describe the materials and methods used to perform an ‘end to
end’ demonstration of the LMC. There is some overlap with the common materials and
methods described in Chapter 2 of this thesis and where relevant this section cross
references the appropriate sections in Chapter 2.
6.5.1 Preparation of liquid extracts
Samples of JSC Mars-1 were spiked and extracted by Dr Alex Baki, Imperial College
London. Dr Baki’s procedure for spiking JSC Mars-1 is described in the following
section.
6.5.1.1 Spiking JSC Mars-1 with fluorescein model target molecule
JSC Mars-1, a commonly used martian regolith simulant (Allen et al, 1997), was
cleaned prior to spiking to remove any residual organics, or other contamination. This
was achieved by addition of 3 ml of 80/20 % (v/v) water/methanol (Fisher scientific,
Loughborough, UK cat no. M14056/17) to one gram of JSC Mars-1 in a glass test tube
followed by twenty minutes of sonication in an ultrasonic bath (Thermo Fisher
Scientific, Loughborough, UK, cat no. FB15048). The JSC Mars-1 was then allowed to
settle by standing and the supernatant was decanted. This process was repeated to a
total of two extractions. Following the two pre-extractions JSC Mars-1 was dried in an
oven set at a temperature of 120°C for 12 hours.
Following pre-extraction and drying JSC Mars-1 was spiked with fluorescein sodium
salt (Fluka, part of Thermo Fisher Scientific, Loughborough, UK, cat. no.28803), in this
context as a model martian target molecule, at two concentrations; 0 µg/g and 2.7µg/g.
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These concentrations were calculated with the aim of producing liquid extracts with
fluorescein concentrations that were 0 x and 30 x the IC50 value of the fluorescein
microarray assay (3 ng/ml) assuming a 10 % extraction efficiency. The appropriate
quantity of fluorescein sodium salt was dissolved in one mililitre of 18 MΩ.cm water and 
mixed well with one gram of pre-extracted JSC Mars-1 by vortexing. The solvent was
then evaporated over a period of several hours using a RVC 2-18 CD rotational
vacuum concentrator (Christ, Osterode am Harz, Germany). Once the solvent had
been removed the spiked JSC Mars-1 samples were dried further in an oven set at
40°C for 12 hours.
6.5.1.2 Extraction of spiked JSC Mars-1
Three millilitres of MeOH P80 was added to 1g JSC Mars-1 in a glass test tube and
sonicated for 20 minutes with a Sonotrode Ultasonic UP100H probe and UP50H
ultrasonic processor set at 40 % amplitude (Hielscher Ultrasonics, Teltow, Germany).
This extraction protocol simulates the extraction protocol for the LMC. After
ultrasonication, the mixture was allowed to stand for 10 minutes, and the supernatant
that had formed above the sedimented JSC Mars-1 was clarified by filtration through a
0.45 µm cellulose acetate filter and then stored at 2 - 8°C in glass vials until tested in
the immunoassay14.
Estimation of extraction efficiency by fluorescence of liquid extract
In order to estimate the concentration of fluorescein extracted from spiked JSC Mars-1,
200 µl of liquid extract was placed in a white microtitre plate (Pierce, part of Thermo
Scientific, Leicestershire, UK, cat. no. 15042) and the fluorescence measured using a
Variskan Flash plate reader (Thermo Scientific, Leicestershire, UK) (λex. = 494nm, λem
=521nm). A standard curve was constructed in the same microtitre plate by dissolving
known concentrations of sodium fluorescein in MeOH P80 over the concentration
range 0 – 5 µg/ml. The concentration of sodium fluorescein salt in the liquid extract
(and hence the extraction efficiency) was calculated by linear regression and was
found to be approximately 90 ng/ml, which is approximately 30x the IC50 for the
fluorescein microarray immunoassay.
14 Note that this work was carried out before the finding (discussed previously in Section
4.6.2.3) that filtration can result in loss of hydrophobic target molecules, by absorption to the
filter membrane. This is unlikely to have an impact on the extraction efficiency of the more polar
fluorescein used in this study.
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6.5.2 Preparation of immunoassay components for ABB assay
6.5.2.1 Silanisation of optical waveguide chips
Optical waveguide chips were treated to produce a hydrophobic surface for
immobilisation of target molecules/target molecule-protein conjugates, following the
protocol described in Chapter 2 (Section 2.2.3.1) for silicon nitride chips.
6.5.2.2 Printing and immobilisation of microarrays onto optical waveguide chips
via physical adsorbtion
Microarrays of immobilised antigen were printed onto optical waveguide chips, which
had been treated as described in Section 6.5.2.1, using the SPI spotting robot following
the protocol described in Chapter 2 (Section 2.2.3.4). A single microarray was printed
onto each waveguide chip in the array area so that spots were printed directly on top of
the ten optical waveguides. Each microarray consisted of rows of 10 spots of (i) high
ratio labelled AF633 BSA, (ii) GroEL, (iii) BSA-FITC and (iv) low ratio AF633 labelled
BSA. GroEL and FITC-BSA are the immobilised versions of the target molecules
required for the GroEL and fluorescein immunoassays respectively. The high and low
ratio AF633 labelled BSA spots were included in the array as a positive control to
confirm coupling of laser light and to allow calibration/normalisation across different
optical waveguide chips, which are likely to have been coupled with differing efficiency.
Alignment of the printing pin with the optical waveguides was achieved using the
camera microscopes on the spotting robot with the aid of the alignment crosses at the
edges of the array area on the optical waveguide chips (Figure 6-3).
6.5.2.3 Freeze drying of antibodies into glass fibre pads
Glass fibre pads were prepared by cutting binder free borosilicate glass fibre sheet with
a specified thickness of 215.9-292.1 µm (Pall Corporation, Port Washington, New York,
USA) to dimensions of 1.6 mm x 8.65 mm with a Fenix CO2 laser cutting /engraving
system (Synrad, Mukilteo, WA, USA).
Residual organics were removed by agitating the pads in an aqueous solution of 0.1%
(w/v) sodium dodecylsulphate (SDS) (Sigma Aldrich, Poole, UK, cat. no. L4390) on an
orbital mixer for 1 hour. After 1 hour the SDS solution was discarded and the pads
were rinsed three times by filling the beaker with 18 MΩ.cm water, swirling to ensure all 
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pads were immersed, and then decanting the liquid taking care that the pads remained
in the beaker.
The pads were agitated for a further hour in a 1M solution of hydrochloric acid followed
by three washes with water using the method described previously.
The pads were then blocked (to prevent binding of antibodies to the pad material) by
agitating with BSA blocking solution (0.5 % (w/v) Cohn fraction V BSA (Sigma Aldrich,
Poole, UK, cat. no. A4503) in 100 mM N[2-hydroxyethyl]piperazine-N[2-ethanesulfonic
acid] (HEPES buffer) pH 7.4 (Sigma Aldrich, Poole, UK, cat. no. H7523) for one hour,
followed by three water washes. The pads were dried at room temperature for a
minimum of 1 hour then sealed inside clean polystyrene Petri-dishes with desiccant (to
prevent absorbance of moisture) until use.
Anti-fluorescein and anti-GroEL primary antibodies, their associated secondary
antibodies and streptavidin Alexa Fluor® 633 were diluted to the desired
concentrations (See Table 2-1 in Chapter 2) in freeze drying cocktail (See Table 2-3 in
Chapter 2). The required numbers of glass fibre pads were arranged on a glass
microscope slide and 7.5 µl of antibodies diluted in freeze drying cocktail solution was
pipetted next to each glass fibre pad. The glass fibre pads were then pushed over the
solution with a pipette tip and allowed to absorb the liquid.
Glass fibre pads containing antibodies diluted in freeze drying cocktail were rapidly
frozen by dropping them into a beaker of liquid nitrogen. The beaker now containing
the frozen glass fibre pads was covered with aluminium foil, which was pierced several
times. The beaker was then placed inside a Scanvac Coolsafe freeze drier (LaboGene
APS, Lynge, Denmark) set at a temperature of minus 60°C and a vacuum was applied
for a minimum of four hours. After freeze drying, glass fibre pads were stored in a clean
polystyrene Petri-dish with desiccant until use. Any bent or damaged pads were
discarded.
6.5.3 Running microarray assays with liquid extracts using the
assay breadboard
Glass fibre pads and printed optical waveguide chips were assembled into the ABB
immunoassay module as shown in Figure 6-2. The fluidic path was sealed by
tightening the screws on the top plate of the aluminium chip holder such that there was
211
a spacing of 0.3 mm between the aluminium holder and the top plate. Note that in order
to reduce loss of antibodies and target molecules via adsorption to surfaces, the glass
fluidic cover and Viton® gasket were blocked with BSA blocking solution (0.5 % (w/v)
Cohn fraction V BSA (Sigma Aldrich, Poole, UK, cat. no. A4503) in 100 mM N[2-
hydroxyethyl]piperazine-N[2-ethanesulfonic acid] (HEPES buffer) pH 7.4 (Sigma
Aldrich, Poole, UK, cat. no. H7523), for a minimum of 1 hour prior to running an assay.
The liquid extract from JSC Mars-1 was loaded into the syringe, ensuring there were no
trapped air bubbles and the capillary tubing was primed by pumping liquid extract
through the tubing at a flow rate of 10 µl/min, until fluid exited from the end of the
capillary tubing.The immunoassay module was mounted onto the ABB and the inlet
port on the aluminium chip holder was connected to the vertically mounted syringe
pump using capillary tubing, as shown in Figure 6-1.
The webcam, mounted on the rotation and translation stage on the ABB, was
positioned above the immunoassay module so that the image produced showed the
pad chamber and array chamber. The resulting video feed was used to visually inspect
the progression of the liquid front through the pad and array chambers and to
determine when to stop the syringe pump to allow incubation of the liquid within each
chamber.
Liquid extract was pumped using the syringe pump, through the capillary tubing and
into the microfluidic channel in the glass cover via the inlet port on the aluminium chip
holder and from there into the pad chamber at a flow rate of 1 µl/min. Once the pad
chamber was full and the glass fibre pad was completely wetted, as determined by
observation of the video feed, the pump was stopped and the mixture was allowed to
incubate for 50 minutes in the pad chamber. After 50 minutes the syringe pump was
restarted at a flow rate of 1 µl/min and the video feed was used to observe the
progression of the liquid front into the assay chamber. Once the assay chamber had
filled with liquid, as determined by observation of the video feed, the syringe pump was
stopped and the solution was incubated in the array chamber for a further 50 minutes.
After this incubation period unbound antibody was washed away by pumping more
liquid extract through the microfluidic path, maintaining the same flow rate. The
efficiency of washing was monitored by observation of the colour of the liquid passing
out of the exit port to waste, using the red dye present in the freeze dried cocktail as a
tracer for all of the dissolved reagents. A flow of liquid extract was maintained until the
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fluid passing out of the system was colourless, this took approximately 15 minutes. The
syringe pump was then stopped and the array area on the optical waveguide chip was
imaged in-situ, without disconnecting any of the tubing.
6.5.3.1 Evanescent excitation and fluorescent imaging of microarrays
Laser light was coupled into the incoupling waveguide of the optical waveguide chip by
adjusting the position of the FAU using the XYZ translation stage. Successful coupling
was confirmed by observation of laser light passing through, and scattering from, the
optical waveguides on the array area of the optical waveguide chip. The microarray
area of the optical waveguide chip was imaged with the CCD camera, mounted on the
translation stage of the ABB, using exposure times varying from 30 seconds to 5
minutes. During imaging the ABB was isolated from external light sources by covering
with a black box.
6.5.3.2 Image analysis
Images of microarrays on optical waveguide chips were analysed by measuring the
mean pixel intensity of each spot using ImageJ software as described in Section
2.2.3.9. When imaging the optical waveguide chips a number of exposure times were
used. Images with an exposure time such that pixel intensity was as high as possible,
but where none of the spots had reached saturation (mean pixel intensity of 65000)
were selected for analysis. Since the intensity of the microarray spots produced is
dependent on the efficiency with which the laser light was coupled into the microarray,
there is significant potential for variation between chips. This variation may result from
the skill of the operator in optimising the coupling efficiency or from differences
between the optical waveguide chips resulting in varying efficiency independent of the
skill of the operator, e.g. quality of the optical face of the incoupling waveguide. In order
to account for this variation mean pixel intensities were normalised against the mean
pixel intensities of the high ratio AF633 labelled BSA spots printed onto the same
optical waveguide chip.
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6.6 Results and discussion
6.6.1 Fluidic operation of ABB with liquid extracts from JSC Mars-1
Liquid extracts were produced by ultrasonication of 1 g of JSC Mars-1, spiked with 0
µg/g and 2.7 µg/g fluorescein, with 3 ml of MeOH P80 (Figure 6-5). The liquid extract
produced from the unspiked sample was colourless whereas the liquid extract
produced from the spiked sample had a yellow coloration. Both liquid extracts were
cloudy, after filtration through a 0.45 µm membrane filter, indicating that the extracts
contained a level of fine (sub-0.45 µm) particulate material.
Figure 6-5: Photograph of liquid extracts produced by extracting 1 g of JSC Mars-1
spiked with (left) 0 µg/g fluorescein and (right) 2.7 µg/g fluorescein using 3 ml of MeOH
P80 with ultrasonication
Both liquid extracts were analysed using ABB format multiplexed microarray
immunoassays. No evidence of blockage of the microfluidic channels, including the
capillary tubing (internal diameter of 125 μm), due to the presence of fine particulate 
materials was observed.
The liquid extract from JSC Mars-1 spiked with 0 µg/g fluorescein was analysed first
(run 1), followed by analysis, on the same day of the liquid extract from the 2.7 µg/g
fluorescein spiked JSC Mars-1 (run 2). However during run 2 problems were
encountered with air bubbles becoming trapped in the array chamber, this issue is
discussed in more detail later in this section. Therefore, although the intention had
been to perform a single replicate run for each liquid extract, it was necessary to
perform a second analysis of the 2.7 µg/g fluorescein spiked JSC Mars-1 (run 3). Run 3
was carried out using a glass fibre pad from the same batch as runs 1 and 2, but an
optical waveguide chip had to be freshly prepared for run 3.
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Figure 6-6 shows a series of images of the microfluidic channel captured from the
video footage recorded during each ABB run showing filling of the pad chamber.
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Figure 6-6: Images captured from video footage of pad chamber filling during ABB
assays.
Each row shows images from a single run taken 2.5 min, 4.5 min and 6.5 min from
starting the syringe pump to fill the pad chamber (fluid fill direction from right to left in
each image)
In each of the three runs carried out, the pad chamber filled with liquid extract in a time
of approximately 6.5 minutes from starting the syringe pump. As the liquid front moved
through the glass fibre pad the red dye included in the freeze drying cocktail, which is
used as a proxy for the position of all of the other solutes in the pad, migrated through
the pad and was concentrated at the end of the pad closest to the exit to the array
chamber. Once the pad was completely wetted the gaps around the edge of the pad
then filled. There was some variation in the speed in which the pads filled and not all of
the pads filled evenly. In some cases areas of the pad remained unwetted as the liquid
front passed, and then were backfilled later as shown in the image for run 2 at 2.5
minutes (Figure 6-6).
After 50 minutes of incubation the syringe pump was restarted and the liquid extract
was pumped from the pad chamber into the array chamber (Figure 6-7). The liquid that
filled the array chamber was red in colour indicating that the dissolved solutes were
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also transferred into the array chamber. Complete filling of the array chamber took
approximately 3.5 minutes from starting the syringe pump. After this period of time
some red coloration was still present in the pad, indicating that some of the dissolved
solutes had not been transferred to the array chamber.
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Figure 6-7: Images captured from video footage of array chamber filling during ABB
assays. Each row shows images from a single run taken 1.5 min, 2.5 min and 3.5 min
from starting the syringe pump to fill the assay chamber (fluid fill direction from right to
left in each image)
The way in which the array chamber filled varied between the three runs and in two
cases air became trapped in the array chamber. In run 1 with the liquid extract from 0
µg/g spiked JSC Mars-1 the liquid front filled the array chamber around the edges first
before the middle of the chamber then began to back fill. This resulted in an air bubble
becoming trapped in the chamber that could not be dislodged by tapping. The air
bubble partially overlapped with the microarray on the optical waveguide chip, but the
majority of the spots on the microarray were not in contact with the air bubble. In run 2
with the extract from 2.7 µg/g spiked JSC Mars-1 during the 50 minutes incubation in
the pad chamber liquid from the pad chamber passed into the array chamber, filling it
around the edges and trapping an air bubble in the array chamber. This was probably
as a result of not stopping the pump early enough during pad chamber filling and
allowing some liquid to pass into the channel between the pad and array chambers. In
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this instance the trapped air bubble covered the whole area of the microarray and the
assay had to be repeated with a new optical waveguide chip and pad. In run 3 the
liquid pumped into the array chamber formed as a drop on the top of the array chamber
before dropping down into the bottom of the chamber and filling the array chamber
evenly with no air bubble becoming trapped.
Similar problems with trapped air bubbles have been observed previously when
running ABB assays with buffered solutions, therefore it is unlikely that the problem is
directly related to the use of a liquid extract with associated fine particulates. The
formation of trapped air bubbles is thought to be caused by the presence of surface
contaminants (e.g. particulates from the air, grease etc.) resulting from insufficient
cleaning of the Viton® gasket and glass fluidic cover, which for ABB assays are reused
for multiple runs. In the flight format instrument the gaskets and glass covers will be
single use components and will be assembled and prepared under clean room
conditions with strict quality control procedures, so this is unlikely to be an issue.
After 50 minute incubation in the array chamber, further liquid extract was pumped
through the chip to remove unbound antibody. The removal of all unbound antibody
was assessed by observing the colour of the liquid exiting from the waste capillary tube
(Figure 6-8).
Figure 6-8: Photographs of liquid exiting waste capillary on ABB taken approx. 1 minute
after starting wash (left) showing red coloration and approx. 15 minutes after starting
wash (right) showing colourless liquid, indicating complete washing away of red dye
and other solutes.
The first drop of liquid exiting the capillary tubing was red. After approximately 15
minutes at a flow rate of 1 µl/min the drop of liquid exiting the chip was colourless
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indicating that all of the dye and other dissolved solutes had been washed out.
Observation of the pad within the pad chamber also showed that all of the residual red
coloration in the pad had been washed out.
6.6.1.1 Assay readout of using ABB with liquid extracts from JSC Mars-1
The fluorescent images of the microarrays shown in Figure 6-9, captured after running
ABB immunoassays with liquid extracts from 0 µg/g and 2.7 µg/g fluorescein sodium
salt spiked JSC Mars-1 (from run 1 (0 µg/g), and run 3 (2.7 µg/g)), show that
fluorophores on the high and low ratio AF633 labelled BSA spots fluoresce. This
indicates that laser light was coupled into the optical waveguide chips generating an
evanescent field which excited the fluorophores on the immobilised BSA-fluorophore
conjugates. There was no evidence of significant scatter due to presence of sub 0.45
µm particulates in the liquid extract, neither was there any evidence of high background
signal, indicating that the optical aspects of the ABB assay are compatible with liquid
extracts from JSC Mars-1.
For the microarray run with a liquid extract from 0 µg/g spiked JSC Mars-1, the GroEL
and FITC-BSA spots on the microarray fluoresce showing that both the GroEL and
fluorescein immunoassays have functioned in the liquid extract. For the microarray run
with a liquid extract from JSC Mars-1 spiked with 2.7 µg/g fluorescein the GroEL spots
on the microarray still fluoresce brightly, whereas the BSA-FITC spots give a much
fainter signal indicating that the anti-fluorescein antibody has been inhibited from
binding to the microarray by the presence of extracted fluorescein.
Closer inspection of the individual microarray spots in Figure 6-9 shows that the
intensity of the microarray spots is not homogeneous across the individual waveguides.
This is due to two factors; striation of the evanescent field strength across the width of
the waveguide and poor alignment of microarray spots with the optical waveguides.
Additionally for the microarray on the left hand side of Figure 6-9, three of the GroEL
microarray spots are abnormally small and one of the low ratio AF633 labelled BSA
spots in missing from the image on the right hand side of Figure 6-9. This is most likely
related to problems with the printing procedure i.e. printing pin sticking in print head as
a result of residual moisture from pin washing step.
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Figure 6-9: Fluorescent images of optical waveguide chips after running ABB assays
with (left) extract from JSC Mars-1 spiked with 0 µg/g sodium fluorescein and (right)
extract from sample spiked with 2.7 µg/g fluorescein.
Microarrays consists of rows of ten spots of (from top to bottom) low ratio AF633-BSA
spots, BSA-fluorescein, GroEL and high ratio AF633 BSA. Position of each row of
microarray spots is indicated by red arrows. Image taken using evanescent excitation
on ABB with an exposure time of 2 minutes. Image brightness and contrast have been
adjusted to aid visualisation of spots. Absolute mean pixel intensity of high ratio
labelled BSA spots was approx 17000 in left hand image and 12000 in right hand
image
6.6.1.2 Image analysis
The pixel intensity of microarray spots was measured using ImageJ software. In the
images taken with a 5 minute exposure time the intensity of the GroEL microarray
spots had reached saturation, therefore the images with an exposure time of 2 minutes
were selected for analysis. The absolute signal intensity of the high ratio AF633
labelled BSA spots on the image with a 2 minute exposure time was higher for the
microarray run with the liquid extract from 0 µg/ml spiked JSC Mars -1 (left image in
Figure 6-9) compared to the microarray run with 2.7 µg/ml spiked JSC Mars -1 (right
image in Figure 6-9) approx 17000 compared to 12000. The signal intensity generated
is dependent on the coupling efficiency (i.e. how well laser light is coupled into the in-
coupling fibre on the optical waveguide chip) which is determined by how well the
operator has aligned the FAU and is also dependent on the finish of the in-coupling
area on each individual optical waveguide chip. In order to compensate for this, the
mean pixel intensity for each set of spots was normalised against the mean pixel
intensity of the high ratio AF633 labelled BSA spots printed onto the same optical
waveguide chip. In the image where an air bubble had partially overlapped with the
microarray (left hand image in Figure 6-9), microarray spots which were under the
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trapped air bubble, or at the interface between the air bubble and the liquid extract
were excluded from the analysis.
Analysis of the intensity of the immunoassay spots (Figure 6-10) showed that the
intensity of BSA-FITC spots was significantly reduced, relative to the high ratio AF633
labelled BSA spots on the same waveguide, by a liquid extract from JSC Mars-1 spiked
with 2.7 µg/g (2.7 ppm) sodium fluorescein compared to a liquid extract from JSC
Mars-1 spiked with 0 µg/g (0 ppm) sodium fluorescein.
Figure 6-10: Mean pixel intensity of microarray spots after ABB immunoassay run with
liquid extract from JSC Mars-1 spiked with 0 and 2.7 µg/g sodium fluorescein salt.
Mean pixel intensity normalised against mean pixel intensity for high ratio AF633
labelled BSA spot on same optical waveguide. Error bars = +/- 1 standard deviation of
the mean, n = 5-10 (some spots removed from analysis due to presence of air bubble)
Conversely the intensity of GroEL spots, relative to the high ratio AF633 labelled BSA
spots on the same waveguide, was unchanged by a liquid extract from JSC Mars-1
spiked with 2.7 µg/g (2.7 ppm) sodium fluorescein compared to a liquid extract from
JSC Mars-1 spiked with 0 µg/g (0 ppm) sodium fluorescein. The implication is that the
anti fluorescein antibody was inhibited from binding to the BSA-FITC microarray spots
by the extracted fluorescein, whereas the anti-GroEL antibody was not. Thus GroEL
was a successful positive control immunoassay. It should be noted that there was a
reduction in the relative intensity of the low ratio labelled AF633-BSA spots between
the immunoassays run with liquid extract from JSC Mars-1 spiked with 2.7 µg/g (2.7
ppm) sodium fluorescein compared to a liquid extract from JSC Mars-1 spiked with 0
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µg/g (0 ppm) sodium fluorescein. This may be due to variation in printing between the
two optical waveguide chips (since the optical waveguide chips used were not printed
alongside each other), or it might indicate a level of cross reactivity between the anti-
fluorescein antibody and the AF633 labelled BSA spots, although if that were the case
the antibody would also be expected to cross react with the high ratio AF633 labelled
BSA spots.
6.6.2 Summary discussion and future work
The objective of the work in this study was to demonstrate the function of the LMC in a
flight representative format. The specific objectives set for this piece of work were
1) To confirm the compatibility of liquid extracts from Mars analogue samples with
the optical and microfluidic aspects of the flight representative ABB
2) To confirm the function of LMC relevant immunoassays in liquid extracts from
Mars analogue samples in flight representative ABB assays
The work reported in this chapter successfully met both specific objectives by
demonstrating the function of the LMC (from extraction through to detection) in flight
representative ABB assay format, both in terms of the compatibility of liquid extracts
with the optical and microfluidic aspects of the ABB and in terms of immunoassay
function. As noted in the results section some issues were encountered relating to the
reproducibility of microarray printing e.g. missing/mis-sized microarray spots,
reproducibility between chips and also relating to the formation of air bubbles in the
assay array chamber. Although none of these issues were directly caused by the use
of liquid extracts they clearly require resolution in order to move forward with
development of the LMC flight instrument.
However despite meeting the objectives set for this work the study was limited in that it
was only based on three runs on the ABB, using a single Mars analogue sample
matrix. No replicates runs were carried out due to limited availability of optical
waveguide chips and the time consuming nature of performing immunoassays on the
ABB. Within the context of this study this is deemed to be acceptable but in order to
progress LMC development it is important that reproducibility is considered. The Mars
analogue JSC Mars-1 is representative of only one of many sample matrix types that
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may be encountered on Mars. The highest risk aspect relating to sample matrix is likely
to be precipitation of components of the sample extract when mixed with the buffer
salts in the pad chamber and further work with an extended range of Mars analogues
and individual sample matrix components is necessary.
The data from this study, which used GroEL and fluorescein as LMC relevant
immunoassays, supports the assumption that immunoassays that have been
demonstrated to function in liquid extracts (i.e. extraction solvent and sample matrix
components) in ELISA and pooled microarray format are likely to also function in flight
representative microfluidic format. However as new assays are developed and
transferred into microarray format for the LMC it is essential that this finding is
confirmed. Furthermore the selection of fluorescein as a model target molecule,
although sufficient for the purposes of this study, was not ideal because fluorescein will
not be a target molecule for the LMC, rather a positive control molecule that is not
expected to be found on Mars. Fluorescein is also significantly more polar than LMC
high priority markers of extinct life.
Despite these limitations this study has performed an initial ‘de-risking’ of the operation
of the LMC flight format instrument with liquid extracts from martian samples and also
satisfied the requirement to perform an end-to end demonstration of LMC extraction
ansd detection in order to gain an acceptable TRL level to enable progression to the
next phase of development.
6.7 Conclusions
The work in this chapter has successfully demonstrated extraction and detection of a
small molecule from a single martian analogue sample matrix using LMC relevant
multiplexed microarray assays implemented within a microfluidic channel in a flight
representative format. Although this study had several limitations i.e. no replicates
performed, small number of immunoassays tested in the microarray, it has confirmed
that fundamentally the LMC immunoassay can function in a flight representative format,
in addition to contributing to successful award of TRL level 4, enabling the LMC to
progress to the next phase of development.
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7 Thesis Summary, Conclusions and Future Work
Development of the LMC instrument continues beyond the period of this thesis, but this
work has contributed significantly towards the preparation of the LMC instrument for
flight in 2018. In summary, this thesis includes work that has advanced the current
state of scientific knowledge in four key areas for the development of the LMC
instrument: by validating the use of a water miscible organic solvent/water/surfactant
extraction solvent, by demonstrating that immunoassays can function with model
martian samples, by contributing to a program of work to produce antibodies against
extinct life biomarker targets, and by performing an end-to end demonstration of LMC
instrument function in flight representative format. This section briefly summarises the
developments made within each key area of work, the status of each area of work at
the conclusion of this thesis and plans for future work.
7.1 Compatibility of the proposed extraction solvent for the
LMC with LMC format immunoassays
7.1.1 Summary and conclusions
The solvent used for the LMC instrument must both efficiently extract polar and apolar
target molecules from martian rock and regolith, and must also be compatible with
immunoassays. The objective of the work within this chapter was to confirm whether
the proposed extraction solvent for the LMC (20 % methanol 1.5 g/L P80) was
compatible with LMC format immunoassays. In order to investigate this, a set of model
LMC immunoassays were tested for performance in MeOH P80 in ELISA and
microarray format. The representative data in Table 7-1 shows the successful detection
of six out of seven of the model target molecules used in this study in the LMC
extraction solvent by ELISA.
This study has confirmed that the proposed extraction solvent for the LMC is generally
compatible with immunoassays, although there is a risk that specific immunoassays
may have poor function in the proposed extraction solvent and may therefore be
unsuitable for inclusion on the flight instrument. In addition immunoassays were also
shown to be compatible with 30 fold concentrated liquid extract, although the ability to
concentrate the extracted sample has since been removed from the instrument design,
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and a number of potential back-up solvents were identified should the current preferred
solvent prove unsuitable for any reason in the future.
Table 7-1: IC50 values for inhibition ELISAs run in MeOH P80 and 45 g/L P80
IC50 (ng/ml)
water (*10 % MeOH) MeOH P80
Atrazine *1.4 24.2
B[a]P *6.2 53.8
cAMP 274.8 717.0
Fluorescein 300.0 375.0
GroEL 2447.0 2096.5
LPS 190.5 Not calculated
LTA 2.0 1.0
For the LMC project, instrument design should therefore move forward (and has done
so) based on the expectation of using MeOH P80 as extraction solvent. Beyond the
scope of the LMC, the compatibility of these types of solvents with immunoassays,
combined with their ability to efficiently extract apolar molecules is likely to be of
interest to the planetary exploration community, and in-particular may be of benefit in
the development of other immunoassay based instruments for life detection, and
especially extinct life detection. In addition this type of extraction solvent may be of
interest to the broader immunoassay/biosensor community due to its potential for use
in in-situ immunoassay analysis of environmental contaminants such as pesticides.
7.1.2 Future work
It is recommended that as new antibodies become available for the LMC, they should
be tested immediately for compatibility with the LMC extraction solvent, in ELISA and
especially microarray format before investing significant effort transferring antibody
assays into flight representative formats.
Future work is required to test how the LMC extraction solvent affects the specificity of
antibodies, which was not addressed within this work. Antibodies for the LMC should
ideally cross react with classes of related molecules and the solvent environment may
affect this cross reactivity. This testing will be built into the routine assay development
procedure for new antibodies.
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Work is also required to assess the stability of the extraction solvent to space mission
conditions, including the radiation environment and also to the temperature cycling that
is likely to be experienced during the mission cruise phase. A number of the back-up
solvents identified within this study should also be subject to radiation and temperature
testing.
7.2 Impact of liquid extracts from martian samples on LMC
format immunoassays
7.2.1 Summary and conclusions
Immunoassays performance can be significantly influenced by sample matrix. The
objective of the work within this chapter was to determine whether immunoassays are
likely to function with martian samples. In order to achieve this, the performance of a
set of model immunoassays, in ELISA and microarray format, was tested with Mars
relevant sample matrix components and with liquid extracts from Mars analogue
samples. The typical response of ELISA signal to a range of Mars relevant sample
matrix components is shown in Figure 7-1 and an example of a successful microarray
format immunoassay performed in liquid extracts from four Mars analogue samples is
shown in Figure 7-2.
Figure 7-1: Normalised background corrected ELISA binding signal for cAMP
immunoassay run in MeOH P80 with martian relevant sample matrix components at
concentrations of 10, 100 and 500 mM.
Binding signals normalised against binding signal with no sample matrix component.
Error bars = ± standard error, n = 2
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Figure 7-2: Mean background corrected pixel intensity for pooled multiplexed format
fluorescein and cAMP microarray assays run with cAMP spiked liquid extracts
from (A) control (extraction solvent only), (B) liquid extract from basalt rock, (C) liquid
extract from gypsum (Haughton Crater), (D) liquid extract from JSC Mars-1. Error bars
= ± 1 std deviation, n = 5
These studies, to investigate the likely interaction of liquid extracts from martian
samples, have shown that immunoassays, in LMC format, are likely to function with
martian samples similar to those encountered by the Phoenix lander. Samples with
high concentrations of extractable salts, and especially iron ion containing salts may
compromise assay performance and it may be necessary to avoid analysis of these
types of sample. Studies also revealed that some immunoassays have poorer
tolerance to the addition of sample matrix components and that signal loss with a single
component/liquid extract may vary for each immunoassay tested. This has highlighted
the need to screen antibodies against sample matrix components at an early stage in
assay development and to include a number of well characterised control assays, to
reduce the risk of data misinterpretation.
This work has significantly de-risked the operation of the LMC with martian samples,
and has also identified a number of routes that can be investigated in order to improve
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assay performance with martian samples. More broadly the results of this study are of
interest to other immunoassay instruments for planetary exploration and for
immunoassay analysis in other extreme environments on Earth.
7.2.2 Future work
It is recommended that as new antibodies for the LMC become available that they are
tested, at an early stage, for their stability to a range of Mars relevant sample matrix
components and liquid extracts from analogue samples. This testing should be carried
out prior to investing significant effort transferring assays into microarray format and
antibodies with poor stability should be deselected for further work. A number of control
assays with differing tolerances to sample matrix should also be sourced for inclusion
in the flight instrument to aid data interpretation.
There is a need to carry out further testing of assay performance with Mars relevant
sample matrix components and liquid extracts from analogue samples in microarray
format immunoassays. However before this work can be carried out effort is required to
optimise the performance of LMC microarray format assays, including the investigation
of covalent immobilisation of target molecule-protein conjugates to chip surfaces. The
use of covalent immobilisation, rather than the current physical adsorption onto
hydrophobic surfaces, may improve assay performance in the presence of sample
matrix components.
In addition to altering the surface chemistry for the assay the inclusion of increased
buffering capacity in the solutes freeze dried with antibodies in the glass fibre pads
should be investigated in order to try and improve assay performance with Mars
relevant sample matrix components that form acidic solutions.
In order to better predict the likely proportion of soluble salts in Mars samples, testing
should be performed to characterise and quantify the extractable components of Mars
analogue samples. This will allow the identification of sample/rock types that are likely
to be unsuitable for analysis by the LMC. Testing should also be expanded to include a
wider range of analogues than have been studied to date.
Finally work is required, in collaboration with other ExoMars instrument teams, to
understand how data from the other instruments can be used to guide selection of
suitable samples for analysis by LMC.
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7.3 Generation of antibodies for the detection of markers of
extinct life
7.3.1 Summary, conclusions and future work
The objective of the work within this chapter was to generate antibodies which bind to
markers of extinct life using an immunised recombinant antibody library, since there are
few antibodies available for this high priority class of LMC targets. Within this work two
screening strategies were applied to an immunised recombinant antibody library for the
production of antibodies against markers of extinct life. Despite the use of protocols
specifically designed for the isolation of antibodies against small molecules, both of the
screening strategies used resulted in the isolation of cross reactive and/or non-specific
antibodies (Figure 7-3).
Figure 7-3: scAb binding ELISA showing cross reactive nature of selected clones with a
range of hapten-BSA conjugates.
Plotted values are the mean of two replicates, error bars = +/- standard error.
This outcome indicates that the screening of immunised recombinant antibody libraries
is unlikely to be a suitable route for the generation of antibodies that bind to markers of
extinct life for the LMC given the available resources and timescales. These results led
to the conclusion that either the sheep used to construct the immunised library did not
have an appropriate immune response (e.g. the targets were not recognised by the
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immune system) or that there was a fundamental issue with the screening strategy
(e.g. low throughput analysis did not allow the isolation of rare clones) and led to
suggestions for methods to improve the probability of isolating appropriate clones.
The findings of this work may be applied beyond the LMC project for the development
of antibodies against small and hydrophobic targets, for examples in the field of
environmental monitoring.
Although no antibodies were produced as a direct result of the work carried out within
this thesis, the findings were used to influence the implementation of a future program
of work to produce antibodies (described fully in Table 5-14), which exploits immunised
and non-immunised libraries from a number of sources, and also the use of high
throughput screening facilities available via other organisations. The probability of
producing antibodies against markers of extinct life markers in this future program of
work has been significantly enhanced by the findings of the work within this thesis and
in October 2011 an antibody that specifically binds to 5β-sterane was isolated from a 
semi-synthetic library using high throughput screening as a direct result of the
implemented program of work.
7.4 Demonstration of LMC format extraction and detection in
flight representative hardware
7.4.1 Summary and conclusions
The objective of the work reported within the final chapter of this thesis was to
determine whether LMC format extraction and detection function with flight
representative hardware. In order to investigate this, a Mars analogue sample was
spiked with a representative small molecule target and the sample was subject to LMC
format extraction and detection using the flight representative assay bread board.
Figure 7-4 illustrates the successful detection of fluorescein, a representative target
molecule from a spiked sample of Mars analogue JSC Mars-1.
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Figure 7-4: Mean pixel intensity of microarray spots after ABB immunoassay run with
liquid extract from JSC Mars-1 spiked with 0 and 2.7 µg/g sodium fluorescein salt.
Decreased intensity of Fluorescein microarray assay spots with 2.7 µg/g spiked sample
demonstrates successful extraction and detection of fluorescein. Mean pixel intensity
normalised against mean pixel intensity for high ratio AF633 labelled BSA spot on
same optical waveguide. Error bars = +/- 1 standard deviation of the mean, n = 5-10
(some spots removed from analysis due to presence of air bubble)
This work brought together aspects of the work carried out in Chapters 3 and 4 by
confirming that LMC immunoassays function with LMC extraction solvent liquid extracts
from Mars analogue samples in a flight representative format. In addition the
successful completion of an end to end demonstration contributed towards award of
Technology Readiness Level (TRL) 4 at the completion of the ESA funded TRL
upgrade study for the LMC, enabling progression to the next stage of instrument
development.
7.4.2 Future Work
Future work will involve the performance of further extractions and detections with flight
representative hardware using a wider range of analogue samples and representative
target molecules as the relevant antibodies become available. The eventual goal is to
perform an end to end demonstration with a real sample, with target molecule
incorporated within the sample, rather than with spiked samples.
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APPENDICES
Appendix A Appendix to Chapter 3
A.1 Additional inhibition immunoassay curves for ELISAs run in MeOH
P80 and 45 g/L P80
Figure A. 1: atrazine inhibition ELISA in (●) 10 % methanol, (X) MeOH P80, (▲) 4.5 g/L 
P80.
Each data point represents a single replicate. Immunoassay curves were plotted by
fitting mean signal to a four parameter binding equation for assays run with (solid line)
10 % methanol (dotted line) MeOH P80, (dashed line) 45 g/L P80.
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Figure A.2: (a) LPS and (b) LTA inhibition ELISA in (●) water, (X) MeOH P80, (▲) 4.5 
g/L P80.
Each data point represents a single replicate. Immunoassay curves were plotted by
fitting mean signal to a four parameter binding equation for assays run with (solid line)
water (dotted line) MeOH P80, (dashed line) 45 g/L P80.
Figure A.3: (a) fluorescein and (b) GroEL inhibition ELISA in (●) water, (X) MeOH P80, 
(▲) 4.5 g/L P80.  
Each data point represents a single replicate. Immunoassay curves were plotted by
fitting mean signal to a four parameter binding equation for assays run with (solid line)
water (dotted line) MeOH P80, (dashed line) 45 g/L P80.
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A.2 Absolute ELISA binding data for full concentration range of alternative extraction solvents
Table A.1: Mean binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in DMSO and DMSO/methanol
containing extraction solvents and water as a control.
Also showing binding signal generated by HRP enzyme independently of the immunoassays as a control. All binding signals are given in
units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Water 2 % DMSO
2.5 g/L P80
5 % DMSO
2.5 g/L P80
2 % DMSO
15 % MeOH
2.5 g/L P80
5 % DMSO
15 % MeOH
2.5 g/L P80
x¯ x¯ x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.78 0.05 0.81 0.04 0.82 0.04 0.80 0.04 0.82 0.04
Atrazine 0.57 0.14 0.09 0.05 0.15 0.05 0.32 0.05 0.25 0.05
B[a]P 0.27 0.12 0.48 0.05 0.67 0.20 1.13 0.07 1.08 0.04
cAMP 0.71 0.05 0.66 0.05 0.65 0.04 0.64 0.04 0.63 0.04
Fluorescein 0.86 0.05 0.75 0.01 0.73 0.04 0.68 0.04 0.70 0.04
GroEL 0.68 0.05 0.62 0.04 0.61 0.04 0.65 0.04 0.62 0.04
LPS 0.54 0.13 0.20 0.07 0.22 0.08 0.12 0.08 0.15 0.08
LTA 0.97 0.16 0.15 0.05 0.13 0.05 0.100 0.06 0.11 0.05
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Table A.2: Mean binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in acetone containing extraction
solvents and water as a control.
Also showing binding signal generated by HRP enzyme independently of the immunoassays as a control. All binding signals are given in
units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Water 10 % acetone
2.5 g/L P80
20 % acetone
2.5 g/L P80
30 % acetone
2.5 g/L P80
x¯ x¯ x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.78 0.05 0.76 0.04 0.82 0.04 0.81 0.04
Atrazine 0.57 0.14 0.11 0.05 0.07 0.05 0.06 0.05
B[a]P 0.27 0.12 1.03 0.04 1.02 0.04 0.96 0.05
cAMP 0.71 0.05 0.64 0.04 0.62 0.04 0.55 0.05
Fluorescein 0.86 0.05 0.65 0.05 0.63 0.05 0.58 0.05
GroEL 0.68 0.05 0.60 0.04 0.59 0.04 0.59 0.04
LPS 0.54 0.13 0.18 0.10 0.12 0.06 0.09 0.05
LTA 0.97 0.16 0.12 0.06 0.13 0.05 0.07 0.05
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Table A.3: Mean binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in acetonitrile containing extraction
solvents and water as a control.
Also showing binding signal generated by HRP enzyme independently of the immunoassays as a control. All binding signals are given in
units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Water 10 % MeCN
2.5 g/L P80
20 % MeCN
2.5 g/L P80
30 % MeCN
2.5 g/L P80
x¯ x¯ x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.78 0.05 0.74 0.04 0.70 0.04 0.66 0.04
Atrazine 0.57 0.14 0.18 0.05 0.13 0.05 0.06 0.05
B[a]P 0.27 0.12 0.98 0.04 0.76 0.05 0.45 0.05
cAMP 0.71 0.05 0.68 0.04 0.41 0.04 0.05 0.05
Fluorescein 0.86 0.05 0.64 0.16 0.63 0.05 0.48 0.05
GroEL 0.68 0.05 0.53 0.04 0.48 0.05 0.37 0.04
LPS 0.54 0.13 0.18 0.08 0.09 0.06 0.06 0.05
LTA 0.97 0.16 0.15 0.06 0.06 0.06 0.06 0.06
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A.3 Additional inhibition ELISA curves with alternative extraction
solvents
Figure A.4: (a) atrazine and (b) B[a]P LMC format inhibition ELISAs in 10 % methanol
and alternative LMC extraction solvents
(●) 10 % methanol, (X) 5 % DMSO 2.5 g/L P80, (▲) 30 % acetone 2.5 g/L P80 and (+) 
30 % acetonitrile 2.5 g/L P80. Each data point represents a single replicate.
Immunoassay curves were plotted by fitting mean signal to a four parameter binding
equation, or by linear interpolation of the mean OD where the data did not fit a four
parameter binding equation (solid line) 10 % methanol, (dotted line) 5 % DMSO 2.5 g/L
P80, (short dashed line) 30 % acetone 2.5 g/L P80, (long dashed line) 30 % acetonitrile
2.5 g/L P80.
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Figure A.5: (a) cAMP and (b) GroEL LMC format inhibition ELISAs in water and
alternative LMC extraction solvents
(●) water, (X) 5 % DMSO 2.5 g/L P80, (▲) 30 % acetone 2.5 g/L P80 and (+) 30 % 
acetonitrile 2.5 g/L P80. Each data point represents a single replicate. Immunoassay
curves were plotted by fitting mean signal to a four parameter binding equation, or by
linear interpolation of the mean OD where the data did not fit a four parameter binding
equation (solid line) 10 % methanol, (dotted line) 5 % DMSO 2.5 g/L P80, (short
dashed line) 30 % acetone 2.5 g/L P80, (long dashed line) 30 % acetonitrile 2.5 g/L
P80.
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Figure A.6: LTA LMC format inhibition ELISA in water and alternative LMC extraction
solvents
(●) water, (X) 5 % DMSO 2.5 g/L P80, (▲) 30 % acetone 2.5 g/L P80 and (+) 30 % 
acetonitrile 2.5 g/L P80. Each data point represents a single replicate. Immunoassay
curves were plotted by fitting mean signal to a four parameter binding equation, or by
linear interpolation of the mean OD where the data did not fit a four parameter binding
equation (solid line) 10 % methanol, (dotted line) 5 % DMSO 2.5 g/L P80, (short
dashed line) 30 % acetone 2.5 g/L P80, (long dashed line) 30 % acetonitrile 2.5 g/L
P80.
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Appendix B Appendix to Chapter 4
B.1 ELISA binding data for full range of sample matrix components
Table B1: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of magnesium
perchlorate salts. Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm (n = 2 or 3)
Control 10 mM Mg(ClO4)2 100 mM Mg(ClO4)2 500 mM Mg(ClO4)2
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.44 0.04 0.44 0.04 0.42 0.04
Atrazine 0.51 0.04 0.53 0.05 0.34 0.07 0.06 0.07
B[a]P 0.53 0.05 0.47 0.04 0.14 0.05 0.05 0.05
cAMP 0.60 0.04 0.69 0.04 0.52 0.08 0.05 0.05
Fluorescein 0.63 0.04 0.69 0.05 0.69 0.05 0.24 0.05
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Table B2: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of calcium
perchlorate salts. Also showing signal generated by HRP enzyme independently of immunoassay as a control. All binding signals are
given in units of optical density measured at an absorption wavelength of 450 nm (n = 2 or 3)
Table B3: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of iron (III)
perchlorate salts. Also showing signal generated by HRP enzyme independently of immunoassay as a control. All binding signals are
given in units of optical density measured at an absorption wavelength of 450 nm (n = 2 or 3)
Control Ca(ClO4)2 10 mM Ca(ClO4)2 100 mM Ca(ClO4)2 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.49 0.04 0.41 0.04 0.39 0.04
Atrazine 0.51 0.04 0.61 0.07 0.40 0.15 0.39 0.35
B[a]P 0.53 0.05 0.51 0.05 0.19 0.07 0.27 0.23
cAMP 0.60 0.04 0.70 0.06 0.46 0.08 0.14 0.11
Fluorescein 0.63 0.04 0.73 0.06 0.68 0.08 0.45 0.26
Control Fe(ClO4)3 10 mM Fe(ClO4)3 100 mM Fe(ClO4)3 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.42 0.05 0.06 0.07 0.05 0.04
Atrazine 0.51 0.04 0.27 0.30 0.06 0.06 0.05 0.06
B[a]P 0.53 0.05 0.21 0.20 0.06 0.07 0.06 0.06
cAMP 0.60 0.04 0.95 1.49 0.06 0.07 0.06 0.06
Fluorescein 0.63 0.04 0.30 0.28 0.06 0.06 0.05 0.05
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Table B4: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of iron (II)
perchlorate salts. Also showing signal generated by HRP enzyme independently of immunoassay as a control. All binding signals are
given in units of optical density measured at an absorption wavelength of 450 nm (n = 2 or 3)
Table B5: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of sodium chloride.
Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Control Fe(ClO4)2 10 mM Fe(ClO4)2 100 mM Fe(ClO4)2 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.35 0.06 0.22 0.16 0.39 0.04
Atrazine 0.51 0.04 0.80 0.74 0.76 0.69 0.18 0.19
B[a]P 0.53 0.05 1.67 1.85 0.75 0.90 0.14 0.16
cAMP 0.60 0.04 1.26 1.21 0.68 0.78 0.23 0.20
Fluorescein 0.63 0.04 0.69 0.58 0.59 0.59 0.12 0.12
Control NaCl 10 mM NaCl 100 mM NaCl 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.33 0.04 0.41 0.04 0.43 0.04
Atrazine 0.51 0.04 0.47 0.04 0.52 0.04 0.39 0.04
B[a]P 0.53 0.05 0.53 0.04 0.30 0.04 0.10 0.04
cAMP 0.60 0.04 0.67 0.04 0.56 0.04 0.52 0.08
Fluorescein 0.63 0.04 0.63 0.04 0.71 0.04 0.67 0.04
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Table B6: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of potassium
chloride. Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Table B7: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of magnesium
sulphate. Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Control KCl 10 mM KCl 100 mM KCl 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.45 0.04 0.45 0.04 0.43 0.04
Atrazine 0.51 0.04 0.49 0.04 0.48 0.04 0.34 0.05
B[a]P 0.53 0.05 0.57 0.04 0.34 0.04 0.10 0.05
cAMP 0.60 0.04 0.73 0.04 0.69 0.04 0.56 0.05
Fluorescein 0.63 0.04 0.64 0.04 0.71 0.04 0.66 0.04
Control MgSO4 10 mM MgSO4 100 mM MgSO4 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.39 0.04 0.37 0.04 0.38 0.04
Atrazine 0.51 0.04 0.59 0.04 0.49 0.05 0.36 0.06
B[a]P 0.53 0.05 0.46 0.04 0.20 0.05 0.07 0.05
cAMP 0.60 0.04 0.71 0.04 0.58 0.04 0.31 0.05
Fluorescein 0.63 0.04 0.68 0.04 0.62 0.04 0.50 0.05
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Table B8: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of sodium sulphate.
Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Table B9: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of sodium
carbonate. Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Control Na2SO4 10 mM Na2SO4 100 mM Na2SO4 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.40 0.04 0.39 0.04 0.33 0.04
Atrazine 0.51 0.04 0.50 0.04 0.53 0.04 0.45 0.05
B[a]P 0.53 0.05 0.51 0.04 0.29 0.04 0.11 0.05
cAMP 0.60 0.04 0.68 0.05 0.63 0.04 0.44 0.43
Fluorescein 0.63 0.04 0.67 0.04 0.66 0.04 0.63 0.05
Control Na2CO3 10 mM Na2CO3 100 mM Na2CO3 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.39 0.04 0.44 0.04 0.32 0.04
Atrazine 0.51 0.04 0.55 0.04 0.21 0.06 0.14 0.09
B[a]P 0.53 0.05 0.52 0.04 0.06 0.06 0.07 0.04
cAMP 0.60 0.04 0.68 0.04 0.52 0.07 0.08 0.08
Fluorescein 0.63 0.04 0.64 0.04 0.65 0.05 0.26 0.08
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Table B10: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of iron (III) chloride.
Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Table B11: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of iron (II) sulphate.
Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Control FeCl3 10 mM FeCl3 100 mM FeCl3 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.37 0.04 0.42 0.04 0.06 0.06 0.09 0.06
Atrazine 0.51 0.04 0.62 0.30 0.06 0.06 0.06 0.07
B[a]P 0.53 0.05 1.94 2.21 0.07 0.07 0.07 0.08
cAMP 0.60 0.04 0.79 0.68 0.07 0.07 0.07 0.07
Fluorescein 0.63 0.04 0.74 0.83 0.06 0.06 0.06 0.06
Control Fe(II)SO4 10 mM Fe(II)SO4 100 mM Fe(II)SO4 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.49 0.05 0.49 0.10 0.50 0.12 0.52 0.20
Atrazine 0.49 0.04 0.49 0.10 0.50 0.12 0.52 0.20
B[a]P 0.34 0.04 0.94 0.99 0.63 0.71 0.64 0.74
cAMP 0.63 0.04 0.89 0.850 0.75 0.80 0.80 0.86
Fluorescein 0.68 0.04 0.89 0.95 0.73 0.80 0.70 0.95
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Table B12: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of iron (III)
sulphate. Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Table B13: Mean Binding signal (x¯ ) and mean background signal (x¯ bg), for LMC relevant ELISAs run in the presence of hydrogen
peroxide. Also showing signal generated by HRP enzyme independently of immunoassay as a control.
All binding signals are given in units of optical density measured at an absorption wavelength of 450 nm, n = 2 or 3
Control Fe(III)2(SO4)3 10 mM Fe(III)2(SO4)3 100 mM Fe(III)2(SO4)3 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.49 0.05 0.45 0.04 0.05 0.05 0.05 0.05
Atrazine 0.49 0.04 0.45 0.04 0.05 0.05 0.05 0.05
B[a]P 0.34 0.04 0.28 0.30 0.05 0.05 0.05 0.05
cAMP 0.63 0.04 0.29 0.38 0.05 0.05 0.05 0.05
Fluorescein 0.68 0.04 0.23 0.34 0.05 0.05 0.05 0.06
Control H2O2 10 mM H2O2 100 mM H2O2 500 mM
x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg x¯ x¯ bg
HRP 0.49 0.05 0.51 0.04 0.40 0.04 0.27 0.04
Atrazine 0.49 0.04 0.51 0.04 0.40 0.04 0.27 0.04
B[a]P 0.34 0.04 0.38 0.04 0.21 0.04 0.08 0.04
cAMP 0.63 0.04 0.66 0.04 0.47 0.04 0.15 0.04
Fluorescein 0.68 0.04 0.69 0.05 0.43 0.06 0.12 0.04
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B.2 inhibition immunoassay curves for ELISAs run in sample matrix components
Figure B1: Atrazine inhibition ELISA in the presence of Mars relevant sample matrix components
A sodium chloride, B magnesium sulphate and C magnesium perchlorate at ■ 0 mM, ♦ 10 mM, ▲100 mM and X 500 mM concentration. 
Each data point represents a single replicate. Immunoassay curves for each concentration of each sample matrix component were plotted
by fitting mean signal to a four parameter binding equation, or by linear regression of the mean signal where the data did not fit a four
parameter binding equation.(solid line) 0 mM, (dotted line) 10 mM, (short dashed line) 100 mM and (long dashed line) 500 mM.
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Figure B2: Benzo[a]pyrene inhibition ELISA in the presence of sample matrix components A sodium chloride, B magnesium sulphate and
C magnesium perchlorate at ■ 0 mM, ♦ 10 mM, ▲100 mM and X 500 mM concentration.  
Each data point represents a single replicate. Immunoassay curves for each concentration of each sample matrix component were plotted
by fitting mean signal to a four parameter binding equation, or by linear regression of the mean signal where the data did not fit a four
parameter binding equation.(solid line) 0 mM, (dotted line) 10 mM, (short dashed line) 100 mM and (long dashed line) 500 mM. Note that
pyrene (rather than benzo[a]pyrene) was used as inhibiting antigen
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Figure B3: Fluorescein inhibition ELISA in the presence of sample matrix components A sodium chloride, B magnesium sulphate and C
magnesium perchlorate at ■ 0 mM, ♦ 10 mM, ▲100 mM and X 500 mM concentration.  
Each data point represents a single replicate. Immunoassay curves for each concentration of each sample matrix component were plotted
by fitting mean signal to a four parameter binding equation, or by linear regression of the mean signal where the data did not fit a four
parameter binding equation.(solid line) 0 mM, (dotted line) 10 mM, (short dashed line) 100 mM and (long dashed line) 500 mM.
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ABSTRACT
The Life Marker Chip intends to use an aqueous surfactant solution to extract both polar AND nonpolar
biomarkers from the martian soil for transport to an antibody-based detection system. Currently, a solution of
1.5 g l-1 polysorbate 80 in 20:80 (vol:vol) methanol:water is being considered and appears to be suitable.
However, should this solution be shown to be unsuitable for the LMC or the martian environment, it will be
necessary to use a different surfactant. Here, we have investigated the ability of a range of other surfactant
solutions to extract a suite of eight standards spiked on the surfaces of the martian soil simulant JSC Mars-1 and
tested the compatibility of the best two surfactants with a representative antibody assay for the detection of
pyrene. The results show that using 20:80 (vol:vol) methanol:water as the solvent leads to greater recoveries of
standards than using water alone. The poloxamer surfactants Pluronic® F-68 and F-108 are not effective at
extracting the standards from JSC Mars-1 at any of the concentrations tested here. The fluorosurfactant Zonyl®
FS-300 is able to extract the standards, but not as efficiently as polysorbate 80 solutions. Most successful of the
alternative surfactants was the siloxane-based surfactant poly[dimethylsiloxane-co-[3-(2-(2-
hydroxyethoxy)ethoxy)propyl]methylsiloxane] (PDMSHEPMS) which is able to extract the standards from JSC
Mars-1 about as efficiently as polysorbate 80 solutions. Enhanced recovery of the standards using polysorbate
80 solutions can be achieved by increasing the concentration of polysorbate 80, from 1.5 g l-1 to 10 g l-1,
leading to an increase in the recovery of standards of about 50%; a similar increase in effectiveness is also
apparent for PDMSHEPMS. Polysorbate 80 at concentrations of 1.5 g l-1 and 10 g l-1 and Zonyl® FS-300 and
PDMSHEPMS (both at a concentration of 10 g l-1) are also compatible with the representative pyrene antibody
assay.
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ABSTRACT
The proposed ExoMars mission, due to launch in 2018, aims to look for evidence of extant and extinct life in
martian rocks and regolith. Previous attempts to detect organic molecules of biological or abiotic origin on Mars
have been unsuccessful, which may be attributable to destruction of these molecules by perchlorate salts during
pyrolysis sample extraction techniques. Organic molecules can also be extracted and measured with solvent
based systems. The ExoMars payload includes the Life Marker Chip (LMC) instrument, capable of detecting
biomarker molecules of extant and extinct Earth-like life in liquid extracts of martian samples with an antibody
microarray assay. The aim of the work reported here was to investigate whether the presence of perchlorate
salts, at levels similar to those at the NASA Phoenix landing site, would compromise the LMC extraction and
detection method. To test this, we implemented an LMC representative sample extraction process with an LMC
representative antibody assay and used these to extract and analyze a model sample that consisted of a martian
analogue sample matrix (JSC Mars-1) spiked with a representative organic molecular target (pyrene, an example
of abiotic meteoritic in-fall targets) in the presence of perchlorate salts. We found no significant change in
immunoassay function when using pyrene standards with added perchlorate salts. When model samples spiked
with perchlorate salts were subjected to an LMC representative liquid extraction, immunoassays functioned in a
liquid extract and detected extracted pyrene. For the same model sample matrix without perchlorate salts, we
observed anomalous assay signals that coincided with yellow coloration of the extracts. This unexpected
observation is being studied further. This initial study indicates that the presence of perchlorate salts, at levels
similar to those detected at the NASA Phoenix landing site, is unlikely to prevent the LMC from extracting and
detecting organic molecules from martian samples.
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ABSTRACT
The Life Marker Chip (LMC) is one of the instruments being developed for possible flight on the 2018 ExoMars
mission. The instrument uses solvents to extract organic compounds from samples of martian regolith and to
transfer the extracts to dedicated detectors based around the use of antibodies. The scientific aims of the
instrument are to detect organics in the form of biomarkers that might be associated with extinct life, extant life
or abiotic sources of organics. The instrument relies on a novel surfactant-based solvent system and bespoke,
commercial and research-developed antibodies against a number of distinct biomarkers or molecular types. The
LMC comprises a number of subsystems designed to accept up to four discrete samples of martian regolith or
crushed rock, implement the solvent extraction, perform microfluidic-based multiplexed antibody-assays for
biomarkers and other targets, optically detect the fluorescent output of the assays, control the internal instrument
pressure and temperature, in addition to the associated instrument control electronics and software. The
principle of operation, the design and the instrument development status as of December 2011 are reported here.
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ABSTRACT
The Life Marker Chip (LMC) is a multi-sample, multiplexed immunoassay microarray based instrument
currently under development by an international consortium for flight on the European Space Agency’s
ExoMars mission to Mars. The mission is currently scheduled for launch in 2018. The LMC has been proposed
as part of the mission’s organics instrument suite to search for molecular organic evidence of life on Mars. This
mission will include for the first time a rover equipped with a drilling system to extract samples from depths
down to 2 metres below the surface where evidence of life may be preserved.
The LMC instrument comprises an optical waveguide substrate that evanescently excites fluorescent labels
associated with a one hundred spot multiplexed immunoassay microarray. The array is in a micro-fluidic
channel that also contains pre-dosed and dried assay reagents that dissolve into an incoming liquid sample. The
LMC instrument contains multiple single-use array / micro-fluidic channels to enable multiple samples to be
analysed on the Martian surface. The instrument also contains a sample processing system to automate the
extraction of organics from a Martian regolith or crushed rock sample. The LMC analytical targets include
organic molecules that are from the following classes: biomarkers of extinct life, biomarkers of extant life,
markers of meteoritic organic material, markers of terrestrial contamination, and synthetic control markers.
Progress in LMC development will be reported and to include: (i) development of breadboard hardware
demonstrators including microfluidic assay and sample extraction and processing breadboards; (ii) development
of recombinant antibodies and assays to LMC targets; (iii) development of sample processing protocols and (iv)
storage and stability testing of LMC assay reagents in space mission relevant scenarios.
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